#Patient Identifier	Sample Identifier	Sample Timepoint	Fusion	Specific Diagnosis at Inclusion	ELN 2017 Risk Classification	ELN 2008 Risk Classification	Specific Diagnosis at Acquisition	Group	Site of Sample	Platform	RNA Sequenced	Whole Exome Sequencing	Ex Vivo Drug Testing	RNA Seq Analysis	Exome Seq Analysis	Drug Testing data in Analysis	Cumulative Treatment Type Count	Cumulative Treatment Types	Cumulative Treatment Regimen Count	Cumulative Treatment Regimens	Number of Cumulative Treatment Stages	Cumulative Treatment Stages	Response to Induction Treatment	Type of Induction Treatment	Duration of Induction Treatment	Most Recent Treatment Type	Current Regimen	Current Stage	Most Recent Treatment Duration	Karyotype and Sample Acquisition Interval Difference in Days	Basophils Percent in Peripheral Blood	Bone Marrow Blast Percentage	PB Blast Percentage	CEBPA Biallelic Mutation	Eosinophils Percent in Peripheral Blood	Immature Granulocytes Percent in Peripheral Blood	Lymphocytes Percent in Peripherial Blood	Monocytes Percent in Peripherial Blood	Neutrophils Percent in Peripheral Blood	Nucleated RBCs Percent in Peripheral Blood	Alanine Aminotransferase Level in PB per litre	Aspartate Aminotransferase Level in PB per litre	Albumin Levels in PB  (g/dL)	Hematology serum creatinine laboratory result value in mg dl	FAB	Hematocrit Levels (%)	Hemoglobin level	Karyotype	Laboratory Procedure Lactate Dehydrogenase Result	Mean corpuscular volume (fL)	FISH Results from Cytogenetics Report	Platelet count	Surface Antigens	Total Protein Levels in the Blood (g/dL)	WBC	FLT3-ITD Consensus Call	NPM1 Consensus Call	CEBPA Mutation	BRAF mutation	DNMT3A Mutation	Negative for FLT3	IDH1 Mutation	IDH2 Negative	JAK2 Negative	Negative for KIT	KRAS Mutation	NRAS Mutation	TP53 Mutation	Age At Procurement	Somatic Status	Oncotree Code	Cancer Type	Cancer Type Detailed	TMB (nonsynonymous)
#Identifier to uniquely specify a patient.	A unique sample identifier.	Sample sequential timepoint (T1 = timepoint 1, T2 = timepoint 2, etc.)	Fusion	Specific Diagnosis at Inclusion	Risk classification assigned to the Specimen based on European Leukemia Network 2017 guidelines	Risk classification assigned to the Specimen based on European Leukemia Network 2008 guidelines	Specific Diagnosis at Acquisition	Group	Sample Site	Platform.	RNA Sequenced	Whole Exome Sequencing	Is Ex Vivo Drug Testing performed on sample?	Is RNA Seq data of the sample used in Analysis?	Is Exome Seq data of the sample used in Analysis?	Is Drug Testing data of the sample used in analysis?	The unique number of treatment types for the Disease instance	The unique treatment types for the Disease instance	Unique number of chemotherapy treatment regiments for the Disease instance	Chemotherapy treatment regimens for the Disease instance	Number of Treatment Stages for the Disease instance	Number of unique treatment stages for the disease instance	Response to Induction Treatment	Type of Induction Treatment received	Duration of Induction Treatment (Days)	Treatment type of the most recent treatment determined by start date	The most current treatment	Stage of the most current treatment	Most Recent Treatment Duration (Days)	Difference in days of karyotype result reported and date of Specimen acquisition	% Basophils in the peripheral blood	Bone marrow blast percentage.	PB blast percentage	CEBPA Biallelic Mutation	% Eosinophils in the peripheral blood	Immature Granulocytes Percent in Peripheral Blood	% Lymphocytes in the peripheral blood	% Monocytes in the peripheral blood	% Neutrophils in the peripheral blood	% Nucleated RBCs in the peripheral blood	Alanine aminotransferase levels in the peripheral blood (units/litre)	Aspartate aminotransferase levels in the peripheral blood (units/litre)	Albumin levels in the peripheral blood  (g/dL)	Hematology serum creatinine laboratory result value in mg dl	FAB.	Hematocrit Levels (%)	Hemoglobin result	Karyotype.	Information related to the result of the medical procedure that involves testing a sample of blood for lactic dehydrogenase, a family of homotetrameric cytoplasmic enzymes involved in the conversion of L-lactate and NAD to pyruvate and NADH in the final step of anaerobic glycolysis.	Mean corpuscular volume (fL)	FISH results pulled from cytogenetics report in EMR	Platelet qualitative result	Surface antigens as determined by clinical flow	Total Protein Levels in the Blood (g/dL)	White bloodcell count.	Consensus call for FLT3 -ITD	Consensus call for NPM1	CEBPA mutation.	BRAF mutation	DNMT3A Mutation	Negative for FLT3	IDH1 mutation is present	Is the IDH2 status negative	JAK2 Negative	Negative for KIT	KRAS mutation is present.	NRAS Mutation	TP53 mutation is present.	Age At Procurement Of The Submitted Specimen	Somatic Status	Oncotree Code	Cancer Type	Cancer Type Detailed	TMB (nonsynonymous)
#STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	NUMBER	STRING	STRING	STRING	NUMBER	NUMBER	NUMBER	NUMBER	NUMBER	STRING	NUMBER	NUMBER	NUMBER	NUMBER	NUMBER	NUMBER	NUMBER	NUMBER	NUMBER	NUMBER	STRING	NUMBER	NUMBER	STRING	NUMBER	NUMBER	STRING	NUMBER	STRING	NUMBER	NUMBER	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	STRING	NUMBER	STRING	STRING	STRING	STRING	STRING
#1	1	1	1	1	1	1	1	1	1	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	0	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	0	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
PATIENT_ID	SAMPLE_ID	SAMPLE_TIMEPOINT	FUSION	SPECIFIC_DIAGNOSIS_AT_INCLUSION	ELN_2017	ELN_2008	SPECIFIC_DIAGNOSIS_AT_ACQUISITION	GROUP	SAMPLE_SITE	PLATFORM	RNA_SEQUENCED	WHOLE_EXOME_SEQUENCING	EX_VIVO_DRUG_TESTING	RNA_SEQ_ANALYSIS	EXOME_SEQ_ANALYSIS	DRUG_TESTING_IN_ANALYSIS	CUMULATIVE_TREATMENT_TYPE_COUNT	CUMULATIVE_TREATMENT_TYPES	CUMULATIVE_TREATMENT_REGIMEN_COUNT	CUMULATIVE_TREATMENT_REGIMENS	CUMULATIVE_TREATMENT_STAGE_COUNT	CUMULATIVE_TREATMENT_STAGES	INDUCTION_RESPONSE	TYPE_INDUCTION_TREATMENT	DURATION_OF_INDUCTION_TREATMENT	MOST_RECENT_TREATMENT_TYPE	CURRENT_REGIMEN	CURRENT_STAGE	MOST_RECENT_TREATMENT_DURATION	KARYOTYPE_SAMPLE_ACQUISITION_INTERVAL_DIFFERENCE	PB_BASOPHILS_PERCENTAGE	BM_BLAST_PERCENTAGE	PB_BLAST_PERCENTAGE	CEBPA_BIALLELIC_MUTATION	PB_EOSINOPHILS_PERCENTAGE	PB_IMMATURE_GRANULOCYTES_PERCENTAGE	PB_LYMPHOCYTES_PERCENTAGE	PB_MONOCYTES_PERCENTAGE	PB_NEUTROPHILS_PERCENTAGE	PB_NUCLEATED_RBC_PERCENTAGE	PB_ALT_LEVEL	PB_AST_LEVEL	PB_ALBUMIN_LEVEL	CREATININE_LEVEL_PRERESECTION	FAB	HEMATOCRIT_LEVEL	HEMOGLOBIN_LEVEL	KARYOTYPE	LDH_LEVEL	MEAN_CORPUSCULAR_VOLUME	CYTOGENETICS_OTHER	PLATELET_COUNT	SURFACE_ANTIGENS	TOTAL_PROTEIN_LEVEL	WBC	FLT3_ITD_CONSENSUS_CALL	NPM1_CONSENSUS_CALL	CEBPA_MUTATION	BRAF_MUTATION	DNMT3A_MUTATION	FLT3_NEGATIVE	IDH1_MUTATION	IDH2_NEGATIVE	JAK2_NEGATIVE	KIT_NEGATIVE	KRAS_MUTATION	NRAS_MUTATION	TP53_MUTATION	AGE_AT_PROCUREMENT	SOMATIC_STATUS	ONCOTREE_CODE	CANCER_TYPE	CANCER_TYPE_DETAILED	TMB_NONSYNONYMOUS
aml_ohsu_2018_163	aml_ohsu_2018_09-00705	Denovo	None	AML with mutated NPM1	Favorable or Intermediate	Intermediate-I	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	WES	No	Yes	Yes	No	Yes	No	2	Standard Chemotherapy | Targeted Therapy - Kinase Inhibitor(s)	3	7+3 (Cytarabine, Idarubicin)|MiDAC|AC220 (Ambit)	3	Consolidation | Induction | Experimental	Complete Response	Standard Chemotherapy	5	Targeted Therapy - Kinase Inhibitor(s)	AC220 (Ambit)	Experimental	30	0	0	94	97	No	0		2	1	0		19	28	4.1	0.79	M1	19.3	6.8	46,XY[20]	441	100.5	Normal	89	CD11b, CD13, CD33, dim CD56, CD64, CD117, and dim MPO positive, CD34 negative, HLA-DR negative	7.6	94	Positive	Positive				Negative			Negative	Negative				73	Unmatched	AMLNPM1	Leukemia	AML with Mutated NPM1	0.1
aml_ohsu_2018_174	aml_ohsu_2018_10-00136	Denovo	None	Acute myelomonocytic leukaemia	Adverse	Intermediate-II	Acute myelomonocytic leukaemia	Initial Acute Leukemia Diagnosis	Leukapheresis	WES	No	Yes	Yes	No	Yes	No	2	Standard Chemotherapy | Targeted Therapy - Kinase Inhibitor(s)	4	7+3 (Cytarabine, Idarubicin)|MiDAC|Hydroxyurea|AC220 (Ambit)	4	Consolidation | Induction | Experimental | Re-induction	Complete Response	Standard Chemotherapy	4	Standard Chemotherapy	Hydroxyurea	Re-induction	3	0	0	80	19	No	0		5	3	11		56	56	3.2	1.68	M4		7.7	47,XY,+8[cp9]/46,XY[11]	4559		Signal copy for CEP 8 and ETO	66	dim CD4, partial CD7, CD13, CD33, CD34, dim CD45, dim CD56, variable CD64, CD117, CD123, HLA-DR and MPO positive	5.4	282.1	Positive	Negative	Negative											69	Unmatched	AML	Leukemia	Acute Myeloid Leukemia	0.133333333333
aml_ohsu_2018_175	aml_ohsu_2018_10-00172	Denovo	None	Acute myelomonocytic leukaemia	Intermediate or Adverse	Intermediate-II	Acute myelomonocytic leukaemia	Initial Acute Leukemia Diagnosis	Leukapheresis	WES	No	Yes	Yes	No	Yes	No	3	Standard Chemotherapy | Bone Marrow Transplant | Targeted Therapy - Kinase Inhibitor(s)	5	7+3 (Cytarabine, Idarubicin)|HiDAC|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Quizartinib|Busulfan, Cyclophosphamide	5	Consolidation | Induction | Experimental | Re-induction | Allogeneic - Matched Unrelated Donor	Complete Response	Standard Chemotherapy	7	Standard Chemotherapy	FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)	Re-induction	4	0	0	91	99	No	0		31	16	5		84	90	1.9	0.86	M4	22.9	7.9	47,XX,+13[18]/46,XX[2]	3587	90.5	trisomy 13	48	Blast immunophenotype: dim CD4, variable CD11b, CD13, CD33, partial CD34, dim CD45, variable CD64, partial CD117, CD123, HLA-DR and MPO positive; Promonocyte immunophenotype: dim CD4, CD11b, CD13, CD33, CD45, bright CD64, CD123, HLA-DR, and dim MPO positive	4.6	29.7	Positive	Negative	Negative			Negative			Negative	Negative				59	Unmatched	AML	Leukemia	Acute Myeloid Leukemia	0.2
aml_ohsu_2018_45	aml_ohsu_2018_10-00507	Denovo	None	AML with mutated NPM1	Favorable or Intermediate	Intermediate-I	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Leukapheresis	WES	No	Yes	No	No	Yes	No	2	Standard Chemotherapy | Intrathecal	3	7+3 (Cytarabine, Idarubicin)|MiDAC|Cytarabine, Methotrexate	2	Consolidation | Induction	Refractory	Standard Chemotherapy	6	Standard Chemotherapy	MiDAC	Consolidation	5	0	0	97	97	No	0		10	0	3		30	38	2.8	0.92	M1		10.9	46,XX[20]	592		Normal	8	CD13, CD33, dimCD45, CD56, partial CD117, MPO/positive	5.8	112.3	Positive	Positive												70	Unmatched	AMLNPM1	Leukemia	AML with Mutated NPM1	0.266666666667
aml_ohsu_2018_174	aml_ohsu_2018_10-00542	Relapse	None	Acute myelomonocytic leukaemia	Adverse	Intermediate-II	Acute myelomonocytic leukaemia	Relapse|Post-Chemotherapy	Peripheral Blood	WES	No	Yes	Yes	No	Yes	No	2	Standard Chemotherapy | Targeted Therapy - Kinase Inhibitor(s)	4	7+3 (Cytarabine, Idarubicin)|MiDAC|Hydroxyurea|AC220 (Ambit)	4	Consolidation | Induction | Experimental | Re-induction	Complete Response	Standard Chemotherapy	4	Standard Chemotherapy	Hydroxyurea	Re-induction	3	0	0	87	80	No	0		11	0	9		14	20	3.9	0.67	M4	36	12.6	47,XY,+8[cp20]		91	trisomy 8	134	CD7, CD13, CD33, CD34, CD117, CD123, HLA-DR, and MPO-positive	6.3	35.9	Positive	Negative												69	Unmatched	AML	Leukemia	Acute Myeloid Leukemia	0.133333333333
aml_ohsu_2018_17	aml_ohsu_2018_10-00669		None	AML with mutated NPM1	Intermediate	Intermediate-I	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	WES	No	Yes	Yes	No	Yes	No	3	Standard Chemotherapy | Bone Marrow Transplant | Targeted Therapy - Kinase Inhibitor(s)	6	7+3 (Cytarabine, Idarubicin)|HiDAC|Fludarabine, TBI|Sorafenib|Hydroxyurea|Decitabine	5	Consolidation | Induction | Experimental | Re-induction | Allogeneic - Matched Unrelated Donor	Unknown	Standard Chemotherapy	2	Targeted Therapy - Kinase Inhibitor(s)	Sorafenib	Experimental	105	3	0			No	0		7	2	2		8	15	2.3	0.69		17.7	6.3	46,XX[20]	426	101.6	Normal	13		5.4	58.8	Positive	Positive	No Mutation info: RAF: 10-20%											27	Unmatched	AMLNPM1	Leukemia	AML with Mutated NPM1	0.0666666666667
aml_ohsu_2018_201	aml_ohsu_2018_10-00692	Denovo	None	AML with mutated NPM1	Intermediate	Intermediate-I	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	WES	No	Yes	Yes	No	Yes	No	3	Standard Chemotherapy | Bone Marrow Transplant | Targeted Therapy - Kinase Inhibitor(s)	4	7+3 (Cytarabine, Idarubicin)|Hydroxyurea|Quizartinib|Busulfan, Cyclophosphamide	3	Allogeneic - Sibling | Induction | Experimental	Refractory	Standard Chemotherapy	5	Bone Marrow Transplant	Busulfan, Cyclophosphamide	Allogeneic - Sibling	-1	0	0	40	51	No	0		5	11	23		23	31	3.1	1.8	NOS	30.8	10.6	46,XY[20]		103.1	Normal	136	partial CD7, CD13, CD33, partial CD34, dim CD45, CD117, CD123, HLA-DR, and partial TdT/positive	6.3	65.2	Positive	Positive												60	Unmatched	AMLNPM1	Leukemia	AML with Mutated NPM1	0.166666666667
aml_ohsu_2018_203	aml_ohsu_2018_10-00715		None	AML with minimal differentiation	Intermediate	Intermediate-I	AML with minimal differentiation	Residual Disease	Bone Marrow Aspirate	WES	No	Yes	No	No	Yes	No	2	Standard Chemotherapy | Targeted Therapy - Kinase Inhibitor(s)	4	7+3 (Cytarabine, Idarubicin)|HiDAC|Quizartinib|Idarubicin and Cytarabine	3	Consolidation | Induction | Experimental	Complete Response	Standard Chemotherapy	7	Targeted Therapy - Kinase Inhibitor(s)	Quizartinib	Experimental	155	0	1	75	30	No	0		64	0	4		16	22	3.7	0.9	M0	25.8	9.1	46,XY[18]	137	89.5	Normal	43	partial CD7, dim CD11b, dim CD13, CD22, dim CD33, bright CD34, CD38, dim CD45, partial CD117, CD123, HLA-DR, and TdT positive	6.3	2.5	Negative	Negative	Negative			Negative			Negative	Negative				70	Unmatched	AMLMD	Leukemia	AML with Minimal Differentiation	0.266666666667
aml_ohsu_2018_191	aml_ohsu_2018_10-00791	Relapse	None	AML with mutated NPM1	Intermediate	Intermediate-I	AML with mutated NPM1	Relapse	Bone Marrow Aspirate	WES	No	Yes	Yes	No	Yes	No	3	Standard Chemotherapy | Supportive/Palliative Care | Targeted Therapy - Kinase Inhibitor(s)	5	7+3 (Cytarabine, Idarubicin)|HiDAC|MEC (Cytarabine, Etoposide, Mitoxantrone)|Etoposide, Mitoxantrone|Quizartinib	5	Salvage | Consolidation | Induction | Experimental | Supportive/Palliative Care	Complete Response	Standard Chemotherapy	6	Supportive/Palliative Care	Etoposide, Mitoxantrone	Supportive/Palliative Care	0	0	0	83	41	No	0		3	1	28		42	45	3.7	1.06	NOS	30.9	10.4	46,XX[20]	451	100.4	Normal	57	partial CD7, CD13, CD33, partial CD34, partial dim CD64, CD117, and CD123 positive	6.3	48.2	Positive	Positive												61	Unmatched	AMLNPM1	Leukemia	AML with Mutated NPM1	0.266666666667
aml_ohsu_2018_163	aml_ohsu_2018_10-00792	Relapse	None	AML with mutated NPM1	Intermediate	Intermediate-I	AML with mutated NPM1	Relapse|Post-Chemotherapy	Bone Marrow Aspirate	WES	No	Yes	Yes	No	Yes	No	2	Standard Chemotherapy | Targeted Therapy - Kinase Inhibitor(s)	3	7+3 (Cytarabine, Idarubicin)|MiDAC|AC220 (Ambit)	3	Consolidation | Induction | Experimental	Complete Response	Standard Chemotherapy	5	Targeted Therapy - Kinase Inhibitor(s)	AC220 (Ambit)	Experimental	30	0	0	95	84	No	0		3	3	3		21	26	3.8	1.04	M1	27.8	9.9	46,XY[20]	195	101.8	Normal	20	CD11b, CD13, CD33, dim CD56, CD64, CD117, and dim MPO positive; Negative for expression of CD34 and HLA-DR	5.8	53.5	Positive	Positive												74	Unmatched	AMLNPM1	Leukemia	AML with Mutated NPM1	0.166666666667
aml_ohsu_2018_127	aml_ohsu_2018_10-00819		None	Acute myelomonocytic leukaemia	Adverse	Intermediate-I	Acute myelomonocytic leukaemia	Post-Chemotherapy|Residual Disease	Bone Marrow Aspirate	WES	No	Yes	Yes	No	Yes	No	3	Standard Chemotherapy | Supportive/Palliative Care | Targeted Therapy - Kinase Inhibitor(s)	3	Decitabine|Quizartinib|Mitoxantrone	3	Induction | Experimental | Supportive/Palliative Care	Refractory	Standard Chemotherapy	1025	Supportive/Palliative Care	Mitoxantrone	Supportive/Palliative Care	18	0	0	85	77	No	0		10	2	9		14	23	4	1.63	M4	31.3	10.7	46,XY[17]	419	103.3	Normal	69	CD2, dim CD4, partial CD7, partial/dim CD64, CD13, partial CD22, dim CD33, partial CD34, CD117, CD123, HLA-DR, partial cCD79, partial TdT,  partial PAX/5 and partial MPO positive	6.4	16.1	Positive	Negative												77	Unmatched	AML	Leukemia	Acute Myeloid Leukemia	0.166666666667
aml_ohsu_2018_174	aml_ohsu_2018_11-00049		None	Acute myelomonocytic leukaemia	Intermediate or Adverse	Intermediate-II	Acute myelomonocytic leukaemia	Residual Disease|Post-Chemotherapy	Bone Marrow Aspirate	WES	No	Yes	No	No	Yes	No	2	Standard Chemotherapy | Targeted Therapy - Kinase Inhibitor(s)	4	7+3 (Cytarabine, Idarubicin)|MiDAC|Hydroxyurea|AC220 (Ambit)	4	Consolidation | Induction | Experimental | Re-induction	Complete Response	Standard Chemotherapy	4	Standard Chemotherapy	Hydroxyurea	Re-induction	3	0	0	90	97	No	0		5	0	1		29	36	2.9	0.82	M4	26.3	9.2	47,XY,+8[cp20]	575	88.3	trisomy 8	68	CD7, CD13, CD33, CD34, CD117, CD123 and HLA-DR positive	4.7	62.9	Positive	Negative												70	Unmatched	AML	Leukemia	Acute Myeloid Leukemia	0.1
aml_ohsu_2018_211	aml_ohsu_2018_11-00090	After or at the time transformation from another heme malignancy	None	AML with mutated NPM1	Intermediate	Intermediate-I	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Peripheral Blood	WES	No	Yes	Yes	No	Yes	No	4	Standard Chemotherapy | Bone Marrow Transplant | Intrathecal | Targeted Therapy - Kinase Inhibitor(s)	5	Fludarabine, Melphalan|7+3 (Cytarabine, Idarubicin)|MiDAC|Quizartinib|Methotrexate	5	Consolidation | Induction | Experimental | CNS | Allogeneic - Matched Unrelated Donor	Complete Response	Standard Chemotherapy	5	Bone Marrow Transplant	Fludarabine, Melphalan	Allogeneic - Matched Unrelated Donor	-1	0	0	70	75	No	0		6	3	8						NOS	25.9	9.1	46,XX[20]		94.3	Normal	123	CD7, CD11b, CD13, CD33, variable CD34, dim CD64, CD117, CD123, HLA-DR and MPO positive		51.8	Positive	Positive	Negative			Negative			Negative	Negative				65	Unmatched	AMLNPM1	Leukemia	AML with Mutated NPM1	0.233333333333
aml_ohsu_2018_176	aml_ohsu_2018_11-00162	After or at the time transformation from another heme malignancy	None	Mastocytosis	Favorable	Not Enough Information	AML with mutated NPM1	Residual Disease|Post-Chemotherapy	Bone Marrow Aspirate	WES	No	Yes	Yes	No	Yes	No	2	Standard Chemotherapy | Targeted Therapy - Kinase Inhibitor(s)	4	7+3 (Cytarabine, Idarubicin)|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Azacitidine|Quizartinib	4	Consolidation | Induction | Experimental | Re-induction	Complete Response	Standard Chemotherapy	7	Targeted Therapy - Kinase Inhibitor(s)	Quizartinib	Experimental	57	0	0	75	63	No	0		8	0	23		107	47	3.7	0.83	NOS	35	12	46,XY[20]	226	95.2	Normal	74	CD13, CD33, partial CD34, CD38, CD117 and CD123	5.6	11.9	Negative	Positive												67	Unmatched	MCD	Mastocytosis	Mastocytosis	0.2
aml_ohsu_2018_203	aml_ohsu_2018_11-00170		None	AML with minimal differentiation	Intermediate	Intermediate-I	AML with minimal differentiation	Post-Chemotherapy|Residual Disease	Peripheral Blood	WES	No	Yes	Yes	No	Yes	No	2	Standard Chemotherapy | Targeted Therapy - Kinase Inhibitor(s)	4	7+3 (Cytarabine, Idarubicin)|HiDAC|Quizartinib|Idarubicin and Cytarabine	3	Consolidation | Induction | Experimental	Complete Response	Standard Chemotherapy	7	Targeted Therapy - Kinase Inhibitor(s)	Quizartinib	Experimental	155	0	0	80	80	No	0		3	2	1		36	29	2.2	1.04		22	7.4	46,XY[20]		89.7	Normal	10	CD34, CD38, CD58, CD117, dimCD123,  HLA-DR, TDT	4.6	23.1	Positive	Positive												71	Unmatched	AMLMD	Leukemia	AML with Minimal Differentiation	0.333333333333
aml_ohsu_2018_191	aml_ohsu_2018_11-00178		None	AML with mutated NPM1	Intermediate	Intermediate-I	AML with mutated NPM1	Residual Disease|Post-Chemotherapy	Peripheral Blood	WES	No	Yes	No	No	Yes	No	3	Standard Chemotherapy | Supportive/Palliative Care | Targeted Therapy - Kinase Inhibitor(s)	5	7+3 (Cytarabine, Idarubicin)|HiDAC|MEC (Cytarabine, Etoposide, Mitoxantrone)|Etoposide, Mitoxantrone|Quizartinib	5	Salvage | Consolidation | Induction | Experimental | Supportive/Palliative Care	Complete Response	Standard Chemotherapy	6	Supportive/Palliative Care	Etoposide, Mitoxantrone	Supportive/Palliative Care	0	0	1	95	60	No	0		17	14	6		34	28	3.4	1.06	NOS	25.7	9.1	46,XX[20]	268	86.8	Normal	18	partial CD7, CD13, CD33, partial CD34, partial dim CD64, CD117, and CD123 positive	6.1	21.5	Positive	Positive												61	Unmatched	AMLNPM1	Leukemia	AML with Mutated NPM1	0.3
aml_ohsu_2018_191	aml_ohsu_2018_11-00254		None	AML with mutated NPM1	Intermediate	Intermediate-I	AML with mutated NPM1	Residual Disease|Post-Chemotherapy	Peripheral Blood	WES	No	Yes	No	No	Yes	No	3	Standard Chemotherapy | Supportive/Palliative Care | Targeted Therapy - Kinase Inhibitor(s)	5	7+3 (Cytarabine, Idarubicin)|HiDAC|MEC (Cytarabine, Etoposide, Mitoxantrone)|Etoposide, Mitoxantrone|Quizartinib	5	Salvage | Consolidation | Induction | Experimental | Supportive/Palliative Care	Complete Response	Standard Chemotherapy	6	Supportive/Palliative Care	Etoposide, Mitoxantrone	Supportive/Palliative Care	0	0	0			No	0		2	1	0		67	67	2.6	1.6		27	9.3	46,XX[20]		81.8	Normal	21		5.9	79.7	Positive	Positive												61	Unmatched	AMLNPM1	Leukemia	AML with Mutated NPM1	0.266666666667
aml_ohsu_2018_127	aml_ohsu_2018_11-00261		None	Acute myelomonocytic leukaemia	Intermediate	Not Enough Information	Acute myelomonocytic leukaemia	Post-Chemotherapy|Residual Disease	Peripheral Blood	WES	No	Yes	Yes	No	Yes	Yes	3	Standard Chemotherapy | Supportive/Palliative Care | Targeted Therapy - Kinase Inhibitor(s)	3	Decitabine|Quizartinib|Mitoxantrone	3	Induction | Experimental | Supportive/Palliative Care	Refractory	Standard Chemotherapy	1025	Supportive/Palliative Care	Mitoxantrone	Supportive/Palliative Care	18	-20	0		96	No	0		2	1	0		13	24	3	1.48	M4		8.7	46,XY[20]	696		Normal	15	CD2, dim CD4, partial CD7, partial/dim CD64, CD13, partial CD22, dim CD33, partial CD34, CD117, CD123, HLA-DR, partial cCD79, partial TdT,  partial PAX/5 and partial MPO positive	5.4	459.6	Positive	Negative												77	Unmatched	AML	Leukemia	Acute Myeloid Leukemia	0.166666666667
aml_ohsu_2018_45	aml_ohsu_2018_11-00295	Relapse	None	AML with mutated NPM1	Favorable or Intermediate	Intermediate-I	AML with mutated NPM1	Relapse|Post-Chemotherapy	Bone Marrow Aspirate	WES	No	Yes	No	No	Yes	No	2	Standard Chemotherapy | Intrathecal	3	7+3 (Cytarabine, Idarubicin)|MiDAC|Cytarabine, Methotrexate	2	Consolidation | Induction	Refractory	Standard Chemotherapy	6	Standard Chemotherapy	MiDAC	Consolidation	5	0	2	92	66	No	0		11	0	18		26	41	4.1	0.85	M1	32.5	11.2	46,XX[20]	386	98.3	Normal	25	CD13, CD33, CD38, CD56, CD117, and MPO positive	6.7	31.1	Positive	Positive												71	Unmatched	AMLNPM1	Leukemia	AML with Mutated NPM1	0.233333333333
aml_ohsu_2018_211	aml_ohsu_2018_11-00319	After or at the time transformation from another heme malignancy	None	AML with mutated NPM1	Intermediate	Intermediate-II	AML with mutated NPM1	Post-Chemotherapy|Residual Disease	Bone Marrow Aspirate	WES	No	Yes	Yes	No	Yes	No	4	Standard Chemotherapy | Bone Marrow Transplant | Intrathecal | Targeted Therapy - Kinase Inhibitor(s)	5	Fludarabine, Melphalan|7+3 (Cytarabine, Idarubicin)|MiDAC|Quizartinib|Methotrexate	5	Consolidation | Induction | Experimental | CNS | Allogeneic - Matched Unrelated Donor	Complete Response	Standard Chemotherapy	5	Bone Marrow Transplant	Fludarabine, Melphalan	Allogeneic - Matched Unrelated Donor	-1	0	0	72	45	No	0		19	5	30		61	44	4.1	0.74	NOS	33.1	11.7	46,XX,t(1;15)(p32;q15)[19]/46,XX[1]	443	95	Normal	93	CD7, CD13, CD33, partial CD34, CD38, dim CD45, CD58, CD71, CD117, CD123, and HLA-DR-positive	6.6	18.4	Positive	Positive				Negative								66	Unmatched	AMLNPM1	Leukemia	AML with Mutated NPM1	0.333333333333
aml_ohsu_2018_550	aml_ohsu_2018_12-00023	Denovo	None	Acute monoblastic and monocytic leukaemia	Intermediate	Intermediate-I	Acute monoblastic and monocytic leukaemia	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	RNA-seq	Yes	No	Yes	Yes	No	Yes	2	Standard Chemotherapy | Bone Marrow Transplant	4	5+2 (Cytarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin)|MiDAC|Bu/Flu/TBI (Busulfan, Fludarabine, Total Body Irradiation)	4	Allogeneic - Sibling | Consolidation | Induction | Re-induction	Refractory	Standard Chemotherapy	7	Bone Marrow Transplant	Bu/Flu/TBI (Busulfan, Fludarabine, Total Body Irradiation)	Allogeneic - Sibling	-1	0	0	68		No	1		30	49	3		14	18	3	0.85	M5	21.9	7.6	46,XX[20]	313	102.9	Normal	125	Blast Immunphenotype: CD13, CD33, CD34, CD38, dim CD45, CD117, CD123, and HLA-DR positive; Promonocyte Immunophenotype: CD11b, CD13, CD14, CD33, CD64, and HLA-DR	5.5	14.9	Negative	Negative	Negative	G596R		Negative	Negative	Negative	Negative	Negative	Negative	Negative		71	Matched	AMOL	Leukemia	Acute Monoblastic/Monocytic Leukemia	NA
aml_ohsu_2018_635	aml_ohsu_2018_12-00051	Denovo	None	AML with mutated NPM1	Favorable or Intermediate	Intermediate-I	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	RNA-seq	Yes	No	Yes	Yes	No	Yes	2	Standard Chemotherapy | Bone Marrow Transplant	3	Fludarabine, Melphalan|7+3 (Cytarabine, Idarubicin)|HiDAC	3	Consolidation | Induction | Allogeneic - Matched Unrelated Donor	Complete Response	Standard Chemotherapy	7	Bone Marrow Transplant	Fludarabine, Melphalan	Allogeneic - Matched Unrelated Donor	-1	0	0	88	93	No	0		6	0	1		19	26	3.4	0.88		28.2	9.6	46,XX[20]	678	99.9	Normal	19	partial CD7, CD13, CD25, CD33, partial CD34, dim CD45, CD117, CD123, and partial HLA-DR positive	6.8	17.9	Positive	Positive	Negative			Negative	Negative	Negative	Negative	Negative	Negative	Negative		55	Matched	AMLNPM1	Leukemia	AML with Mutated NPM1	NA
aml_ohsu_2018_559	aml_ohsu_2018_12-00066	After or at the time transformation from another heme malignancy	None	Chronic myelomonocytic leukaemia	Intermediate	Intermediate-I	Acute myelomonocytic leukaemia	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	RNA-seq	Yes	No	Yes	Yes	No	Yes	2	Standard Chemotherapy | Targeted Therapy - Kinase Inhibitor(s)	4	Dasatinib|7+3 (Cytarabine, Idarubicin)|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Azacitidine	4	Salvage | Induction | Experimental | Re-induction	Refractory	Standard Chemotherapy	153	Standard Chemotherapy	FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)	Salvage	4	0	5	36	9	No	5		21	38	22		19	22	3.6	1.18	M4	28.7	9.7	46,XY[20]	231	99.6	Normal	47	CD11b, CD13, CD14, CD15, variable CD16, dim CD33, CD58, bright CD64, HLA-DR positive	7.1	21	Positive	Negative				Negative	Negative	Negative	Negative	Negative	Negative	Negative		70	Matched	CMML	Myelodysplastic/Myeloproliferative Neoplasms	Chronic Myelomonocytic Leukemia	NA
aml_ohsu_2018_652	aml_ohsu_2018_12-00069	Denovo	None	Acute myeloid leukaemia, NOS	Adverse	Intermediate-I	Acute myeloid leukaemia, NOS	Initial Acute Leukemia Diagnosis	Peripheral Blood	WES	No	Yes	Yes	No	Yes	Yes	3	Standard Chemotherapy | Supportive/Palliative Care | Targeted Therapy - Kinase Inhibitor(s)	5	5+2 (Cytarabine, Idarubicin)|Dasatinib|7+3 (Cytarabine, Idarubicin)|Azacitidine|Hydroxyurea	5	Consolidation | Induction | Experimental | Re-induction | Supportive/Palliative Care	Refractory	Standard Chemotherapy	6	Supportive/Palliative Care	Hydroxyurea	Supportive/Palliative Care	9	1	0	81	60	No	0		5	24	4		42	45	3.3	0.93	NOS		8.7	46,XY[20]	673		Normal	83	CD13, CD34, CD38, CD117, CD123, HLA-DR	6.9	179.1	Positive	Negative	Negative			Negative	Negative	Negative	Negative	Negative	Negative	Negative		71	Unmatched	AMLNOS	Leukemia	AML, NOS	0.3
aml_ohsu_2018_707	aml_ohsu_2018_12-00127	Denovo	None	AML with mutated NPM1	Favorable	Favorable	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Leukapheresis	WES	No	Yes	Yes	No	Yes	Yes	2	Standard Chemotherapy | Bone Marrow Transplant	5	Fludarabine, Melphalan|7+3 (Cytarabine, Idarubicin)|HiDAC|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone)	4	Consolidation | Induction | Re-induction | Allogeneic - Matched Unrelated Donor	Complete Response	Standard Chemotherapy	23	Bone Marrow Transplant	Fludarabine, Melphalan	Allogeneic - Matched Unrelated Donor	-1	0	0	93	99	No	0		1	3	1		15	19	1.7	1.03	M1	24	8.2	46,XY[20]		92.7	Normal	62	partial CD7, CD13, CD33, CD117, CD123, dim HLA-DR, and MPO positive	4.4	64.3	Negative	Positive	Negative				Negative	Negative	Negative	Negative	Negative	Negative		53	Matched	AMLNPM1	Leukemia	AML with Mutated NPM1	1.2
aml_ohsu_2018_722	aml_ohsu_2018_12-00150		Unknown	unknown	Intermediate	Not Enough Information	unknown	Unknown	Peripheral Blood	RNA-seq	Yes	No	Yes	Yes	No	Yes	0		0		0					NONE	NONE	NONE		0				No																						Negative	Negative												18	Matched	AML	Leukemia	Acute Myeloid Leukemia	NA
aml_ohsu_2018_764	aml_ohsu_2018_12-00211	Denovo	None	AML with mutated NPM1	Favorable	Intermediate-II	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	RNA-seq	Yes	No	Yes	Yes	No	Yes	2	Standard Chemotherapy | Bone Marrow Transplant	4	7+3 (Cytarabine, Idarubicin)|ATRA (Tretinoin)|HiDAC|Bu/Flu/TBI (Busulfan, Fludarabine, Total Body Irradiation)	3	Allogeneic - Sibling | Consolidation | Induction	Complete Response	Standard Chemotherapy	27	Bone Marrow Transplant	Bu/Flu/TBI (Busulfan, Fludarabine, Total Body Irradiation)	Allogeneic - Sibling	-1	0	0	90	82	No	0		1	0	2		19	30	2.8	0.86		26.4	9.1	46,XX,t(11;17)(q13;q21)[20]	1165	97.7	While the chromosome 17 breakpoint is clearly within band 17q21 by metaphase chromosome analysis, these results suggest that it is not within the RARA gene	8	dim CD4, CD13, dim CD15, dim CD33, CD38, CD58,CD64, CD117, CD123, dim HLA-DR, and cMPO	5.3	84.1	Negative	Positive	Negative				Negative	Negative	Negative	Negative	Negative	Negative		50	Matched	AMLNPM1	Leukemia	AML with Mutated NPM1	NA
aml_ohsu_2018_799	aml_ohsu_2018_12-00258	After or at the time transformation from another heme malignancy	None	Therapy-related myeloid neoplasms	Adverse	Adverse	Therapy-related myeloid neoplasms	Post-Chemotherapy|Residual Disease	Peripheral Blood	RNA-seq	Yes	No	Yes	Yes	No	Yes	1	Supportive/Palliative Care	1	Azacitidine	1	Supportive/Palliative Care				Supportive/Palliative Care	Azacitidine	Supportive/Palliative Care	42	-112	0			No	0		12	33	7		60	64	3.2	1.08	M5	26.6	8.8	46,XX,t(8;16)(p11.2;p13.3)[8]/46,XX,del(7)(q11.2q22),del(20)(q13.1q13.3)[cp3]/46,XX[12]	2700	92.4		46		6.3	37.1	Negative	Negative												81	Matched	TMN	Leukemia	Therapy-Related Myeloid Neoplasms	NA
aml_ohsu_2018_825	aml_ohsu_2018_12-00294	Denovo	None	AML with myelodysplasia-related changes	Adverse	Intermediate-I	AML with myelodysplasia-related changes	Initial Acute Leukemia Diagnosis	Leukapheresis	RNA-seq	Yes	No	Yes	Yes	No	Yes	0		0		0					NONE	NONE	NONE		0	0	95	96	No	0		3	0	1		47	58	2.7	0.96	M4	16.5	5.6	46,XY[20]	697	114	Normal	51	Blasts: partial CD13, CD34, CD38, CD58, dim CD123, cTdT, HLA-DR, and partial/dim cMPO positive; Promonocyte/monoblast: CD11b, CD14, dim CD33, CD38, CD58, CD64, HLA-DR and dim cMPO positive	4.9	97	Positive	Negative	Negative			Negative	Negative		Negative	Negative		Negative		72	Matched	AMLMRC	Leukemia	AML with Myelodysplasia-Related Changes	NA
aml_ohsu_2018_829	aml_ohsu_2018_12-00301	Denovo	CBFB-MYH11	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	Favorable	Favorable	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	Initial Acute Leukemia Diagnosis	Peripheral Blood	WES + RNA-seq	Yes	No	Yes	No	No	Yes	1	Standard Chemotherapy	2	7+3 (Cytarabine, Idarubicin)|MiDAC	2	Consolidation | Induction	Complete Response	Standard Chemotherapy	7	Standard Chemotherapy	MiDAC	Consolidation	108	-4	0		15	No	0		11	71	2		71	48	2.7	1.54	M4	25.9	8.8	46,XY,inv(16)(p13q22)[20]	454	95.9	CBFB rearrangement	14		6.1	20.7	Negative	Negative	Negative			Negative	Negative		Negative	Negative	Negative	Negative		65	Matched	AMLCBFBMYH11	Leukemia	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22);CBFB-MYH11	NA
aml_ohsu_2018_652	aml_ohsu_2018_12-00362		None	Acute myeloid leukaemia, NOS	Adverse	Intermediate-I	Acute myeloid leukaemia, NOS	Post-Chemotherapy|Residual Disease	Bone Marrow Aspirate	WES	No	Yes	Yes	No	Yes	Yes	3	Standard Chemotherapy | Supportive/Palliative Care | Targeted Therapy - Kinase Inhibitor(s)	5	5+2 (Cytarabine, Idarubicin)|Dasatinib|7+3 (Cytarabine, Idarubicin)|Azacitidine|Hydroxyurea	5	Consolidation | Induction | Experimental | Re-induction | Supportive/Palliative Care	Refractory	Standard Chemotherapy	6	Supportive/Palliative Care	Hydroxyurea	Supportive/Palliative Care	9	-36	3	34	33	No	1		28	5	23		90	37	3.7	0.63	NOS	21.8	7.3	46,XY[20]	477	94.3	Normal	322	dim/partial CD7, CD13, CD34, CD38, CD58, CD117, CD123,and HLA-DR positive	6.5	7.6	Positive	Negative												71	Unmatched	AMLNOS	Leukemia	AML, NOS	0.333333333333
aml_ohsu_2018_555	aml_ohsu_2018_12-00371	Relapse	None	AML with mutated NPM1	Intermediate	Not Enough Information	AML with mutated NPM1	Post-Chemotherapy|Relapse	Bone Marrow Aspirate	WES	No	Yes	Yes	No	Yes	Yes	2	Standard Chemotherapy | Targeted Therapy - Kinase Inhibitor(s)	8	7+3 (Cytarabine, Idarubicin)|HiDAC|Cytarabine|3+7 (Cytarabine, Daunorubicin)|Azacitidine|Sorafenib|Clofarabine|Clofarabine, Cytarabine	5	Consolidation | Salvage | Induction | Experimental | Re-induction	Complete Response	Standard Chemotherapy	6	Standard Chemotherapy	Cytarabine	Consolidation	64	-121	0	77.5	75	No	1		16	1	4						NOS	26.3	9.3	46,XY[4]		87.8	Normal	9	CD13, CD33, partial CD56, CD58, CD64, dim CD117, CD123and partial/dim cMPO positive		7.9	Positive	Positive												60	Unmatched	AMLNPM1	Leukemia	AML with Mutated NPM1	0.266666666667
aml_ohsu_2018_555	aml_ohsu_2018_12-00372	Relapse	None	AML with mutated NPM1	Intermediate	Not Enough Information	AML with mutated NPM1	Relapse|Post-Chemotherapy	Peripheral Blood	RNA-seq	Yes	No	Yes	Yes	No	Yes	2	Standard Chemotherapy | Targeted Therapy - Kinase Inhibitor(s)	8	7+3 (Cytarabine, Idarubicin)|HiDAC|Cytarabine|3+7 (Cytarabine, Daunorubicin)|Azacitidine|Sorafenib|Clofarabine|Clofarabine, Cytarabine	5	Consolidation | Salvage | Induction | Experimental | Re-induction	Complete Response	Standard Chemotherapy	6	Standard Chemotherapy	Cytarabine	Consolidation	64	-121	0	77.5	75	No	1		16	1	4						NOS	26.3	9.3	46,XY[4]		87.8	Normal	9	CD13, CD33, partial CD56, CD58, CD64, dim CD117, CD123and partial/dim cMPO positive		7.9	Positive	Positive												60	Unmatched	AMLNPM1	Leukemia	AML with Mutated NPM1	NA
aml_ohsu_2018_923	aml_ohsu_2018_12-00423	Denovo	None	AML with maturation	Intermediate	Not Enough Information	AML with maturation	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	RNA-seq	Yes	No	Yes	Yes	No	Yes	1	Standard Chemotherapy	1	3+7 (Cytarabine, Daunorubicin)	1	Induction	Refractory	Standard Chemotherapy	7	Standard Chemotherapy	3+7 (Cytarabine, Daunorubicin)	Induction	7	0	0	46	66	No	1		24	5	4		18	34	3.2	1.05	M2	26.4	8.8	46,XY[20]	551	89.1	Normal	72	CD13, CD33, CD34, CD117, dim CD123, HLA-DR,partial MPO (+)	7	16.5	Negative	Negative												61	Matched	AM	Leukemia	AML with Maturation	NA
aml_ohsu_2018_50	aml_ohsu_2018_12-00426	Relapse	DEK-NUP214	AML with t(6;9)(p23;q34); DEK-NUP214	Adverse	Adverse	AML with t(6;9)(p23;q34); DEK-NUP214	Relapse|Post-Transplant|Post-Chemotherapy	Bone Marrow Aspirate	RNA-seq	Yes	No	Yes	Yes	No	Yes	5	DLI | Standard Chemotherapy | Bone Marrow Transplant | Targeted Therapy - Kinase Inhibitor(s) | Intrathecal	13	Cyclophosphamide, TBI|HAM (Cytarabine, Mitoxantrone)|MEC (Cytarabine, Etoposide, Mitoxantrone)|Decitabine|Cytarabine, Mitoxantrone, Sorafenib|ADE (Cytarabine, Daunorubicin & Etoposide)|Donor Lymphocyte Infusion|Cytarabine|Sorafenib|FLAG (Fludarabine, High-dose Cytarabine, G-CSF)|Treo/Flu/TBI (Treosulfan, Fludarabine, Total Body Irradiation)|Methotrexate|Etoposide, Cytarabine	8	Allogeneic - Sibling | Consolidation | Unknown | Induction | Experimental | Intensification | Re-induction | Allogeneic - Matched Unrelated Donor	Refractory	Standard Chemotherapy	9	Targeted Therapy - Kinase Inhibitor(s)	Sorafenib	Experimental	187	0	0	80	0	No	3		78	3	16		42	38	4.3	0.66	M2	41.6	14.3	48,X,-Y,+4,t(6;9)(p22;q34),+8,+10,del(15)(q11.2q15)[20]		102.9	DEK/NUP probe set; 70/100 (70%) interphasecells scored had a 1 red/ 1 green/ 2 yellow fusion signal pattern,consistent with DEK/NUP fusion and the 6;9 translocation observed in themetaphase karyotype.	50	CD13, CD33, CD34, CD38, CD117,  CD123, dim HLA-DR, partial MPO	7.6	2.2	Positive													14	Matched	AMLDEKNUP214	Leukemia	AML with t(6;9)(p23;q34.1);DEK-NUP214	NA
aml_ohsu_2018_652	aml_ohsu_2018_13-00004		None	Acute myeloid leukaemia, NOS	Adverse	Not Enough Information	Acute myeloid leukaemia, NOS	Post-Chemotherapy|Residual Disease	Bone Marrow Aspirate	WES	No	Yes	Yes	No	Yes	No	3	Standard Chemotherapy | Supportive/Palliative Care | Targeted Therapy - Kinase Inhibitor(s)	5	5+2 (Cytarabine, Idarubicin)|Dasatinib|7+3 (Cytarabine, Idarubicin)|Azacitidine|Hydroxyurea	5	Consolidation | Induction | Experimental | Re-induction | Supportive/Palliative Care	Refractory	Standard Chemotherapy	6	Supportive/Palliative Care	Hydroxyurea	Supportive/Palliative Care	9	-71	11	65	13	No	11		52	3	10		47	54	2.3	0.91	NOS	23.3	7.7	46,XY[20]	888	91	Normal	49	dim/partial CD7, CD13, CD33, CD34, variable CD38, CD58,variable CD117, CD123, and HLA-DR positive	5.8	6.8	Positive	Negative												72	Unmatched	AMLNOS	Leukemia	AML, NOS	0.3
aml_ohsu_2018_29	aml_ohsu_2018_13-00007		None	AML with mutated NPM1	Intermediate	Adverse	AML with mutated NPM1	Post-Chemotherapy|Residual Relapse	Bone Marrow Aspirate	RNA-seq	Yes	No	Yes	Yes	No	Yes	1	Standard Chemotherapy	4	7+3 (Cytarabine, Idarubicin)|HiDAC|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone)	4	Consolidation | Salvage | Induction | Re-induction	Complete Response	Standard Chemotherapy	6	Standard Chemotherapy	FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)	Salvage	43	0	1	90	30	No	0		46	30	8		43	11	2.8	0.92		25.5	9.1	46,XY,add(17)(p13)[19]/46,XY[1]	123	85	Normal	14	partial CD7, CD13, CD33, CD38, dim CD45, dimCD58, CD117, CD123, and HLA-DR	5.8	0.6	Positive	Positive												36	Matched	AMLNPM1	Leukemia	AML with Mutated NPM1	NA
aml_ohsu_2018_953	aml_ohsu_2018_13-00028	Denovo	None	Acute myelomonocytic leukaemia	Intermediate	Intermediate-II	Acute myelomonocytic leukaemia	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	RNA-seq	Yes	No	Yes	Yes	No	Yes	3	DLI | Standard Chemotherapy | Bone Marrow Transplant	5	7+3 (Cytarabine, Idarubicin)|HiDAC|Donor Lymphocyte Infusion|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Busulfan, Cyclophosphamide	5	Consolidation | Unknown | Induction | Re-induction | Allogeneic - Matched Unrelated Donor	Complete Response	Standard Chemotherapy	6	DLI	Donor Lymphocyte Infusion	Unknown	0	0	0	88	94	No	0		3	40	3		13	14	2.8	0.62	M4	31.7	10.9	47,XY,+10[18]/46,XY[2]	419	86.3	Normal	89	CD11b, dim CD13, dim CD14, CD33, CD34, dim CD38, partialCD56, CD58, partial CD64, CD117, CD123, dim HLA-DR, and MPO	5.8	21.7	Negative	Negative	Negative		Negative	Negative			Negative	Negative	Negative	Negative		24	Matched	AML	Leukemia	Acute Myeloid Leukemia	NA
aml_ohsu_2018_958	aml_ohsu_2018_13-00034		Unknown	Therapy-related myeloid neoplasms	Intermediate	Not Enough Information	Therapy-related myeloid neoplasms	Initial Acute Leukemia Diagnosis	Peripheral Blood	RNA-seq	Yes	No	Yes	Yes	No	Yes	0		0		0					NONE	NONE	NONE		0	1	50	89	No	1		0	0	0		61		2.5	0.84		25.3	8.4			102.8		24	CD2(-), CD4(dim +), CD7(-), CD11b(partial +), CD13(partial +), CD14(partial +), CD15(variably and slightly bright +), CD16 (-), CD33(variably bright +), CD34(-), CD36(partial +), CD38(variably +), CD45(variably +), CD56(+), CD64(partial +), CD117(-), HLA-DR(partial dim +), MPO(+), TdT(-).	4.5	53	Negative	Negative				Negative								61	Matched	TMN	Leukemia	Therapy-Related Myeloid Neoplasms	NA
aml_ohsu_2018_1011	aml_ohsu_2018_13-00098	Denovo	None	AML with mutated NPM1	Favorable	Not Enough Information	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	1	Standard Chemotherapy	3	7+3 (Cytarabine, Idarubicin)|HiDAC|MEC (Cytarabine, Etoposide, Mitoxantrone)	2	Consolidation | Induction	Complete Response	Standard Chemotherapy	7	Standard Chemotherapy	MEC (Cytarabine, Etoposide, Mitoxantrone)	Induction	5	0	1.4	76	0	No	0.1		94.3	1.5	2.7		22	20	3.6	0.48		32.6	10.9	46,XX[14]	184		nuc ish(D5S721,D5S23,EGR1)x2[200],(D7Z1,D7S522)x2[199],(D8Z2,D20S108)x2[200],(RUNX1T1,RUNX1)x2[200],	32	CD4(few +), CD7(-), CD11b(-), CD13(-), CD14(-), CD15(partial +), CD16(-), CD34(-), CD36(-), CD38(+), CD45(+), CD56(few +), CD64(-), CD117(partial +), HLA-DR(-), MPO(+) and TdT (+)	7.5	1.5	Negative	Positive												64	Matched	AMLNPM1	Leukemia	AML with Mutated NPM1	1.23333333333
aml_ohsu_2018_231	aml_ohsu_2018_13-00106		DEK-NUP214	AML with t(6;9)(p23;q34); DEK-NUP214	Adverse	Adverse	AML with t(6;9)(p23;q34); DEK-NUP214	Residual Disease|Post-Transplant|Post-DLI	Bone Marrow Aspirate	WES	No	Yes	Yes	No	Yes	Yes	4	DLI | Standard Chemotherapy | Bone Marrow Transplant | Supportive/Palliative Care	9	Fludarabine, Melphalan|5+2 (Cytarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin)|Donor Lymphocyte Infusion|HAM (Cytarabine, Mitoxantrone)|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|GCLAC (GCSF, Clofarabine & Cytarabine)|MEC (Cytarabine, Etoposide, Mitoxantrone)|Decitabine	7	Consolidation | Salvage | Unknown | Induction | Re-induction | Supportive/Palliative Care | Allogeneic - Matched Unrelated Donor	Complete Response	Standard Chemotherapy	7	DLI	Donor Lymphocyte Infusion	Unknown	-1	0	1	83		No	0		60	3	36		81	48	3	0.5	NOS	30.5	11.3	46,XX,t(1;19)(p32;q13.3),t(6;9)(p22;q34),t(12;16)(p12;q21)[cp20]		82.6	t(6;9)(p22;q34)	13	CD13, CD33, CD34, CD38, CD58, dim CD64, dim CD117, TdT and partial MPO	6.6	0.9	Negative	Negative												33	Unmatched	AMLDEKNUP214	Leukemia	AML with t(6;9)(p23;q34.1);DEK-NUP214	0.133333333333
aml_ohsu_2018_685	aml_ohsu_2018_13-00118	Relapse	None	AML with mutated NPM1	Favorable	Intermediate-II	AML with mutated NPM1	Relapse|Post-Chemotherapy	Bone Marrow Aspirate	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	1	Standard Chemotherapy	7	7+3 (Cytarabine, Idarubicin)|HiDAC|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Azacitidine|GCLAC (GCSF, Clofarabine & Cytarabine)|MEC (Cytarabine, Etoposide, Mitoxantrone)|Decitabine	5	Consolidation | Salvage | Induction | Re-induction | Maintenance	Complete Response	Standard Chemotherapy	7	Standard Chemotherapy	Decitabine	Re-induction	160	-349	3	71	83	No	2		5	10	4		35	31	3.9	0.81	M4	33.7	11.7	47,XY,+21[15]/46,XY[5]	438	100.6	Trisomy 21	119	CD13, CD33, CD38, CD58, dim CD64, CD117, and CD123	7.1	33.8	Negative	Positive												57	Unmatched	AMLNPM1	Leukemia	AML with Mutated NPM1	0.233333333333
aml_ohsu_2018_1027	aml_ohsu_2018_13-00123		None	Therapy-related myeloid neoplasms	Favorable	Intermediate-II	Therapy-related myeloid neoplasms	Initial Acute Leukemia Diagnosis	Peripheral Blood	RNA-seq	Yes	No	Yes	Yes	No	Yes	0		0		0					NONE	NONE	NONE		-1	0		90	No	0		9	7	4		242	341	1.9	2.48	M5	17.6	6.2	47,XY,+8[6]/46,XY[13]	2037	94.5	trisomy 8	14	Immunophenotype:  CD11b, CD13, dimCD14, CD15, dim CD16, CD33,     CD56,     CD58, CD64, CD123, and HLA-DR positive	3.6	85.9	Negative	Positive												83	Matched	TMN	Leukemia	Therapy-Related Myeloid Neoplasms	NA
aml_ohsu_2018_1045	aml_ohsu_2018_13-00145		None	AML with myelodysplasia-related changes	Intermediate	Intermediate-II	AML with myelodysplasia-related changes	Post-Chemotherapy|Residual Disease	Peripheral Blood	RNA-seq	Yes	No	Yes	Yes	No	Yes	2	Standard Chemotherapy | Supportive/Palliative Care	2	7+3 (Cytarabine, Idarubicin)|Azacitidine	2	Hypomethylating/Low Dose Cytarabine | Induction	Refractory	Standard Chemotherapy	-1	Supportive/Palliative Care	Azacitidine	Hypomethylating/Low Dose Cytarabine	-1	-22			78	No			12	5	3					1.12		24.7	8.2	46,XY,del(7)(q22q36)[7]/47,idem,+22[cp12]/46,XY[1]		89.2	nuc ish(D5S721,D5S23,EGR1)x2[200],(D7Z1x2,D7S522x1)[187/200], (D8Z2,D20S108)x2[199],(RUNX1T1,RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200], (5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	18			24.4	Positive	Negative												71	Matched	AMLMRC	Leukemia	AML with Myelodysplasia-Related Changes	NA
aml_ohsu_2018_1046	aml_ohsu_2018_13-00146	Denovo	RUNX1-RUNX1T1	AML with t(8;21)(q22;q22); RUNX1-RUNX1T1	Favorable	Favorable	AML with t(8;21)(q22;q22); RUNX1-RUNX1T1	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	RNA-seq	Yes	No	Yes	Yes	No	Yes	1	Standard Chemotherapy	1	COG-AAML1031 (IT/IV Cytarabine, Daunorubicin, Etoposide, Mitoxantrone +/- Bortezomib or Sorafenib)	2	Induction | Re-induction	Complete Response	Standard Chemotherapy	9	Standard Chemotherapy	COG-AAML1031 (IT/IV Cytarabine, Daunorubicin, Etoposide, Mitoxantrone +/- Bortezomib or Sorafenib)	Re-induction	-1	0	0	85	30	No	0		42	0	27		18	19	3.9	0.41		27.7	9.4	46,XX,t(8;21)(q22;q22)[19]/46,XX[1]	747	90.5	AML/ETO fusion, t(8;21)	71	CD13, CD33, CD34, CD56, CD71, CD117, HLA-DR, MPO-positive	7.3	4.8	Negative	Negative	Negative		Negative	Negative	Negative		Negative		Negative	Negative	Negative	7	Matched	AMLRUNX1RUNX1T1	Leukemia	AML with t(8;21)(q22;q22.1);RUNX1-RUNX1T1	NA
aml_ohsu_2018_819	aml_ohsu_2018_13-00147		None	AML with mutated NPM1	Intermediate	Intermediate-I	AML with mutated NPM1	Residual Disease|Post-Chemotherapy	Peripheral Blood	RNA-seq	Yes	No	Yes	Yes	No	Yes	1	Standard Chemotherapy	2	7+3 (Cytarabine, Idarubicin)|HiDAC	2	Consolidation | Induction	Unknown	Standard Chemotherapy	-1	Standard Chemotherapy	HiDAC	Consolidation	-1	-14				No														46,XX[20]			Normal					Positive	Positive				Negative								58	Matched	AMLNPM1	Leukemia	AML with Mutated NPM1	NA
aml_ohsu_2018_1049	aml_ohsu_2018_13-00149		None	AML with mutated CEBPA	Intermediate	Intermediate-II	AML with mutated CEBPA	Post-Chemotherapy|Residual Disease	Bone Marrow Aspirate	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	1	Standard Chemotherapy	1	Decitabine	1	Induction	Refractory	Standard Chemotherapy	-1	Standard Chemotherapy	Decitabine	Induction	-1	0	0	87	72	No	1		17	4	1		19	41	3.4	0.75		32.3	10.6	45,X,-Y[19]/46,XY[1]	460	103.6	Normal	15	CD7, CD13, CD33, partial CD34, CD117, CD123, HLA-DR, MPO +	6.2	8.5	Negative	Negative	1031?1032 ins AAC; MAF 50%		Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	79	Unmatched	AMLCEBPA	Leukemia	AML with Biallelic Mutations of CEBPA	0.133333333333
aml_ohsu_2018_1051	aml_ohsu_2018_13-00150		None	Mixed phenotype acute leukaemia, T/myeloid, NOS	Adverse	Adverse	Mixed phenotype acute leukaemia, T/myeloid, NOS	Post-Transplant|Post-Chemotherapy|Residual Disease	Peripheral Blood	RNA-seq	Yes	No	Yes	Yes	No	Yes	3	Standard Chemotherapy | Bone Marrow Transplant | Targeted Therapy - Kinase Inhibitor(s)	6	7+3 (Cytarabine, Idarubicin)|Sunitinib|HAM (Cytarabine, Mitoxantrone)|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Decitabine|Busulfan, Cyclophosphamide	5	Salvage | Induction | Re-induction | Supportive/Palliative Care | Allogeneic - Matched Unrelated Donor	Refractory	Standard Chemotherapy	6	Standard Chemotherapy	Decitabine	Salvage	80	-2	0		59	No	0		9	2	29		32	34	3.7	0.68		34	11.1	45~48,XY,+5,add(5)(q11.2)x2,t(7;7)(q22;q36),+11,add(13)(q13),-22[cp9]/45~47,sl,-add(5)(q11.2),der(11)t(11;12)(p11.2;q13),-12[cp6]/46,sl,t(Y;18)(p11.2;q21),der(9)t(9;17)(p13;q11.2),-17[2]/46,XY[3]	167	102.8	Deleted 5q	152		6.7	14	Negative	Negative												53	Matched	MPALTNOS	Leukemia	Mixed Phenotype Acute Leukemia, T/Myeloid, NOS	NA
aml_ohsu_2018_1054	aml_ohsu_2018_13-00157	Denovo	None	AML with mutated NPM1	Favorable	Favorable	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	1	Standard Chemotherapy	2	7+3 (Cytarabine, Idarubicin)|MiDAC	2	Consolidation | Induction	Complete Response	Standard Chemotherapy	6	Standard Chemotherapy	MiDAC	Consolidation	104	0	0	80	32	No	0		11	13	23		32	50	2.9	0.64		41.1	13.4	46,XX[20]	660	86.1	Normal	228	partial CD7, partial CD11b, CD13, CD33, dim CD45, CD58,     partial CD64, partial CD117, CD123, dimHLA-DR,  MPO positive	7.4	53.9	Negative	Positive	Negative		p.Q696fs*9; MAF 40%	Negative	p.R132H; MAF 40%		Negative	Negative	Negative	Negative	Negative	60	Unmatched	AMLNPM1	Leukemia	AML with Mutated NPM1	0.2
aml_ohsu_2018_967	aml_ohsu_2018_13-00160	After or at the time transformation from another heme malignancy	None	AML with myelodysplasia-related changes	Intermediate	Intermediate-I	AML with myelodysplasia-related changes	Post-Chemotherapy	Bone Marrow Aspirate	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	1	Standard Chemotherapy	2	7+3 (Cytarabine, Idarubicin)|Azacitidine	2	Induction | Maintenance	Complete Response	Standard Chemotherapy	6	Standard Chemotherapy	Azacitidine	Maintenance	-1	-93				No														46,XY[19]			Normal					Negative	Negative												73	Unmatched	AMLMRC	Leukemia	AML with Myelodysplasia-Related Changes	0.166666666667
aml_ohsu_2018_1058	aml_ohsu_2018_13-00163	Denovo	CBFB-MYH11	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	Favorable	Favorable	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	3	Standard Chemotherapy | Bone Marrow Transplant | Intrathecal	4	7+3 (Cytarabine, Idarubicin)|HiDAC|Cytarabine, Methotrexate|Busulfan, Cyclophosphamide	4	Allogeneic - Sibling | Consolidation | Unknown | Induction	Complete Response	Standard Chemotherapy	6	Bone Marrow Transplant	Busulfan, Cyclophosphamide	Allogeneic - Sibling	-1	0	0	50	6	No	0		19	52	16						M4	26.3	9.2	47,XY,inv(16)(p13q22),+22[20]		91.5	inv(16)	53	- 14% Myeloid blasts: CD13, CD34, CD38, CD58, partial CD64,     CD117, CD123,          HLA-DR, and MPO positive     - 30% Monoblasts/promonocytes: CD11b, CD13, CD14, CD38, CD58, bright CD64,     HLA-DR, and MPO		13.8	Negative	Negative	Negative		Negative	Negative	Negative	Negative	Negative		Negative	Negative	Negative	24	Unmatched	AMLCBFBMYH11	Leukemia	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22);CBFB-MYH11	0.0666666666667
aml_ohsu_2018_1060	aml_ohsu_2018_13-00165	Denovo	None	AML with mutated NPM1	Intermediate	Intermediate-I	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Peripheral Blood	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	2	Standard Chemotherapy | Bone Marrow Transplant	4	Busulfan, Fludarabine|7+3 (Cytarabine, Idarubicin)|HiDAC|HAM (Cytarabine, Mitoxantrone)	4	Allogeneic - Sibling | Consolidation | Induction | Re-induction	Refractory	Standard Chemotherapy	-1	Bone Marrow Transplant	Busulfan, Fludarabine	Allogeneic - Sibling	-1	-2				No														46,XX[7]								Positive	Positive												33	Matched	AMLNPM1	Leukemia	AML with Mutated NPM1	0.566666666667
aml_ohsu_2018_1061	aml_ohsu_2018_13-00166		Unknown	AML with maturation	Intermediate	Intermediate-II	AML with maturation	Post-Chemotherapy|Residual Relapse	Peripheral Blood	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	1	Standard Chemotherapy	8	GCLAM (G-CSF, Cladribine, Cytarabine, and Mitoxantrone) |7+3 (Cytarabine, Idarubicin)|HiDAC|HAM (Cytarabine, Mitoxantrone)|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Azacitidine|MEC (Cytarabine, Etoposide, Mitoxantrone)|Cladribine	6	Hypomethylating/Low Dose Cytarabine | Salvage | Consolidation | Unknown | Induction | Re-induction	Refractory	Standard Chemotherapy	6	Standard Chemotherapy	Cladribine	Unknown	5	0	0		77	No	0		15	1	3		18	10	3.6	1.01	M2	28.1	9.3		132	93.5		22		6.3	19.5	Negative	Negative												67	Unmatched	AM	Leukemia	AML with Maturation	0.233333333333
aml_ohsu_2018_1072	aml_ohsu_2018_13-00186	After or at the time transformation from another heme malignancy	None	AML with myelodysplasia-related changes	Adverse	Intermediate-I	AML with myelodysplasia-related changes	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	0		0		0					NONE	NONE	NONE		0	0	60	29	No	1		26	18	24		250	160	3.2	0.59		22	7.1	46,XY[20]	399	87.4		107	partial CD7, CD13, CD33, CD34, CD38, CD58, CD117, CD123, TdT, and HLA-DR positive	7	11.8	Negative	Negative	Negative		Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	74	Unmatched	AMLMRC	Leukemia	AML with Myelodysplasia-Related Changes	0.166666666667
aml_ohsu_2018_1078	aml_ohsu_2018_13-00195	Denovo	None	AML with mutated NPM1	Favorable	Favorable	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	1	Standard Chemotherapy	2	7+3 (Cytarabine, Idarubicin)|MiDAC	2	Consolidation | Induction	Complete Response	Standard Chemotherapy	6	Standard Chemotherapy	MiDAC	Consolidation	74	0	0	90	24	No	0		14	61	1		19	14	2.4	1.13	M5	23.9	7.9	46,XY[20]	387	103.6	Normal	122	CD11b, dim/partial CD13, CD14, CD33, CD38, CD58, CD64,     partial CD117, dim/partial CD123, and HLA-DR positive	6.3	28	Negative	Positive	Negative		p.R882H; MAF 50%	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	66	Matched	AMLNPM1	Leukemia	AML with Mutated NPM1	0.566666666667
aml_ohsu_2018_1082	aml_ohsu_2018_13-00201	Denovo	None	AML with mutated NPM1	Favorable or Intermediate	Intermediate-I	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	WES	No	Yes	No	No	Yes	No	2	Standard Chemotherapy | Bone Marrow Transplant	3	7+3 (Cytarabine, Idarubicin)|HiDAC|Busulfan, Cyclophosphamide	3	Consolidation | Induction | Allogeneic - Matched Unrelated Donor	Complete Response	Standard Chemotherapy	7	Bone Marrow Transplant	Busulfan, Cyclophosphamide	Allogeneic - Matched Unrelated Donor	-1	0	0	90	64	No	2		12	17	2		70	53	4.2	0.97	NOS	32.2	10.7	46,XY[20]	683	87	Normal	38	CD11b, CD13, CD33, CD38, CD58, CD64, dim CD117, CD123, MPO+	7.9	61.2	Positive	Positive	Negative		p.N879D; MAF 50%	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	56	Matched	AMLNPM1	Leukemia	AML with Mutated NPM1	1.03333333333
aml_ohsu_2018_1086	aml_ohsu_2018_13-00202	Denovo	None	AML with mutated NPM1	Favorable	Favorable	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	WES + RNA-seq	Yes	Yes	No	Yes	Yes	No	0		0		0					NONE	NONE	NONE		-1		73	32	No														46,XY[20]			Normal		atypical monocytic cells expressing weaker than   normal CD13 and CD33, with increased promonocytes/monoblasts representing approximately 44% of the leukocytes,		22.79	Negative	Positive	Negative											53	Unmatched	AMLNPM1	Leukemia	AML with Mutated NPM1	0.266666666667
aml_ohsu_2018_1088	aml_ohsu_2018_13-00204	Denovo	PML-RARA	Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA	Favorable	Adverse	Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	1	Standard Chemotherapy	2	ATRA (Tretinoin)|3+7 (Cytarabine, Daunorubicin)	1	Induction	Unknown	Standard Chemotherapy	5	Standard Chemotherapy	3+7 (Cytarabine, Daunorubicin)	Induction	3	0	0	72	57	No	0		36	1	8		24	33	2.9	0.6	M3	20.7	6.8	46,X,der(X)add(X)(p22.1)add(X)(q22~24),add(7)(p15),der(15)t(15;17)(q22;q21),der(17)t(15;17)(q22;q21)inv(17)(q21q21)del(17)(q21)[17]/46,XX[3]	398	90.2	Unusual t(15;17), with the fusion signal on the derivative chromosome 15	10	partial CD2, CD13, CD33, partial CD34, CD117, CD123, MPO-positive	5.6	9.8	Positive	Negative	Negative		Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	65	Matched	APLPMLRARA	Leukemia	APL with PML-RARA	0.9
aml_ohsu_2018_1094	aml_ohsu_2018_13-00218	Denovo	RUNX1-RUNX1T1	AML with t(8;21)(q22;q22); RUNX1-RUNX1T1	Favorable	Favorable	AML with t(8;21)(q22;q22); RUNX1-RUNX1T1	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	WES	No	Yes	No	No	Yes	No	2	Standard Chemotherapy | Bone Marrow Transplant	4	7+3 (Cytarabine, Idarubicin)|HiDAC|MEC (Cytarabine, Etoposide, Mitoxantrone)|Busulfan, Cyclophosphamide	4	Consolidation | Induction | Re-induction | Allogeneic - Matched Unrelated Donor	Complete Response	Standard Chemotherapy	6	Bone Marrow Transplant	Busulfan, Cyclophosphamide	Allogeneic - Matched Unrelated Donor	-1	0	0	80	52	No	0		44	3	1		48	30	2.6	0.35	NOS	23.6	8.2	46,XX,t(8;21)(q22;q22)[12]/45,idem,-X[6]/46,XX[2]	389	94.4	RUNX1T1 / RUNX1 t(8;21): 87% of cells had a dual fusion signal pattern consistent with RUNX1T1/RUNX1 fusion and t(8;21), as seen on metaphase analysis.	9	CD13, dim CD33, CD34, CD38,     CD58, dim/partial CD64, CD117, dim CD123, HLA-DR, and MPO	6.8	5.8	Negative	Negative	Negative		Negative	Negative	Negative		Negative	Negative	Negative	Negative	Negative	41	Matched	AMLRUNX1RUNX1T1	Leukemia	AML with t(8;21)(q22;q22.1);RUNX1-RUNX1T1	0.966666666667
aml_ohsu_2018_928	aml_ohsu_2018_13-00226	After or at the time transformation from another heme malignancy	PML-RARA	Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA	Favorable	Adverse	Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	1	Standard Chemotherapy	2	ATRA, Arsenic Trioxide|Idarubicin	2	Induction | Symptom Control	Complete Response	Standard Chemotherapy	253	Standard Chemotherapy	Idarubicin	Symptom Control	0	0	0	75	2.1	No	0		17	2	23		14	9	3.7	0.7	M3	23.4	8.1	46,XX,t(15;17)(q24;q21)[12]/46,XX,idem,del(16)(q12.1q24)[3]/46,XX[5]	367	86.2	16q deletion		CD13, CD33, partial CD34, CD64, CD117, CD123, and MPO-positive	6.8	6	Negative	Negative	Negative		Negative		Negative			Negative	Negative	Negative	Negative	83	Matched	APLPMLRARA	Leukemia	APL with PML-RARA	0.933333333333
aml_ohsu_2018_1101	aml_ohsu_2018_13-00232	Denovo	None	AML with mutated CEBPA	Intermediate	Favorable	AML with mutated CEBPA	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	2	Standard Chemotherapy | Bone Marrow Transplant	3	Busulfan, Fludarabine|7+3 (Cytarabine, Idarubicin)|HiDAC	3	Consolidation | Induction | Allogeneic - Matched Unrelated Donor	Complete Response	Standard Chemotherapy	6	Bone Marrow Transplant	Busulfan, Fludarabine	Allogeneic - Matched Unrelated Donor	-1	0	0	55	29	No	2		7	33	24		67	16	2.2	0.64	M4	24	8	46,XX[24]	373	95.2	Normal	34	CD7, CD13, CD33, CD34, CD38, CD56, partial CD64,     CD117,        dim CD123, HLA-DR and MPO+	6.5	29.4	Negative	Negative	p.D107fs*; MAF ~50%		Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	22	Matched	AMLCEBPA	Leukemia	AML with Biallelic Mutations of CEBPA	0.433333333333
aml_ohsu_2018_1103	aml_ohsu_2018_13-00236		None	AML with myelodysplasia-related changes	Adverse	Adverse	AML with myelodysplasia-related changes	Residual Disease|Post-Transplant|Post-Chemotherapy	Peripheral Blood	WES	No	Yes	Yes	No	Yes	Yes	2	Standard Chemotherapy | Bone Marrow Transplant	5	Cyclophosphamide, Fludarabine, TBI|FLAG (Fludarabine, High-dose Cytarabine, G-CSF)|COG-AAML0531 (Cytarabine, Daunorubicin, Etoposide, L-Asparaginase, Mitoxantrone +/- Gemtuzumab)|Treo/Flu/TBI (Treosulfan, Fludarabine, Total Body Irradiation)|COG-AAML07P1 (Bortezomib, Cytarabine, Etoposide, Idarubicin)	3	Induction | Re-induction | Allogeneic - Matched Unrelated Donor	Complete Response	Standard Chemotherapy	153	Bone Marrow Transplant	Treo/Flu/TBI (Treosulfan, Fludarabine, Total Body Irradiation)	Allogeneic - Matched Unrelated Donor	-1	-10	0			No	2		67	6	25		20	34	3.3	0.49	M5	27.8	9.4	46,X,del(X)(q24),del(3)(q23q27),t(4;7)(q12;p15),add(5)(p13),+6,del(6)(q13q23),+8,del(8)(q22),-9,add(9)(q34.1),t(10;11)(p12;q23)inv(11)(q13q23),-20[cp12]/46,XX[8]		96.9		106		6.9	1.5	Negative	Negative												5	Unmatched	AMLMRC	Leukemia	AML with Myelodysplasia-Related Changes	0.0333333333333
aml_ohsu_2018_1104	aml_ohsu_2018_13-00237	After or at the time transformation from another heme malignancy	None	AML with myelodysplasia-related changes	Adverse	Intermediate-II	AML with myelodysplasia-related changes	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	WES	No	Yes	Yes	No	Yes	Yes	1	Standard Chemotherapy	1	3+7 (Cytarabine, Daunorubicin)	1	Induction	Complete Response	Standard Chemotherapy	6	Standard Chemotherapy	3+7 (Cytarabine, Daunorubicin)	Induction	6	0	0		5	No	2		8	70	20		66	26	3.6	0.69	M4	25.9	8.7	46,XY,del(12)(p11.2p13)[15]/46,XY[5]	219	92.2	12p deletion	23	CD13, dim CD33, CD34, CD38, CD58, CD117, HLA-DR and MPO positive	7.2	22.8	Negative	Negative	Negative		Negative		Negative	Negative	Negative	Negative	Negative	Negative	Negative	72	Matched	AMLMRC	Leukemia	AML with Myelodysplasia-Related Changes	0.733333333333
aml_ohsu_2018_1093	aml_ohsu_2018_13-00242		None	AML with myelodysplasia-related changes	Adverse	Adverse	AML with myelodysplasia-related changes	Post-Chemotherapy	Peripheral Blood	WES	No	Yes	No	No	Yes	No	1	Standard Chemotherapy	3	7+3 (Cytarabine, Idarubicin)|HiDAC|MEC (Cytarabine, Etoposide, Mitoxantrone)	3	Consolidation | Induction | Re-induction	Complete Response i	Standard Chemotherapy	7	Standard Chemotherapy	MEC (Cytarabine, Etoposide, Mitoxantrone)	Re-induction	5	0	0	0.5	0	No	0		100	0	0		8	16	3	0.69	NOS	25	9	46,XY,add(2)(p23),t(3;22)(p21;q13),add(3)(q26),del(6)(q13q27),add(9)(q22),add(9)(q13),add(10)(p11.2),del(14)	224		nuc ish(D5S721,D5S23,EGR1)x2[200],(D7Z1,D7S522)x2[199],(D8Z2,D20S108)x2[198],(5'MLL,3'MLL)x2(5'MLLcon3'MLLx2)[199]	22	CD2(-), CD7(partial and variably +), CD13(+), CD14(-), CD15(-), CD33(bright +), CD34(+), CD36(variably +), CD38(bright +), CD45(+), CD64(-), CD117(variably +), HLA-DR(partial +).	6	0.6	Negative	Negative											Positive	62	Matched	AMLMRC	Leukemia	AML with Myelodysplasia-Related Changes	0.0666666666667
aml_ohsu_2018_1108	aml_ohsu_2018_13-00245	Denovo	RUNX1-RUNX1T1	AML with t(8;21)(q22;q22); RUNX1-RUNX1T1	Favorable	Favorable	AML with t(8;21)(q22;q22); RUNX1-RUNX1T1	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	1	Standard Chemotherapy	1	COG-AAML1031 (IT/IV Cytarabine, Daunorubicin, Etoposide, Mitoxantrone +/- Bortezomib or Sorafenib)	2	Induction | Intensification	Complete Response	Standard Chemotherapy	11	Standard Chemotherapy	COG-AAML1031 (IT/IV Cytarabine, Daunorubicin, Etoposide, Mitoxantrone +/- Bortezomib or Sorafenib)	Intensification	62	0	0	30	17	No	0		33	17	20					0.53	M2	29.3	10.3	46,XY,t(8;21)(q22;q22)[5]/46,idem,der(7)t(7;8)(q22;q11.2)[13]/46,XY[2]		93.5	t(8;21)	109	dim CD7, CD13, CD33, CD34, CD38, partial CD56,CD58, CD117, CD123, dim HLA-DR, and MPO		19.5	Negative	Negative				Negative								8	Unmatched	AMLRUNX1RUNX1T1	Leukemia	AML with t(8;21)(q22;q22.1);RUNX1-RUNX1T1	0.0666666666667
aml_ohsu_2018_1105	aml_ohsu_2018_13-00247	Denovo	RUNX1-RUNX1T1	AML with t(8;21)(q22;q22); RUNX1-RUNX1T1	Favorable	Favorable	AML with t(8;21)(q22;q22); RUNX1-RUNX1T1	Initial Acute Leukemia Diagnosis	Peripheral Blood	WES	No	Yes	No	No	Yes	No	1	Standard Chemotherapy	2	7+3 (Cytarabine, Idarubicin)|HiDAC	2	Consolidation | Induction	Complete Response	Standard Chemotherapy	6	Standard Chemotherapy	HiDAC	Consolidation	109	-4			22	No														46,XX,t(8;21)(q21.3;q22)[18]/46,XX[2]	588		RUNX1T1/RUNX1 fusion				5.1	Negative	Negative	Negative		Negative	Negative	Negative				Negative	Negative	Negative	53	Matched	AMLRUNX1RUNX1T1	Leukemia	AML with t(8;21)(q22;q22.1);RUNX1-RUNX1T1	0.633333333333
aml_ohsu_2018_1111	aml_ohsu_2018_13-00250	After or at the time transformation from another heme malignancy	Unknown	AML with myelodysplasia-related changes	Intermediate	Not Enough Information	AML with myelodysplasia-related changes	Post-Chemotherapy|Residual Disease	Peripheral Blood	WES + RNA-seq	Yes	Yes	No	Yes	Yes	No	1	Standard Chemotherapy	2	Azacitidine|Decitabine	2	Hypomethylating/Low Dose Cytarabine | Induction	Unknown	Standard Chemotherapy	-1	Standard Chemotherapy	Decitabine	Hypomethylating/Low Dose Cytarabine	-1	0				No																						Negative	Negative												78	Unmatched	AMLMRC	Leukemia	AML with Myelodysplasia-Related Changes	0.233333333333
aml_ohsu_2018_1113	aml_ohsu_2018_13-00253	Denovo	Unknown	AML with mutated CEBPA	Intermediate	Not Enough Information	AML with mutated CEBPA	Initial Acute Leukemia Diagnosis	Peripheral Blood	WES + RNA-seq	Yes	Yes	No	Yes	Yes	No	1	Standard Chemotherapy	2	7+3 (Cytarabine, Idarubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone)	2	Induction | Re-induction	Refractory	Standard Chemotherapy	6	Standard Chemotherapy	MEC (Cytarabine, Etoposide, Mitoxantrone)	Re-induction	4	0	0	70	9	No	0		43	6	38		36	28	3.5	0.81	M7	34.8	12		762	85.2	Extra signals were observed for BCR (22q11.2), PML (15q22), MLL (11q23),     RUNX1T1 (8q21.3) and RUNX1 (21q22) in roughly 45-60% of interphase cells.     These results suggest the presence of a hyperdiploid clone.	13	CD7, CD13, CD33, CD58, partial CD61, CD71, and Factor 8 positive	6.8	7.9	Negative	Negative	p.V119?M120insV; MAF 30%		Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	42	Matched	AMLCEBPA	Leukemia	AML with Biallelic Mutations of CEBPA	0.666666666667
aml_ohsu_2018_1104	aml_ohsu_2018_13-00255	After or at the time transformation from another heme malignancy	None	AML with myelodysplasia-related changes	Adverse	Intermediate-II	AML with myelodysplasia-related changes	Initial Acute Leukemia Diagnosis	Peripheral Blood	RNA-seq	Yes	No	Yes	Yes	No	Yes	1	Standard Chemotherapy	1	3+7 (Cytarabine, Daunorubicin)	1	Induction	Complete Response	Standard Chemotherapy	6	Standard Chemotherapy	3+7 (Cytarabine, Daunorubicin)	Induction	6	-8	0		5	No	1		3	77	8		57	27	3.5	0.61	M4	26.3	8.7	46,XY,del(12)(p11.2p13)[15]/46,XY[5]	324	92.8	12p deletion	19		7.2	56.5	Negative	Negative	Negative		Negative		Negative	Negative	Negative	Negative	Negative	Negative	Negative	72	Matched	AMLMRC	Leukemia	AML with Myelodysplasia-Related Changes	NA
aml_ohsu_2018_1117	aml_ohsu_2018_13-00260	Denovo	RUNX1-RUNX1T1	AML with t(8;21)(q22;q22); RUNX1-RUNX1T1	Favorable	Adverse	AML with t(8;21)(q22;q22); RUNX1-RUNX1T1	Initial Acute Leukemia Diagnosis	Peripheral Blood	RNA-seq	Yes	No	Yes	Yes	No	Yes	1	Standard Chemotherapy	1	COG-AAML0531 (Cytarabine, Daunorubicin, Etoposide, L-Asparaginase, Mitoxantrone +/- Gemtuzumab)	1	Induction	Complete Response	Standard Chemotherapy	133	Standard Chemotherapy	COG-AAML0531 (Cytarabine, Daunorubicin, Etoposide, L-Asparaginase, Mitoxantrone +/- Gemtuzumab)	Induction	133	0	0	62	64	No	0		28	1	7		15	9	4.1	0.58	M2	18.5	6.3	45,X,-Y,t(8;21)(q22;q22)[4]/45,idem,del(9)(q12q22)[13]/46,XY[3]	486	105.8	RUNX1T1/ RUNX1 fusion and t(8;21),	63	CD13, CD33, CD34, dim CD45, partial CD56, CD58, dim CD117, HLA-DR, MPO, and partial TdT-positive	7.9	13.3	Negative	Negative	Negative		Negative	Negative	Negative		Negative	Negative	Negative	Negative	p.S366A; MAF 50%	14	Matched	AMLRUNX1RUNX1T1	Leukemia	AML with t(8;21)(q22;q22.1);RUNX1-RUNX1T1	NA
aml_ohsu_2018_1118	aml_ohsu_2018_13-00262		None	AML with mutated NPM1	Adverse	Adverse	AML with mutated NPM1	Post-Chemotherapy|Residual Disease	Peripheral Blood	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	2	Standard Chemotherapy | Targeted Therapy - Kinase Inhibitor(s)	5	Crenolanib|MEC, plexifor, GCSF|Sorafenib|7+3 (Cytarabine, Idarubicin) plus LBH|Clofarabine, Cytarabine	4	Salvage | Induction | Experimental | Re-induction	Refractory	Standard Chemotherapy	21	Targeted Therapy - Kinase Inhibitor(s)	Crenolanib	Experimental	124	-1		81	94	No			6				87	47	2.8	0.53		27.2	9.7	46,XX,t(3;11)(q21;p11.2),t(15;15)(q15;q22)[19]/46,XX,t(2;14)(q21;q11.2)[2]	743		nuc ish(RUNX1T1,RUNX1)x2[199],(5'MLL,3'MLL)x2 (5'MLL con 3'MLLx2)[198],(PML,RARA)x2[199],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	11	CD7(partial +), CD15(partial +), CD33(bright +), CD34(partial +), CD45(+), and CD117(variably +).	5.2	26	Positive	Positive												65	Unmatched	AMLNPM1	Leukemia	AML with Mutated NPM1	0.166666666667
aml_ohsu_2018_1119	aml_ohsu_2018_13-00266	Denovo	None	AML with myelodysplasia-related changes	Adverse	Adverse	AML with myelodysplasia-related changes	Initial Acute Leukemia Diagnosis	Peripheral Blood	RNA-seq	Yes	No	Yes	Yes	No	Yes	1	Standard Chemotherapy	1	7+3 (Cytarabine, Idarubicin)	1	Induction	Refractory	Standard Chemotherapy	7	Standard Chemotherapy	7+3 (Cytarabine, Idarubicin)	Induction	7	1			47	No														46,XY,-7,+13,i(17)(q10)[20]			Monosomy 7		CD13, CD33, CD34, CD117, dim CD123, and HLA-DR-positive		25.3	Negative	Negative	Negative		Negative	Negative	Negative		Negative	Negative	Negative	Negative	Negative	77	Matched	AMLMRC	Leukemia	AML with Myelodysplasia-Related Changes	NA
aml_ohsu_2018_1121	aml_ohsu_2018_13-00268	After or at the time transformation from another heme malignancy	Unknown	AML with myelodysplasia-related changes	Intermediate	Adverse	AML with myelodysplasia-related changes	Post-Chemotherapy|Residual Disease	Peripheral Blood	WES	No	Yes	Yes	No	Yes	Yes	1	Standard Chemotherapy	3	GCLAM (G-CSF, Cladribine, Cytarabine, and Mitoxantrone) |3+7 (Cytarabine, Daunorubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone)	3	Salvage | Induction | Re-induction	Refractory	Standard Chemotherapy	6	Standard Chemotherapy	GCLAM (G-CSF, Cladribine, Cytarabine, and Mitoxantrone)	Salvage	6	0	0		5	No	0		0	10	84		22	24	3.4	0.94	NOS	27.8	9.1		808	90.4		136		5.8	40.8	Negative	Negative												56	Unmatched	AMLMRC	Leukemia	AML with Myelodysplasia-Related Changes	0.166666666667
aml_ohsu_2018_1123	aml_ohsu_2018_13-00270	Denovo	CBFB-MYH11	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	Favorable	Favorable	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	Initial Acute Leukemia Diagnosis	Peripheral Blood	WES + RNA-seq	Yes	Yes	No	Yes	Yes	No	1	Standard Chemotherapy	1	COG-AAML1031 (IT/IV Cytarabine, Daunorubicin, Etoposide, Mitoxantrone +/- Bortezomib or Sorafenib)	2	Induction | Re-induction	Refractory	Standard Chemotherapy	-1	Standard Chemotherapy	COG-AAML1031 (IT/IV Cytarabine, Daunorubicin, Etoposide, Mitoxantrone +/- Bortezomib or Sorafenib)	Re-induction	-1	0	0	50	22	No	0		24	49	20		13	15	3.6	0.77	M4	21	7.4	46,XX,inv(16)p13.1q22)[4]/47,idem,+22[15]/46,XX[1]	415	97.8	CBFB rearrangement and inv(16)	23	Blast phenotype:  CD13, CD33, CD34, CD38, CD58, dim CD123,     HLA-DR-positive               - Monocytic phenotype:  CD11b, CD13, CD14, CD33, CD58, CD64, HLA-DR-positive	7.6	8.8	Negative	Negative	Negative				Negative		Negative	Negative	p.G13D; MAF 10%	p.G13D; MAF 30%	Negative	18	Unmatched	AMLCBFBMYH11	Leukemia	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22);CBFB-MYH11	0.0666666666667
aml_ohsu_2018_1126	aml_ohsu_2018_13-00273	Denovo	None	AML with mutated NPM1	Favorable or Intermediate	Intermediate-I	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Peripheral Blood	WES	Yes	Yes	No	No	Yes	No	2	Standard Chemotherapy | Bone Marrow Transplant	4	Fludarabine, Melphalan|7+3 (Cytarabine, Idarubicin)|HiDAC|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)	4	Consolidation | Induction | Re-induction | Allogeneic - Matched Unrelated Donor	Complete Response	Standard Chemotherapy	6	Standard Chemotherapy	FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)	Re-induction	3	-2	2			No	0		14	13	68		31	20	3.1	0.95		24.7	8.2	46,XX[20]		86.2	Normal	99		6.8	21.7	Positive	Positive	Negative		p.R882H; MAF 50%	Negative	Negative		Negative	Negative	Negative	Negative		51	Unmatched	AMLNPM1	Leukemia	AML with Mutated NPM1	0.1
aml_ohsu_2018_1131	aml_ohsu_2018_13-00281	After or at the time transformation from another heme malignancy	None	AML with myelodysplasia-related changes	Intermediate	Intermediate-II	AML with myelodysplasia-related changes	Initial Acute Leukemia Diagnosis	Peripheral Blood	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	1	Standard Chemotherapy	1	Azacitidine, Lenalidomide	1	Salvage				Standard Chemotherapy	Azacitidine, Lenalidomide	Salvage	137	0		73	56	No				1										46,XX,del(16)(p11.2)[3]/46,XX[2]					CD34, CD4(dim), CD7, CD11c(dim), CD13, CD33(dim),CD38, CD117, and HLA-DR		8.7	Negative	Negative	Negative	Negative	Negative	Negative	Negative		Negative	Negative	Negative	Negative	Negative	79	Matched	AMLMRC	Leukemia	AML with Myelodysplasia-Related Changes	0.466666666667
aml_ohsu_2018_1137	aml_ohsu_2018_13-00286	Denovo	None	AML with mutated NPM1	Favorable or Intermediate	Intermediate-I	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	WES	No	Yes	No	No	Yes	No	1	Standard Chemotherapy	3	HiDAC|7+3 (Cytarabine, Idarubicin)|Busulfan, Cyclophosphamide	3	Consolidation | Induction | Allogeneic - Matched Unrelated Donor	Complete Response	Standard Chemotherapy	7	Standard Chemotherapy	Busulfan, Cyclophosphamide	Allogeneic - Matched Unrelated Donor	-1	2				No														46,XY[7]								Positive	Positive	Negative	Negative	Negative	Negative	Negative	Negative		Negative	Negative	Negative	Negative	53	Matched	AMLNPM1	Leukemia	AML with Mutated NPM1	0.366666666667
aml_ohsu_2018_1098	aml_ohsu_2018_13-00294	Transformation from another heme malignancy and Relapse	None	AML with myelodysplasia-related changes	Intermediate	Not Enough Information	AML with myelodysplasia-related changes	Relapse|Post-Chemotherapy|Post-Transplant	Bone Marrow Aspirate	WES	No	Yes	Yes	No	Yes	Yes	4	Standard Chemotherapy | Bone Marrow Transplant | Targeted Therapy - Other | Targeted Therapy - Kinase Inhibitor(s)	9	Fludarabine, Melphalan|Dasatinib|7+3 (Cytarabine, Idarubicin)|HiDAC|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Azacitidine|MEC (Cytarabine, Etoposide, Mitoxantrone)|Rituximab|Busulfan, Cyclophosphamide	7	Allogeneic - Sibling | Hypomethylating/Low Dose Cytarabine | Consolidation | Salvage | Induction | Experimental | Re-induction	Complete Response	Standard Chemotherapy	-1	Targeted Therapy - Kinase Inhibitor(s)	Dasatinib	Experimental	24	-4	2	18	0	No	0		14	8	68							29.6	10.2	46,XX			nuc ish(DXZ1x2)[200]	91			1.3	Negative	Negative				Negative								36	Unmatched	AMLMRC	Leukemia	AML with Myelodysplasia-Related Changes	0.133333333333
aml_ohsu_2018_1153	aml_ohsu_2018_13-00331	Relapse	None	AML with mutated NPM1	Favorable	Favorable	AML with mutated NPM1	Post-Chemotherapy|Relapse	Bone Marrow Aspirate	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	2	Standard Chemotherapy | Bone Marrow Transplant	5	7+3 (Cytarabine, Idarubicin)|HiDAC|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone)|Cyclophosphamide, Etoposide, TBI	5	Allogeneic - Sibling | Consolidation | Salvage | Induction | Re-induction	Complete Response	Standard Chemotherapy	6	Standard Chemotherapy	FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)	Re-induction	53	0		92	97	No											M5			46,XX[5]					CD45, DIM CD64, DIM CD13, DIM CD33, CD15, CD38, MPO, CD11C, DIM CD4, DIM PARTIAL CD19, CD117, AND HLA-DR		140	Negative	Positive	Negative	Negative	Negative		Positive	Negative		Negative	Negative	Negative	Negative	37	Matched	AMLNPM1	Leukemia	AML with Mutated NPM1	0.666666666667
aml_ohsu_2018_1157	aml_ohsu_2018_13-00338	Relapse	CBFB-MYH11	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	Favorable	Favorable	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	Post-Chemotherapy|Relapse	Peripheral Blood	WES + RNA-seq	Yes	Yes	No	Yes	Yes	No	1	Standard Chemotherapy	5	7+3 (Cytarabine, Idarubicin)|3+7 (Cytarabine, Daunorubicin)|Azacitidine, Gemtuzumab|MEC (Cytarabine, Etoposide, Mitoxantrone)|Etoposide, Cytarabine	2	Induction | Re-induction	Refractory	Standard Chemotherapy	-1	Standard Chemotherapy	Azacitidine, Gemtuzumab	Re-induction	-1	0		82	25	No				19							M4eo			47,XX,t(16;16)(p13;q22),+22[20]			Positive				4.3	Negative	Negative	Negative	Negative	Negative		Negative	Negative		Negative	Negative	Negative	Negative	60	Unmatched	AMLCBFBMYH11	Leukemia	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22);CBFB-MYH11	0.1
aml_ohsu_2018_1159	aml_ohsu_2018_13-00342	Relapse	None	AML with mutated CEBPA	Favorable	Favorable	AML with mutated CEBPA	Relapse|Post-Chemotherapy	Bone Marrow Aspirate	WES + RNA-seq	Yes	Yes	No	Yes	Yes	No	4	DLI | Standard Chemotherapy | Bone Marrow Transplant | Supportive/Palliative Care	7	7+3 (Cytarabine, Idarubicin)|HiDAC|Donor Lymphocyte Infusion|GCLAC (GCSF, Clofarabine & Cytarabine)|MEC (Cytarabine, Etoposide, Mitoxantrone)|Decitabine|Fludarabine, Cyclophosphamide, TBI	6	Allogeneic - Sibling | Consolidation | Salvage | Unknown | Induction | Re-induction	Complete Response	Standard Chemotherapy	8	Supportive/Palliative Care	Decitabine	Salvage	-1	0		28	23	Yes				6										46,XY[20]					CD34, CD117, CD38, MPO, CD11c (dim),CD13, CD33, CD15, and HLA-DR,CD7 and CD56 (partial)		4	Negative	Negative	Double mutation	Negative	Negative	Negative	Negative	Negative		Negative	Negative	Negative	Negative	32	Matched	AMLCEBPA	Leukemia	AML with Biallelic Mutations of CEBPA	0.833333333333
aml_ohsu_2018_1162	aml_ohsu_2018_13-00346		None	AML with myelodysplasia-related changes	Adverse	Not Enough Information	AML with myelodysplasia-related changes	Post-Chemotherapy|Post-Transplant|Residual Relapse	Peripheral Blood	WES	No	Yes	No	No	Yes	No	3	Standard Chemotherapy | Bone Marrow Transplant | Targeted Therapy - Kinase Inhibitor(s)	7	Azacitidine, Sorafenib|7+3 (Cytarabine, Idarubicin)|HiDAC|Crenolanib|PLX3397|Fludarabine, Cyclophosphamide, Thiotepa, TBI|AC220 (Ambit)	6	Hypomethylating/Low Dose Cytarabine | Consolidation | Induction | Experimental | Re-induction | Double Umbilical Cord Blood Transplant (DUCBT)	Complete Response i	Standard Chemotherapy	9	Targeted Therapy - Kinase Inhibitor(s)	Crenolanib	Experimental	-1	0	0	41	42	No	0		40	0	10		33	38	3.6			23	7.9	46,X,t(X;11)(p22.1;q13),add(7)(p22),add(17)(q21)[cp3]/45,X,-X,add(1)(q21),add(2)(q37),add(5)(q35),add(7)[cp3]/46,XX[4]			Normal	11	CD2(dim +), CD7(-), CD13(partial dim +), CD14(-), CD15(partial +), CD33(+), CD34(+), CD38(partial +), CD45(moderately +), CD117(partial +), HLA-DR(variably +)	6.7	0.8	Positive	Negative												47	Unmatched	AMLMRC	Leukemia	AML with Myelodysplasia-Related Changes	0.233333333333
aml_ohsu_2018_1161	aml_ohsu_2018_13-00353		MLLT3-KMT2A	Therapy-related myeloid neoplasms	Intermediate	Intermediate-II	Therapy-related myeloid neoplasms	Post-Chemotherapy|Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	2	Standard Chemotherapy | Supportive/Palliative Care	4	GCLAM (G-CSF, Cladribine, Cytarabine, and Mitoxantrone) |7+3 (Cytarabine, Idarubicin)|HiDAC|Decitabine	4	Consolidation | Salvage | Induction | Supportive/Palliative Care	Complete Response	Standard Chemotherapy	6	Supportive/Palliative Care	Decitabine	Supportive/Palliative Care	31	0	0	64	65	No	0		28.9	25.4	19.3	1.7	48	33	3.6	0.64		21.8	7.5	46,XX,t(9;11)(p11;q34)[19]/46,XX[1]		111.8	Disruption of MLL signal and t(9;11)	29	CD11b, CD13, CD14,  CD33, CD64, CD56, CD123 and HLA-DR positive	6.1	29.25	Negative	Negative	Negative		Negative		Negative		Negative	Negative	Negative	Negative	Negative	30	Matched	TMN	Leukemia	Therapy-Related Myeloid Neoplasms	0.666666666667
aml_ohsu_2018_1163	aml_ohsu_2018_13-00354	Denovo	None	Acute monoblastic and monocytic leukaemia	Intermediate	Intermediate-I	Acute monoblastic and monocytic leukaemia	Initial Acute Leukemia Diagnosis	Peripheral Blood	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	2	Standard Chemotherapy | Bone Marrow Transplant	4	5+2 (Cytarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin)|Decitabine|Stanford Protocol 9153 (TLI, ATG)	4	Hypomethylating/Low Dose Cytarabine | Consolidation | Induction | Allogeneic - Mismatched Unrelated Donor	Complete Response	Standard Chemotherapy	-1	Bone Marrow Transplant	Stanford Protocol 9153 (TLI, ATG)	Allogeneic - Mismatched Unrelated Donor	-1	0		84	71	No				6										46,XY[20]					 CD4(subset), CD11c(partial), CD13(partial), CD14(partial), CD15(partial), CD33(subset), CD34(subset), CD38, CD64(subset), CD117(subset), HLA-DR and MPO		16.2	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative		Negative	Negative	Negative	Negative	73	Matched	AMOL	Leukemia	Acute Monoblastic/Monocytic Leukemia	0.866666666667
aml_ohsu_2018_1171	aml_ohsu_2018_13-00365	Denovo	None	AML with mutated NPM1	Adverse	Not Enough Information	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Peripheral Blood	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	1	Standard Chemotherapy	2	Azacitidine, Lenalidomide|Temozolomide, Vorinostat	2	Induction | Re-induction	Refractory	Standard Chemotherapy	-1	Standard Chemotherapy	Temozolomide, Vorinostat	Re-induction	-1	-13				No														46,XX,del(5)(q31q35),inv(7)(p15q32),del(12)(q?15)[2]/45~46,idem,add(3)(q27),-9,-del(12)(q?15),+add(12)(q13),-16,-17,+mar1,+mar2x2[cp16]/46,XX[2]								Positive	Positive	Negative	Negative	Negative	Negative	Negative	Negative		Negative	Negative	Negative	Positive	72	Matched	AMLNPM1	Leukemia	AML with Mutated NPM1	0.166666666667
aml_ohsu_2018_1181	aml_ohsu_2018_13-00383	Denovo	None	Acute myeloid leukaemia, NOS	Intermediate	Intermediate-II	Acute myeloid leukaemia, NOS	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	WES	No	Yes	No	No	Yes	No	3	Standard Chemotherapy | Bone Marrow Transplant | Supportive/Palliative Care	3	Cytarabine|Azacitidine|Stanford Protocol 9153 (TLI, ATG)	3	Hypomethylating/Low Dose Cytarabine | Supportive/Palliative Care | Allogeneic - Matched Unrelated Donor				Standard Chemotherapy	Cytarabine	Supportive/Palliative Care	9	0		34	8	No				15										46,XX,t(8;19)(q24;q13),del(11)?(q14q23)[19]/46,XX[1]					CD34, CD117, CD38, DIM CD13, CD33, HLA-DR, AND PARTIAL CD7		4.2	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative		Negative	Negative	Negative	Negative	71	Unmatched	AMLNOS	Leukemia	AML, NOS	0.0333333333333
aml_ohsu_2018_1181	aml_ohsu_2018_13-00384	Denovo	None	Acute myeloid leukaemia, NOS	Intermediate	Not Enough Information	Acute myeloid leukaemia, NOS	Initial Acute Leukemia Diagnosis	Peripheral Blood	WES + RNA-seq	Yes	Yes	No	Yes	Yes	No	3	Standard Chemotherapy | Bone Marrow Transplant | Supportive/Palliative Care	3	Cytarabine|Azacitidine|Stanford Protocol 9153 (TLI, ATG)	3	Hypomethylating/Low Dose Cytarabine | Supportive/Palliative Care | Allogeneic - Matched Unrelated Donor				Standard Chemotherapy	Cytarabine	Supportive/Palliative Care	9	0		34	8	No				15										46,XX,t(8;19)(q24;q13),del(11)?(q14q23)[19]/46,XX[1]					CD34, CD117, CD38, DIM CD13, CD33, HLA-DR, AND PARTIAL CD7		4.2	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative		Negative	Negative	Negative	Negative	71	Unmatched	AMLNOS	Leukemia	AML, NOS	0.0333333333333
aml_ohsu_2018_1184	aml_ohsu_2018_13-00393	Denovo	None	AML with myelodysplasia-related changes	Adverse	Adverse	AML with myelodysplasia-related changes	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	3	Standard Chemotherapy | Bone Marrow Transplant | Targeted Therapy - Other	5	7+3 (Cytarabine, Idarubicin)|HiDAC|AG-221|HAM (Mitoxantrone, Cytarabine) plus Crenolanib|Fludarabine, Melphalan, ATG	5	Consolidation | Salvage | Induction | Experimental | Allogeneic - Matched Unrelated Donor	Refractory	Standard Chemotherapy	15	Bone Marrow Transplant	Fludarabine, Melphalan, ATG	Allogeneic - Matched Unrelated Donor	-1	0		21	5	No			68	4	23		17	23	3.6	0.89		28.3	8.5	89<4n>,XXY,-Y,-7,-12,+13,+13,-17,-21[2]/46,XY[18]	183		nuc ish(RUNX1T1x4,RUNX1x3)[33/200],(5'MLL,3'MLL)x4(5'MLL con 3'MLLx4)[41/200],(PMLx4,RARAx3~4)[31/200],(5'CBFB,3'CBFB)x4(5'CBFB con 3'CBFBx4)[27/200]	22	partialCD4, partialCD15, dimCD33, CD34, CD38, dimCD45, CD117, HLA-DR, TdT, MPO	7.5	3.42	Negative	Negative												52	Matched	AMLMRC	Leukemia	AML with Myelodysplasia-Related Changes	0.9
aml_ohsu_2018_1187	aml_ohsu_2018_13-00396	Denovo	None	AML with myelodysplasia-related changes	Adverse	Adverse	AML with myelodysplasia-related changes	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	2	Standard Chemotherapy | Bone Marrow Transplant	3	7+3 (Cytarabine, Idarubicin)|Decitabine|Bu/Flu/TBI (Busulfan, Fludarabine, Total Body Irradiation)	3	Consolidation | Induction | Allogeneic - Matched Unrelated Donor	Complete Response	Standard Chemotherapy	6	Standard Chemotherapy	Decitabine	Consolidation	-1	-2	1.8	51	3.5	No	0.9		41.2	37.7	11.4	0	20	20	3.2	1.37	M4	33.7	11	42~45,XY,del(4)(q31q35),del(5)(q13q35),add(9)(q21),add(13)(p11.2),-16,-21[cp15]/40~46,sl,+9,-add(9)(q21),-15,+der(16)t(15;16)(q11.1;p13.3),-18,+mar[cp5]		92.6	Extra MLL signal	24	CD13, CD33, CD34, CD56, CD58, dim CD64, CD117 and partial HLA-DR.	7.1	5.23	Negative	Negative	Negative			Negative	Negative		Negative	Negative	Negative	Negative	p.R273S; MAF 40%	63	Matched	AMLMRC	Leukemia	AML with Myelodysplasia-Related Changes	0.433333333333
aml_ohsu_2018_1190	aml_ohsu_2018_13-00406	Denovo	None	Acute monoblastic and monocytic leukaemia	Adverse	Intermediate-I	Acute monoblastic and monocytic leukaemia	Initial Acute Leukemia Diagnosis	Leukapheresis	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	0		0		0					NONE	NONE	NONE		0	0	95	66.3	No	0		9.5	1.9	4.8	0.2	93	104	3.2	1.85	M5	26.2	8.5	46,XY[20]	2941	104.8	Normal	92	CD4, CD11b, CD13, CD14, partial CD16, CD33, CD38,      partial CD56, CD58, CD64, CD123, and HLA-DR positive	6.5	250.23	Positive	Negative	Negative		p. R882C; MAF 50%	Negative	Negative		Negative	Negative	Negative	Negative	Negative	62	Matched	AMOL	Leukemia	Acute Monoblastic/Monocytic Leukemia	0.4
aml_ohsu_2018_1190	aml_ohsu_2018_13-00409	Denovo	None	Acute monoblastic and monocytic leukaemia	Intermediate or Adverse	Intermediate-I	Acute monoblastic and monocytic leukaemia	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	WES + RNA-seq	Yes	Yes	No	Yes	Yes	No	0		0		0					NONE	NONE	NONE		0	0	95	95	No	0		9.5	1.9	4.8	0.2	93	104	3.2	1.85	M5	26.2	8.5	46,XY[20]	2941	104.8	Normal	92	CD4, CD11b, CD13, CD14, partial CD16, CD33, CD38, partial CD56, CD58, CD64, CD123, and HLA-DR positive	6.5	250.23	Positive	Negative	Negative		p.R882C; MAF 50%	Negative	Negative		Negative	Negative	Negative	Negative	Negative	62	Matched	AMOL	Leukemia	Acute Monoblastic/Monocytic Leukemia	0.233333333333
aml_ohsu_2018_1193	aml_ohsu_2018_13-00417	Denovo	None	AML with mutated NPM1	Favorable or Intermediate	Intermediate-I	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	WES	No	Yes	No	No	Yes	No	1	Standard Chemotherapy	1	Decitabine, Midostaurin	1	Induction	Refractory	Standard Chemotherapy	-1	Standard Chemotherapy	Decitabine, Midostaurin	Induction	-1	0		84	44	No				3										46,XY[20]					CD34+, EXPRESSING CD13, CD33,MPO, AND HLA-DR, WITH ABERRANT COEXPRESSION OF CD15 AND CD117, AND PARTIAL LOSS OF CD38		2	Positive	Positive	Negative	Negative		Negative	Negative	Negative		Negative	Negative	Negative	Negative	71	Matched	AMLNPM1	Leukemia	AML with Mutated NPM1	0.433333333333
aml_ohsu_2018_1194	aml_ohsu_2018_13-00420		None	Acute myeloid leukaemia, NOS	Adverse	Adverse	Acute myeloid leukaemia, NOS	Residual Disease|Post-Chemotherapy	Peripheral Blood	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	1	Standard Chemotherapy	5	7+3 (Cytarabine, Idarubicin)|HiDAC|Azacitidine|MEC (Cytarabine, Etoposide, Mitoxantrone)|Decitabine	4	Consolidation | Induction | Re-induction | Maintenance	Complete Response	Standard Chemotherapy	-1	Standard Chemotherapy	Azacitidine	Maintenance	34	-98				No														47,XY,+8,inv(9)(p11q12)c[1]/48,idem,+3[5]/49,idem,+3,+15[1]/50,idem,+3,+8,+mar(8]/46,XY,inv(9}(p11q12)c[5]			nuc ish (D8Z2x3~4)[134/200],(D15Z4x3)[114/200]					Negative	Negative												75	Matched	AMLNOS	Leukemia	AML, NOS	2.23333333333
aml_ohsu_2018_1196	aml_ohsu_2018_13-00424	Denovo	None	AML with myelodysplasia-related changes	Adverse	Not Enough Information	AML with myelodysplasia-related changes	Initial Acute Leukemia Diagnosis	Peripheral Blood	WES	No	Yes	No	No	Yes	No	1	Standard Chemotherapy	1	Azacitidine, Lenalidomide	1	Induction	Refractory	Standard Chemotherapy	-1	Standard Chemotherapy	Azacitidine, Lenalidomide	Induction	-1	-6				No														46,XY,del(9)(q13q34)[3]/46,XY[14]								Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative		Negative	Negative	Negative	Positive	77	Matched	AMLMRC	Leukemia	AML with Myelodysplasia-Related Changes	1.06666666667
aml_ohsu_2018_1197	aml_ohsu_2018_13-00425	Denovo	MLLT3-KMT2A	AML with t(9;11)(p22;q23); MLLT3-MLL	Intermediate	Intermediate-II	AML with t(9;11)(p22;q23); MLLT3-MLL	Initial Acute Leukemia Diagnosis	Peripheral Blood	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	2	Standard Chemotherapy | Bone Marrow Transplant	3	7+3 (Cytarabine, Idarubicin)|HiDAC|Busulfan, Cyclophosphamide	3	Allogeneic - Sibling | Consolidation | Induction	Complete Response	Standard Chemotherapy	-1	Standard Chemotherapy	HiDAC	Consolidation	5	-1		84	29	No			63	3	5		21	23	3.7	0.65		35	12	46,XX,t(9;11)(p22;q23)[20]	613		nuc ish(RUNX1T1,RUNX1)x2[200],(ABL1,BCR)x2[200],(5'MLL,3'MLL)x2(5'MLL sep 3'MLLx1) [179/200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	34	brightCD4, partialCD11b, brightCD15, brightCD33, partialCD36, partialCD38, CD45, brightCD64, partialCD117, HLA-DR	6.5	9.1	Negative	Negative												40	Unmatched	AMLRGA	Leukemia	AML with Recurrent Genetic Abnormalities	0.0666666666667
aml_ohsu_2018_1224	aml_ohsu_2018_13-00450	Relapse	Unknown	AML with mutated NPM1	Favorable	Intermediate-I	AML with mutated NPM1	Post-Chemotherapy|Relapse	Peripheral Blood	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	2	Standard Chemotherapy | Targeted Therapy - Kinase Inhibitor(s)	2	7+3 (Cytarabine, Idarubicin)|Crenolanib	2	Induction | Experimental	Complete Response	Standard Chemotherapy	4	Targeted Therapy - Kinase Inhibitor(s)	Crenolanib	Experimental	14	0				No																						Positive	Positive												79	Matched	AMLNPM1	Leukemia	AML with Mutated NPM1	1.0
aml_ohsu_2018_1226	aml_ohsu_2018_13-00454	Denovo	CBFB-MYH11	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	Favorable	Favorable	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	Initial Acute Leukemia Diagnosis	Peripheral Blood	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	1	Standard Chemotherapy	2	7+3 (Cytarabine, Idarubicin)|HiDAC	2	Consolidation | Induction	Complete Response i	Standard Chemotherapy	5	Standard Chemotherapy	HiDAC	Consolidation	95	0			45	No	3		25	20	7					1.04		22	7.4	46,XX,inv(16)(p13.1q22)[11]/47,idem,+22[4]/46,XX[5]	229		nuc ish(D4Z1,D10Z1)x2[199],(SCFD2,LNX,PDGFRA/KIT)x2[200],(5'PDGFRB,3'PDGFRB)x2(5'PDGFRB con 3'PDGFRBx2)[200],(5'FGFR1,3'FGFR1)x2([200],(RUNX1T1,RUNX1)x2[200](ABL1x2,BCRx3)[63/200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[197],(ETV6,RUNX1)x2[198],(PML,RARA)x2[200],(CBFBx2)(5CBFB sep 3CBFBx1)[147/200]	30	CD2(-), CD4(-), CD7(-), CD11b(-), CD13(variably +), CD14(-), CD15(partial+), CD16(-), CD22(few +), CD33(dim + to -), CD34(+), CD36(-), CD38(variably +), CD41(-), CD45(variably +), CD56(-), CD61(-), CD64(-), CD117(variably +), HLA-DR(partial +), Gly-A(-), MPO(+), TdT(partial +)		13.63	Negative	Negative	Negative			Negative								31	Unmatched	AMLCBFBMYH11	Leukemia	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22);CBFB-MYH11	0.0666666666667
aml_ohsu_2018_1566	aml_ohsu_2018_13-00466	Denovo	Unknown	Acute myeloid leukaemia, NOS	Intermediate	Not Enough Information	Acute myeloid leukaemia, NOS	Initial Acute Leukemia Diagnosis	Peripheral Blood	WES + RNA-seq	Yes	Yes	No	Yes	Yes	No	2	Standard Chemotherapy | Targeted Therapy - Other	4	7+3 (Cytarabine, Idarubicin)|HiDAC|Cytarabine|BL-8040	4	Consolidation | Salvage | Induction | Experimental	Complete Response	Standard Chemotherapy	-1	Standard Chemotherapy	Cytarabine	Salvage	-1	0	0.5		0	No	2.5		56.8	2.6	37.6		21	27	3.9	0.93		33.4	11.2		195			89		6.9	2	Negative	Negative												71	Matched	AMLNOS	Leukemia	AML, NOS	0.1
aml_ohsu_2018_1233	aml_ohsu_2018_13-00468		None	AML with myelodysplasia-related changes	Adverse	Intermediate-II	AML with myelodysplasia-related changes	Residual Disease|Post-Chemotherapy	Bone Marrow Aspirate	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	1	Standard Chemotherapy	4	5+2 (Cytarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone)|Decitabine	3	Salvage | Induction | Re-induction	Refractory	Standard Chemotherapy	6	Standard Chemotherapy	Decitabine	Salvage	126	0		17	10	No			27.7		39.2		47	22	3.8	0.5		25.8	8.5	47~49,XY,-21,+1~4mar[cp21]/46,XY[2]		86.6	Monosomy 21	40	CD13, CD33, CD34. CD45, subset CD64, CD79a, CD117,HLA-DR, and subset TdT positive).	7.6	5.5	Negative	Negative	Negative		Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	61	Matched	AMLMRC	Leukemia	AML with Myelodysplasia-Related Changes	0.8
aml_ohsu_2018_1243	aml_ohsu_2018_13-00487	Denovo	CBFB-MYH11	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	Favorable	Favorable	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	1	Standard Chemotherapy	2	7+3 (Cytarabine, Idarubicin)|HiDAC	2	Consolidation | Induction	Complete Response	Standard Chemotherapy	6	Standard Chemotherapy	HiDAC	Consolidation	94	0	0	49.4	28.6	No	1.8		19.6	37.5	7.1	0	20	17	3.1	0.88	M4	14.3	4.8	46,XX,t(16;16)(p13.1;q22)[16]/47,idem,+22[4]	505	100.7	Trisomy 22	36	Myeloid blasts (21%): CD13, CD33, CD34, CD38, CD58, CD117, CD123, HLA-DR, and MPO positive. Promonocytic/monocytic cells (55%): CD11b, CD13, CD14, CD33, dim/partial CD34, CD38, CD58, CD64, variable CD123, HLA-DR, and MPO-positive.	7.8	49.4	Negative	Negative	Negative			Negative	Negative	Negative	Negative		Negative	G13D; MAF 6%	Negative	35	Matched	AMLCBFBMYH11	Leukemia	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22);CBFB-MYH11	0.0333333333333
aml_ohsu_2018_1246	aml_ohsu_2018_13-00493		None	AML with mutated NPM1	Intermediate	Not Enough Information	AML with mutated NPM1	Post-Chemotherapy|Residual Relapse	Peripheral Blood	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	No	3	Standard Chemotherapy | Bone Marrow Transplant | Targeted Therapy - Kinase Inhibitor(s)	6	7+3 (Cytarabine, Idarubicin)|HiDAC|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Crenolanib|Clofarabine, Cytarabine|Busulfan, Cyclophosphamide	5	Consolidation | Induction | Experimental | Re-induction | Allogeneic - Matched Unrelated Donor	Complete Response	Standard Chemotherapy	24	Targeted Therapy - Kinase Inhibitor(s)	Crenolanib	Experimental	141	0	0	81	59	No	0		0	0	10		34	15	4			30.2	10.7	46,XY				17	CD2(-), CD4(dim +), CD10(-), CD11b(-), CD13(+), CD14(-), CD15(variably +), CD16(-), CD33(bright +), CD34(-), CD36(-), CD38(+), CD45(moderately +), CD56(-), CD64 (partial +), CD117(variably +), HLA-DR(-), MPO(+), TdT(-).	6	1.8	Positive	Positive			Foundation, R882H; MAF 9%									63	Matched	AMLNPM1	Leukemia	AML with Mutated NPM1	1.0
aml_ohsu_2018_1247	aml_ohsu_2018_13-00496	Denovo	CBFB-MYH11	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	Favorable	Favorable	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	Initial Acute Leukemia Diagnosis	Peripheral Blood	WES + RNA-seq	Yes	Yes	No	Yes	Yes	No	1	Standard Chemotherapy	2	7+3 (Cytarabine, Idarubicin)|HiDAC	2	Consolidation | Induction	Complete Response	Standard Chemotherapy	-1	Standard Chemotherapy	HiDAC	Consolidation	103	0	0	72	18	No	0		38	26	3		85	30	3.4			25.9	9	47,XX,inv(16)(p13.1q22),+22			nuc ish(D5S721,D5S23,EGR1)x2[200],(D7Z1,D7S522)x2[200],(D8Z2x3, D20S108x2)[7/200],(RUNX1T1,RUNX1)x2[197],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[198], (CBFBx2)(5CBFB sep 3CBFBx1)[140/200]	18	CD2(-), CD7(-), CD11b(-), CD13(variably +), CD14(-), CD15(variably +), CD16(-), CD33(+), CD34(variably +), CD36(-), CD38(+), CD45(+), CD56(-), CD64(partial +), CD117(+), HLA-DR(+)	6.1	26.3	Negative	Negative	Negative			Negative				Negative				33	Matched	AMLCBFBMYH11	Leukemia	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22);CBFB-MYH11	0.0333333333333
aml_ohsu_2018_1247	aml_ohsu_2018_13-00497	Denovo	CBFB-MYH11	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	Favorable	Favorable	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	WES	No	Yes	Yes	No	Yes	Yes	1	Standard Chemotherapy	2	7+3 (Cytarabine, Idarubicin)|HiDAC	2	Consolidation | Induction	Complete Response	Standard Chemotherapy	-1	Standard Chemotherapy	HiDAC	Consolidation	103	0	0	72	18	No	0		38	26	3		85	30	3.4			25.9	9	47,XX,inv(16)(p13.1q22),+22			nuc ish(D5S721,D5S23,EGR1)x2[200],(D7Z1,D7S522)x2[200],(D8Z2x3, D20S108x2)[7/200],(RUNX1T1,RUNX1)x2[197],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[198], (CBFBx2)(5CBFB sep 3CBFBx1)[140/200]	18	CD2(-), CD7(-), CD11b(-), CD13(variably +), CD14(-), CD15(variably +), CD16(-), CD33(+), CD34(variably +), CD36(-), CD38(+), CD45(+), CD56(-), CD64(partial +), CD117(+), HLA-DR(+)	6.1	26.3	Negative	Negative	Negative			Negative				Negative				33	Matched	AMLCBFBMYH11	Leukemia	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22);CBFB-MYH11	0.233333333333
aml_ohsu_2018_1248	aml_ohsu_2018_13-00500		None	Acute myeloid leukaemia, NOS	Intermediate	Intermediate-I	Acute myeloid leukaemia, NOS	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	1	Standard Chemotherapy	1	Azacitidine	1	Hypomethylating/Low Dose Cytarabine				Standard Chemotherapy	Azacitidine	Hypomethylating/Low Dose Cytarabine	55	0	0	76	58	No	2		38	6	14		27	25	3.1			25	8.5	46,XY			nuc ish(D5S721,D5S23,EGR1)x2[200],(D7Z1x2,D7S522x1)[29/200],(D8Z2,D20S108)x2[199],(RUNX1T1,RUNX1)x2 [200],(5'MLL,3'MLL)x3(5'MLL con 3'MLLx3)[11/200],(PML,RARA)x2[199],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	93	CD2(-), CD4(partial dim +), CD7(partial +), CD11b(partial +), CD13(partial +), CD15(-), CD19(-), CD22(partial +), CD33(partial and variably +), CD34(variably +), CD36(partial +), CD38(variably +), CD45(partial +), CD56(-), CD64(partial +), CD117 (partial +), HLA-DR(+), TdT(partial +), MPO(-)	5.8	7.5	Negative	Negative	Negative			Negative				Negative				71	Matched	AMLNOS	Leukemia	AML, NOS	1.1
aml_ohsu_2018_1255	aml_ohsu_2018_13-00513	Denovo	MLLT3-KMT2A	AML with t(9;11)(p22;q23); MLLT3-MLL	Adverse	Intermediate-II	AML with t(9;11)(p22;q23); MLLT3-MLL	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	1	Standard Chemotherapy	4	7+3 (Cytarabine, Idarubicin)|HiDAC|MEC (Cytarabine, Etoposide, Mitoxantrone)|Decitabine	3	Consolidation | Salvage | Induction	Complete Response	Standard Chemotherapy	6	Standard Chemotherapy	MEC (Cytarabine, Etoposide, Mitoxantrone)	Salvage	4	-274	1.4	75		No	8.5		11.4	8.5	34	0.2	62	31	3.8	1.44	M5	38.1	12.2	46,XY,t(9;11)(p22;q23)[20]	497	87.6	MLL rearrangement and t(9;11)	32		7.9	10.21	Positive	Positive								Negative				55	Matched	AMLRGA	Leukemia	AML with Recurrent Genetic Abnormalities	0.1
aml_ohsu_2018_1257	aml_ohsu_2018_13-00515	After or at the time transformation from another heme malignancy	None	AML with myelodysplasia-related changes	Adverse	Intermediate-II	AML with myelodysplasia-related changes	Post-Chemotherapy|Residual Disease	Peripheral Blood	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	2	Standard Chemotherapy | Targeted Therapy - Kinase Inhibitor(s)	7	Cytarabine, Fludarabine, Sorafenib|Crenolanib|Azacitidine|Sorafenib|Decitabine, Sorafenib |Clofarabine, Cytarabine|Sapacitabine (CYC682-06)	6	Hypomethylating/Low Dose Cytarabine | Salvage | Unknown | Induction | Experimental | Re-induction	Refractory	Standard Chemotherapy	39	Targeted Therapy - Kinase Inhibitor(s)	Crenolanib	Experimental	33	0	1	32	67	No	2		8	3	14		15	30	4.1			32.8	11	46,XY,+1,dic(1;15)(q12;p11.2)[2]/46,XY[18]			18].nuc ish(D5S721,D5S23,EGR1)x2[200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2 [200],(RUNX1T1,RUNX1)x2[198],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	90	CD4(partial dim +), CD7(-), CD10(-), CD11b(-), CD13(+), CD14(-), CD15(-), CD16(-), CD19(-), CD20(-), CD22(-), CD33(variably +), CD34(+), CD36(-), CD38(variably +), CD45 (variably +), CD56(-), CD64(-), CD79a(-)	5.8	24.2	Positive	Negative				Negative								74	Matched	AMLMRC	Leukemia	AML with Myelodysplasia-Related Changes	0.8
aml_ohsu_2018_1261	aml_ohsu_2018_13-00522	After or at the time transformation from another heme malignancy	None	Secondary myelofibrosis	Adverse	Adverse	AML with myelodysplasia-related changes	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	WES + RNA-seq	Yes	Yes	No	Yes	Yes	No	2	Standard Chemotherapy | Bone Marrow Transplant	3	Cyclophosphamide, Fludarabine, TBI|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Azacitidine	3	Allogeneic - Sibling | Hypomethylating/Low Dose Cytarabine | Induction	Complete Response	Standard Chemotherapy	-1	Standard Chemotherapy	Azacitidine	Hypomethylating/Low Dose Cytarabine	-1	0		29	40	No														46,XX,der(9)t(9;12)(p13;q13),del(11)(q21q25),der(12)add(12)(p11.2)add(12)(q13),del(13)(q14q22)[9]/46,idem,add(12)(q24.3),+13,-del(13)[9]/46,idem,add(17)(p13)[2]							11.36	Negative	Negative												68	Matched	MPN	Myeloproliferative Neoplasms	Myeloproliferative Neoplasms	0.9
aml_ohsu_2018_1281	aml_ohsu_2018_13-00532		Unknown	Acute myeloid leukaemia, NOS	Intermediate	Not Enough Information	Acute myeloid leukaemia, NOS	Residual Disease|Post-Chemotherapy	Peripheral Blood	WES + RNA-seq	Yes	Yes	No	Yes	Yes	No	2	Standard Chemotherapy | Targeted Therapy - Kinase Inhibitor(s)	13	HiDAC|Crenolanib|Etoposide|Topotecan|Decitabine|Clofarabine|Thioguanine|7+3 (Cytarabine, Idarubicin)|Cyclophosphamide|Thiotepa|Sorafenib|Mitoxantrone|Vinorelbine	4	Induction | Experimental | Re-induction | Supportive/Palliative Care	Refractory	Standard Chemotherapy	5	Targeted Therapy - Kinase Inhibitor(s)	Crenolanib	Experimental	15	0	0	88	92	No	0		8	0	0		22	20	3.3	0.51		25.8	9.1		208					6.4	3.2	Negative	Negative												22	Matched	AMLNOS	Leukemia	AML, NOS	0.633333333333
aml_ohsu_2018_1355	aml_ohsu_2018_13-00535	Denovo	None	AML with mutated NPM1	Favorable	Not Enough Information	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Peripheral Blood	WES	No	Yes	Yes	No	Yes	Yes	1	Standard Chemotherapy	3	7+3 (Cytarabine, Idarubicin)|HiDAC|MEC (Cytarabine, Etoposide, Mitoxantrone)	3	Consolidation | Salvage | Induction	Complete Response	Standard Chemotherapy	5	Standard Chemotherapy	MEC (Cytarabine, Etoposide, Mitoxantrone)	Salvage	2197	0		50	24	No	1		28	5	42					0.71		26.1	8.7	46,XX[20]	335		nuc ish(RUNX1T1,RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	108	CD2(-), CD4(partial dim +), CD5(-),CD7(-), CD11b(-), CD15(partial +/subset bright +), CD16(-), CD22(partial +), CD33(bright +), CD34(partial +), CD36(partial +), CD38(variably +), CD41(partial +), CD45(moderately +), CD56(-), CD61(partial +), CD64(-), CD71(+), CD117(+), HLA-DR(variably +), Gly-A(-).		4.06	Negative	Positive				Negative								51	Matched	AMLNPM1	Leukemia	AML with Mutated NPM1	0.6
aml_ohsu_2018_757	aml_ohsu_2018_13-00537		None	AML with maturation	Intermediate	Favorable	AML with maturation	Residual Disease|Post-Transplant	Bone Marrow Aspirate	WES	Yes	Yes	Yes	No	Yes	Yes	3	DLI | Standard Chemotherapy | Bone Marrow Transplant	9	HiDAC|Decitabine, Sirolimus|Donor Lymphocyte Infusion|3+7 (Cytarabine, Daunorubicin)|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone)|FLAG (Fludarabine, High-dose Cytarabine, G-CSF)|Decitabine|Busulfan, Cyclophosphamide	6	Consolidation | Salvage | Induction | Re-induction | Post-Transplant Relapse | Allogeneic - Matched Unrelated Donor	Complete Response	Standard Chemotherapy	6	Standard Chemotherapy	Decitabine, Sirolimus	Salvage	127	-18		90	30	No			56.8		9.9		62	39	3.5	0.6		30.6	10.2	46,XX[19]/46,XY[1]	145	91.3	Normal	17	CD7, CD13, CD33, CD34, dim CD45, CD56, CD117, CD123, and HLA-DR positive.	7.1	2	Negative	Negative	Q305?Q312del RNVETQ; MAF: 50%		Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	38	Unmatched	AM	Leukemia	AML with Maturation	0.166666666667
aml_ohsu_2018_1283	aml_ohsu_2018_13-00540	Denovo	Unknown	Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA	Favorable	Not Enough Information	Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA	Initial Acute Leukemia Diagnosis	Peripheral Blood	WES	No	Yes	No	No	Yes	No	1	Standard Chemotherapy	1	ATRA, Arsenic Trioxide	1	Induction	Complete Response	Standard Chemotherapy	-1	Standard Chemotherapy	ATRA, Arsenic Trioxide	Induction	-1	0			54	No																	PML-RARA+ 0.70743		Large population of atypical CD117 positive, bright myeloperoxidase positive, CD34 negative, HLA-DR negative immature myeloid cells, representing approximately 90% of the leukocytes.		1.04	Negative	Negative												55	Matched	APLPMLRARA	Leukemia	APL with PML-RARA	1.2
aml_ohsu_2018_1285	aml_ohsu_2018_13-00544	After or at the time transformation from another heme malignancy	Unknown	Acute myeloid leukaemia, NOS	Intermediate	Adverse	Acute myeloid leukaemia, NOS	Initial Acute Leukemia Diagnosis	Peripheral Blood	RNA-seq	Yes	No	Yes	Yes	No	Yes	1	Standard Chemotherapy	1	7+3 (Cytarabine, Idarubicin)	1	Induction	Refractory	Standard Chemotherapy	5	Standard Chemotherapy	7+3 (Cytarabine, Idarubicin)	Induction	5	0			41	No																					9.5	Negative	Negative												68	Matched	AMLNOS	Leukemia	AML, NOS	NA
aml_ohsu_2018_1286	aml_ohsu_2018_13-00545		GATA2-MECOM	AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1	Adverse	Adverse	AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1	Residual Disease|Post-Chemotherapy	Peripheral Blood	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	2	Standard Chemotherapy | Targeted Therapy - Kinase Inhibitor(s)	4	Dasatinib|7+3 (Cytarabine, Idarubicin)|Azacitidine|Decitabine	4	Hypomethylating/Low Dose Cytarabine | Induction | Experimental | Maintenance	Refractory	Standard Chemotherapy	-1	Standard Chemotherapy	Azacitidine	Hypomethylating/Low Dose Cytarabine	-1	2				No														45,XY,-7,t(3;3)[20]								Positive	Negative	Negative	Negative	Negative		Negative	Negative		Negative	Negative	Negative	Negative	72	Matched	AMLRGA	Leukemia	AML with Recurrent Genetic Abnormalities	0.833333333333
aml_ohsu_2018_1286	aml_ohsu_2018_13-00546		GATA2-MECOM	AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1	Adverse	Adverse	AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1	Post-Chemotherapy|Residual Disease	Bone Marrow Aspirate	RNA-seq	Yes	No	Yes	Yes	No	Yes	2	Standard Chemotherapy | Targeted Therapy - Kinase Inhibitor(s)	4	Dasatinib|7+3 (Cytarabine, Idarubicin)|Azacitidine|Decitabine	4	Hypomethylating/Low Dose Cytarabine | Induction | Experimental | Maintenance	Refractory	Standard Chemotherapy	-1	Standard Chemotherapy	Azacitidine	Hypomethylating/Low Dose Cytarabine	-1	2				No														45,XY,-7,t(3;3)[20]								Negative	Negative	Negative	Negative	Negative		Negative	Negative		Negative	Negative	Negative	Negative	72	Matched	AMLRGA	Leukemia	AML with Recurrent Genetic Abnormalities	NA
aml_ohsu_2018_1314	aml_ohsu_2018_13-00551		None	Acute myeloid leukaemia, NOS	Intermediate	Intermediate-I	Acute myeloid leukaemia, NOS	Post-Chemotherapy|Residual Disease	Peripheral Blood	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	2	Standard Chemotherapy | Bone Marrow Transplant	3	7+3 (Cytarabine, Idarubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone)|Busulfan, Cyclophosphamide	3	Allogeneic - Sibling | Induction | Re-induction	Refractory	Standard Chemotherapy	-1	Bone Marrow Transplant	Busulfan, Cyclophosphamide	Allogeneic - Sibling	-1	-3			1	No			17	35	23		16	14	3.7	0.8		25	8.7	46,XY[20]		83.8		16		6.8	3.2	Negative	Negative	Negative			Negative								51	Unmatched	AMLNOS	Leukemia	AML, NOS	0.133333333333
aml_ohsu_2018_1315	aml_ohsu_2018_13-00552		None	AML with minimal differentiation	Adverse	Adverse	AML with minimal differentiation	Residual Disease	Peripheral Blood	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	1	Standard Chemotherapy	3	FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Azacitidine|Etoposide, Mitoxantrone	3	Hypomethylating/Low Dose Cytarabine | Salvage | Induction	Refractory	Standard Chemotherapy	-1	Standard Chemotherapy	FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)	Salvage	-1	-7				No														46,XY,add(1)(p34),del(7)(q22),del(20)(q11.2)[20]			normal, no evidence of RUNX1T1/RUNX1 transloc or 11q23 or 16q22					Positive	Negative												75	Matched	AMLMD	Leukemia	AML with Minimal Differentiation	1.46666666667
aml_ohsu_2018_1339	aml_ohsu_2018_13-00554		None	AML with myelodysplasia-related changes	Adverse	Intermediate-I	AML with myelodysplasia-related changes	Residual Disease	Bone Marrow Aspirate	WES	No	Yes	No	No	Yes	No	0		0		0					NONE	NONE	NONE		0	0.8	30		No	1.5	0	71.5	1.5	24.7	0	21	17	3.6	0.77		28.1	9.1	46,XY[21]	180	117.1	Loss of ERG1 signal	47	CD13, CD33, CD34, dim CD38, CD117, and HLA-DR positive (10/31/13).	7.1	1.3	Negative	Negative	Negative		Negative	Negative	Negative		Negative	Negative	Negative	Negative	C238R; MAF 5% (not confirmed by Sanger seq)	64	Matched	AMLMRC	Leukemia	AML with Myelodysplasia-Related Changes	0.2
aml_ohsu_2018_1233	aml_ohsu_2018_13-00557		None	AML with myelodysplasia-related changes	Adverse	Intermediate-II	AML with myelodysplasia-related changes	Residual Disease	Bone Marrow Aspirate	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	1	Standard Chemotherapy	4	5+2 (Cytarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone)|Decitabine	3	Salvage | Induction | Re-induction	Refractory	Standard Chemotherapy	6	Standard Chemotherapy	Decitabine	Salvage	126	0		17	2	No			32.2		34.2		34	15	3.7	0.3		32.4	10.4	46~49,XY,-21,+1~4mar[cp20]		87.2	Monosomy 21	21	CD11b, CD13, CD33, CD34, CD38, CD58, partial CD64, CD117, HLA-DR and partial TdT positive; aberrant monocytic population: CD11b, CD13, CD14, bright CD33, dim CD56, CD64, and HLA-DR positive.	7	7.2	Negative	Negative												62	Matched	AMLMRC	Leukemia	AML with Myelodysplasia-Related Changes	0.966666666667
aml_ohsu_2018_1341	aml_ohsu_2018_13-00558	After or at the time transformation from another heme malignancy	None	AML with myelodysplasia-related changes	Adverse	Adverse	AML with myelodysplasia-related changes	Residual Disease|Post-Chemotherapy	Bone Marrow Aspirate	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	2	Standard Chemotherapy | Bone Marrow Transplant	5	5+2 (Cytarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin)|HAM (Cytarabine, Mitoxantrone)|Hydroxyurea|Busulfan, Cyclophosphamide	5	Allogeneic - Sibling | Salvage | Induction | Re-induction | Symptom Control	Refractory	Standard Chemotherapy	6	Bone Marrow Transplant	Busulfan, Cyclophosphamide	Allogeneic - Sibling	-1	0	0	25	20	No	13		6	12	55	0.9	45	34	3.1	0.8		31.1	9.8	42~44,XY,t(1;10)(q12;q21),-5,-7,-11,add(13)(p11.1),der(18)t(11;18)(q14;q21.1),add(20)(q12),+1~3mar[cp4]/41~44,sl,add(4)(q23)[cp9]/41~44,sl,del(4)(q21q?27)[cp5]/41~42,		88.9	Monosomy 5	243	CD13, CD33, CD34, CD117, and MPO+.	6.4	96.64	Negative	Negative												61	Matched	AMLMRC	Leukemia	AML with Myelodysplasia-Related Changes	0.166666666667
aml_ohsu_2018_1343	aml_ohsu_2018_13-00563	Denovo	None	AML with myelodysplasia-related changes	Adverse	Not Enough Information	AML with myelodysplasia-related changes	Initial Acute Leukemia Diagnosis	Peripheral Blood	WES + RNA-seq	Yes	Yes	No	Yes	Yes	No	2	Standard Chemotherapy | Bone Marrow Transplant	2	Fludarabine, BCNU, Melphalan|Decitabine, Midostaurin	2	Allogeneic - Sibling | Induction	Complete Response	Standard Chemotherapy	249	Bone Marrow Transplant	Fludarabine, BCNU, Melphalan	Allogeneic - Sibling	-1	-2				No														46,XX,t(2;3)(p13;q25~26)[2]/46,idem,i(14)(q10)[18]								Positive	Negative	Negative	Negative	Negative	Negative	Negative	Negative		Negative	Negative	Negative	Negative	64	Matched	AMLMRC	Leukemia	AML with Myelodysplasia-Related Changes	1.53333333333
aml_ohsu_2018_1348	aml_ohsu_2018_13-00572		None	Therapy-related myeloid neoplasms	Adverse	Adverse	Therapy-related myeloid neoplasms	Residual Disease|Post-Chemotherapy	Peripheral Blood	WES + RNA-seq	Yes	Yes	No	Yes	Yes	No	1	Standard Chemotherapy	7	Nelarabine|POMP (Prednisone, Methotrexate, 6-MP, Vincristine)|3+7 (Cytarabine, Daunorubicin)|HyperCVAD|Azacitidine|GCLAC (GCSF, Clofarabine & Cytarabine)|CLAG-M (Cladribine, Cytarabine, Mitoxantrone, Filgrastim)	5	Hypomethylating/Low Dose Cytarabine | Salvage | Induction | Maintenance | Re-induction	Complete Response	Standard Chemotherapy	-1	Standard Chemotherapy	GCLAC (GCSF, Clofarabine & Cytarabine)	Re-induction	-1	0		59.3	28	No														46,XY,t(10;11)(p13;q14)[11]/45,sl,-Y[7]/46,sdl1,t(1;8)(q12;p21)[2]			Normal		Increased atypical myeloblasts (partial CD34+, weak CD7+, partial CD61+), representing approximately 91% of the leukocytes, consistent with persistent acute myeloid leukemia.		1.7	Negative	Negative												39	Unmatched	TMN	Leukemia	Therapy-Related Myeloid Neoplasms	0.366666666667
aml_ohsu_2018_1349	aml_ohsu_2018_13-00573		Unknown	AML with myelodysplasia-related changes	Intermediate	Not Enough Information	AML with myelodysplasia-related changes	Residual Disease|Post-Chemotherapy	Peripheral Blood	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	1	Standard Chemotherapy	1	Decitabine	1	Supportive/Palliative Care				Standard Chemotherapy	Decitabine	Supportive/Palliative Care	169	0	0			No	0		17	44	39	0	15	9	3.5	0.9		25.7	8.2		175	88		18		6.9	13.22	Negative	Negative												86	Unmatched	AMLMRC	Leukemia	AML with Myelodysplasia-Related Changes	0.266666666667
aml_ohsu_2018_1353	aml_ohsu_2018_13-00578		DEK-NUP214	AML with t(6;9)(p23;q34); DEK-NUP214	Adverse	Adverse	AML with t(6;9)(p23;q34); DEK-NUP214	Residual Disease|Post-Chemotherapy	Peripheral Blood	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	2	Standard Chemotherapy | Targeted Therapy - Kinase Inhibitor(s)	6	7+3 (Cytarabine, Idarubicin)|Crenolanib|Azacitidine|MEC (Cytarabine, Etoposide, Mitoxantrone)|Decitabine, Sorafenib |Quizartinib	3	Salvage | Induction | Experimental	Refractory	Standard Chemotherapy	-1	Targeted Therapy - Kinase Inhibitor(s)	Crenolanib	Experimental	52	3			47	No							49	31	4.2	0.85				47~49,XX,t(6;9)(p23;q24),+8,+13,+15[cp8]/47~49,idem,+del(13)(q12q22)[cp12]	329			10		6.3	20.2	Positive	Negative												31	Matched	AMLDEKNUP214	Leukemia	AML with t(6;9)(p23;q34.1);DEK-NUP214	0.7
aml_ohsu_2018_1353	aml_ohsu_2018_13-00581		DEK-NUP214	AML with t(6;9)(p23;q34); DEK-NUP214	Adverse	Adverse	AML with t(6;9)(p23;q34); DEK-NUP214	Residual Disease|Post-Chemotherapy	Bone Marrow Aspirate	RNA-seq	Yes	No	Yes	Yes	No	Yes	2	Standard Chemotherapy | Targeted Therapy - Kinase Inhibitor(s)	6	7+3 (Cytarabine, Idarubicin)|Crenolanib|Azacitidine|MEC (Cytarabine, Etoposide, Mitoxantrone)|Decitabine, Sorafenib |Quizartinib	3	Salvage | Induction | Experimental	Refractory	Standard Chemotherapy	-1	Targeted Therapy - Kinase Inhibitor(s)	Crenolanib	Experimental	52	0		65	52	No	0		10	0	28			26	3.9	0.87		22.4	7.9	47~49,XX,t(6;9)(p23;q24),+8,+13,+15[cp8]/47~49,idem,+del(13)(q12q22)[cp12]		90.9		20	CD34(partial +), CD13(+), CD14(-), CD15(few +), CD30(-), CD33(+), CD38(variably +), CD45 (moderately +), CD64(variably +), CD4(partial +), CD117(+), CD123(variably +), HLA-DR(+), CD79a(-), CD22(-), intracellular CD3(-), TdT(-), MPO(partial +), other myeloid and lymphoid antigens(-).		43.3	Positive													31	Matched	AMLDEKNUP214	Leukemia	AML with t(6;9)(p23;q34.1);DEK-NUP214	NA
aml_ohsu_2018_1257	aml_ohsu_2018_13-00593	After or at the time transformation from another heme malignancy	None	AML with myelodysplasia-related changes	Adverse	Intermediate-I	AML with myelodysplasia-related changes	Post-Chemotherapy|Residual Disease	Bone Marrow Aspirate	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	2	Standard Chemotherapy | Targeted Therapy - Kinase Inhibitor(s)	7	Cytarabine, Fludarabine, Sorafenib|Crenolanib|Azacitidine|Sorafenib|Decitabine, Sorafenib |Clofarabine, Cytarabine|Sapacitabine (CYC682-06)	6	Hypomethylating/Low Dose Cytarabine | Salvage | Unknown | Induction | Experimental | Re-induction	Refractory	Standard Chemotherapy	39	Targeted Therapy - Kinase Inhibitor(s)	Crenolanib	Experimental	33	0	6	66	40	No	2		19	20	8		22	36	4.3			34.7	11.6	46,XY			nuc ish(D5S721,D5S23,EGR1)x2[198],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[199],(RUNX1T1, RUNX1)x2[198],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[199]	67	CD2(-), CD4(-), CD7(-), CD8(-), CD10(-), CD11b(partial +), CD13(+), CD14(-), CD15(-), CD16(-), CD19(-), CD20(-), CD22(-), CD33(variable and bright +), CD34(variably +)	6.2	13.9	Positive	Negative												74	Matched	AMLMRC	Leukemia	AML with Myelodysplasia-Related Changes	0.533333333333
aml_ohsu_2018_1368	aml_ohsu_2018_13-00600	After or at the time transformation from another heme malignancy	Unknown	AML with myelodysplasia-related changes	Intermediate	Not Enough Information	AML with myelodysplasia-related changes	Initial Acute Leukemia Diagnosis	Peripheral Blood	WES	No	Yes	No	No	Yes	No	1	Standard Chemotherapy	4	7+3 (Cytarabine, Idarubicin)|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone)|Decitabine	3	Hypomethylating/Low Dose Cytarabine | Induction | Re-induction	Refractory	Standard Chemotherapy	7	Standard Chemotherapy	FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)	Re-induction	45	0	0	30	35	No	1.2		16	7.4	30.7	0	45	31	3.2	0.94		25.4	8.6		389	99.6	Monosomy 7	24	CD13, partial CD33, CD34, partial CD56, partial CD64, CD117, partial CD123, HLA-DR and MPO-positive	6.5	3.28	Negative	Negative	Negative			Negative	Negative		Negative	Negative	Negative	Negative	Negative	53	Matched	AMLMRC	Leukemia	AML with Myelodysplasia-Related Changes	0.866666666667
aml_ohsu_2018_1369	aml_ohsu_2018_13-00601		None	Refractory anaemia with excess blasts	Intermediate		Refractory anaemia with excess blasts	Unknown	Bone Marrow Aspirate	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	1	Standard Chemotherapy	1	Decitabine	1	Induction	Unknown	Standard Chemotherapy	60	Standard Chemotherapy	Decitabine	Induction	60	-3				No														46,XY[20]			nuc ish(D5S721,D5S23,EGR1)x2[200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[200],(RUNX1T1,RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]					Negative	Negative													Matched	MDSEB	Myelodysplastic Syndromes	MDS with Excess Blasts	0.966666666667
aml_ohsu_2018_1370	aml_ohsu_2018_13-00602	Denovo	None	AML with myelodysplasia-related changes	Adverse	Intermediate-II	AML with myelodysplasia-related changes	Initial Acute Leukemia Diagnosis	Peripheral Blood	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	2	Standard Chemotherapy | Bone Marrow Transplant	3	Fludarabine, Melphalan|7+3 (Cytarabine, Idarubicin)|HiDAC	3	Consolidation | Induction | Allogeneic - Matched Unrelated Donor	Complete Response	Standard Chemotherapy	5	Bone Marrow Transplant	Fludarabine, Melphalan	Allogeneic - Matched Unrelated Donor	-1	-2			85	Yes	0		9	3	3		16	27	2.9	0.75				46,XY,del(11)(q14q23)[13]/46,XY[7].ishdel(11)(5'MLL-,3'MLL+)[2].	682		nuc ish(D5S721,D5S23,EGR1)x2[198],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[200],(5'MLLx1,3'MLLx2)(5'MLL con 3'MLLx1)[118/200]			6.6	33	Negative	Negative				Negative								63	Matched	AMLMRC	Leukemia	AML with Myelodysplasia-Related Changes	0.9
aml_ohsu_2018_1374	aml_ohsu_2018_13-00614	Denovo	None	Acute erythroid leukaemia	Intermediate	Not Enough Information	Acute erythroid leukaemia	Initial Acute Leukemia Diagnosis	Peripheral Blood	WES	No	Yes	No	No	Yes	No	1	Standard Chemotherapy	3	7+3 (Cytarabine, Idarubicin)|Azacitidine|MiDAC	3	Hypomethylating/Low Dose Cytarabine | Consolidation | Induction	Complete Response	Standard Chemotherapy	-1	Standard Chemotherapy	Azacitidine	Hypomethylating/Low Dose Cytarabine	-1	0		20		No														46,XY[20]			Normal		Atypical myeloblasts (partial CD7+) representing approximately 35% of the total leukocytes. 31% of the leukocytes are lymphocytes, 1% are monocytes, 33% are myeloid cells, and 35% are atypical cells with dim CD45.			Negative	Negative	Negative											67	Matched	PERL	Leukemia	Pure Erythroid Leukemia	0.1
aml_ohsu_2018_1375	aml_ohsu_2018_13-00615	Denovo	RUNX1-RUNX1T1	AML with t(8;21)(q22;q22); RUNX1-RUNX1T1	Favorable	Favorable	AML with t(8;21)(q22;q22); RUNX1-RUNX1T1	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	1	Standard Chemotherapy	1	FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)	1	Induction	Complete Response	Standard Chemotherapy	-1	Standard Chemotherapy	FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)	Induction	-1	0		52	57	No				6										46,XY,t(8;21)(q22;q22)[14]					CD34, PARTIAL CD38, CD33, CD13, CD64, PARTIAL CD11C, PARTIAL CD19, HLA-DR, PARTIAL CD15, CD117, AND MPO		12.9	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative			Negative	Positive	Negative	62	Matched	AMLRUNX1RUNX1T1	Leukemia	AML with t(8;21)(q22;q22.1);RUNX1-RUNX1T1	1.06666666667
aml_ohsu_2018_1373	aml_ohsu_2018_13-00619		Unknown	AML with mutated NPM1	Favorable	Not Enough Information	AML with mutated NPM1	Residual Disease|Post-Chemotherapy	Peripheral Blood	WES + RNA-seq	Yes	Yes	No	Yes	Yes	No	2	Standard Chemotherapy | Targeted Therapy - Kinase Inhibitor(s)	2	Crenolanib|MEC (Cytarabine, Etoposide, Mitoxantrone)	2	Salvage | Experimental				Standard Chemotherapy	MEC (Cytarabine, Etoposide, Mitoxantrone)	Salvage	4	0	0		72	No	0		28	0	0		10	17	2.8	0.56		14.5	5.3		291			10		5.1	1.2	Negative	Positive												47	Matched	AMLNPM1	Leukemia	AML with Mutated NPM1	0.866666666667
aml_ohsu_2018_1377	aml_ohsu_2018_13-00622		GATA2-MECOM	AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1	Adverse	Adverse	AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1	Residual Disease|Post-Chemotherapy	Bone Marrow Aspirate	WES	No	Yes	No	No	Yes	No	1	Standard Chemotherapy	5	S0919 Trial (Pravastatin, Idarubicin, Cytarabine)|7+3 (Cytarabine, Idarubicin)|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Lenalidomide|Decitabine	3	Hypomethylating/Low Dose Cytarabine | Induction | Re-induction	Refractory	Standard Chemotherapy	-1	Standard Chemotherapy	S0919 Trial (Pravastatin, Idarubicin, Cytarabine)	Re-induction	-1	0		36	0	No				15							M1			45,XX,?add(2)(q35~37),inv(3)(q21q26),-7[4]/46,XX[1]					CD38, CD7, CD13, partial CD33, partial CD11c, dim CD5, dim CD19, CD4, HLA-DR, partial CD15, and partial CD117		0.3	Negative	Negative												48	Matched	AMLRGA	Leukemia	AML with Recurrent Genetic Abnormalities	0.833333333333
aml_ohsu_2018_1378	aml_ohsu_2018_13-00625	Denovo	None	AML with myelodysplasia-related changes	Adverse	Adverse	AML with myelodysplasia-related changes	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	WES + RNA-seq	Yes	Yes	No	Yes	Yes	No	2	Standard Chemotherapy | Bone Marrow Transplant	2	SWOG S1203 (7+3 +/- Vorinostat)|Fludarabine, Cyclophosphamide, TBI	2	Allogeneic - Sibling | Induction	Complete Response	Standard Chemotherapy	177	Bone Marrow Transplant	Fludarabine, Cyclophosphamide, TBI	Allogeneic - Sibling	-1	0		66	1	No				17							M1			45,XY,-7[6]/47,XY,+13[cp5]/46,XY[12]					CD34, CD4, CD13, CD15, partial CD33, CD38, partial CD117, partial CD11c, HLA-DR, MPO and TdT		2.1	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative		Negative	Negative	Positive	Negative	21	Matched	AMLMRC	Leukemia	AML with Myelodysplasia-Related Changes	0.8
aml_ohsu_2018_2737	aml_ohsu_2018_13-00650		Unknown	AML with mutated NPM1	Favorable	Not Enough Information	AML with mutated NPM1	Unknown	Peripheral Blood	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	0		0		0					NONE	NONE	NONE		0				No																						Negative	Positive												20	Unmatched	AMLNPM1	Leukemia	AML with Mutated NPM1	0.166666666667
aml_ohsu_2018_1394	aml_ohsu_2018_13-00654		MLLT3-KMT2A	AML with t(9;11)(p22;q23); MLLT3-MLL	Intermediate	Intermediate-II	AML with t(9;11)(p22;q23); MLLT3-MLL	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	WES	No	Yes	No	No	Yes	No	2	Standard Chemotherapy | Bone Marrow Transplant	5	7+3 (Cytarabine, Idarubicin)|Fludarabine, TBI|MiDAC|FATE Trial RIC (Fludarabine, Melphalan, Rabbit ATG) |ODSH (2 O, 3-O Desulfated Heparin)	3	Consolidation | Induction | Allogeneic - Matched Unrelated Donor	Complete Response	Standard Chemotherapy	-1	Bone Marrow Transplant	Fludarabine, TBI	Allogeneic - Matched Unrelated Donor	-1	-1		93	58	No											M5a			47,XY,+8,t(9;11)(p21;q23)[9]/46,XY[11]			8q22 (RUNX1T1): gain present  11q23 (MLL): rearrangement present		Large population of promonocytes/monoblasts that represent approximately 88% of the leukocytes, consider acute monoblastic leukemia.		14.66	Negative	Negative	Negative							Negative				62	Matched	AMLRGA	Leukemia	AML with Recurrent Genetic Abnormalities	0.833333333333
aml_ohsu_2018_1394	aml_ohsu_2018_13-00655		MLLT3-KMT2A	AML with t(9;11)(p22;q23); MLLT3-MLL	Intermediate	Intermediate-II	AML with t(9;11)(p22;q23); MLLT3-MLL	Initial Acute Leukemia Diagnosis	Peripheral Blood	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	2	Standard Chemotherapy | Bone Marrow Transplant	5	7+3 (Cytarabine, Idarubicin)|Fludarabine, TBI|MiDAC|FATE Trial RIC (Fludarabine, Melphalan, Rabbit ATG) |ODSH (2 O, 3-O Desulfated Heparin)	3	Consolidation | Induction | Allogeneic - Matched Unrelated Donor	Complete Response	Standard Chemotherapy	-1	Bone Marrow Transplant	Fludarabine, TBI	Allogeneic - Matched Unrelated Donor	-1	-1		93	58	No											M5a			47,XY,+8,t(9;11)(p21;q23)[9]/46,XY[11]			8q22 (RUNX1T1): gain present  11q23 (MLL): rearrangement present		Large population of promonocytes/monoblasts that represent approximately 88% of the leukocytes, consider acute monoblastic leukemia.		14.66	Negative	Negative	Negative							Negative				62	Matched	AMLRGA	Leukemia	AML with Recurrent Genetic Abnormalities	0.866666666667
aml_ohsu_2018_1396	aml_ohsu_2018_13-00658	Denovo	None	AML with mutated NPM1	Favorable	Favorable	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	1	Standard Chemotherapy	2	7+3 (Cytarabine, Idarubicin)|MiDAC	2	Consolidation | Induction	Complete Response	Standard Chemotherapy	6	Standard Chemotherapy	MiDAC	Consolidation	114	0	0.8	30	42.4	No	4.5		19.7	8.3	15.9	0.3	49	23	3.5	1.22		30.6	10.6	46,XY[21]	536	95.6	Normal	141	CD7, CD13, CD33, partial CD34, CD38, CD58, CD117, CD123,HLA-DR, and MPO positive	7.2	11.93	Negative	Positive	p. Q83fs*27 (c.245?246insTGTTCCA); MAF 50%		Negative		Negative	Negative	Negative	Negative	Negative	Negative	Negative	60	Unmatched	AMLNPM1	Leukemia	AML with Mutated NPM1	0.166666666667
aml_ohsu_2018_1397	aml_ohsu_2018_13-00659	Denovo	None	Acute myelomonocytic leukaemia	Intermediate	Intermediate-II	Acute myelomonocytic leukaemia	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	WES + RNA-seq	Yes	Yes	No	Yes	Yes	No	2	Standard Chemotherapy | Bone Marrow Transplant	4	5+2 (Cytarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin)|HiDAC|Busulfan, Cyclophosphamide	4	Allogeneic - Sibling | Consolidation | Induction | Re-induction	Refractory	Standard Chemotherapy	5	Bone Marrow Transplant	Busulfan, Cyclophosphamide	Allogeneic - Sibling	-1	0	0	54	54	No	0		14	59.6	5.3	0	463	477	2.7	1.14	M4	19.3	6.6	47,XY,+8[16]/46,XY[4]		93.7	Trisomy 8	47	partial CD13, CD15,  CD33, CD56, CD38, CD58, CD64, dimCD123, HLA-DR and MPO positive	5.7	16.66	Negative	Negative	Negative		Negative	Negative	Negative	Negative	Negative	Negative	Negative	p.G12R, MAF 50%	Negative	55	Matched	AML	Leukemia	Acute Myeloid Leukemia	0.466666666667
aml_ohsu_2018_1398	aml_ohsu_2018_13-00660	After or at the time transformation from another heme malignancy	None	AML with myelodysplasia-related changes	Adverse	Adverse	AML with myelodysplasia-related changes	Initial Acute Leukemia Diagnosis	Peripheral Blood	WES + RNA-seq	Yes	Yes	No	Yes	Yes	No	1	Standard Chemotherapy	1	Decitabine	1	Hypomethylating/Low Dose Cytarabine				Standard Chemotherapy	Decitabine	Hypomethylating/Low Dose Cytarabine	-1	0	2.6	41		No	0		15.3	9.3	28.8	0.6	36	31	3.8	1.66		23.3	7.2	46,XY,-7,+mar.ishder(7)del(7)(p11.2)del(7)(q11.2)(D7Z1+)[20]/45,XY,-7[2]/46,XY[3]	398	82	Two of twenty-five metaphase cells examined were monosomy 7, shown by  fluorescent in situ hybridization (FISH) in  a companion study  (GLC-13-06587) to be a true clone.  Twenty cells appeared to be missing a  chromosome 7 with an additional small marker.	42	CD13, dimCD19, partial CD33, partial CD34, CD38, CD58, dim cCD79a, CD117, and TdT positive.	6.6	12.44	Negative	Negative	Negative		Negative	Negative	Negative	Negative		Negative	Negative	Negative	Negative	72	Matched	AMLMRC	Leukemia	AML with Myelodysplasia-Related Changes	0.466666666667
aml_ohsu_2018_1400	aml_ohsu_2018_14-00001	Denovo	None	AML with mutated NPM1	Favorable or Intermediate	Intermediate-I	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	RNA-seq	Yes	No	No	Yes	No	No	1	Standard Chemotherapy	2	7+3 (Cytarabine, Idarubicin)|HiDAC	3	Consolidation | Induction | Re-induction	Refractory	Standard Chemotherapy	6	Standard Chemotherapy	HiDAC	Consolidation	111	0	0.8	95	95	No	0		25.6	0	0	0.7	27	16	3.4	0.97		11.1	3.7	46,XY[20]	314	95.7	Normal	20	CD13, CD33, CD38, partial CD56 (7%), CD58, CD117, CD123, and partial MPO positive	7.1	13.26	Positive	Positive	Negative		Negative	Negative	Negative		Negative	Negative	Negative	Negative	Negative	56	Matched	AMLNPM1	Leukemia	AML with Mutated NPM1	NA
aml_ohsu_2018_1400	aml_ohsu_2018_14-00004	Denovo	None	AML with mutated NPM1	Favorable or Intermediate	Intermediate-I	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Peripheral Blood	WES	No	Yes	No	No	Yes	No	1	Standard Chemotherapy	2	7+3 (Cytarabine, Idarubicin)|HiDAC	3	Consolidation | Induction | Re-induction	Refractory	Standard Chemotherapy	6	Standard Chemotherapy	HiDAC	Consolidation	111	0	0.8	95	95	No	0		25.6	0	0	0.7	27	16	3.4	0.97		11.1	3.7	46,XY[20]	314	95.7	Normal	20	CD13, CD33, CD38, partial CD56 (7%), CD58, CD117, CD123, and partial MPO positive	7.1	13.26	Positive	Positive	Negative		Negative	Negative	Negative		Negative	Negative	Negative	Negative	Negative	56	Matched	AMLNPM1	Leukemia	AML with Mutated NPM1	0.766666666667
aml_ohsu_2018_1406	aml_ohsu_2018_14-00012	Denovo	None	AML with mutated NPM1	Favorable	Not Enough Information	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Peripheral Blood	WES + RNA-seq	Yes	Yes	No	Yes	Yes	No	1	Supportive/Palliative Care	1	Hydroxyurea	1	Supportive/Palliative Care				Supportive/Palliative Care	Hydroxyurea	Supportive/Palliative Care	-1	0		94	71	No				0							M5			48,XYY,+8[21]					CD38, CD56, CD13(dim), CD64, CD11c, CD4, CD56, HLA-DR, and CD15		24.2	Negative	Positive	Negative	Negative	Negative		Negative	Negative		Negative	Negative	Negative	Negative	72	Matched	AMLNPM1	Leukemia	AML with Mutated NPM1	0.666666666667
aml_ohsu_2018_1161	aml_ohsu_2018_14-00015	Relapse	MLLT3-KMT2A	Therapy-related myeloid neoplasms	Intermediate	Intermediate-II	Therapy-related myeloid neoplasms	Relapse|Post-Chemotherapy	Bone Marrow Aspirate	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	2	Standard Chemotherapy | Supportive/Palliative Care	4	GCLAM (G-CSF, Cladribine, Cytarabine, and Mitoxantrone) |7+3 (Cytarabine, Idarubicin)|HiDAC|Decitabine	4	Consolidation | Salvage | Induction | Supportive/Palliative Care	Complete Response	Standard Chemotherapy	6	Supportive/Palliative Care	Decitabine	Supportive/Palliative Care	31	0	0	75	35	No	0		9.9	9.9	37.2	0.8	37	39	3.1	0.56		22.1	7.7	46,XX,t(9;11)(p22;q23)[20]/46,XX[1]		89.8	MLL disruption and t(9;11)	39	dim/partial CD13, CD33, CD38, CD56, CD58, CD64, partialCD117, CD123 and HLA-DR positive	6	43.72	Negative	Negative	Negative						Negative	Negative				31	Matched	TMN	Leukemia	Therapy-Related Myeloid Neoplasms	0.766666666667
aml_ohsu_2018_1408	aml_ohsu_2018_14-00021	After or at the time transformation from another heme malignancy	None	AML with myelodysplasia-related changes	Intermediate	Not Enough Information	AML with myelodysplasia-related changes	Initial Acute Leukemia Diagnosis	Peripheral Blood	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	1	Standard Chemotherapy	4	Hydroxyurea|Decitabine|Temozolomide, Vorinostat|Azacitidine, MLN4924	4	Salvage | Induction | Re-induction | Symptom Control	Refractory	Standard Chemotherapy	-1	Standard Chemotherapy	Decitabine	Salvage	-1	-49				No														46,XY								Negative	Negative												74	Matched	AMLMRC	Leukemia	AML with Myelodysplasia-Related Changes	0.3
aml_ohsu_2018_1409	aml_ohsu_2018_14-00023	Denovo	Unknown	AML with mutated NPM1	Favorable	Favorable	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Peripheral Blood	RNA-seq	Yes	No	Yes	Yes	No	Yes	1	Standard Chemotherapy	1	3+7 (Cytarabine, Daunorubicin)	1	Induction	Complete Response	Standard Chemotherapy	6	Standard Chemotherapy	3+7 (Cytarabine, Daunorubicin)	Induction	6	0	0.9			No	0		11.4	44.7	35.1	7.1	17	28	2.6	0.79		28.1	9.4		645	98.3		71		6.2	35.91	Negative	Positive												74	Matched	AMLNPM1	Leukemia	AML with Mutated NPM1	NA
aml_ohsu_2018_1410	aml_ohsu_2018_14-00026	After or at the time transformation from another heme malignancy	Unknown	AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1	Intermediate	Adverse	AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1	Post-Chemotherapy|Residual Disease	Peripheral Blood	WES + RNA-seq	Yes	Yes	No	Yes	Yes	No	2	Standard Chemotherapy | Supportive/Palliative Care	4	7+3 (Cytarabine, Idarubicin)|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Azacitidine|MEC (Cytarabine, Etoposide, Mitoxantrone)	4	Salvage | Unknown | Induction | Maintenance	Refractory	Standard Chemotherapy	5	Standard Chemotherapy	FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)	Unknown	6	0			16	No			20	10	54		152	49	4.3	0.77		30.5	10.6		340			215		7	4.01	Negative	Negative												39	Matched	AMLRGA	Leukemia	AML with Recurrent Genetic Abnormalities	0.566666666667
aml_ohsu_2018_1431	aml_ohsu_2018_14-00034	Denovo	None	AML with mutated CEBPA	Favorable	Favorable	AML with mutated CEBPA	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	2	Standard Chemotherapy | Bone Marrow Transplant	4	7+3 (Cytarabine, Idarubicin)|HiDAC|Azacitidine|Busulfan, Cyclophosphamide	3	Consolidation | Induction | Allogeneic - Matched Unrelated Donor	Complete Response	Standard Chemotherapy	6	Bone Marrow Transplant	Busulfan, Cyclophosphamide	Allogeneic - Matched Unrelated Donor	-1	0	0	50	25	Yes	0		45.3	19.6	9.3	6	27	20	3.7	1.01		30.6	10.1	46,XY[20]		98.4	Normal	15	CD7, CD13, CD33, CD34, CD38, CD64, CD123, HLA-DR, and MPO	6.3	3.85	Negative	Negative	c.242?243insCTTGGTT (7bp out-of-frame insertion); MAF 50%			Negative	Negative	Negative	Negative	Negative				55	Matched	AMLCEBPA	Leukemia	AML with Biallelic Mutations of CEBPA	1.16666666667
aml_ohsu_2018_1434	aml_ohsu_2018_14-00041	Denovo	GATA2-MECOM	AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1	Adverse	Adverse	AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1	Initial Acute Leukemia Diagnosis	Peripheral Blood	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	1	Standard Chemotherapy	1	AG-221	1	Hypomethylating/Low Dose Cytarabine				Standard Chemotherapy	AG-221	Hypomethylating/Low Dose Cytarabine	-1	0		22	8	No				10							M4			46,XX,inv(3)?(q21q25)[21]					CD34, CD117, CD38, CD56 (minor subset), partial CD13, partial CD33, CD11c, and HLA-DR		2.6	Negative	Negative	Negative	Negative	Negative	Negative	Negative			Negative	Negative	Negative	Negative	71	Matched	AMLRGA	Leukemia	AML with Recurrent Genetic Abnormalities	0.333333333333
aml_ohsu_2018_1153	aml_ohsu_2018_14-00044		None	AML with mutated NPM1	Favorable	Not Enough Information	AML with mutated NPM1	Residual Relapse|Post-Chemotherapy|Post-Transplant	Peripheral Blood	RNA-seq	Yes	No	Yes	Yes	No	Yes	2	Standard Chemotherapy | Bone Marrow Transplant	5	7+3 (Cytarabine, Idarubicin)|HiDAC|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone)|Cyclophosphamide, Etoposide, TBI	5	Allogeneic - Sibling | Consolidation | Salvage | Induction | Re-induction	Complete Response	Standard Chemotherapy	6	Standard Chemotherapy	FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)	Re-induction	53	-159				No														46,XX[5]								Negative	Positive												37	Matched	AMLNPM1	Leukemia	AML with Mutated NPM1	NA
aml_ohsu_2018_1435	aml_ohsu_2018_14-00045	Relapse	None	AML with myelodysplasia-related changes	Adverse	Intermediate-I	AML with myelodysplasia-related changes	Post-Chemotherapy|Post-Transplant|Relapse	Peripheral Blood	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	2	Standard Chemotherapy | Bone Marrow Transplant	4	7+3 (Cytarabine, Idarubicin)|HiDAC|MEC (Cytarabine, Etoposide, Mitoxantrone)|Busulfan, Cyclophosphamide	4	Allogeneic - Sibling | Consolidation | Salvage | Induction	Refractory	Standard Chemotherapy	-1	Standard Chemotherapy	MEC (Cytarabine, Etoposide, Mitoxantrone)	Salvage	-1	0	0	62	66	No	0		7	0	13		24	40	3.4			35.5	12.1	46,XX			nuc ish(D5S721,D5S23,EGR1)x2[200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[200],(RUNX1T1, RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[198],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	29	CD2(-), CD4(partial +), CD7(-), CD11b(partial +), CD13(+), CD14(-), CD15(partial +), CD16(-), CD33(bright +), CD34(partial +), CD36(-), CD38(variably +), CD45(variably +), CD56(partial +), CD64(-), CD117(partial +), HLA-DR(partial dim +)	5.8	58.5	Positive	Negative	Negative			Negative	Negative	Negative						48	Unmatched	AMLMRC	Leukemia	AML with Myelodysplasia-Related Changes	0.0333333333333
aml_ohsu_2018_1438	aml_ohsu_2018_14-00052	Denovo	GATA2-MECOM	AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1	Adverse	Adverse	AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	WES	No	Yes	Yes	No	Yes	Yes	1	Standard Chemotherapy	3	CPX-351 (Liposomal Cytarabine + Daunorubicin)|Lenalidomide|MEC (Cytarabine, Etoposide, Mitoxantrone)	2	Induction | Re-induction	Refractory	Standard Chemotherapy	23	Standard Chemotherapy	MEC (Cytarabine, Etoposide, Mitoxantrone)	Re-induction	4	-14				No														45,XY,inv(3)(q21q26),-7[20]								Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative		Negative	Negative	Negative	Negative	71	Matched	AMLRGA	Leukemia	AML with Recurrent Genetic Abnormalities	1.13333333333
aml_ohsu_2018_1438	aml_ohsu_2018_14-00053	Denovo	GATA2-MECOM	AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1	Adverse	Adverse	AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1	Initial Acute Leukemia Diagnosis	Peripheral Blood	RNA-seq	Yes	No	No	Yes	No	No	1	Standard Chemotherapy	3	CPX-351 (Liposomal Cytarabine + Daunorubicin)|Lenalidomide|MEC (Cytarabine, Etoposide, Mitoxantrone)	2	Induction | Re-induction	Refractory	Standard Chemotherapy	23	Standard Chemotherapy	MEC (Cytarabine, Etoposide, Mitoxantrone)	Re-induction	4	-14				No														45,XY,inv(3)(q21q26),-7[20]								Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative		Negative	Negative	Negative	Negative	71	Matched	AMLRGA	Leukemia	AML with Recurrent Genetic Abnormalities	NA
aml_ohsu_2018_1441	aml_ohsu_2018_14-00060		None	Myelodysplastic syndrome, unclassifiable	Adverse		Myelodysplastic syndrome, unclassifiable	Unknown	Peripheral Blood	WES + RNA-seq	Yes	Yes	No	Yes	Yes	No	1	Standard Chemotherapy	1	Azacitidine	1	Induction	Unknown	Standard Chemotherapy	6	Standard Chemotherapy	Azacitidine	Induction	6	-13	0		15	No	1.7		38.7	3.4	30.3	0	27	23	3	1.18		21	7	45~48,XY,del(5)(q22q35),+8,del(13)(q12q14),- 20,der(21)t(20;21)(p11.2;p11.1),+der(22)t(?;22)(?;q11.2)[cp15]/46,XY[4]	1138	88.6		26	CD13, CD33, CD34, CD38, CD58, CD117, CD123 and HLA-DR positive	5.7	2.42	Negative	Negative												68	Matched	MDSU	Myelodysplastic Syndromes	MDS, Unclassifiable	1.06666666667
aml_ohsu_2018_202	aml_ohsu_2018_14-00061	Relapse	None	Therapy-related myeloid neoplasms	Adverse	Adverse	Therapy-related myeloid neoplasms	Relapse	Peripheral Blood	RNA-seq	Yes	No	Yes	Yes	No	Yes	1	Standard Chemotherapy	3	7+3 (Cytarabine, Idarubicin)|MiDAC|Decitabine	3	Consolidation | Induction | Supportive/Palliative Care	Complete Response	Standard Chemotherapy	7	Standard Chemotherapy	Decitabine	Supportive/Palliative Care	9	-2	0			No	0		14.9	0.8	2.5	0						22.7	7.6	47,XY,del(9)(q22),+13[18]/48,idem,+mar[2]	556	93.8	Missing ABL and ASS signal	32			47.2	Negative	Negative	Negative		Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	72	Matched	TMN	Leukemia	Therapy-Related Myeloid Neoplasms	NA
aml_ohsu_2018_1443	aml_ohsu_2018_14-00063	Denovo	None	AML with myelodysplasia-related changes	Adverse	Adverse	AML with myelodysplasia-related changes	Initial Acute Leukemia Diagnosis	Peripheral Blood	WES + RNA-seq	Yes	Yes	No	Yes	Yes	No	1	Unknown	1	Bevacizumab	1	Unknown				Unknown	Bevacizumab	Unknown	-1	-4				No														44-47,XX,del(5)(q13q33),der(14;18)(q10;q10),-20,-21,+1-4mar[cp15]								Negative	Negative												80	Unmatched	AMLMRC	Leukemia	AML with Myelodysplasia-Related Changes	0.133333333333
aml_ohsu_2018_1444	aml_ohsu_2018_14-00064		None	AML with myelodysplasia-related changes	Intermediate	Intermediate-I	AML with myelodysplasia-related changes	Post-Chemotherapy|Residual Disease	Bone Marrow Aspirate	WES + RNA-seq	Yes	Yes	No	Yes	Yes	No	2	Standard Chemotherapy | Targeted Therapy - Other	8	E7070, Idarubicin, Cytarabine|5+2 (Cytarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin)|HiDAC|GCLAC (GCSF, Clofarabine & Cytarabine)|MEC (Cytarabine, Etoposide, Mitoxantrone)|BL-8040|IGN523	4	Salvage | Induction | Experimental | Re-induction	Refractory	Standard Chemotherapy	-1	Standard Chemotherapy	MEC (Cytarabine, Etoposide, Mitoxantrone)	Salvage	-1	0	1	10	6	No	0		32.7	12.6	53.7		45	19	3.7	0.69		26.8	9.4	46,XY[20]	88		nuc ish(D5S721,D5S23,EGR1)x2[200],(D7Z1,D7S522)x1[47/200],(D8Z2,D20S108)x2[200],(RUNX1T1, RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[199],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	75	CD2 (-), CD4(+), CD7(+), CD11b(-), CD13(+), CD14(-), CD15(-), CD16(-), CD33(+), CD34(bright +), CD36(-), CD38(variable +), CD45(moderately +), CD56(-), CD64(-), CD117(+), HLA-DR(+).	5.8	1.6	Negative	Negative	Negative			Negative	Negative	Negative						59	Matched	AMLMRC	Leukemia	AML with Myelodysplasia-Related Changes	0.433333333333
aml_ohsu_2018_1446	aml_ohsu_2018_14-00066		None	Acute erythroid leukaemia	Intermediate	Intermediate-II	Acute erythroid leukaemia	Residual Disease|Post-Chemotherapy	Bone Marrow Aspirate	WES	No	Yes	No	No	Yes	No	2	Standard Chemotherapy | Bone Marrow Transplant	2	Fludarabine, Melphalan|Azacitidine	2	Induction | Allogeneic - Matched Unrelated Donor	Complete Response	Standard Chemotherapy	-1	Bone Marrow Transplant	Fludarabine, Melphalan	Allogeneic - Matched Unrelated Donor	-1	0	0.9	10		No	3.5	0.4	54.5	3	37.7	0	83	52	3.8	1.12		32.8	11	46,XY,del(20)(q12)[14]/46,XY[6]	284	100.9	20q deletion	99	The analysis shows CD34+ blasts comprise approximately 4.2% of total CD45+ events and show variable expression of CD13, CD33, CD117, and dim partial CD123.  Please see below for antibodies tested.  B-cells (2% of lymphocyte gate) show polytypic surface light chain expression.	8.2	2.31	Negative	Negative	Negative			Negative	Negative		Negative	Negative	Negative	Negative	Negative	51	Matched	PERL	Leukemia	Pure Erythroid Leukemia	0.433333333333
aml_ohsu_2018_1448	aml_ohsu_2018_14-00067		None	Myelodysplastic syndrome, unclassifiable	Adverse		Myelodysplastic syndrome, unclassifiable	Post-Chemotherapy|Residual Disease	Bone Marrow Aspirate	WES	No	Yes	No	No	Yes	No	2	Standard Chemotherapy | Bone Marrow Transplant	3	Fludarabine, Melphalan|Lenalidomide|Decitabine	3	Hypomethylating/Low Dose Cytarabine | Induction | Allogeneic - Mismatched Unrelated Donor	Refractory	Standard Chemotherapy	61	Bone Marrow Transplant	Fludarabine, Melphalan	Allogeneic - Mismatched Unrelated Donor	-1	0		12	1	No							80	54	4.3			24.7	8.3	44~45,XX,add(4)(p16),der(5)t(5;12)(q13;q14),-7,-12,del(17)(p11.2p13),+1~3mar[cp14]/45,idem,dup(11)(q23q14)[1]/44,idem,add (1)(p36.3)[cp3]/46,XX[2]			nuc ish(D5S721x2,D5S23x2,EGR1x1)[149/200],(D7Z1,D7S522)x1[155/200],(D8Z2,D20S108)x2[200], (RUNX1T1,RUNX1)x2[199],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[199],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	91	CD2(-), CD4(variably +), CD7(-), CD11b(-), CD13(+), CD14(-), CD15(-), CD16(-), CD33(+), CD34(+), CD36(-), CD38(partial +), CD45(+), CD56(-), CD64(-), CD117(+), HLA-DR(+), TdT(-), MPO(-)	7.9	5.9	Negative	Negative	Negative			Negative								62	Matched	MDSU	Myelodysplastic Syndromes	MDS, Unclassifiable	0.833333333333
aml_ohsu_2018_1450	aml_ohsu_2018_14-00078	Denovo	Unknown	Acute myeloid leukaemia, NOS	Intermediate	Intermediate-I	Acute myeloid leukaemia, NOS	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	WES + RNA-seq	Yes	Yes	No	Yes	Yes	No	1	Standard Chemotherapy	3	COG-AAML1031 (IT/IV Cytarabine, Daunorubicin, Etoposide, Mitoxantrone +/- Bortezomib or Sorafenib)|Clofarabine, Cyclophosphamide, Etoposide|HAM (Cytarabine, Mitoxantrone)	2	Induction | Re-induction	Refractory	Standard Chemotherapy	74	Standard Chemotherapy	Clofarabine, Cyclophosphamide, Etoposide	Re-induction	5	0	0			No	0		48.5	0.6	1.2	1.6	18	11	3.5	0.7		25.6	9.1			87.4	Normal	25		6.9	4.34	Negative	Negative	Negative		Negative	Negative	Negative		Negative	Negative	Negative	Negative	Negative	17	Unmatched	AMLNOS	Leukemia	AML, NOS	0.266666666667
aml_ohsu_2018_1453	aml_ohsu_2018_14-00081	Denovo	None	AML with myelodysplasia-related changes	Adverse	Adverse	AML with myelodysplasia-related changes	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	WES + RNA-seq	Yes	Yes	No	Yes	Yes	No	1	Standard Chemotherapy	3	7+3 (Cytarabine, Idarubicin)|Azacitidine, Lenalidomide|Decitabine	3	Consolidation | Induction | Re-induction	Complete Response	Standard Chemotherapy	6	Standard Chemotherapy	Azacitidine, Lenalidomide	Re-induction	28	0	0	46	49.1	No	0		20.5	8	17	0.9	32	39	3.3	0.73	M2	20.7	6.4	42~45,XX,add(5)(q13),der(17)add(17)(p11.2)add(17)(q11.2),-18,-22[cp6]/43~44,sl,add(13)(q32),add(14)(q11.2),+mar[cp12]/43~44,sl,add(14)(q11.2),-21,	685	79	5q deletion	11	partial CD7, CD13, partial CD33, CD34, partial CD38, CD58, CD117, dim/partial CD123, partial TdT, HLA-DR positive.	6.6	12.87	Negative	Negative	Negative		Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	V173M; MAF 80%	71	Matched	AMLMRC	Leukemia	AML with Myelodysplasia-Related Changes	0.666666666667
aml_ohsu_2018_1989	aml_ohsu_2018_14-00083		None	AML with mutated NPM1	Favorable	Favorable	AML with mutated NPM1	Residual Disease	Bone Marrow Aspirate	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	1	Standard Chemotherapy	5	HiDAC|GCLAC (GCSF, Clofarabine & Cytarabine)|SWOG S1203 (7+3 +/- Vorinostat)|MEC, Lenalidomide|Etoposide, Cytarabine	4	Consolidation | Salvage | Induction | Re-induction	Complete Response	Standard Chemotherapy	6	Standard Chemotherapy	GCLAC (GCSF, Clofarabine & Cytarabine)	Salvage	-1	-2				No														46,XY[20]								Negative	Positive	Negative	Negative	Positive	Negative	Positive	Negative		Negative	Negative	Positive	Negative	46	Matched	AMLNPM1	Leukemia	AML with Mutated NPM1	0.966666666667
aml_ohsu_2018_1461	aml_ohsu_2018_14-00092	Denovo	None	AML with mutated NPM1	Favorable	Favorable	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	2	Standard Chemotherapy | Bone Marrow Transplant	3	Fludarabine, Melphalan|7+3 (Cytarabine, Idarubicin)|HiDAC	3	Consolidation | Induction | Allogeneic - Matched Unrelated Donor	Complete Response	Standard Chemotherapy	6	Bone Marrow Transplant	Fludarabine, Melphalan	Allogeneic - Matched Unrelated Donor	-1	0	1.7	13	14	No	0.8		9.4	28.2	49.6	1.6	18	26	2.8	0.74	M4	21.2	7.3	46,XX[20]	514	101.4	Normal	57	CD13, CD33, CD38, CD58, CD117, CD123, HLA-DR, and MPO positive	6.1	63.75	Negative	Positive	Negative		p.T138I; MAF 50%		Negative	Negative			Negative	p.Q61H; MAF 40%	Negative	63	Matched	AMLNPM1	Leukemia	AML with Mutated NPM1	0.533333333333
aml_ohsu_2018_1464	aml_ohsu_2018_14-00096	Denovo	None	AML with myelodysplasia-related changes	Adverse	Not Enough Information	AML with myelodysplasia-related changes	Initial Acute Leukemia Diagnosis	Peripheral Blood	WES + RNA-seq	Yes	Yes	No	Yes	Yes	No	2	Standard Chemotherapy | Bone Marrow Transplant	3	7+3 (Cytarabine, Idarubicin)|GCLAC (GCSF, Clofarabine & Cytarabine)|Busulfan, Cyclophosphamide	3	Allogeneic - Sibling | Induction | Re-induction	Complete Response	Standard Chemotherapy	27	Bone Marrow Transplant	Busulfan, Cyclophosphamide	Allogeneic - Sibling	-1	0		72	88	No				1										40~43,XY,add(1)(p36),-2,-4,-5,-8,-12,-14,-15,-16,-17,?add(17)(p13),der(19)?t(8;19)(q11.2;p13),-20,-22,+7mar[cp18]					CD34, CD38 (dim), CD13, CD33 (dim),CD64 (partial), CD11c, CD4 (partial), CD15, CD117, HLA-DR, and MPO(partial).		12.9	Positive	Negative	Negative	Negative	Negative	Negative	Negative	Negative		Negative	Negative	Negative	Negative	56	Matched	AMLMRC	Leukemia	AML with Myelodysplasia-Related Changes	0.633333333333
aml_ohsu_2018_584	aml_ohsu_2018_14-00111	Relapse	None	AML with maturation	Intermediate	Intermediate-II	AML with maturation	Relapse|Post-Chemotherapy	Bone Marrow Aspirate	WES	No	Yes	No	No	Yes	No	2	Standard Chemotherapy | Bone Marrow Transplant	3	7+3 (Cytarabine, Idarubicin)|HiDAC|Cyclophosphamide, Fludarabine, TBI	4	Allogeneic - Sibling | Consolidation | Induction | Re-induction	Complete Response	Standard Chemotherapy	7	Bone Marrow Transplant	Cyclophosphamide, Fludarabine, TBI	Allogeneic - Sibling	-1	0	1.4	20		No	1.4	0.5	33.8	4.5	58.4	0	114	45	4.3	0.75		31.1	11.2	46,XY,del(20)(q11.2)[2]/46,XY[18]	177	99	20/200 cells (10%) were missing a signal for D20S108 (20q12)	83	CD13, CD33, CD34, CD38, CD117, and dim HLA-DR positive	7.1	2.22	Negative	Negative	Negative		Negative	Negative	Negative				Negative	Negative	Negative	62	Unmatched	AM	Leukemia	AML with Maturation	0.166666666667
aml_ohsu_2018_1466	aml_ohsu_2018_14-00113		PML-RARA	Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA	Favorable	Not Enough Information	Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA	Post-Chemotherapy|Post-Transplant	Peripheral Blood	WES + RNA-seq	Yes	Yes	No	Yes	Yes	No	2	Standard Chemotherapy | Bone Marrow Transplant	7	Busulfan, Fludarabine|Etoposide, TBI|PETHEMA Trial LPA05 (ATRA (Tretinoin), Idarubicin, Mitoxantrone, Cytarabine)|Idarubicin, Mitoxantrone|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|ATRA, Arsenic Trioxide|ATRA, 6-MP, Methotrexate	5	Allogeneic - Sibling | Consolidation | Induction | Maintenance | Re-induction	Complete Response	Standard Chemotherapy	-1	Bone Marrow Transplant	Etoposide, TBI	Allogeneic - Sibling	-1	-3				No														46,XY[20]			48% PML/RARA translocation					Negative	Negative												44	Matched	APLPMLRARA	Leukemia	APL with PML-RARA	NA
aml_ohsu_2018_1477	aml_ohsu_2018_14-00125	Denovo	CBFB-MYH11	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	Favorable	Favorable	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	RNA-seq	Yes	No	Yes	Yes	No	Yes	1	Standard Chemotherapy	1	COG-AAML1031 (IT/IV Cytarabine, Daunorubicin, Etoposide, Mitoxantrone +/- Bortezomib or Sorafenib)	3	Induction | Intensification | Re-induction	Complete Response	Standard Chemotherapy	10	Standard Chemotherapy	COG-AAML1031 (IT/IV Cytarabine, Daunorubicin, Etoposide, Mitoxantrone +/- Bortezomib or Sorafenib)	Intensification	29	-2	0.8			No	0		10.5	21	7.3	0.5			2.1	0.41		24.7	8.3	46,XX,inv(16)(p13q22)[17]/46,XX[3]	702	88.5	CBFB rearrangement and inverted 16	31			55.35	Negative	Negative												10	Matched	AMLCBFBMYH11	Leukemia	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22);CBFB-MYH11	NA
aml_ohsu_2018_1451	aml_ohsu_2018_14-00126	Denovo	Unknown	Mixed phenotype acute leukaemia, T/myeloid, NOS	Intermediate	Not Enough Information	Mixed phenotype acute leukaemia, T/myeloid, NOS	Initial Acute Leukemia Diagnosis	Peripheral Blood	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	0		0		0					NONE	NONE	NONE		0				No																						Negative	Negative												46	Matched	MPALTNOS	Leukemia	Mixed Phenotype Acute Leukemia, T/Myeloid, NOS	0.366666666667
aml_ohsu_2018_1481	aml_ohsu_2018_14-00127		None	AML with myelodysplasia-related changes	Adverse	Adverse	AML with myelodysplasia-related changes	Residual Disease|Post-Chemotherapy	Peripheral Blood	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	2	Standard Chemotherapy | Supportive/Palliative Care	2	7+3 (Cytarabine, Idarubicin)|Azacitidine	2	Induction | Maintenance	Refractory	Standard Chemotherapy	6	Supportive/Palliative Care	Azacitidine	Maintenance	-1	-1	0		95	No	0		0.9	0	0	0.1	17	56	1.8	0.6		23	7.9	48~54,XY,add(2)(p13),+5,add(5)(q13),del(5)(q13),+10,+11,+13,+13,del(13)(q32),+14,-15,-16,del(17)(p12),-20,+21,+21,+22,+mar[cp9]/49~52,sl,-del(17)(p12)[cp8]/51~54,sl		86.8	Extra chromosome 5	20	CD10, CD13, CD33, CD34, CD56 and HLA-DR positive	5.3	38.47	Negative	Negative	Negative		Negative	Negative	Negative	Negative	Negative	Negative	Negative	p.G13D, MAF 46%	p.R273H, MAF 96%	38	Unmatched	AMLMRC	Leukemia	AML with Myelodysplasia-Related Changes	0.2
aml_ohsu_2018_1484	aml_ohsu_2018_14-00134	Transformation from another heme malignancy and Relapse	None	AML with mutated NPM1	Intermediate	Adverse	AML with mutated NPM1	Post-Transplant|Relapse	Bone Marrow Aspirate	WES	No	Yes	No	No	Yes	No	3	Standard Chemotherapy | Bone Marrow Transplant | Supportive/Palliative Care	4	Fludarabine, Melphalan|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone)|Decitabine	4	Allogeneic - Sibling | Salvage | Re-induction | Supportive/Palliative Care				Supportive/Palliative Care	Decitabine	Supportive/Palliative Care	-1	0	0	30	14	No	0.9		3.6	21.2	69	1	27	21	3.7	0.8		34.4	11.3	49,XX,+X,+8,+10[13]/46,XY[7]	245	95.3	Trisomy 8	299	dim CD13, CD33, CD34, CD117, CD123, and dim HLADR	7.3	6.23	Positive	Positive	Negative		p.R882H; MAF 30%	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	63	Unmatched	AMLNPM1	Leukemia	AML with Mutated NPM1	0.166666666667
aml_ohsu_2018_1485	aml_ohsu_2018_14-00135	Denovo	None	AML with myelodysplasia-related changes	Adverse	Adverse	AML with myelodysplasia-related changes	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	1	Standard Chemotherapy	2	Azacitidine|Decitabine	3	Consolidation | Induction | Maintenance	Unknown	Standard Chemotherapy	38	Standard Chemotherapy	Azacitidine	Maintenance	36	0	0	55	46	No	0		27.8	27	20.6	0	32	31	2.2	1.37	M4	20.6	6.6	43~44,X,-Y,t(3;11)(p21.3;p11.2),del(5)(q11.1;q31.1),add(12)(p11.2),-21[cp17]/44~45,idem,-t(3;11),+9[cp4]	435	85.8	Previous FISH results were consistent with the deleted 5q and trisomy 9	33	CD13, CD33, CD34, partial CD56,variable CD117, dim CD123, and dim HLA-DR+	5.9	20.82	Negative	Negative	Negative		Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	p.H193R; MAF 92%	72	Matched	AMLMRC	Leukemia	AML with Myelodysplasia-Related Changes	0.366666666667
aml_ohsu_2018_1488	aml_ohsu_2018_14-00141	Denovo	None	Acute myelomonocytic leukaemia	Intermediate	Not Enough Information	Acute myelomonocytic leukaemia	Initial Acute Leukemia Diagnosis	Peripheral Blood	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	1	Standard Chemotherapy	1	Decitabine, Midostaurin	1	Induction	Complete Response	Standard Chemotherapy	-1	Standard Chemotherapy	Decitabine, Midostaurin	Induction	-1	-15				No														46,XY[14]								Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative		Negative	Negative	Negative	Negative	85	Matched	AML	Leukemia	Acute Myeloid Leukemia	0.566666666667
aml_ohsu_2018_1494	aml_ohsu_2018_14-00150	After or at the time transformation from another heme malignancy	None	AML with mutated CEBPA	Intermediate	Not Enough Information	AML with mutated CEBPA	Post-Chemotherapy|Initial Acute Leukemia Diagnosis	Peripheral Blood	WES	No	Yes	No	No	Yes	No	1	Standard Chemotherapy	1	CPX-351 (Liposomal Cytarabine + Daunorubicin)	1	Induction	Complete Response	Standard Chemotherapy	-1	Standard Chemotherapy	CPX-351 (Liposomal Cytarabine + Daunorubicin)	Induction	-1	0		67	67	No				0							M4			45,X,-Y,del(7)(p15)[4]/46,XY[16]					CD34, CD117, CD2,PARTIAL CD4, CD13, CD33, CD38, PARTIAL CD64, PARTIAL CD11c, HLA-DR AND DIM MPO		1.6	Negative	Negative	Double positive	Negative	Negative	Negative	Negative	Negative		Negative	Negative	Negative	Negative	78	Unmatched	AMLCEBPA	Leukemia	AML with Biallelic Mutations of CEBPA	0.233333333333
aml_ohsu_2018_1495	aml_ohsu_2018_14-00152	Denovo	None	Acute myelomonocytic leukaemia	Intermediate	Intermediate-II	Acute myelomonocytic leukaemia	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	WES + RNA-seq	Yes	Yes	No	Yes	Yes	No	1	Standard Chemotherapy	5	7+3 (Cytarabine, Idarubicin)|CLAG (Cladribine, Cytarabine, Filgrastim)|MiDAC|ODSH (2 O, 3-O Desulfated Heparin) |SGN-CD33A	2	Consolidation | Induction	Complete Response	Standard Chemotherapy	21	Standard Chemotherapy	CLAG (Cladribine, Cytarabine, Filgrastim)	Consolidation	-1	-1		64	7	No											M4			46,XY,add(8)(p21),t(8;19)(p11.2;q13.3)[18]/46,XY[2]			Normal		Large population of atypical myelomonocytic cells (CD4+, bright CD64+, MPO positive, partial CD14), representing 85% of the total leukocytes		4.67	Negative	Negative												75	Unmatched	AML	Leukemia	Acute Myeloid Leukemia	0.0666666666667
aml_ohsu_2018_1505	aml_ohsu_2018_14-00171	After or at the time transformation from another heme malignancy	None	AML with myelodysplasia-related changes	Adverse	Favorable	AML with myelodysplasia-related changes	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	WES	No	Yes	No	No	Yes	No	3	Standard Chemotherapy | Unknown | Bone Marrow Transplant	4	CPX-351 (Liposomal Cytarabine + Daunorubicin)|Azacitidine|Methotrexate|Busulfan, Cyclophosphamide	4	Allogeneic - Sibling | Hypomethylating/Low Dose Cytarabine | Unknown | Induction	Refractory	Standard Chemotherapy	4	Standard Chemotherapy	Azacitidine	Hypomethylating/Low Dose Cytarabine	182	0	0	39	5	No	0.9		84.1	8.8	2.7	0	35	15	3.2	1.13		30.8	10.6	46,XY[20]	168	107.7	Normal	131	partial CD7, CD13, dim CD33, CD34, CD38, CD58, CD117, CD123, HLA-DR, and TdT-positive	5.8	2.51	Negative	Negative	Negative		Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	62	Matched	AMLMRC	Leukemia	AML with Myelodysplasia-Related Changes	0.866666666667
aml_ohsu_2018_1495	aml_ohsu_2018_14-00173	Denovo	None	Acute myelomonocytic leukaemia	Intermediate	Not Enough Information	Acute myelomonocytic leukaemia	Initial Acute Leukemia Diagnosis	Peripheral Blood	WES	No	Yes	No	No	Yes	No	1	Standard Chemotherapy	5	7+3 (Cytarabine, Idarubicin)|CLAG (Cladribine, Cytarabine, Filgrastim)|MiDAC|ODSH (2 O, 3-O Desulfated Heparin) |SGN-CD33A	2	Consolidation | Induction	Complete Response	Standard Chemotherapy	21	Standard Chemotherapy	CLAG (Cladribine, Cytarabine, Filgrastim)	Consolidation	-1	-6				No														46,XY,add(8)(p21),t(8;19)(p11.2;q13.3)[18]/46,XY[2]			Normal					Negative	Negative												75	Unmatched	AML	Leukemia	Acute Myeloid Leukemia	NA
aml_ohsu_2018_1508	aml_ohsu_2018_14-00175	Denovo	Unknown	Acute monoblastic and monocytic leukaemia	Intermediate	Not Enough Information	Acute monoblastic and monocytic leukaemia	Initial Acute Leukemia Diagnosis	Peripheral Blood	WES + RNA-seq	Yes	Yes	No	Yes	Yes	No	3	DLI | Standard Chemotherapy | Bone Marrow Transplant	8	Busulfan, Fludarabine|7+3 (Cytarabine, Idarubicin)|HiDAC|Donor Lymphocyte Infusion|Azacitidine|CLAG-M (Cladribine, Cytarabine, Mitoxantrone, Filgrastim)|Clofarabine|ODSH (2 O, 3-O Desulfated Heparin)	6	Allogeneic - Sibling | Hypomethylating/Low Dose Cytarabine | Consolidation | Induction | Re-induction | Post-Transplant Relapse	Complete Response	Standard Chemotherapy	-1	DLI	Donor Lymphocyte Infusion	Post-Transplant Relapse	-1	0		25.9	0.5	No											M5						Normal		Increased atypical CD56 positive, weak CD117 positive myelomonocytic cells representing approximately 23% of the leukocytes		3.6	Negative	Negative								Negative				46	Matched	AMOL	Leukemia	Acute Monoblastic/Monocytic Leukemia	0.0333333333333
aml_ohsu_2018_924	aml_ohsu_2018_14-00180	Relapse	None	AML with mutated NPM1	Favorable	Favorable	AML with mutated NPM1	Relapse	Bone Marrow Aspirate	WES	No	Yes	No	No	Yes	No	1	Standard Chemotherapy	4	3+7 (Cytarabine, Daunorubicin)|Azacitidine|Azacitidine, Lenalidomide|Decitabine	3	Hypomethylating/Low Dose Cytarabine | Salvage | Induction	Complete Response	Standard Chemotherapy	-1	Standard Chemotherapy	Azacitidine, Lenalidomide	Salvage	-1	0	0	45		No	1	1	48	5.1	44.9	2	28	25	3.9	1		22.7	7.4	46,XY[20]	166	103.7		68		6.6	0.98	Negative	Positive		Negative	Negative	Negative	p.R132S; MAF 20%	Negative	Negative	Negative	Negative	Negative	Negative	73	Matched	AMLNPM1	Leukemia	AML with Mutated NPM1	1.2
aml_ohsu_2018_1513	aml_ohsu_2018_14-00184		None	Therapy-related myeloid neoplasms	Intermediate	Not Enough Information	Therapy-related myeloid neoplasms	Initial Acute Leukemia Diagnosis|Post-Transplant	Peripheral Blood	WES + RNA-seq	Yes	Yes	No	Yes	Yes	No	2	Standard Chemotherapy | Bone Marrow Transplant	3	ADE (Cytarabine, Daunorubicin & Etoposide)|Cyclophosphamide, TBI|Bu/Flu/TBI (Busulfan, Fludarabine, Total Body Irradiation)	3	Allogeneic - Sibling | Induction | Allogeneic - Matched Unrelated Donor	Complete Response	Standard Chemotherapy	9	Bone Marrow Transplant	Bu/Flu/TBI (Busulfan, Fludarabine, Total Body Irradiation)	Allogeneic - Sibling	-1	0	0		80	No	0		33	0	0	0	12	32	3	0.44	M5	17.1	5.7	46,XY[25]	1072	98.8	MLL rearrangement	34	CD4, CD11b, CD15, CD33, bright CD34, CD38, CD58, CD64,CD71, CD117, CD123, HLA-DR and dim/partial MPO positive	7.4	95.2	Negative	Negative												5	Unmatched	TMN	Leukemia	Therapy-Related Myeloid Neoplasms	0.0666666666667
aml_ohsu_2018_1519	aml_ohsu_2018_14-00193	Denovo	CBFB-MYH11	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	Favorable	Adverse	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	Initial Acute Leukemia Diagnosis	Peripheral Blood	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	1	Standard Chemotherapy	1	7+3 (Cytarabine, Idarubicin)	1	Induction	Unknown	Standard Chemotherapy	3	Standard Chemotherapy	7+3 (Cytarabine, Idarubicin)	Induction	3	0	0		54	No	0		38	8	0		15	23	3	1.3				46,XY,del(5)(q15q35),inv(16)(p13.1q22)[20]	409		nuc ish(D5S721x2,D5S23x2,EGR1x1)[182/200],(D7Z1,D7S522)x2[199], (RUNX1T1,RUNX1)x2[199],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[192],(PML,RARA)x2[198],(5'CBFB,3'CBFB)x2(5'CBFB sep 3'CBFBx1)[176/200]			6.6	8.2	Negative	Negative										Q61H; MAF 5%		57	Unmatched	AMLCBFBMYH11	Leukemia	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22);CBFB-MYH11	0.166666666667
aml_ohsu_2018_1527	aml_ohsu_2018_14-00212		None	Atypical chronic myeloid leukaemia, BCR-ABL1 negative	Intermediate		Atypical chronic myeloid leukaemia, BCR-ABL1 negative	Residual Disease	Peripheral Blood	WES	No	Yes	Yes	No	Yes	Yes	0		0		0					NONE	NONE	NONE		0		10	17	No														47,XX,+8,del(11)(q23)[18]	283		Missing MLL signal		CD13, CD33, CD34, CD38, CD58, CD117, CD123, and partial HLA-DR		31.85	Negative	Negative	Negative			Negative			Negative	Negative				47	Matched	ACML	Myelodysplastic/Myeloproliferative Neoplasms	Atypical Chronic Myeloid Leukemia, BCR-ABL1-	0.766666666667
aml_ohsu_2018_1532	aml_ohsu_2018_14-00228	Denovo	None	AML with mutated NPM1	Favorable	Favorable	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	1	Standard Chemotherapy	4	7+3 (Cytarabine, Idarubicin)|Azacitidine|MEC (Cytarabine, Etoposide, Mitoxantrone)|MiDAC	3	Consolidation | Induction | Re-induction	Complete Response	Standard Chemotherapy	7	Standard Chemotherapy	Azacitidine	Consolidation	339	0	0	80	45	No	1.6		9.9	14.9	10.7	0	52	28	2.5	0.77	M4	25.2	8.4	46,XX[20]	550	88.1	Normal	107	dim CD11b, CD13, CD33, partial CD34, dim CD45, dim CD64, CD117, CD123, and dim HLA-DR+	6.3	57.23	Negative	Positive	Negative		p.R882C; MAF 46%	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	46	Matched	AMLNPM1	Leukemia	AML with Mutated NPM1	0.266666666667
aml_ohsu_2018_1533	aml_ohsu_2018_14-00231		Complex	Therapy-related myeloid neoplasms	Adverse	Adverse	Therapy-related myeloid neoplasms	Initial Acute Leukemia Diagnosis	Peripheral Blood	RNA-seq	Yes	No	Yes	Yes	No	Yes	2	Standard Chemotherapy | Supportive/Palliative Care	4	7+3 (Cytarabine, Idarubicin)|HiDAC|Cytarabine|Decitabine, Hydroxyurea	4	Consolidation | Induction | Re-induction | Supportive/Palliative Care	Refractory	Standard Chemotherapy	5	Supportive/Palliative Care	Decitabine, Hydroxyurea	Supportive/Palliative Care	-1	0	0	76	79	No	0		9	5	4		45	41	3.2			28.6	9.6	46~47,XX,t(1;11)(p34;p15),der(8)del(8)(p11.2p23)t(1;8)(q21;q24.3),add(9)(q34),del(9)(q13q22),add(16)(p13.3),+1~2mar[cp11] /47~48,idem,+13[cp2]/47~48,idem,-13,der(21)t(8;21)(q13;p12),+2~3mar[cp6]/46,XX[1]			nuc ish(D5S721,D5S23,EGR1)x2[200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[200], (5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[199],(RUNX1T1x3,RUNX1x2)[69/200]/(RUNX1T1x2,RUNX1x3)[7/200],(PML,RARA)x2 [200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	64	CD2(-), CD4(+), CD5(equivocal), CD7(-), CD11b(+), CD13(-), CD14(partial +), CD15(+), CD16(-), CD33 (bright +), CD34(-), CD36(+), CD38(variably +), CD45(variably +), CD56(+), CD64(+), CD117(partial +), HLA-DR(+)	6.3	19.5	Negative	Negative	Negative			Negative	Negative	Negative						57	Matched	TMN	Leukemia	Therapy-Related Myeloid Neoplasms	NA
aml_ohsu_2018_1540	aml_ohsu_2018_14-00240	Denovo	None	AML with myelodysplasia-related changes	Adverse	Adverse	AML with myelodysplasia-related changes	Initial Acute Leukemia Diagnosis	Peripheral Blood	WES	Yes	Yes	Yes	No	Yes	Yes	1	Other	1	Azacitidine	1	Supportive/Palliative Care				Other	Azacitidine	Supportive/Palliative Care	-1	-17			1	No			6	49	35		9	15	2.9	1.09		26.1	8.3	45,XX,+i(5)(p10),psudic(12;5)(p13;q11.2),-16,del(17)(p11.2p13)[5]/44,idem,-i(5)[3]/46,XX[12]	342		nuc ish(D5S721x2,D5S23x2,EGR1x1)[57/200]/(D5S721x4,D5S23x4,EGR1x1)[29/200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[200],(RUNX1T1,RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[199],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x1(5'CBFB con 3'CBFBx1)[83/200]	50		6.7	51.64	Negative	Negative	Negative			Negative								78	Unmatched	AMLMRC	Leukemia	AML with Myelodysplasia-Related Changes	0.2
aml_ohsu_2018_1536	aml_ohsu_2018_14-00242		None	Refractory anaemia with excess blasts	Intermediate	Not Enough Information	Refractory anaemia with excess blasts	Residual Disease|Post-Chemotherapy	Bone Marrow Aspirate	WES	No	Yes	No	No	Yes	No	3	Standard Chemotherapy | Supportive/Palliative Care | Targeted Therapy - Other	4	Azacitidine|Decitabine|Rigosertib|Clofarabine, Cytarabine	4	Hypomethylating/Low Dose Cytarabine | Consolidation | Induction | Experimental	Refractory	Standard Chemotherapy	-1	Supportive/Palliative Care	Decitabine	Hypomethylating/Low Dose Cytarabine	-1	0		22	1	No	3		54	3	37		38	29	4.3	0.95		33.3	11.7	46,XY[20]	195	104.3	nuc ish(FGFR3,IGH)x2[200],(D5S721,D5S23,EGR1)x2[199],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2 [199],(RUNX1T1,RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(IGH,BCL2)x2[198],(PML,RARA)x2 [200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[199]	115	CD2(-), CD4(-), CD7(-), CD11b(-), CD13(+), CD14(-), CD15(few +), CD16(-), CD33(+), CD34(bright +), CD33(-), CD38(dim and variably +), CD45(+), CD56(-), CD64(-), CD117(+), HLA-DR(+)	7	1.9	Negative	Negative												63	Matched	MDSEB	Myelodysplastic Syndromes	MDS with Excess Blasts	0.0666666666667
aml_ohsu_2018_1410	aml_ohsu_2018_14-00244	After or at the time transformation from another heme malignancy	GATA2-MECOM	AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1	Adverse	Adverse	AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1	Post-Chemotherapy|Residual Disease	Bone Marrow Aspirate	WES	No	Yes	Yes	No	Yes	Yes	2	Standard Chemotherapy | Supportive/Palliative Care	4	7+3 (Cytarabine, Idarubicin)|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Azacitidine|MEC (Cytarabine, Etoposide, Mitoxantrone)	4	Salvage | Unknown | Induction | Maintenance	Refractory	Standard Chemotherapy	5	Standard Chemotherapy	FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)	Unknown	6	0	0	37	26	No	0		17	12	44							23.9	8.3	46,XY,t(3;3)(q21;q26.2),del(5)(q13q31)[cp12]/43~45,idem,-7[cp3]/46,XY[6]			nuc ishFGFR3,IGH)x2[200],(D5S721x2,D5S23x2,EGR1x1)[130/200],(D7Z1x1,D7S522x1)[50/200],(D8Z2,D20S108)x2[198],(RUNX1T1,RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],IGH,BCL2)x2[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con3'CBFBx2)[198]	55	CD2(-),CD4(dim +), CD7(partial +), CD11b(partial +), CD13(+), CD14(-), CD15(partial dim +), CD16(-), CD33(slightly bright +),CD34(+), CD36(equivocal), CD38(partial dim +), CD45(+), CD56(variably +), CD64(-), CD117(+), HLA-DR(+/variable).		4.3	Negative	Negative				Negative	Negative	Negative						39	Matched	AMLRGA	Leukemia	AML with Recurrent Genetic Abnormalities	0.8
aml_ohsu_2018_1528	aml_ohsu_2018_14-00245		None	Acute myeloid leukaemia, NOS	Intermediate	Not Enough Information	Acute myeloid leukaemia, NOS	Residual Disease|Post-Chemotherapy	Bone Marrow Aspirate	WES	No	Yes	No	No	Yes	No	2	Standard Chemotherapy | Bone Marrow Transplant	3	5+2 (Cytarabine, Idarubicin)|3+7 (Cytarabine, Daunorubicin)|Busulfan, Cyclophosphamide	3	Induction | Re-induction | Allogeneic - Matched Unrelated Donor	Refractory	Standard Chemotherapy	6	Bone Marrow Transplant	Busulfan, Cyclophosphamide	Allogeneic - Matched Unrelated Donor	-1	-19		20		No						0	27	14	2.6	0.78		30.3	10.7	46,XY,der(7)t(7;11)(q22;q13)[14]/46,XY[6]	136	81.9	Missing D7S486 signal	31	dim/partial CD7, CD13, dim CD33, CD34, CD38, CD58, CD117, CD123, and HLA-DR positive	6.6	0.49	Negative	Negative	Negative		p.R309G; MAF 31%	Negative	p.R132C; MAF 33%		Negative	Negative	Negative	Negative		62	Matched	AMLNOS	Leukemia	AML, NOS	0.233333333333
aml_ohsu_2018_1545	aml_ohsu_2018_14-00253	Denovo	None	AML with myelodysplasia-related changes	Adverse	Not Enough Information	AML with myelodysplasia-related changes	Initial Acute Leukemia Diagnosis	Peripheral Blood	WES	No	Yes	No	No	Yes	No	1	Standard Chemotherapy	2	5+2 (Cytarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin)	2	Induction | Re-induction	Refractory	Standard Chemotherapy	-1	Standard Chemotherapy	5+2 (Cytarabine, Idarubicin)	Re-induction	-1	0		78	15	No				1										50,XY,+8,+9,+13,+22[17]/46,XY[3]					CD34, CD38, PARTIAL CD56, CD13, PARTIAL CD64, HLA-DR, CD117, PARTIAL MPO, PARTIAL CD79A, AND DIM PARTIAL TDT		1.2	Negative	Negative	Negative	Negative	Negative	Negative	Positive	Negative		Negative	Negative	Negative	Negative	72	Matched	AMLMRC	Leukemia	AML with Myelodysplasia-Related Changes	0.733333333333
aml_ohsu_2018_1546	aml_ohsu_2018_14-00259	Denovo	None	AML with mutated NPM1	Favorable or Intermediate	Intermediate-I	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	2	Standard Chemotherapy | Bone Marrow Transplant	5	Fludarabine, Melphalan|7+3 (Cytarabine, Idarubicin)|Fludarabine|FLAG (Fludarabine, High-dose Cytarabine, G-CSF)|MiDAC	4	Consolidation | Salvage | Induction | Allogeneic - Matched Unrelated Donor	Complete Response	Standard Chemotherapy	6	Standard Chemotherapy	Fludarabine	Consolidation	4	0	0.1	70		No	0.1	1.7	8.3	85.2	4.6	0.2	16	13	2.7	0.87	M4	30.4	9.6	46,XX[20]	506	101.7	Normal	112	CD11b, partial CD13, partial CD14, dim CD15, partial      CD16, CD33, CD38, CD58, CD64, partial CD123 and HLA-DR positive	7.4	58.86	Positive	Positive	Negative		p.R882H; MAF 50%		Negative		Negative	Negative	Negative	Negative	Negative	65	Matched	AMLNPM1	Leukemia	AML with Mutated NPM1	0.266666666667
aml_ohsu_2018_1552	aml_ohsu_2018_14-00268		None	AML with myelodysplasia-related changes	Adverse	Adverse	AML with myelodysplasia-related changes	Initial Acute Leukemia Diagnosis|Post-Chemotherapy	Bone Marrow Aspirate	WES	No	Yes	No	No	Yes	No	1	Standard Chemotherapy	2	Azacitidine|Decitabine	2	Hypomethylating/Low Dose Cytarabine | Supportive/Palliative Care				Standard Chemotherapy	Decitabine	Supportive/Palliative Care	-1	0	0	45	25	No	4		57	4	35		21	33	2.7	0.65		24.5	8.3	46,XY,idic(7)(q11.2)[1]/47,idem,+8[9]46,XY[10]	266	99.9	nuc ish(RUNX1T1x3,RUNX1x2)[133/200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2) [200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[199]	68	CD2(-), CD4(partial dim +), CD7(partial +), CD11b(-), CD13(+), CD14(-), CD15(-), CD16(-), CD33 (partial +), CD34(+), CD36(-), CD38(partial +), CD45(moderately +), CD56(-), CD64(-), CD117(+), HLA-DR(partial +), MPO (partial +), TdT(-)	5.6	1.5	Negative	Negative	Negative			Negative								74	Matched	AMLMRC	Leukemia	AML with Myelodysplasia-Related Changes	1.13333333333
aml_ohsu_2018_1553	aml_ohsu_2018_14-00270		None	Myelodysplastic syndrome, unclassifiable	Intermediate	Intermediate-I	Myelodysplastic syndrome, unclassifiable	Post-Chemotherapy	Bone Marrow Aspirate	WES	No	Yes	Yes	No	Yes	Yes	1	Standard Chemotherapy	4	7+3 (Cytarabine, Idarubicin)|HiDAC|Azacitidine|Clofarabine, Cytarabine	4	Hypomethylating/Low Dose Cytarabine | Salvage | Consolidation | Induction	Complete Response	Standard Chemotherapy	5	Standard Chemotherapy	HiDAC	Consolidation	5	0		8	2	No			27	6	65		73	53		0.65		22.7	7.7	46,XX[20]	249		nuc ish(D4Z1,D10Z1)x2[200],(D5S721,D5S23,EGR1)x2[200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[200],(RUNX1T1,RUNX1)x2[199],(ABL1,BCR)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(ETV6,RUNX1)x2[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	13			3.42	Positive	Negative												39	Matched	MDSU	Myelodysplastic Syndromes	MDS, Unclassifiable	0.8
aml_ohsu_2018_1554	aml_ohsu_2018_14-00272	Denovo	None	AML with mutated CEBPA	Favorable	Favorable	AML with mutated CEBPA	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	WES	No	Yes	Yes	No	Yes	Yes	1	Standard Chemotherapy	2	7+3 (Cytarabine, Idarubicin)|HiDAC	2	Consolidation | Induction	Complete Response	Standard Chemotherapy	24	Standard Chemotherapy	HiDAC	Consolidation	105	-1		87	87	Yes				0										46,XX[20]					CD34, CD117,partial CD13, CD33, CD38, partial CD64, dim CD7, variable CD15, HLA-DR and bright MPO		99.3	Negative	Negative	Double positive: p.Ser17Profs*99 and p.Lys313dup	Negative		Negative	Negative	Negative		Negative	Positive	Negative	Negative	34	Matched	AMLCEBPA	Leukemia	AML with Biallelic Mutations of CEBPA	0.6
aml_ohsu_2018_1554	aml_ohsu_2018_14-00273	Denovo	None	AML with mutated CEBPA	Intermediate	Not Enough Information	AML with mutated CEBPA	Initial Acute Leukemia Diagnosis	Peripheral Blood	WES	Yes	Yes	No	No	Yes	No	1	Standard Chemotherapy	2	7+3 (Cytarabine, Idarubicin)|HiDAC	2	Consolidation | Induction	Complete Response	Standard Chemotherapy	24	Standard Chemotherapy	HiDAC	Consolidation	105	-1		87	87	No				0										46,XX[20]					CD34, CD117,partial CD13, CD33, CD38, partial CD64, dim CD7, variable CD15, HLA-DR and bright MPO		99.3	Negative	Negative	Double positive: p.Ser17Profs*99 and p.Lys313dup	Negative		Negative	Negative	Negative		Negative	Positive	Negative	Negative	34	Matched	AMLCEBPA	Leukemia	AML with Biallelic Mutations of CEBPA	0.6
aml_ohsu_2018_1558	aml_ohsu_2018_14-00279	Denovo	CBFB-MYH11	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	Favorable	Favorable	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	1	Standard Chemotherapy	1	SWOG S1203 (7+3 +/- Vorinostat)	1	Induction	Complete Response	Standard Chemotherapy	8	Standard Chemotherapy	SWOG S1203 (7+3 +/- Vorinostat)	Induction	8	0		91	79	No				0										46,XX,inv(16)(p13.1q22)[cp20]					CD34, PARTIAL CD117, CD15, CD38, PARTIAL CD13, CD33, CD64, PARTIAL CD14(SUBSET), PARTIAL CD11c, DIM CD4, HLA-DR AND BRIGHT MPO		28.1	Negative	Negative	Negative	Negative		Negative	Negative	Negative		Negative	Negative	Negative	Negative	52	Matched	AMLCBFBMYH11	Leukemia	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22);CBFB-MYH11	0.333333333333
aml_ohsu_2018_1561	aml_ohsu_2018_14-00289		None	Therapy-related myeloid neoplasms	Adverse	Adverse	Therapy-related myeloid neoplasms	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	2	Standard Chemotherapy | Targeted Therapy - Kinase Inhibitor(s)	2	Trametinib|HAEP (Cytarabine, Etoposide, Cisplatin)	3	Consolidation | Induction | Experimental	Complete Response	Standard Chemotherapy	8	Targeted Therapy - Kinase Inhibitor(s)	Trametinib	Experimental	197	0	3.2	3	20.4	No	2.1		25.8	1.1	36.6	43.4	32	131	3	0.91		17.9	5.7	48,XY,add(6)(p22),der(7)t(7;19)(p11.1;p12),i(13)(q10)x2,add(14)(q24),+mar1,+mar2[cp20]	16499	95.2	Low-level tetraploidy or near-tetraploidy	24		5.6	40.76	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	p.G12C; MAF 86%	p.G245S; MAF 87%	23	Matched	TMN	Leukemia	Therapy-Related Myeloid Neoplasms	0.566666666667
aml_ohsu_2018_1569	aml_ohsu_2018_14-00311		None	Therapy-related myeloid neoplasms	Adverse	Not Enough Information	Therapy-related myeloid neoplasms	Initial Acute Leukemia Diagnosis	Peripheral Blood	WES	No	Yes	No	No	Yes	No	1	Standard Chemotherapy	1	Decitabine	1	Hypomethylating/Low Dose Cytarabine				Standard Chemotherapy	Decitabine	Hypomethylating/Low Dose Cytarabine	-1	-1		54.8	25	No														43,XX,-5,add(7)(q22),t(10;13)(p13;q22),-12,-17[12]/46,XX[8]			deletion 5q31 involving the EGR1 locus in 96/200 (48.0  percent) cells scored,  deletion 7q31 involving the D7S486 locus in 85/200 (42.5  percent) cells scored.		Large population of CD34 positive myeloblasts, representing approximately 50% of the leukocytes, consistent with acute myeloid leukemia		0.92	Negative	Negative	Negative											73	Matched	TMN	Leukemia	Therapy-Related Myeloid Neoplasms	0.4
aml_ohsu_2018_1585	aml_ohsu_2018_14-00329	Denovo	GATA2-MECOM	AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1	Adverse	Adverse	AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1	Initial Acute Leukemia Diagnosis	Peripheral Blood	WES	No	Yes	Yes	No	Yes	Yes	3	Standard Chemotherapy | Bone Marrow Transplant | Targeted Therapy - Other	5	MiDAC|FATE Trial RIC (Fludarabine, Melphalan, Rabbit ATG) |7+3 (Cytarabine, Idarubicin) plus Sorafenib|ODSH (2 O, 3-O Desulfated Heparin) |SGN-CD33A	4	Consolidation | Induction | Experimental | Allogeneic - Matched Unrelated Donor	Complete Response	Standard Chemotherapy	24	Targeted Therapy - Other	SGN-CD33A	Experimental	-1	0		59.3	40	No														46,XX,inv(3)(q21;q26.2)[20]			3q21.3q26.2 (RPN1/MECOM): rearrangement present		Most of the atypical cells (percentages shown) are myeloid blasts that express dim CD7, dim CD13, CD33, CD34, CD117, weak myeloperoxidase, and HLA-DR, but do not express cytoplasmic CD3, TDT,   CD14(MO2), CD42b, CD61, or CD64.		44.76	Negative	Negative												72	Matched	AMLRGA	Leukemia	AML with Recurrent Genetic Abnormalities	1.4
aml_ohsu_2018_1586	aml_ohsu_2018_14-00331	Denovo	None	AML with mutated NPM1	Favorable	Not Enough Information	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Peripheral Blood	WES + RNA-seq	Yes	Yes	No	Yes	Yes	No	1	Standard Chemotherapy	2	7+3 (Cytarabine, Idarubicin)|HiDAC	2	Consolidation | Induction	Complete Response	Standard Chemotherapy	5	Standard Chemotherapy	HiDAC	Consolidation	5	0	1	81	68	No			5	2	2		85	52	3.1	0.85		28.8	10.1	46,XY[20]	1205		nuc ish(D4Z1,D10Z1)x2[200],(ABL1,BCR)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(ETV6,RUNX1)x2[200]	20	CD2(-),CD4(partial dim +), CD7(-), CD11b(few +), CD13(+), CD14(-), CD15(partialCD22(-), CD25(appears partial dim +), CD33(bright +), CD34(few +), CD36(-), CD38(variable +), CD45(moderately +), CD56(-), CD64(partial +), CD79a(-), CD117(+), CD123(partial +), HLA-DR(partial +), MPO(+), TdT(-).	6.2	152.75	Negative	Positive												61	Matched	AMLNPM1	Leukemia	AML with Mutated NPM1	0.766666666667
aml_ohsu_2018_17	aml_ohsu_2018_14-00334	Relapse	None	AML with mutated NPM1	Intermediate	Intermediate-II	AML with mutated NPM1	Post-Transplant|Post-Chemotherapy|Relapse	Bone Marrow Aspirate	WES	No	Yes	No	No	Yes	No	3	Standard Chemotherapy | Bone Marrow Transplant | Targeted Therapy - Kinase Inhibitor(s)	6	7+3 (Cytarabine, Idarubicin)|HiDAC|Fludarabine, TBI|Sorafenib|Hydroxyurea|Decitabine	5	Consolidation | Induction | Experimental | Re-induction | Allogeneic - Matched Unrelated Donor	Unknown	Standard Chemotherapy	2	Targeted Therapy - Kinase Inhibitor(s)	Sorafenib	Experimental	105	0	0	93	48	No	0		59.4	1.9	12.3	3.2	13	20	3.4	0.8		31.6	10.9	46,XX,del(6)(q13q23)[18]/46,XY[2]	527	93.5	Missing 6q21 signal while having two copies each of the 6 centromere signal and the MYB (6q23) signal	33	partial CD7, variable CD13, CD33, partial CD34,CD38, CD58, CD117, CD123, and partial HLA-DR positive	6.7	5.3	Positive	Positive												31	Unmatched	AMLNPM1	Leukemia	AML with Mutated NPM1	0.1
aml_ohsu_2018_1598	aml_ohsu_2018_14-00335	After or at the time transformation from another heme malignancy	None	AML with maturation	Adverse	Adverse	AML with maturation	Initial Acute Leukemia Diagnosis	Peripheral Blood	WES	No	Yes	Yes	No	Yes	Yes	2	Standard Chemotherapy | Supportive/Palliative Care	2	Hydroxyurea|Azacitidine, MLN4924	2	Induction | Supportive/Palliative Care	Refractory	Standard Chemotherapy	63	Standard Chemotherapy	Azacitidine, MLN4924	Induction	63	-33				No														46,XX,add(5)(q31),del(17)(p11.2)[12]/46,XX[3]								Negative	Negative	Negative	Negative		Negative	Negative	Negative		Negative	Negative	Negative	Positive	79	Matched	AM	Leukemia	AML with Maturation	1.06666666667
aml_ohsu_2018_1602	aml_ohsu_2018_14-00355	Denovo	None	Acute monoblastic and monocytic leukaemia	Adverse	Not Enough Information	Acute monoblastic and monocytic leukaemia	Initial Acute Leukemia Diagnosis	Peripheral Blood	WES + RNA-seq	Yes	Yes	No	Yes	Yes	No	2	Standard Chemotherapy | Targeted Therapy - Kinase Inhibitor(s)	3	Azacitidine|Sorafenib|Decitabine, Midostaurin	3	Induction | Experimental | Re-induction	Refractory	Standard Chemotherapy	317	Targeted Therapy - Kinase Inhibitor(s)	Sorafenib	Experimental	8	-14				No														46,XY[25]								Positive	Negative	Negative	Negative	Negative	Negative	Negative	Negative		Negative	Negative	Negative	Negative	78	Matched	AMOL	Leukemia	Acute Monoblastic/Monocytic Leukemia	0.133333333333
aml_ohsu_2018_1604	aml_ohsu_2018_14-00359	Denovo	CBFB-MYH11	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	Favorable	Favorable	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	Initial Acute Leukemia Diagnosis	Peripheral Blood	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	1	Standard Chemotherapy	3	7+3 (Cytarabine, Idarubicin)|HiDAC|ODSH (2 O, 3-O Desulfated Heparin)	2	Consolidation | Induction	Complete Response	Standard Chemotherapy	5	Standard Chemotherapy	HiDAC	Consolidation	210	-2				No														48,XY,+8,inv(16)(p13.1q22),+22[18]/49,sl,+21[2]			8q22 (RUNX1T1): gain present  16q22 (CBFB): rearrangement present  21q22 (RUNX1): gain or rearrangement present					Negative	Negative								Negative				58	Matched	AMLCBFBMYH11	Leukemia	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22);CBFB-MYH11	1.06666666667
aml_ohsu_2018_1612	aml_ohsu_2018_14-00369	After or at the time transformation from another heme malignancy	None	AML with myelodysplasia-related changes	Intermediate	Intermediate-II	AML with myelodysplasia-related changes	Residual Disease|Post-Chemotherapy	Bone Marrow Aspirate	WES	No	Yes	No	No	Yes	No	1	Standard Chemotherapy	1	CPX-351 (Liposomal Cytarabine + Daunorubicin)	1	Induction	Refractory	Standard Chemotherapy	-1	Standard Chemotherapy	CPX-351 (Liposomal Cytarabine + Daunorubicin)	Induction	-1	0		78	1	No				1.8										47,XY,+8[17]/46,XY[3]					CD38, CD13, HLA-DR, CD33 (DIM PARTIAL), CD4 (DIM), MPO (DIM PARTIAL), AND TDT		2.2	Negative	Negative	Negative	Negative		Negative	Positive	Negative		Negative	Negative	Negative	Negative	72	Matched	AMLMRC	Leukemia	AML with Myelodysplasia-Related Changes	1.06666666667
aml_ohsu_2018_1614	aml_ohsu_2018_14-00376		None	Refractory anaemia with excess blasts	Intermediate		Refractory anaemia with excess blasts	Unknown	Bone Marrow Aspirate	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	2	Standard Chemotherapy | Bone Marrow Transplant	2	Decitabine|Busulfan, Cyclophosphamide	2	Induction | Allogeneic - Matched Unrelated Donor	Complete Response	Standard Chemotherapy	116	Bone Marrow Transplant	Busulfan, Cyclophosphamide	Allogeneic - Matched Unrelated Donor	-1	0	0	17	5.3	No	0		67.3	22.1	5.3	0	36	20	3.5	0.82		32.5	10.2	47,XY,+8[18]/46,XY[2]	155	83.5	Trisomy 8	105	CD13, CD33, CD34, CD38, CD58, CD117, CD123, MPO+	7.9	0.94	Negative	Negative	Negative		p.R882C; MAF 45%	Negative	p.R132C; MAF 44%	Negative	Negative	Negative	Negative		Negative	48	Matched	MDSEB	Myelodysplastic Syndromes	MDS with Excess Blasts	1.13333333333
aml_ohsu_2018_1616	aml_ohsu_2018_14-00380	After or at the time transformation from another heme malignancy	None	AML with myelodysplasia-related changes	Adverse	Adverse	AML with myelodysplasia-related changes	Post-Chemotherapy|Initial Acute Leukemia Diagnosis	Peripheral Blood	WES + RNA-seq	Yes	Yes	No	Yes	Yes	No	1	Standard Chemotherapy	3	Azacitidine|Decitabine|Clofarabine	2	Hypomethylating/Low Dose Cytarabine | Induction	UNKNOWN	Standard Chemotherapy	-1	Standard Chemotherapy	Decitabine	Hypomethylating/Low Dose Cytarabine	-1	-10				No														42,X,add(Y)(p11.1),add(3)(q12),add(4)(q25),del(5)(q12q33),-7,add(8)(p11.2),-11,add(13)(p11.2),del(16)(q22),-17,add(19)(q12.3),-20,add(21)(p11.2),-22,+mar[20]			43% del 5q31, 56% del 7q31, 58% del20q					Negative	Negative												67	Matched	AMLMRC	Leukemia	AML with Myelodysplasia-Related Changes	NA
aml_ohsu_2018_17	aml_ohsu_2018_14-00395		None	AML with mutated NPM1	Intermediate	Intermediate-II	AML with mutated NPM1	Post-Transplant|Residual Disease	Peripheral Blood	WES	No	Yes	No	No	Yes	No	3	Standard Chemotherapy | Bone Marrow Transplant | Targeted Therapy - Kinase Inhibitor(s)	6	7+3 (Cytarabine, Idarubicin)|HiDAC|Fludarabine, TBI|Sorafenib|Hydroxyurea|Decitabine	5	Consolidation | Induction | Experimental | Re-induction | Allogeneic - Matched Unrelated Donor	Unknown	Standard Chemotherapy	2	Targeted Therapy - Kinase Inhibitor(s)	Sorafenib	Experimental	105	-15	0			No	0.8	0.4	75.6	18.9	4.3	5.1	13	22	3.6	0.66		21.6	7.5	46,XX,del(6)(q13q23)[18]/46,XY[2]	512	91.5	Missing 6q21 signal while having two copies each of the 6 centromere signal and the MYB (6q23) signal	28		6.9	2.54	Positive	Positive												31	Unmatched	AMLNPM1	Leukemia	AML with Mutated NPM1	0.133333333333
aml_ohsu_2018_1630	aml_ohsu_2018_14-00401	After or at the time transformation from another heme malignancy	None	AML with myelodysplasia-related changes	Adverse	Not Enough Information	AML with myelodysplasia-related changes	Residual Disease|Post-Chemotherapy	Bone Marrow Aspirate	WES	No	Yes	No	No	Yes	No	2	Standard Chemotherapy | Targeted Therapy - Other	3	AG-221|Azacitidine|Decitabine	2	Hypomethylating/Low Dose Cytarabine | Experimental				Targeted Therapy - Other	AG-221	Experimental	-1	0	0	10	0	No	4		50	8	38		17	21	4.3	0.57		27.6	8.9	46,XX[20]	230	97.5	nuc ish(D5S2064,D5S630,EGR1)x2[200],(D7Z1,D7S522)x2[199],(D8Z2,D20S108)x2[200],(RUNX1T1,RUNX1)x2 [200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	221	CD2 (-), CD4(partial dim +), CD7(-), CD11b(-), CD13(bright +), CD14(-), CD15(-), CD16(-), CD33(variable to bright +), CD34(+), CD36(-), CD38(bright +), CD45(moderately +), CD56(-), CD64(-), CD117(bright +), HLA-DR(variable +), MPO(partial+) and TdT(-).	6.9	2.7	Negative	Negative			F609fs*3; MAF 42%		Negative							79	Matched	AMLMRC	Leukemia	AML with Myelodysplasia-Related Changes	0.966666666667
aml_ohsu_2018_1631	aml_ohsu_2018_14-00404	Denovo	None	AML with myelodysplasia-related changes	Adverse	Adverse	AML with myelodysplasia-related changes	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	WES	No	Yes	No	No	Yes	No	2	Standard Chemotherapy | Supportive/Palliative Care	2	3+7 (Cytarabine, Daunorubicin)|Azacitidine	2	Salvage | Induction	Refractory	Standard Chemotherapy	5	Supportive/Palliative Care	Azacitidine	Salvage	196	0	0	29	0	No	0.9		75.2	17.9	6	0	16	17	3.4	1.02	M4	22.4	8.3	46,XY,add(5)(q23),der(11)t(11;20)(p11.2;p11.2),der(17)t(5;17)(q31;p12),-20,del(21)(q21)+mar[cp21]		90.3	21q deletion	30	CD13, CD33, CD34, CD117, MPO and HLA-DR	6.7	2.12	Negative	Negative	Negative			Negative	Negative	Negative	Negative	Negative			p.T312fs*25 (one nucleotide insertion); MAF 30%	54	Matched	AMLMRC	Leukemia	AML with Myelodysplasia-Related Changes	0.566666666667
aml_ohsu_2018_1644	aml_ohsu_2018_14-00423	Denovo	CBFB-MYH11	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	Favorable	Favorable	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	Initial Acute Leukemia Diagnosis	Peripheral Blood	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	2	Standard Chemotherapy | Bone Marrow Transplant	4	7+3 (Cytarabine, Idarubicin)|HiDAC|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Stanford Protocol 9022 (BU/CY)	3	Consolidation | Induction | Allogeneic - Matched Unrelated Donor	Complete Response	Standard Chemotherapy	7	Bone Marrow Transplant	Stanford Protocol 9022 (BU/CY)	Allogeneic - Matched Unrelated Donor	-1	0		74	61	No				1							M4eo			46,XX,inv(16)(p13q22)[20]					CD34+ EXPRESSING CD38, CD13, CD33, PARTIAL DIM CD2, PARTIAL CD64; DIM PARTIAL CD11C, PARTIAL DIM CD4, COEXPRESSION OF CD117 AND CD15, HLA-DR, MPO, AND PARTIAL DIM TDT		34.4	Negative	Negative	Negative	Negative		Negative	Negative	Negative		Negative	Negative	Negative	Negative	51	Matched	AMLCBFBMYH11	Leukemia	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22);CBFB-MYH11	0.766666666667
aml_ohsu_2018_1646	aml_ohsu_2018_14-00425	Denovo	PML-RARA	Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA	Favorable	Intermediate-II	Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	WES + RNA-seq	Yes	Yes	No	Yes	Yes	No	1	Standard Chemotherapy	2	ATRA, Arsenic Trioxide|APML4 Protocol (ATRA, Arsenic Trioxide, Idarubicin)	2	Consolidation | Induction	Complete Response	Standard Chemotherapy	26	Standard Chemotherapy	ATRA, Arsenic Trioxide	Consolidation	31	0	0			No	0		14.8	13.1	13.9	0.9	19	37	3.3	0.6	M3	19.5	6.5	46,XX,t(15;17)(q24;q21)[4]/45,idem,-22[15]/46,XX[1]	819	70.8		9		7.1	25.11	Positive	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	47	Matched	APLPMLRARA	Leukemia	APL with PML-RARA	0.2
aml_ohsu_2018_1651	aml_ohsu_2018_14-00430	Denovo	None	AML with maturation	Adverse	Intermediate-II	AML with maturation	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	WES	No	Yes	No	No	Yes	No	1	Standard Chemotherapy	1	Azacitidine	1	Hypomethylating/Low Dose Cytarabine				Standard Chemotherapy	Azacitidine	Hypomethylating/Low Dose Cytarabine	-1	0	0	62	17	No	0.9		64.3	11.3	5.2	0	11	9	3.2	0.88	M2	33.7	10.5	47,XX,+8[20]	216	93.9	Trisomy 8	38	CD13, partial dim CD33, CD34, CD38, dim CD58, CD117, CD123, dim HLA-DR, and partial MPO.	7	2.37	Negative	Negative	Negative		Negative	Negative	Negative		Negative	Negative	Negative	Negative	Negative	75	Matched	AM	Leukemia	AML with Maturation	1.7
aml_ohsu_2018_1648	aml_ohsu_2018_14-00434	Denovo	MLLT3-KMT2A	AML with t(9;11)(p22;q23); MLLT3-MLL	Intermediate	Intermediate-II	AML with t(9;11)(p22;q23); MLLT3-MLL	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	1	Standard Chemotherapy	1	Hydroxyurea	1	Induction	Unknown	Standard Chemotherapy	365	Standard Chemotherapy	Hydroxyurea	Induction	365	0		94	83	No				0							M5a			46,XX[1]					CD38, CD56, slightly dim CD4, CD33, dim CD13, CD64, CD11c, CD15 and partial CD117		137.6	Negative	Negative	Negative	Negative		Negative	Negative	Negative		Negative	Negative	Negative	Negative	69	Matched	AMLRGA	Leukemia	AML with Recurrent Genetic Abnormalities	0.566666666667
aml_ohsu_2018_1655	aml_ohsu_2018_14-00447	Denovo	MLLT3-KMT2A	AML with t(9;11)(p22;q23); MLLT3-MLL	Intermediate	Intermediate-II	AML with t(9;11)(p22;q23); MLLT3-MLL	Initial Acute Leukemia Diagnosis	Peripheral Blood	RNA-seq	Yes	No	Yes	Yes	No	Yes	2	Standard Chemotherapy | Bone Marrow Transplant	2	Fludarabine, Melphalan|Idarubicin and Cytarabine	3	Consolidation | Induction | Allogeneic - Matched Unrelated Donor	Complete Response	Standard Chemotherapy	5	Bone Marrow Transplant	Fludarabine, Melphalan	Allogeneic - Matched Unrelated Donor	-1	0	0			No	0		9.5	0	6	0	51	152	3.1	0.85	M5	30.4	9.7	47,XX,+8,t(9;11)(p22;q23)[20]	4484	80.4	MLL rearrangement	87		6	49.29	Negative	Negative	Negative		Negative		Negative	Negative	Negative	Negative	Negative	Negative	Negative	48	Matched	AMLRGA	Leukemia	AML with Recurrent Genetic Abnormalities	NA
aml_ohsu_2018_1656	aml_ohsu_2018_14-00448		None	Therapy-related myeloid neoplasms	Intermediate	Not Enough Information	Therapy-related myeloid neoplasms	Initial Acute Leukemia Diagnosis	Peripheral Blood	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	1	Standard Chemotherapy	1	Azacitidine, MLN4924	1	Induction	Refractory	Standard Chemotherapy	111	Standard Chemotherapy	Azacitidine, MLN4924	Induction	111	0		78	77	No				1										46,XX[20]					CD34 and MPO, with partial CD38, CD33, CD13, CD11c, CD117 and HLADR		5.6	Negative	Negative	Negative	Negative		Negative	Positive	Negative		Negative	Negative	Negative	Negative	78	Matched	TMN	Leukemia	Therapy-Related Myeloid Neoplasms	1.13333333333
aml_ohsu_2018_1656	aml_ohsu_2018_14-00449		None	Therapy-related myeloid neoplasms	Intermediate	Intermediate-I	Therapy-related myeloid neoplasms	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	WES	No	Yes	No	No	Yes	No	1	Standard Chemotherapy	1	Azacitidine, MLN4924	1	Induction	Refractory	Standard Chemotherapy	111	Standard Chemotherapy	Azacitidine, MLN4924	Induction	111	0		78	77	No				1										46,XX[20]					CD34 and MPO, with partial CD38, CD33, CD13, CD11c, CD117 and HLADR		5.6	Negative	Negative	Negative	Negative		Negative	Positive	Negative		Negative	Negative	Negative	Negative	78	Matched	TMN	Leukemia	Therapy-Related Myeloid Neoplasms	0.9
aml_ohsu_2018_1657	aml_ohsu_2018_14-00451	After or at the time transformation from another heme malignancy	None	AML with myelodysplasia-related changes	Adverse	Adverse	AML with myelodysplasia-related changes	Residual Disease	Bone Marrow Aspirate	WES	No	Yes	No	No	Yes	No	1	Standard Chemotherapy	3	3+7 (Cytarabine, Daunorubicin)|FLAG (Fludarabine, High-dose Cytarabine, G-CSF)|5+2 (Ara-C, Daunorubicin)	3	Salvage | Induction | Re-induction	Refractory	Standard Chemotherapy	6	Standard Chemotherapy	FLAG (Fludarabine, High-dose Cytarabine, G-CSF)	Salvage	4	0	1.7	55		No	0.6		70	21.1	6.6							26.6	9.1	46,XY,del(5)(q22q33),del(21)(q22q22)[cp20]		85.2	5q deletion	3	CD13, CD15, CD34 (subset), CD38, CD58, CD64, CD117, CD123 and HLA-DR.		1.2	Negative	Negative	Negative		Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	70	Matched	AMLMRC	Leukemia	AML with Myelodysplasia-Related Changes	0.466666666667
aml_ohsu_2018_1665	aml_ohsu_2018_14-00454		None	Acute myeloid leukaemia, NOS	Adverse	Not Enough Information	Acute myeloid leukaemia, NOS	Post-Chemotherapy|Residual Relapse	Peripheral Blood	WES + RNA-seq	Yes	Yes	No	Yes	Yes	No	3	Standard Chemotherapy | Targeted Therapy - Kinase Inhibitor(s) | Targeted Therapy - Other	8	HiDAC|AG-221|Gilteritinib (ASP2215)|3+7 (Cytarabine, Daunorubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone)|Decitabine|MEC, Lenalidomide|Clofarabine, Cytarabine	5	Hypomethylating/Low Dose Cytarabine | Consolidation | Induction | Experimental | Re-induction	Complete Response	Standard Chemotherapy	-1	Targeted Therapy - Other	AG-221	Experimental	-1	0		96	85	No				5										46,XY,t(4;15)(q31;q22),add(12)(p11~12)[cp7]/46~51,XY,del(7)(q11.2q36),add(12)(p11~12),add(20)(q11.2)[cp5]/46,XY,?inv(8)(p21q22)[cp7]/46,XY[cp2]					CD38, CD33; WITH PARTIAL CD34, CD56, CD13, CD11C, CD2 AND CD15/CD117		0.1	Negative	Negative	Negative	Negative		Negative	Negative			Negative	Negative	Negative	Negative	66	Matched	AMLNOS	Leukemia	AML, NOS	0.733333333333
aml_ohsu_2018_1662	aml_ohsu_2018_14-00458		None	Refractory anaemia with excess blasts	Intermediate		Refractory anaemia with excess blasts	Unknown	Bone Marrow Aspirate	WES + RNA-seq	Yes	Yes	No	Yes	Yes	No	2	Standard Chemotherapy | Bone Marrow Transplant	2	Fludarabine, Melphalan|Azacitidine, Lenalidomide	2	Induction | Allogeneic - Mismatched Unrelated Donor	Complete Response	Standard Chemotherapy	117	Bone Marrow Transplant	Fludarabine, Melphalan	Allogeneic - Mismatched Unrelated Donor	-1	0	0	4	6	No	0		38.9	1.1	56.7		58	51	3.5	0.87		22.4	7.5	47,XY,+8[2]/46,XY[18]	438	93.7	Trisomy 8	20	CD34/CD117 positive myeloid blasts comprise about 4% of total CD45+ cells with possible partial TdT expression	5.9	2.23	Negative	Negative	Negative		Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	51	Matched	MDSEB	Myelodysplastic Syndromes	MDS with Excess Blasts	0.966666666667
aml_ohsu_2018_1664	aml_ohsu_2018_14-00464	Denovo	MLLT3-KMT2A	AML with t(9;11)(p22;q23); MLLT3-MLL	Intermediate	Intermediate-II	AML with t(9;11)(p22;q23); MLLT3-MLL	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	3	Standard Chemotherapy | Bone Marrow Transplant | Targeted Therapy - Other	4	ATRA (Tretinoin)|Cyclophosphamide, TBI|3+7 (Cytarabine, Daunorubicin)|GCLAC (GCSF, Clofarabine & Cytarabine)	4	Induction | Experimental | Re-induction | Allogeneic - Matched Unrelated Donor	Refractory	Standard Chemotherapy	7	Bone Marrow Transplant	Cyclophosphamide, TBI	Allogeneic - Matched Unrelated Donor	-1	0		65	90	No				0.1							M1			46,XX,t(9;11)(p22;q23)[22]					CD34, CD38 (dim partial), CD13, CD33 (dim partial), CD11c, CD4 (dim partial), HLA-DR, CD117 and MPO		40.2	Negative	Negative	Negative	Negative			Negative	Negative		Negative	Negative	Negative	Negative	22	Matched	AMLRGA	Leukemia	AML with Recurrent Genetic Abnormalities	0.133333333333
aml_ohsu_2018_1666	aml_ohsu_2018_14-00473	Denovo	None	AML with myelodysplasia-related changes	Adverse	Adverse	AML with myelodysplasia-related changes	Initial Acute Leukemia Diagnosis	Peripheral Blood	WES + RNA-seq	Yes	Yes	No	Yes	Yes	No	1	Standard Chemotherapy	3	7+3 (Cytarabine, Idarubicin)|HAM (Cytarabine, Mitoxantrone)|MEC (Cytarabine, Etoposide, Mitoxantrone)	2	Salvage | Induction	Complete Response	Standard Chemotherapy	6	Standard Chemotherapy	HAM (Cytarabine, Mitoxantrone)	Salvage	7	0	6.1	22	17.4	No	5.2	16.5	31.3	1.7	21.8	0.2	13	11	3.2	0.78		29.5	9.5	59~62,XX,+X,+1,+2,del(5)(q13q34),+6,+8,+8,+9,+11,+11,i(11)(q10),+12,+14,+16,+19,+22,+mar[cp19]/46,XX[1]	444	101.4	Trisomy 9	34	CD13, CD34, CD58 and CD117	7	10.75	Negative	Negative	Negative		Negative	Negative	Negative	Negative	Negative	Negative	Negative	p.G12D; MAF:11%	p.R280T;  MAF 36%	62	Matched	AMLMRC	Leukemia	AML with Myelodysplasia-Related Changes	1.03333333333
aml_ohsu_2018_1670	aml_ohsu_2018_14-00476	Denovo	None	Acute monoblastic and monocytic leukaemia	Intermediate	Intermediate-II	Acute monoblastic and monocytic leukaemia	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	WES + RNA-seq	Yes	Yes	No	Yes	Yes	No	3	Standard Chemotherapy | Supportive/Palliative Care | Intrathecal	5	HiDAC|Cytarabine|SWOG S1203 (7+3 +/- Vorinostat)|Hydroxyurea|MEC, Lenalidomide	5	Consolidation | Induction | CNS | Re-induction | Supportive/Palliative Care	Complete Response	Standard Chemotherapy	7	Supportive/Palliative Care	Hydroxyurea	Supportive/Palliative Care	9	0		70	79	No				2							M5			46,XY,t(11;19)(q23;p13.1)[20]					CD34+ BLAST POPULATION, 40%, EXPRESSING CD117, CD15 (DIM PARTIAL), CD13 (DIM PARTIAL), CD33 (DIM PARTIAL), CD38, CD4 (DIM PARTIAL), CD11C (DIM PARTIAL), CD64 (DIM PARTIAL), MPO (BRIGHT), AND ABERRANT CD7 (MINOR SUBSET DIM), WITH POSSIBLE CD19		261.2	Positive	Negative												47	Matched	AMOL	Leukemia	Acute Monoblastic/Monocytic Leukemia	0.3
aml_ohsu_2018_1670	aml_ohsu_2018_14-00477	Denovo	None	Acute monoblastic and monocytic leukaemia	Adverse	Not Enough Information	Acute monoblastic and monocytic leukaemia	Initial Acute Leukemia Diagnosis	Peripheral Blood	WES	No	Yes	Yes	No	Yes	Yes	3	Standard Chemotherapy | Supportive/Palliative Care | Intrathecal	5	HiDAC|Cytarabine|SWOG S1203 (7+3 +/- Vorinostat)|Hydroxyurea|MEC, Lenalidomide	5	Consolidation | Induction | CNS | Re-induction | Supportive/Palliative Care	Complete Response	Standard Chemotherapy	7	Supportive/Palliative Care	Hydroxyurea	Supportive/Palliative Care	9	0		70	79	No				2							M5			46,XY,t(11;19)(q23;p13.1)[20]					CD34+ BLAST POPULATION, 40%, EXPRESSING CD117, CD15 (DIM PARTIAL), CD13 (DIM PARTIAL), CD33 (DIM PARTIAL), CD38, CD4 (DIM PARTIAL), CD11C (DIM PARTIAL), CD64 (DIM PARTIAL), MPO (BRIGHT), AND ABERRANT CD7 (MINOR SUBSET DIM), WITH POSSIBLE CD19		261.2	Positive	Negative												47	Matched	AMOL	Leukemia	Acute Monoblastic/Monocytic Leukemia	0.266666666667
aml_ohsu_2018_1672	aml_ohsu_2018_14-00484		None	Acute myeloid leukaemia, NOS	Adverse	Intermediate-I	Acute myeloid leukaemia, NOS	Residual Disease	Bone Marrow Aspirate	WES	No	Yes	No	No	Yes	No	1	Standard Chemotherapy	2	3+7 (Cytarabine, Daunorubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone)	2	Induction | Re-induction	Refractory	Standard Chemotherapy	6	Standard Chemotherapy	MEC (Cytarabine, Etoposide, Mitoxantrone)	Re-induction	4	0	0			No	0	0.9	59.3	31.9	3.5	0						24.6	8.5	46,XY[19]		89.5		46	Partial CD7, CD13, CD33, CD34, CD38, partial CD56, CD58, CD117, CD123, HLA-DR, and partial TdT		2.78	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	63	Matched	AMLNOS	Leukemia	AML, NOS	0.566666666667
aml_ohsu_2018_1675	aml_ohsu_2018_14-00487	Denovo	None	Acute myeloid leukaemia, NOS	Intermediate or Adverse	Intermediate-I	Acute myeloid leukaemia, NOS	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	WES	No	Yes	No	No	Yes	No	2	Standard Chemotherapy | Targeted Therapy - Kinase Inhibitor(s)	6	7+3 (Cytarabine, Idarubicin)|HiDAC|Azacitidine|CLAG-M (Cladribine, Cytarabine, Mitoxantrone, Filgrastim)|7+3 (Cytarabine, Idarubicin) plus Sorafenib|Ponatinib	5	Hypomethylating/Low Dose Cytarabine | Consolidation | Induction | Experimental | Re-induction	Unknown	Standard Chemotherapy	-1	Targeted Therapy - Kinase Inhibitor(s)	Ponatinib	Experimental	-1	-1		86.1	65	No														46,XX[20]			Normal		Large population of atypical CD34 positive myeloblasts (weak CD4+, weak CD33+), representing approximately 78% of the leukocytes suggestive of acute myeloid leukemia		11.38	Positive	Negative	Negative											44	Matched	AMLNOS	Leukemia	AML, NOS	0.766666666667
aml_ohsu_2018_1675	aml_ohsu_2018_14-00488	Denovo	None	Acute myeloid leukaemia, NOS	Intermediate	Not Enough Information	Acute myeloid leukaemia, NOS	Initial Acute Leukemia Diagnosis	Peripheral Blood	WES + RNA-seq	Yes	Yes	No	Yes	Yes	No	2	Standard Chemotherapy | Targeted Therapy - Kinase Inhibitor(s)	6	7+3 (Cytarabine, Idarubicin)|HiDAC|Azacitidine|CLAG-M (Cladribine, Cytarabine, Mitoxantrone, Filgrastim)|7+3 (Cytarabine, Idarubicin) plus Sorafenib|Ponatinib	5	Hypomethylating/Low Dose Cytarabine | Consolidation | Induction | Experimental | Re-induction	Unknown	Standard Chemotherapy	-1	Targeted Therapy - Kinase Inhibitor(s)	Ponatinib	Experimental	-1	-1		86.1	65	No														46,XX[20]			Normal		Large population of atypical CD34 positive myeloblasts (weak CD4+, weak CD33+), representing approximately 78% of the leukocytes suggestive of acute myeloid leukemia		11.38	Positive	Negative	Negative											44	Matched	AMLNOS	Leukemia	AML, NOS	0.966666666667
aml_ohsu_2018_1246	aml_ohsu_2018_14-00495		None	AML with mutated NPM1	Intermediate	Intermediate-II	AML with mutated NPM1	Post-Chemotherapy|Post-Transplant|Residual Disease	Peripheral Blood	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	3	Standard Chemotherapy | Bone Marrow Transplant | Targeted Therapy - Kinase Inhibitor(s)	6	7+3 (Cytarabine, Idarubicin)|HiDAC|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Crenolanib|Clofarabine, Cytarabine|Busulfan, Cyclophosphamide	5	Consolidation | Induction | Experimental | Re-induction | Allogeneic - Matched Unrelated Donor	Complete Response	Standard Chemotherapy	24	Targeted Therapy - Kinase Inhibitor(s)	Crenolanib	Experimental	141	-28				No							23	26	2.9			27.9	9.6	45,XY,der(12;16)(q10;p10)[2]/46,XY[18]			nuc ish(RUNX1T1,RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2) [200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x1(5'CBFB con 3'CBFBx1)[31/200]	30		5	27.4	Positive	Positive			R882H; MAF unlisted									64	Matched	AMLNPM1	Leukemia	AML with Mutated NPM1	2.16666666667
aml_ohsu_2018_1683	aml_ohsu_2018_14-00496	Denovo	None	AML with mutated NPM1	Favorable	Not Enough Information	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Peripheral Blood	WES + RNA-seq	Yes	Yes	No	Yes	Yes	No	1	Standard Chemotherapy	3	7+3 (Cytarabine, Idarubicin)|HiDAC|ODSH (2 O, 3-O Desulfated Heparin)	2	Consolidation | Induction	Complete Response	Standard Chemotherapy	-1	Standard Chemotherapy	HiDAC	Consolidation	129	-1		37	20	No														46,XY[20]			Normal	283	Increased atypical CD117 positive myeloid blasts (weak CD7  positive, HLA-DR negative), representing 18% of the total  leukocytes, consistent with a myeloid neoplasm		16.11	Negative	Positive	Negative							Negative				55	Matched	AMLNPM1	Leukemia	AML with Mutated NPM1	1.06666666667
aml_ohsu_2018_1684	aml_ohsu_2018_14-00498	After or at the time transformation from another heme malignancy	Unknown	Acute myeloid leukaemia, NOS	Adverse	Not Enough Information	Acute myeloid leukaemia, NOS	Initial Acute Leukemia Diagnosis	Peripheral Blood	WES	No	Yes	No	No	Yes	No	1	Standard Chemotherapy	3	5+2 (Cytarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin)|CLAG-M (Cladribine, Cytarabine, Mitoxantrone, Filgrastim)	2	Induction | Re-induction	Refractory	Standard Chemotherapy	7	Standard Chemotherapy	CLAG-M (Cladribine, Cytarabine, Mitoxantrone, Filgrastim)	Re-induction	4	0	0	50	57.4	No	0	0	38.4	1	3.2	0	16	9	2	0.46		22.2	7.4		184	87.4	Tetrasomy 8	6	partial CD7, CD13, CD33 (variable), CD34, CD38 (variable), CD117(variable)	6	0.81	Positive	Negative												62	Matched	AMLNOS	Leukemia	AML, NOS	1.03333333333
aml_ohsu_2018_1689	aml_ohsu_2018_14-00499	Denovo	None	Acute undifferentiated leukaemia	Adverse	Intermediate-I	Acute undifferentiated leukaemia	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	WES	No	Yes	No	No	Yes	No	3	Standard Chemotherapy | Bone Marrow Transplant | Intrathecal	4	HyperCVAD Course B (Cytarabine, Methotrexate)|EWALL Protocol|Bu/Cy/TBI|HyperCVAD Course A (Cyclophosphamide, Dexamethasone, Doxorubicin, Vincristine)	3	Consolidation | Induction | Allogeneic - Matched Unrelated Donor	Complete Response	Standard Chemotherapy	3	Bone Marrow Transplant	Bu/Cy/TBI	Allogeneic - Matched Unrelated Donor	-1	0	1	42	43.8	No	0.9	0	26.7	5.7	20.9	0	23	20	3.5	1.27		32.5	11.2	46,XY[20]	170	100.9	c/w karyotype	57	partial CD7, partial CD10, dimCD13, CD34, partial CD117, dim TdT positive	6.3	2.22	Negative	Negative	Negative		Negative	Negative	Negative	Negative	Negative	Negative	Negative	p.G12S; MAF: 15%	Negative	68	Matched	AUL	Leukemia	Acute Undifferentiated Leukemia	1.23333333333
aml_ohsu_2018_1691	aml_ohsu_2018_14-00502	Denovo	Unknown	Blastic plasmacytoid dendritic cell neoplasm	Intermediate	Not Enough Information	Blastic plasmacytoid dendritic cell neoplasm	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	WES	No	Yes	No	No	Yes	No	0		0		0					NONE	NONE	NONE		0				No																						Negative	Negative													Unmatched	BPDCN	Blastic Plasmacytoid Dendritic Cell Neoplasm	Blastic Plasmacytoid Dendritic Cell Neoplasm	0.3
aml_ohsu_2018_1693	aml_ohsu_2018_14-00504	Denovo	MLLT3-KMT2A	AML with t(9;11)(p22;q23); MLLT3-MLL	Adverse	Adverse	AML with t(9;11)(p22;q23); MLLT3-MLL	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	2	Standard Chemotherapy | Bone Marrow Transplant	3	7+3 (Cytarabine, Idarubicin)|HiDAC|Busulfan, Cyclophosphamide, Thymoglobulin	3	Consolidation | Induction | Allogeneic - Matched Unrelated Donor	Complete Response	Standard Chemotherapy	-1	Bone Marrow Transplant	Busulfan, Cyclophosphamide, Thymoglobulin	Allogeneic - Matched Unrelated Donor	-1	-2				No														46,XY,der(4)t(4;9;11)(p14;p22;q23),der(9)del(9)(p13p22)t(4;9;11),der(11)t(4;9;11)[19]/46,XY[1].isht(4;9;11)(5'MLL-,3'MLL+;5'MLL-,3'MLL-;5'MLL+,3'MLL-)[1]			nuc ish(ABL1,BCR)x2[200],(5'MLL,3'MLL)x2(5'MLL sep 3'MLLx1)[189/200],(PML,RARA)x2 [200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[198]					Positive	Positive	Negative				Negative	Negative						35	Matched	AMLRGA	Leukemia	AML with Recurrent Genetic Abnormalities	1.1
aml_ohsu_2018_1696	aml_ohsu_2018_14-00514	After or at the time transformation from another heme malignancy	Unknown	AML with myelodysplasia-related changes	Intermediate	Not Enough Information	AML with myelodysplasia-related changes	Post-Chemotherapy|Initial Acute Leukemia Diagnosis	Peripheral Blood	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	1	Standard Chemotherapy	1	Azacitidine	1	Hypomethylating/Low Dose Cytarabine				Standard Chemotherapy	Azacitidine	Hypomethylating/Low Dose Cytarabine	107	0	0		50	No	1		17	1	13		19	42	3.2	1.83		23.7	7.7		766	92.2		11		7.1	45.6	Negative	Negative					Negative	Negative						71	Matched	AMLMRC	Leukemia	AML with Myelodysplasia-Related Changes	0.966666666667
aml_ohsu_2018_1700	aml_ohsu_2018_14-00521	Denovo	None	AML without maturation	Intermediate	Not Enough Information	AML without maturation	Initial Acute Leukemia Diagnosis	Peripheral Blood	WES	No	Yes	No	No	Yes	No	1	Standard Chemotherapy	1	SWOG S1203 (7+3 +/- Vorinostat)	1	Induction	Complete Response	Standard Chemotherapy	7	Standard Chemotherapy	SWOG S1203 (7+3 +/- Vorinostat)	Induction	7	0		56	1	No				1.4							M1			46,XX[21]					CD34+ BLAST POPULATION, 51%, EXPRESSING HLA-DR, CD38, CD7, DIM PARTIAL CD13, PARTIAL CD33, CD117, PARTIAL MPO, AND PARTIAL TDT		1	Negative	Negative	Negative	Negative		Negative	Negative	Negative		Negative	Negative	Negative	Negative	60	Matched	AWM	Leukemia	AML without Maturation	0.0333333333333
aml_ohsu_2018_1702	aml_ohsu_2018_14-00527	Relapse	None	AML with myelodysplasia-related changes	Intermediate	Not Enough Information	AML with myelodysplasia-related changes	Post-Chemotherapy|Relapse	Peripheral Blood	WES	No	Yes	Yes	No	Yes	Yes	1	Standard Chemotherapy	4	7+3 (Cytarabine, Idarubicin)|HiDAC|MEC (Cytarabine, Etoposide, Mitoxantrone)|Decitabine	4	Hypomethylating/Low Dose Cytarabine | Salvage | Induction | Maintenance	Refractory	Standard Chemotherapy	6	Standard Chemotherapy	HiDAC	Maintenance	5	0	0	82	47	No	2		34	9	9		11	28	3.8	0.95		36.8	12.1	46,XY[20]	932	87.4	nuc ish(D5S2064,D5S630,EGR1)x2[200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[200],(RUNX1T1, RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	127	CD2(-), CD7(-), CD11b(-), CD13(variably +), CD14(-), CD15(partial +), CD16(-), CD33(partial +), CD34 (variably +), CD36(-), CD38(variably +), CD45(moderate to dim+), CD56(-), CD64(partial +), CD117(+), and HLA-DR(partial +).	7.2	11.7	Negative	Negative				Negative		Negative						63	Matched	AMLMRC	Leukemia	AML with Myelodysplasia-Related Changes	2.76666666667
aml_ohsu_2018_1533	aml_ohsu_2018_14-00528	Relapse	Complex	Therapy-related myeloid neoplasms	Adverse	Not Enough Information	Therapy-related myeloid neoplasms	Post-Chemotherapy|Relapse	Peripheral Blood	RNA-seq	Yes	No	Yes	Yes	No	Yes	2	Standard Chemotherapy | Supportive/Palliative Care	4	7+3 (Cytarabine, Idarubicin)|HiDAC|Cytarabine|Decitabine, Hydroxyurea	4	Consolidation | Induction | Re-induction | Supportive/Palliative Care	Refractory	Standard Chemotherapy	5	Supportive/Palliative Care	Decitabine, Hydroxyurea	Supportive/Palliative Care	-1	-111	0		58	No	0		14	3	19		24	116	3.7			21.4	7.7	46~47,XX,t(1;11)(p34;p15),der(8)del(8)(p11.2p23)t(1;8)(q21;q24.3),add(9)(q34),del(9)(q13q22),add(16)(p13.3),+1~2mar[cp11] /47~48,idem,+13[cp2]/47~48,idem,-13,der(21)t(8;21)(q13;p12),+2~3mar[cp6]/46,XX[1]			nuc ish(D5S721,D5S23,EGR1)x2[200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[200], (5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[199],(RUNX1T1x3,RUNX1x2)[69/200]/(RUNX1T1x2,RUNX1x3)[7/200],(PML,RARA)x2 [200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	10	CD2(-), CD4(+), CD7(-), CD11b(partial +), CD13(partial +), CD14(partial +),CD15(variably +), CD16(-), CD33(variably +), CD34(-), CD36(+), CD38(variably +), CD45(variably +), CD56 (variable +), CD64(partial +), CD117(-), HLA-DR(+).	6	11.2	Negative	Negative												58	Matched	TMN	Leukemia	Therapy-Related Myeloid Neoplasms	NA
aml_ohsu_2018_1707	aml_ohsu_2018_14-00536		None	Therapy-related myeloid neoplasms	Adverse	Adverse	Therapy-related myeloid neoplasms	Residual Disease	Bone Marrow Aspirate	WES	No	Yes	No	No	Yes	No	2	Standard Chemotherapy | Unknown	3	7+3 (Cytarabine, Idarubicin)|Lenalidomide|Azacitidine	2	Unknown | Induction	Unknown	Standard Chemotherapy	75	Standard Chemotherapy	7+3 (Cytarabine, Idarubicin)	Induction	8	0	0	78	15	No	0	0	75	0.9	10.7	0	9	8	2.5	0.5		24.9	8.5	47,XX,del(5)(q22q35),+8[20]	158	86.5	5q deletion	26	CD13, partial CD33, CD34, CD38, dimCD45, CD58, partial CD64, CD117, HLA-DR, and MPO positive.	5.9	1.75	Negative	Negative	Negative		p.R882H; MAF 37%	Negative	p.R132C; MAF 37%	Negative	Negative	Negative			p.I251M; MAF 34%	70	Matched	TMN	Leukemia	Therapy-Related Myeloid Neoplasms	0.9
aml_ohsu_2018_1708	aml_ohsu_2018_14-00537	Denovo	None	Acute myeloid leukaemia, NOS	Intermediate	Intermediate-II	Acute myeloid leukaemia, NOS	Initial Acute Leukemia Diagnosis	Peripheral Blood	WES	Yes	Yes	Yes	No	Yes	Yes	2	Standard Chemotherapy | Bone Marrow Transplant	4	Bu/Cy/ATG|ADE (Cytarabine, Daunorubicin & Etoposide)|HiDAC + Midostaurin|Etoposide, Cytarabine	3	Consolidation | Induction | Allogeneic - Matched Unrelated Donor	Unknown	Standard Chemotherapy	-1	Bone Marrow Transplant	Bu/Cy/ATG	Allogeneic - Matched Unrelated Donor	-1	-3				No														46,XY,t(11;19)(q23;p13.1)[19]/46,XY[1]								Negative	Negative												17	Unmatched	AMLNOS	Leukemia	AML, NOS	0.0666666666667
aml_ohsu_2018_1710	aml_ohsu_2018_14-00542	Denovo	None	AML with mutated NPM1	Favorable	Not Enough Information	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Peripheral Blood	WES + RNA-seq	Yes	Yes	No	Yes	Yes	No	1	Standard Chemotherapy	2	HiDAC|SWOG S1203 (7+3 +/- Vorinostat)	2	Consolidation | Induction	Complete Response	Standard Chemotherapy	8	Standard Chemotherapy	HiDAC	Consolidation	137	0		69	68	No				1							M2			48,XX,+3,+10[2]/46,XX[18]					CD34, CD38, CD13, CD33, CD11C, CD19, PARTIAL CD4, HLA-DR, PARTIAL CD15, CD117, PARTIAL CD61, AND PARTIAL CD7		5.1	Negative	Positive	Negative	Negative		Negative	Negative	Negative		Negative	Negative	Negative	Negative	27	Matched	AMLNPM1	Leukemia	AML with Mutated NPM1	1.5
aml_ohsu_2018_1710	aml_ohsu_2018_14-00543	Denovo	None	AML with mutated NPM1	Favorable	Intermediate-II	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	WES	No	Yes	No	No	Yes	No	1	Standard Chemotherapy	2	HiDAC|SWOG S1203 (7+3 +/- Vorinostat)	2	Consolidation | Induction	Complete Response	Standard Chemotherapy	8	Standard Chemotherapy	HiDAC	Consolidation	137	0		69	68	No				1							M2			48,XX,+3,+10[2]/46,XX[18]					CD34, CD38, CD13, CD33, CD11C, CD19, PARTIAL CD4, HLA-DR, PARTIAL CD15, CD117, PARTIAL CD61, AND PARTIAL CD7		5.1	Negative	Positive	Negative	Negative		Negative	Negative	Negative		Negative	Negative	Negative	Negative	27	Matched	AMLNPM1	Leukemia	AML with Mutated NPM1	1.7
aml_ohsu_2018_1711	aml_ohsu_2018_14-00546	Denovo	PML-RARA	Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA	Favorable	Intermediate-II	Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA	Initial Acute Leukemia Diagnosis	Peripheral Blood	RNA-seq	Yes	No	Yes	Yes	No	Yes	1	Standard Chemotherapy	1	APML4 Protocol (ATRA, Arsenic Trioxide, Idarubicin)	1	Induction	Complete Response	Standard Chemotherapy	-1	Standard Chemotherapy	APML4 Protocol (ATRA, Arsenic Trioxide, Idarubicin)	Induction	-1	0	0	83	77	No	0	0	16.1	5.3	4.5	1.2	31	51	3.2	1.05	M3	22.7	8.1	45,XX,dic(12;18)(p11.2;p11.2),t(15;17)(q22;q21)[19]/46,XX[1]	1816	92.3	PML/RARA fusion	33	dim CD2, CD13, CD33, CD34 (variable), CD56, CD58, CD64, CD117, CD123 and cytoplasmic MPO positive; HLA-DR negative	5.7	16.03	Negative	Negative												69	Matched	APLPMLRARA	Leukemia	APL with PML-RARA	NA
aml_ohsu_2018_1717	aml_ohsu_2018_14-00555		None	Acute myeloid leukaemia, NOS	Intermediate	Adverse	Acute myeloid leukaemia, NOS	Post-Chemotherapy|Residual Relapse	Bone Marrow Aspirate	WES	No	Yes	No	No	Yes	No	1	Standard Chemotherapy	4	7+3 (Cytarabine, Idarubicin)|HiDAC|Azacitidine|MEC (Cytarabine, Etoposide, Mitoxantrone)	3	Hypomethylating/Low Dose Cytarabine | Consolidation | Induction	Complete Response	Standard Chemotherapy	6	Standard Chemotherapy	Azacitidine	Hypomethylating/Low Dose Cytarabine	-1	0	0	68	54	No	0		60	2	0		33	27	2.2	0.51		28.4	9.7	46,XX,del(17)(p11.2p13)[19]/46,XX[1]	183	86.1	nuc ish(D5S2064,D5S630,EGR1)x2[200],(D7Z1,D7S522)x2[199],(D8Z2,D20S108)x2 [200],(RUNX1T1,RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[197],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[197]	10	CD2(-), CD4(partial dim +), CD7(-), CD11b(-), CD13(+), CD14(-), CD15 (partial +), CD16(-), CD33(variably +), CD34(+), CD36(-), CD38(partial +), CD45(dim to moderately +), CD56(-), CD64(-), CD117(partial +), HLA-DR(-), TdT(predominantly -), MPO(+).	6.1		Negative	Negative				Negative	Negative	Negative						54	Matched	AMLNOS	Leukemia	AML, NOS	0.8
aml_ohsu_2018_1721	aml_ohsu_2018_14-00559	Denovo	None	AML with mutated NPM1	Favorable	Favorable	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	1	Standard Chemotherapy	4	7+3 (Cytarabine, Idarubicin)|HiDAC|Azacitidine|MEC (Cytarabine, Etoposide, Mitoxantrone)	4	Consolidation | Induction | Re-induction | Maintenance	Complete Response	Standard Chemotherapy	-1	Standard Chemotherapy	Azacitidine	Maintenance	-1	0	0	79	54	No			10	42	30		8	26	4			20.8	6.8	46,XY			IGH-MYEOV and IGH-CCND1 rearrangement; MAF unlisted	61	CD2(-), CD4(equivocal), CD7(partial +), CD11b (equivocal), CD13(+), CD14(-), CD15(-), CD16(equivocal), CD33(-), CD34(bright +), CD36(-), CD38(dim +), CD45(+), CD56(equivocal), CD64(-), CD117(+), CD123(equivocal), HLA-DR(dim +), MPO(partial +), TdT(-)	7.1	41.4	Negative	Positive	Negative		R882C; MAF 50%	Negative	Negative	Negative				G13D; MAF 44%		68	Matched	AMLNPM1	Leukemia	AML with Mutated NPM1	0.5
aml_ohsu_2018_1719	aml_ohsu_2018_14-00564	Denovo	None	AML with myelodysplasia-related changes	Adverse	Adverse	AML with myelodysplasia-related changes	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	WES + RNA-seq	Yes	Yes	No	Yes	Yes	No	1	Standard Chemotherapy	1	Decitabine	1	Induction	Unknown	Standard Chemotherapy	10	Standard Chemotherapy	Decitabine	Induction	10	0	0	45		No	0.9	27.8	18.2	12.2	40.9	0	32	19	2	0.83		26.9	9.1	44~48,XY,-5,del(7)(q22),+11,idic(11)(p11.2)x2,-12,der(13)t(1;13)(p13;p12),add(17)(q25),der(18)t(12;18)(q13;q11.2),-22,+2mar[cp14]/44~47,sl,-9,+16[cp3]/46~47,sl,der(1)t(1;3)(q21;q21),der(3)t(1;3)(q21;q21)ins(3)(3;?)(p21;?),-idic(11)(p11.2)[cp4]/46,XY[1]		97.1	EGR1/5p; 88% of cells were missing a signal for both probes, consistent with monosomy 5	77	CD13, CD33, CD34, CD71, CD117, dim CD123 and HLA-DR+	6.7	5.92	Negative	Negative	Negative		Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	p.R248Q; MAF 80%	57	Matched	AMLMRC	Leukemia	AML with Myelodysplasia-Related Changes	1.03333333333
aml_ohsu_2018_1723	aml_ohsu_2018_14-00567	Denovo	None	Acute monoblastic and monocytic leukaemia	Intermediate	Intermediate-II	Acute monoblastic and monocytic leukaemia	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	2	Standard Chemotherapy | Bone Marrow Transplant	3	7+3 (Cytarabine, Idarubicin)|MiDAC|Bu/Flu/TBI (Busulfan, Fludarabine, Total Body Irradiation)	3	Consolidation | Induction | Allogeneic - Mismatched Unrelated Donor	Complete Response	Standard Chemotherapy	6	Bone Marrow Transplant	Bu/Flu/TBI (Busulfan, Fludarabine, Total Body Irradiation)	Allogeneic - Mismatched Unrelated Donor	-1	-3	0			No	0	0	6.7	5.1	0	0.1	20	20	2.6	0.62	M5	21.4	7	46,XX,idic(7)(q11.2)[20]	373	93.9		19	CD11b, CD13, CD33, partial CD34,      CD38, CD58, CD64, CD117, CD123, partial HLA-DR and cMPO positive	5.8	78.71	Negative	Negative	Negative		Negative	Negative	p.R132C; MAF 50%	Negative	Negative	Negative	Negative	Negative	Negative	71	Matched	AMOL	Leukemia	Acute Monoblastic/Monocytic Leukemia	0.5
aml_ohsu_2018_1727	aml_ohsu_2018_14-00573	After or at the time transformation from another heme malignancy	None	AML with myelodysplasia-related changes	Adverse	Intermediate-II	AML with myelodysplasia-related changes	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	WES	No	Yes	No	No	Yes	No	2	Standard Chemotherapy | Supportive/Palliative Care	5	GCLAM (G-CSF, Cladribine, Cytarabine, and Mitoxantrone) |7+3 (Cytarabine, Idarubicin)|Azacitidine|MEC (Cytarabine, Etoposide, Mitoxantrone)|Decitabine	4	Hypomethylating/Low Dose Cytarabine | Salvage | Induction | Maintenance	Refractory	Standard Chemotherapy	6	Standard Chemotherapy	GCLAM (G-CSF, Cladribine, Cytarabine, and Mitoxantrone)	Salvage	4	0	0			No	0	7	14.8	25.2	19.1	0	50	32	3.5	0.78		24.2	8.3	47,XY,der(7)t(1;7)(q10;p10),+8[20]		89		59	CD13, variable CD33, CD34, CD38, CD117, CD123, HLA-DR positive	7.1	22.95	Negative	Negative	Negative		Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	45	Matched	AMLMRC	Leukemia	AML with Myelodysplasia-Related Changes	0.933333333333
aml_ohsu_2018_1730	aml_ohsu_2018_14-00578	Denovo	None	Acute monoblastic and monocytic leukaemia	Intermediate or Adverse	Intermediate-I	Acute monoblastic and monocytic leukaemia	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	2	Standard Chemotherapy | Bone Marrow Transplant	4	7+3 (Cytarabine, Idarubicin)|Cytarabine|Fludarabine, TBI|Decitabine	4	Hypomethylating/Low Dose Cytarabine | Consolidation | Induction | Allogeneic - Mismatched Unrelated Donor	Complete Response	Standard Chemotherapy	6	Bone Marrow Transplant	Fludarabine, TBI	Allogeneic - Mismatched Unrelated Donor	-1	0	0	90		No	0	0	6	2.6	0	0.1	18	49	2.6	0.94	M5	26.8	9.1	46,XY[20]	1173	105.5	Normal	45	dim partial CD11b, dim variable CD13, CD33, CD34, CD38, CD58, partial CD64, CD117, CD123, HLA-DR, partial TdT, dim MPO positive	6.8	98.9	Positive	Negative	Negative		p.P777L; MAF 50%	Negative	Negative		Negative	Negative	Negative	Negative	Negative	75	Matched	AMOL	Leukemia	Acute Monoblastic/Monocytic Leukemia	0.166666666667
aml_ohsu_2018_1731	aml_ohsu_2018_14-00581	After or at the time transformation from another heme malignancy	None	AML with mutated CEBPA	Adverse	Not Enough Information	AML with mutated CEBPA	Initial Acute Leukemia Diagnosis	Peripheral Blood	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	1	Standard Chemotherapy	1	CPX-351 (Liposomal Cytarabine + Daunorubicin)	1	Induction	Refractory	Standard Chemotherapy	-1	Standard Chemotherapy	CPX-351 (Liposomal Cytarabine + Daunorubicin)	Induction	-1	-1		33	37	No				8										42~45,XX,-18[cp14]/43~45,idem,+2~3mar[cp3]/47,XX,+8[cp2]/45,X,-X[1]					CD34+ BLAST POPULATION, 33%, EXPRESSING PARTIAL CD38, PARTIAL CD4, PARTIAL CD11C, HLA-DR, CD117, PARTIAL CD13, PARTIAL CD33, PARTIAL CD15, AND MPO		29.1	Negative	Negative	Triple positive	Negative		Negative	Negative			Negative	Negative	Negative	Negative	68	Matched	AMLCEBPA	Leukemia	AML with Biallelic Mutations of CEBPA	0.8
aml_ohsu_2018_1737	aml_ohsu_2018_14-00588	Denovo	None	Acute erythroid leukaemia	Intermediate	Intermediate-II	Acute erythroid leukaemia	Initial Acute Leukemia Diagnosis	Peripheral Blood	WES + RNA-seq	Yes	Yes	No	Yes	Yes	No	2	Standard Chemotherapy | Bone Marrow Transplant	4	7+3 (Cytarabine, Idarubicin)|HiDAC|Busulfan, Cyclophosphamide, Thymoglobulin|Fludarabine, Cyclophosphamide, TBI	3	Consolidation | Induction | Allogeneic - Matched Unrelated Donor	Complete Response	Standard Chemotherapy	6	Bone Marrow Transplant	Fludarabine, Cyclophosphamide, TBI	Allogeneic - Matched Unrelated Donor	-1	-1	0	9	4	No	0		61	10	22		14	40	3.3	0.65		22.1	7.4	46,XX,del(9)(q22q34)[20].		93.4	nuc ish(RUNX1T1,RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200], (5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	38	CD34 (partial +), CD2(partial dim +), CD13(dim +), CD33(variably to bright +), CD25(-), CD38(+), CD45(moderately +), CD15 (partial +), CD117(+), CD123(dim +), HLA-DR(partial +), MPO(+), TdT(-), other myeloid and lymphoid antigens (-)	5.8	2.1	Negative	Negative			R882C; MAF 43%		Negative	Negative						53	Matched	PERL	Leukemia	Pure Erythroid Leukemia	0.366666666667
aml_ohsu_2018_1604	aml_ohsu_2018_14-00597		CBFB-MYH11	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	Intermediate	Favorable	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	Post-Chemotherapy	Peripheral Blood	WES + RNA-seq	Yes	Yes	No	Yes	Yes	No	1	Standard Chemotherapy	3	7+3 (Cytarabine, Idarubicin)|HiDAC|ODSH (2 O, 3-O Desulfated Heparin)	2	Consolidation | Induction	Complete Response	Standard Chemotherapy	5	Standard Chemotherapy	HiDAC	Consolidation	210	0		0.4		No														46,XY[20]			Normal				29.18	Negative	Negative												58	Matched	AMLCBFBMYH11	Leukemia	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22);CBFB-MYH11	0.166666666667
aml_ohsu_2018_1739	aml_ohsu_2018_14-00599	Denovo	None	AML with minimal differentiation	Adverse	Intermediate-II	AML with minimal differentiation	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	WES + RNA-seq	Yes	Yes	No	Yes	Yes	No	1	Standard Chemotherapy	3	5+2 (Cytarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin)|MiDAC	3	Consolidation | Induction | Re-induction	Refractory	Standard Chemotherapy	6	Standard Chemotherapy	MiDAC	Consolidation	63	0	0			No	0	0	78.5	15.1	6.4	2.9	21	15	3.1	1.01	M0	23.5	7.5	47,XY,+8[2]/46,XY[18]		101.7	Consistent with karyotype	47	dim CD13, dimCD33, CD34, dim CD38, CD58, dimCD64, CD117, CD123, dim HLA-DR, TdT positive	6.7	2.05	Negative	Negative	Negative		Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	69	Unmatched	AMLMD	Leukemia	AML with Minimal Differentiation	0.233333333333
aml_ohsu_2018_1746	aml_ohsu_2018_14-00602		None	AML with mutated NPM1	Intermediate or Adverse	Intermediate-I	AML with mutated NPM1	Post-Chemotherapy|Residual Disease	Bone Marrow Aspirate	WES + RNA-seq	Yes	Yes	No	Yes	Yes	No	1	Standard Chemotherapy	4	CPX-351 (Liposomal Cytarabine + Daunorubicin)|Decitabine, Midostaurin|FLAG-IDA, Gemtuzumab|MEC, Lenalidomide	3	Salvage | Induction | Re-induction	Refractory	Standard Chemotherapy	79	Standard Chemotherapy	MEC, Lenalidomide	Salvage	5	-8				No														46,XY[22]								Positive	Negative	Negative	Negative		Negative	Positive	Negative		Negative	Negative	Negative	Negative	69	Matched	AMLNPM1	Leukemia	AML with Mutated NPM1	0.6
aml_ohsu_2018_1746	aml_ohsu_2018_14-00603		None	AML with mutated NPM1	Favorable	Not Enough Information	AML with mutated NPM1	Residual Disease|Post-Chemotherapy	Peripheral Blood	WES	No	Yes	No	No	Yes	No	1	Standard Chemotherapy	4	CPX-351 (Liposomal Cytarabine + Daunorubicin)|Decitabine, Midostaurin|FLAG-IDA, Gemtuzumab|MEC, Lenalidomide	3	Salvage | Induction | Re-induction	Refractory	Standard Chemotherapy	79	Standard Chemotherapy	MEC, Lenalidomide	Salvage	5	-8				No														46,XY[22]								Negative	Positive	Negative	Negative		Negative	Positive	Negative		Negative	Negative	Negative	Negative	69	Matched	AMLNPM1	Leukemia	AML with Mutated NPM1	0.833333333333
aml_ohsu_2018_1749	aml_ohsu_2018_14-00608		None	AML with maturation	Intermediate	Intermediate-I	AML with maturation	Post-Chemotherapy	Bone Marrow Aspirate	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	1	Standard Chemotherapy	1	Azacitidine	1	Hypomethylating/Low Dose Cytarabine				Standard Chemotherapy	Azacitidine	Hypomethylating/Low Dose Cytarabine	1131	-710				No														46,XX[8]								Negative	Negative												77	Matched	AM	Leukemia	AML with Maturation	0.733333333333
aml_ohsu_2018_1752	aml_ohsu_2018_14-00613	Denovo	CBFB-MYH11	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	Favorable	Adverse	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	Initial Acute Leukemia Diagnosis	Peripheral Blood	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	1	Standard Chemotherapy	2	7+3 (Cytarabine, Idarubicin)|HiDAC	2	Consolidation | Induction	Complete Response	Standard Chemotherapy	5	Standard Chemotherapy	HiDAC	Consolidation	5	-1		80	56	No	2		17	21	3		63	39	3.9	0.91		28.8	10.2	46,XY,inv(16)(p13.1q22)[7]/46,idem,add(17)(p11.2)[13]	434		nuc ish(RUNX1T1,RUNX1)x2[200],(ABL1,BCR)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[198],(PML,RARA)x2[198],(CBFBx2)(5CBFB sep 3CBFBx1)[164/200]	34	CD2(partial +), CD4(partial +), CD5(partial dim +), CD7(-), CD11b(-), CD13(+), CD14(-), CD15(partial +), CD16(-), CDCD33(variably +), CD34(variably +), CD36(few +), CD38(variably +), CD45(moderate to dim +), CD56(-), CD64(partial +),CD117(+), CD123(variably +), HLA-DR(partial +), MPO(+), TdT(few +).	8.2	41.35	Negative	Negative												31	Unmatched	AMLCBFBMYH11	Leukemia	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22);CBFB-MYH11	0.1
aml_ohsu_2018_1754	aml_ohsu_2018_14-00618		None	AML with mutated CEBPA	Intermediate	Favorable	AML with mutated CEBPA	Post-Chemotherapy|Residual Disease	Bone Marrow Aspirate	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	2	Standard Chemotherapy | Targeted Therapy - Other	5	7+3 (Cytarabine, Idarubicin)|Cytarabine|Bortezomib|Decitabine|Fludarabine, Cytarabine	4	Hypomethylating/Low Dose Cytarabine | Unknown | Induction | Experimental	Refractory	Standard Chemotherapy	6	Standard Chemotherapy	Decitabine	Hypomethylating/Low Dose Cytarabine	-1	0		73	84	No			10		6		9	13	4.2	0.82				46,XY[20]	165					6.5	13.8	Negative	Negative	L81fs*72; MAF 92%				Negative	Negative						78	Unmatched	AMLCEBPA	Leukemia	AML with Biallelic Mutations of CEBPA	0.233333333333
aml_ohsu_2018_1761	aml_ohsu_2018_14-00632	Denovo	None	Acute myelomonocytic leukaemia	Adverse	Intermediate-II	Acute myelomonocytic leukaemia	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	WES + RNA-seq	Yes	Yes	No	Yes	Yes	No	2	Standard Chemotherapy | Bone Marrow Transplant	6	5+2 (Cytarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin)|R-CEOP (Cyclophosphamide, Etoposide, Prednisolone, Rituximab, Vincristine)|MiDAC|FATE Trial RIC (Fludarabine, Melphalan, Rabbit ATG) |R-CHOP (Cyclophosphamide, Doxorubicin, Prednisolone, Rituximab, Vincristine)	4	Consolidation | Induction | Re-induction | Allogeneic - Matched Unrelated Donor	Refractory	Standard Chemotherapy	6	Standard Chemotherapy	R-CEOP (Cyclophosphamide, Etoposide, Prednisolone, Rituximab, Vincristine)	Induction	3	0	0	90	30	No	0	0	37.5	27.7	0	2.6	37	31	1.8	0.52	M4	23.5	7.7	46,XX,del(17)(q25)[3]/46,sl,del(3)(q12q21)[cp17]	452	94.4		56	dim CD4, partial variable CD7, CD13, CD33, partial CD34, CD38, partial CD58, CD117, CD123, HLA-DR, TDT and partial MPO positive.	6.2	6.44	Negative	Negative	Negative		Negative	Negative	Negative	Negative	Negative	Negative	p.G12V; MAF 30%	p.G12D; MAF 7%	Negative	64	Matched	AML	Leukemia	Acute Myeloid Leukemia	0.866666666667
aml_ohsu_2018_17	aml_ohsu_2018_14-00639		None	AML with mutated NPM1	Intermediate	Not Enough Information	AML with mutated NPM1	Residual Disease|Post-Transplant	Peripheral Blood	WES	No	Yes	No	No	Yes	No	3	Standard Chemotherapy | Bone Marrow Transplant | Targeted Therapy - Kinase Inhibitor(s)	6	7+3 (Cytarabine, Idarubicin)|HiDAC|Fludarabine, TBI|Sorafenib|Hydroxyurea|Decitabine	5	Consolidation | Induction | Experimental | Re-induction | Allogeneic - Matched Unrelated Donor	Unknown	Standard Chemotherapy	2	Targeted Therapy - Kinase Inhibitor(s)	Sorafenib	Experimental	105	-81	0			No	0	0	21.6	4.5	0	0.6	80	180	1.9	1		22.2	7.7	46,XX,del(6)(q13q23)[15]/46,XY[5]	1065	81	6q deletion	17		5	17.79	Positive	Positive												31	Unmatched	AMLNPM1	Leukemia	AML with Mutated NPM1	0.1
aml_ohsu_2018_17	aml_ohsu_2018_14-00640		None	AML with mutated NPM1	Unknown	Not Enough Information	AML with mutated NPM1	Post-Transplant|Residual Disease	Peripheral Blood	WES + RNA-seq	Yes	No	Yes	No	No	Yes	3	Standard Chemotherapy | Bone Marrow Transplant | Targeted Therapy - Kinase Inhibitor(s)	6	7+3 (Cytarabine, Idarubicin)|HiDAC|Fludarabine, TBI|Sorafenib|Hydroxyurea|Decitabine	5	Consolidation | Induction | Experimental | Re-induction | Allogeneic - Matched Unrelated Donor	Unknown	Standard Chemotherapy	2	Targeted Therapy - Kinase Inhibitor(s)	Sorafenib	Experimental	105	-81	0			No	0	0	21.6	4.5	0	0.6	80	180	1.9	1		22.2	7.7	46,XX,del(6)(q13q23)[15]/46,XY[5]	1065	81	6q deletion	17		5	17.79		Positive												31	Unmatched	AMLNPM1	Leukemia	AML with Mutated NPM1	NA
aml_ohsu_2018_1763	aml_ohsu_2018_14-00643	Denovo	RUNX1-RUNX1T1	AML with t(8;21)(q22;q22); RUNX1-RUNX1T1	Favorable	Favorable	AML with t(8;21)(q22;q22); RUNX1-RUNX1T1	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	2	Standard Chemotherapy | Bone Marrow Transplant	4	3+7 (Cytarabine, Daunorubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone)|Etoposide, Mitoxantrone|Busulfan, Cyclophosphamide	4	Salvage | Consolidation | Induction | Allogeneic - Matched Unrelated Donor	Refractory	Standard Chemotherapy	6	Bone Marrow Transplant	Busulfan, Cyclophosphamide	Allogeneic - Matched Unrelated Donor	0	0	0.8			No	0	7.5	17.5	0	37.5	0.4	22	13	3	0.89	M2	15.8	5.5	45,X,-Y,t(8;21)(q22;q22)[20]	411	100.6	RUNX1T1/RUNX1:   94% of cells had the dual fusion signal pattern consistent with RUNX1T1/RUNX1 fusion and t(8;21), as seen on metaphase analysis.	42	dim CD7, CD13, dim CD33, CD34, CD38, CD56, dim partial      CD64, CD117, dim CD123, HLA-DR, MPO, dim TdT positive	7	8.15	Negative	Negative	Negative			Negative	Negative	Negative	Negative		Negative	Negative	Negative	37	Matched	AMLRUNX1RUNX1T1	Leukemia	AML with t(8;21)(q22;q22.1);RUNX1-RUNX1T1	0.5
aml_ohsu_2018_1775	aml_ohsu_2018_14-00658	Denovo	None	AML with mutated NPM1	Intermediate	Intermediate-I	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	2	Standard Chemotherapy | Bone Marrow Transplant	4	Azacitidine, Sorafenib|Busulfan, Fludarabine, Thymoglobulin (Bu/Flu/ATG)|7+3 (Cytarabine, Idarubicin)|HiDAC	4	Hypomethylating/Low Dose Cytarabine | Consolidation | Induction | Allogeneic - Matched Unrelated Donor	Complete Response	Standard Chemotherapy	-1	Standard Chemotherapy	Azacitidine, Sorafenib	Hypomethylating/Low Dose Cytarabine	-1	-1		51.5	72	No														46,XX[20]			Normal		Large population of CD117 positive myeloblasts (predominantly CD34 negative, HLA-DR negative), representing approximately 71% of the leukocytes consistent with acute myeloid leukemia.		89.17	Positive	Positive	Negative							Negative				59	Unmatched	AMLNPM1	Leukemia	AML with Mutated NPM1	0.166666666667
aml_ohsu_2018_1782	aml_ohsu_2018_14-00664	Denovo	None	AML with myelodysplasia-related changes	Adverse	Intermediate-I	AML with myelodysplasia-related changes	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	WES	No	Yes	No	No	Yes	No	1	Standard Chemotherapy	1	7+3 (Cytarabine, Idarubicin)	1	Induction	Complete Response i	Standard Chemotherapy	6	Standard Chemotherapy	7+3 (Cytarabine, Idarubicin)	Induction	6	0	0			No	0	0.8	75.6	4.6	19	3.8	21	11	3.3	1.1		27.9	9.3	46,XY[20]	241	99.6	Normal	31	CD13, CD33, CD34, CD38, CD58, CD117, CD123, and HLA-DR+	6.5	1.31	Negative	Negative	Negative		Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	75	Matched	AMLMRC	Leukemia	AML with Myelodysplasia-Related Changes	0.766666666667
aml_ohsu_2018_1783	aml_ohsu_2018_14-00667	Denovo	None	AML with myelodysplasia-related changes	Adverse	Intermediate-I	AML with myelodysplasia-related changes	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	WES + RNA-seq	Yes	Yes	No	Yes	Yes	No	2	Standard Chemotherapy | Bone Marrow Transplant	3	7+3 (Cytarabine, Idarubicin)|HiDAC|Fludarabine, Melphalan, TBI	3	Allogeneic - Sibling | Consolidation | Induction	Complete Response	Standard Chemotherapy	371	Bone Marrow Transplant	Fludarabine, Melphalan, TBI	Allogeneic - Sibling	-1	-1	0.3			No	0	0.6	32.6	14.7	51.8	0	82	52	3.4	0.78		29.6	10.1	46,XY[20]	160	93.7	Normal	91	CD13, CD33, CD34, CD38, CD58, CD117, CD123, and HLA-DR+	7.5	3.53	Negative	Negative	Negative		Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	57	Matched	AMLMRC	Leukemia	AML with Myelodysplasia-Related Changes	1.3
aml_ohsu_2018_1787	aml_ohsu_2018_14-00670	After or at the time transformation from another heme malignancy	None	AML with myelodysplasia-related changes	Adverse	Not Enough Information	AML with myelodysplasia-related changes	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	3	Standard Chemotherapy | Bone Marrow Transplant | Targeted Therapy - Other	3	AG-221|Azacitidine|Fludarabine, Melphalan, TBI, ATG	3	Hypomethylating/Low Dose Cytarabine | Experimental | Allogeneic - Child				Bone Marrow Transplant	Fludarabine, Melphalan, TBI, ATG	Allogeneic - Child	-1	0	0	20	0	No	0		76	0	24		18	16	4.1	1.24		24.9	8.3	46,XY[20]	148	100.4		72		7.4	1.8	Negative	Negative					Negative							63	Matched	AMLMRC	Leukemia	AML with Myelodysplasia-Related Changes	0.666666666667
aml_ohsu_2018_1786	aml_ohsu_2018_14-00672		None	Essential thrombocythaemia	Intermediate		Essential thrombocythaemia	Residual Disease|Post-Chemotherapy	Bone Marrow Aspirate	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	1	Standard Chemotherapy	3	Ruxolitinib|Imatinib|Hydroxyurea	2	Induction | Re-induction	Refractory	Standard Chemotherapy	4626	Standard Chemotherapy	Ruxolitinib	Re-induction	-1	0		15		No														47,XY,+der(1;9)(q10;p10)[17]/94,idemx2[2]/46,XY[1]			Nineteen of twenty metaphase cells examined had an extra derivative chromosome composed of a chromosome 1 long arm and a chromosome 9 short arm; two of these cells were in the tetraploid state with two copies of the derivative chromosome.		dimCD7, CD13, dim CD33, CD34, CD71, and CD117 positive			Negative	Negative												77	Unmatched	ET	Myeloproliferative Neoplasms	Essential Thrombocythemia	0.166666666667
aml_ohsu_2018_1561	aml_ohsu_2018_14-00676		None	Therapy-related myeloid neoplasms	Adverse	Adverse	Therapy-related myeloid neoplasms	Residual Disease	Bone Marrow Aspirate	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	2	Standard Chemotherapy | Targeted Therapy - Kinase Inhibitor(s)	2	Trametinib|HAEP (Cytarabine, Etoposide, Cisplatin)	3	Consolidation | Induction | Experimental	Complete Response	Standard Chemotherapy	8	Targeted Therapy - Kinase Inhibitor(s)	Trametinib	Experimental	197	0	0	5	10	No	0	2.9	36.2	1.5	47.8		30	146	3.4	0.82		25.5	7.9	48,XY,add(6)(p22),der(7)t(7;19)(p11.2;p12),del(9)(p13p22),i(13)(q10)x2,add(14)(q24),+mar1,+mar2[cp2]/46~48,sl,add(17)(p1?3),add(22)(q13)[cp9]/46~48,sl,add(21)(p11.2)[cp6]/47~48,sl,add(1)(p36.1)[cp2]/48,sl,t(2;17)(p21;p11.2)[1]		98.5	Low-level tetraploidy or near-tetraploidy	48	A CD34 positive blasts population comprises approximately 4% of cellular gated events. Approximately 3% of cells are lymphocytes composed of 28% B cells, 45% T cells and 27% NK cells.	6.1	11.28	Negative	Negative										p.G12C; MAF 97%	p.G245S; MAF 96%	24	Matched	TMN	Leukemia	Therapy-Related Myeloid Neoplasms	4.3
aml_ohsu_2018_1797	aml_ohsu_2018_14-00681	Denovo	None	AML without maturation	Intermediate	Intermediate-II	AML without maturation	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	WES + RNA-seq	Yes	Yes	No	Yes	Yes	No	1	Standard Chemotherapy	2	7+3 (Cytarabine, Idarubicin)|Cytarabine	2	Consolidation | Induction	Complete Response	Standard Chemotherapy	6	Standard Chemotherapy	Cytarabine	Consolidation	133	0	0			No	0	0	31.2	0.9	0	0	19	25	3.3	0.78	M1	21.4	7.4	46,XY,del(13)(q12q2?1)[14]	509	103.4	all 100 interphase cells scored (100%) were missing one set of 13S319 and RB1 probe signals, consistent with deleted 13q and the metaphase karyotype	17	CD13, partial/dim CD33, CD38, CD58, CD117 and MPO	6.6	5.39	Negative	Negative	Negative		p.R882H; MAF 44%	Negative	Negative		Negative	Negative	Negative	Negative	Negative	65	Matched	AWM	Leukemia	AML without Maturation	0.766666666667
aml_ohsu_2018_1800	aml_ohsu_2018_14-00690	Denovo	None	AML with mutated NPM1	Favorable	Adverse	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	WES + RNA-seq	Yes	Yes	No	Yes	Yes	No	2	Standard Chemotherapy | Bone Marrow Transplant	3	Busulfan, Fludarabine|7+3 (Cytarabine, Idarubicin)|HiDAC	3	Consolidation | Induction | Allogeneic - Matched Unrelated Donor	Complete Response	Standard Chemotherapy	-1	Bone Marrow Transplant	Busulfan, Fludarabine	Allogeneic - Matched Unrelated Donor	-1	-1		54	3	No											M5			46,XX,del(17)(p11.2)[15]/46,XX[5]			consistent with karyotype (68% del 17p13)		Most of the atypical cells (data not shown) are myeloid blasts that express CD117, partial CD7 (about 30% positive), CD13, CD33, HLA-DR, weak CD4, and partial CD15 (about 50% positive), but do not express CD34, CD14(MO2), or CD64.			Negative	Positive												49	Matched	AMLNPM1	Leukemia	AML with Mutated NPM1	0.733333333333
aml_ohsu_2018_1810	aml_ohsu_2018_14-00712		None	Therapy-related myeloid neoplasms	Adverse	Intermediate-II	Therapy-related myeloid neoplasms	Initial Acute Leukemia Diagnosis|Post-Chemotherapy	Bone Marrow Aspirate	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	2	Standard Chemotherapy | Other	3	3+7 (Cytarabine, Daunorubicin)|Decitabine|5+2 (Ara-C, Daunorubicin)	3	Salvage | Induction | Re-induction	Refractory	Standard Chemotherapy	6	Standard Chemotherapy	Decitabine	Salvage	9	0	0	18	12	No	0.9	32	7.4	35.2	18.5	4.8	44	165	2.9	1.65		20.1	6.7	46,XY,i(17)(q10)[20]	3923	81	TP53/CEP17: 85% of cells were missing a signal for TP53, consistent with deletion due to the i(17) seen on metaphase analysis.  PML/RARA: 69% of cells had three signals for RARA (17q21), consistent with three copies of 17q due to the i(17) seen on metaphase analysis.	40	CD13, CD33, CD34, CD117, and HLA-DR positive	5.7	161.89	Negative	Negative	Negative		Negative	Negative	Negative	Negative	Negative	Negative	Negative	p.G12D; MAF 46%	Negative	65	Matched	TMN	Leukemia	Therapy-Related Myeloid Neoplasms	0.266666666667
aml_ohsu_2018_1811	aml_ohsu_2018_14-00714		None	AML with myelodysplasia-related changes	Adverse	Not Enough Information	AML with myelodysplasia-related changes	Residual Disease|Post-Chemotherapy	Peripheral Blood	RNA-seq	Yes	No	No	Yes	No	No	2	Standard Chemotherapy | Supportive/Palliative Care	5	7+3 (Cytarabine, Idarubicin)|HiDAC|Azacitidine|Decitabine|MEC, Lenalidomide	4	Hypomethylating/Low Dose Cytarabine | Consolidation | Induction | Re-induction	Complete Response	Standard Chemotherapy	6	Supportive/Palliative Care	Decitabine	Hypomethylating/Low Dose Cytarabine	-1	0		72	81	No														50,XX,del(1)(q32),+8,+9,t(15;16)(q15~21;q12~22),+19,+21[cp20]					ABNORMAL CD34+ BLAST POPULATION, 72%, EXPRESSING DIM PARTIAL CD4, DIM PARTIAL CD7, DIM PARTIAL CD8, CD33, CD38, PARTIAL CD64, CD117, PARTIAL HLA-DR, AND DIM PARTIAL TdT		3.8	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative		Negative	Negative	Negative	Negative	55	Matched	AMLMRC	Leukemia	AML with Myelodysplasia-Related Changes	NA
aml_ohsu_2018_1811	aml_ohsu_2018_14-00715		None	AML with myelodysplasia-related changes	Adverse	Adverse	AML with myelodysplasia-related changes	Residual Disease|Post-Chemotherapy	Bone Marrow Aspirate	WES	No	Yes	No	No	Yes	No	2	Standard Chemotherapy | Supportive/Palliative Care	5	7+3 (Cytarabine, Idarubicin)|HiDAC|Azacitidine|Decitabine|MEC, Lenalidomide	4	Hypomethylating/Low Dose Cytarabine | Consolidation | Induction | Re-induction	Complete Response	Standard Chemotherapy	6	Supportive/Palliative Care	Decitabine	Hypomethylating/Low Dose Cytarabine	-1	0		72	81	No														50,XX,del(1)(q32),+8,+9,t(15;16)(q15~21;q12~22),+19,+21[cp20]					ABNORMAL CD34+ BLAST POPULATION, 72%, EXPRESSING DIM PARTIAL CD4, DIM PARTIAL CD7, DIM PARTIAL CD8, CD33, CD38, PARTIAL CD64, CD117, PARTIAL HLA-DR, AND DIM PARTIAL TdT		3.8	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative		Negative	Negative	Negative	Negative	55	Matched	AMLMRC	Leukemia	AML with Myelodysplasia-Related Changes	1.8
aml_ohsu_2018_1813	aml_ohsu_2018_14-00720		DEK-NUP214	Therapy-related myeloid neoplasms	Adverse	Adverse	Therapy-related myeloid neoplasms	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	WES	No	Yes	No	No	Yes	No	2	Standard Chemotherapy | Targeted Therapy - Other	3	Crenolanib|HAM (Mitoxantrone, Cytarabine) plus Crenolanib|Azacitidine, Pracinostat	2	Induction | Maintenance	Complete Response	Standard Chemotherapy	-1	Targeted Therapy - Other	Crenolanib	Maintenance	433	0		17	0	No			40		60		19	18	4.2	0.64		25.4	8.8	46,XY,t(6;9)(p23;q34)[18]/46,XY[2].	162	119.8	DEK-NUP214 fusion; MAF unavailable	60	CD2(-), CD4(-), CD7(-), CD11b(-), CD13(+), CD14(-), CD15(partial dim +), CD16(-), CD33(bright +), CD34 (partial +), CD36(equivocal), CD38(variably +), CD45(+), CD56(-), CD64(partial dim +), CD117(+), HLA-DR(partial +), TdT (-), MPO(-).	6.5	2	Positive	Negative			F827fs*4; MAF 35%		Negative	Negative						74	Matched	TMN	Leukemia	Therapy-Related Myeloid Neoplasms	0.666666666667
aml_ohsu_2018_1814	aml_ohsu_2018_14-00725	Denovo	None	Acute myeloid leukaemia, NOS	Intermediate	Intermediate-II	Acute myeloid leukaemia, NOS	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	WES + RNA-seq	Yes	Yes	No	Yes	Yes	No	2	Standard Chemotherapy | Bone Marrow Transplant	3	Bu/Cy/ATG|7+3 (Cytarabine, Idarubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone)	3	Induction | Re-induction | Allogeneic - Matched Unrelated Donor	Refractory	Standard Chemotherapy	6	Bone Marrow Transplant	Bu/Cy/ATG	Allogeneic - Matched Unrelated Donor	-1	0	0	24	2	No	2		54	0	44		10	22	4.4	0.49		25.9	9	47,XX,+8[13]/46,XX[7].	125	97.1	nuc ish(D5S2064,D5S630,EGR1)x2[199],(D7Z1,D7S522)x2[197],(D8Z2x3,D20S108x2)[101/200], (RUNX1T1x3,RUNX1x2)[91/200],(ABL1,BCR)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[188], (5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[199]	67	CD2(-), CD4(dim +), CD7(partial +), CD11b(-), CD13(variably +), CD14(-), CD15(partial dim +), CD16(-), CD25(-), CD33(bright +), CD34(-), CD36(-), CD38(+), CD41(-), CD45(+), CD56(-), CD64(-), CD71(+), CD117(+), CD123(+), GLy-A(-), HLA-DR(partial + and variable), TdT(-), MPO(+).	7.1	1.4	Negative	Negative					Negative	Negative						32	Matched	AMLNOS	Leukemia	AML, NOS	0.433333333333
aml_ohsu_2018_1817	aml_ohsu_2018_14-00730	Denovo	PML-RARA	Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA	Favorable	Intermediate-II	Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	WES + RNA-seq	Yes	Yes	No	Yes	Yes	No	1	Standard Chemotherapy	1	ATRA, Arsenic Trioxide	2	Consolidation | Induction	Complete Response	Standard Chemotherapy	33	Standard Chemotherapy	ATRA, Arsenic Trioxide	Consolidation	193	0	0	90	20	No	0	0.8	75.9	0	2.6	2.6	24	15	3.2	0.68	M3	20.3	7.1	46,XX,t(15;17)(q22;q21)[17]/46,XX[3]	259	85.3	58% PML-RARA  (c/w karyotype)	53	CD13, CD33, CD58, CD64, CD117, CD123 and MPO positive	7.3	1.9	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	40	Matched	APLPMLRARA	Leukemia	APL with PML-RARA	0.666666666667
aml_ohsu_2018_1818	aml_ohsu_2018_14-00735	After or at the time transformation from another heme malignancy	None	AML with mutated NPM1	Intermediate	Intermediate-I	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	WES + RNA-seq	Yes	Yes	No	Yes	Yes	No	1	Standard Chemotherapy	2	Azacitidine|Decitabine, Midostaurin	2	Hypomethylating/Low Dose Cytarabine | Induction	Refractory	Standard Chemotherapy	-1	Standard Chemotherapy	Decitabine, Midostaurin	Induction	-1	-6				No														46,XY[13]								Positive	Positive	Negative	Negative	Negative	Negative	Negative	Negative		Negative	Negative	Negative	Negative	83	Matched	AMLNPM1	Leukemia	AML with Mutated NPM1	0.833333333333
aml_ohsu_2018_1819	aml_ohsu_2018_14-00738	After or at the time transformation from another heme malignancy	None	AML with myelodysplasia-related changes	Adverse	Adverse	AML with myelodysplasia-related changes	Initial Acute Leukemia Diagnosis|Post-Chemotherapy	Bone Marrow Aspirate	WES	No	Yes	No	No	Yes	No	1	Standard Chemotherapy	1	Decitabine	1	Induction	Refractory	Standard Chemotherapy	9	Standard Chemotherapy	Decitabine	Induction	9	0	8	30	7	No	7.1	2.7	17	12.5	47.3	1.4	33	50	2.3	0.77		20.1	6.2	45,XY,del(5)(q13q33),del(7)(q11.2),dic(8;9)(q24.3;p22),-18,+r[cp8]/45,XY,del(5)(q13q33),-7,der(18)t(7;18)(p11.2;p11.1)[cp6]/45,sdl1,del(4)(q21q31.1),del(12)(p11.2p13)[cp5]/46,XY[1]		77		9	dim CD7, CD13, dim CD33, CD34, CD38, CD58, partial      CD56, CD117, CD123 and HLA-DR positive	6.4	19.99	Negative	Negative	Negative		Negative	Negative	Negative	Negative		Negative	Negative	Negative	p.V272M; MAF 88%	65	Matched	AMLMRC	Leukemia	AML with Myelodysplasia-Related Changes	1.0
aml_ohsu_2018_1820	aml_ohsu_2018_14-00739	Denovo	None	Acute myeloid leukaemia, NOS	Adverse	Adverse	Acute myeloid leukaemia, NOS	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	2	Standard Chemotherapy | Intrathecal	4	5+2 (Cytarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone)|Methotrexate	3	Induction | CNS | Re-induction	Refractory	Standard Chemotherapy	6	Standard Chemotherapy	MEC (Cytarabine, Etoposide, Mitoxantrone)	Re-induction	4	0	0			No	0	0	28.3	17.7	3.5	0	19	14	3	0.97		31.1	10.7	46,XY,t(6;11)(q27;q23)[20]		98.4	MLL: 80% of cells had a split signal pattern consistent with the disruption of MLL due to the t(6;11).	31		6.2	21.12	Negative	Negative	Negative			Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	39	Matched	AMLNOS	Leukemia	AML, NOS	0.0666666666667
aml_ohsu_2018_1821	aml_ohsu_2018_14-00742		Complex	Myelodysplastic syndrome, unclassifiable	Adverse	Adverse	Myelodysplastic syndrome, unclassifiable	Unknown	Bone Marrow Aspirate	WES + RNA-seq	Yes	Yes	No	Yes	Yes	No	1	Standard Chemotherapy	1	Decitabine	1	Hypomethylating/Low Dose Cytarabine				Standard Chemotherapy	Decitabine	Hypomethylating/Low Dose Cytarabine	4	0	0	9	11	No	0.8		28.2	13.7	43.6		19	28	2.6	0.7		27.2	9.1	44,XX,der(5)t(5;9)(p15;q22)del(5)(q11.2q15),-7,-9,-18,del(20)(q11.2q13.1),+mar[cp8]/43~44,XX,-der(5),del(7)(q11.2q32),add(11)(p15),del(12)(p11.2p13),der(15)t(15;17)(p12;q11.2),-16,-18,+mar[cp9]/43,XX,del(5)(q13q33),del(7),add(11),del(12),der(15),-16,-18,+mar[cp3].ishder(15)(PML+,RARA+)[1].	517	92.4	nuc ish(RUNX1T1,RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200], (PML,RARA)x2[200],(5'CBFB,3'CBFB)x1(5'CBFB con 3'CBFBx1)[108/200]	74	CD2 (-), CD4(- to dim +), CD7(-), CD11b(-), CD13(bright +), CD14(-), CD15(-), CD16(-), CD25(dim +), CD33(+), CD34(+), CD36(-), CD38(partial +), CD45(moderate to slightly dim +), CD56(-), CD64(-), CD117(+), CD123(dim +), HLA-DR(variably+), MPO(-), TdT(-)	6.2		Negative	Negative	Negative			Negative	Negative	Negative						51	Matched	MDSU	Myelodysplastic Syndromes	MDS, Unclassifiable	0.3
aml_ohsu_2018_1827	aml_ohsu_2018_14-00756		None	Acute myeloid leukaemia, NOS	Adverse	Intermediate-II	Acute myeloid leukaemia, NOS	Post-Chemotherapy	Bone Marrow Aspirate	WES	No	Yes	No	No	Yes	No	2	Standard Chemotherapy | Bone Marrow Transplant	3	7+3 (Cytarabine, Idarubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone)|Busulfan, Cyclophosphamide	3	Induction | Re-induction | Allogeneic - Matched Unrelated Donor	Refractory	Standard Chemotherapy	-1	Bone Marrow Transplant	Busulfan, Cyclophosphamide	Allogeneic - Matched Unrelated Donor	-1	0	0	3		No	0	0	57.7	2.7	39.6	5.5	81	45	3	0.71		27.2	9.4	47,XX,+8[11]/46,XX[10]		84.2	RUNX1T1 (8q21.3): 55% of cells had three signals for RUNX1T1 (8q21.3) consistent with trisomy 8, as seen on metaphase analysis	58	population of CD117+ progenitors (~3.5% of total      CD45+ events) that expresses CD13, dim CD33, CD38, CD58, CD117, dim CD123 and HLA-DR, without the expression of CD64.	7	1.09	Negative	Negative	Negative		Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	40	Unmatched	AMLNOS	Leukemia	AML, NOS	0.1
aml_ohsu_2018_1495	aml_ohsu_2018_14-00757		None	Acute myelomonocytic leukaemia	Intermediate	Not Enough Information	Acute myelomonocytic leukaemia	Post-Chemotherapy|Residual Disease	Peripheral Blood	RNA-seq	Yes	No	No	Yes	No	No	1	Standard Chemotherapy	5	7+3 (Cytarabine, Idarubicin)|CLAG (Cladribine, Cytarabine, Filgrastim)|MiDAC|ODSH (2 O, 3-O Desulfated Heparin) |SGN-CD33A	2	Consolidation | Induction	Complete Response	Standard Chemotherapy	21	Standard Chemotherapy	CLAG (Cladribine, Cytarabine, Filgrastim)	Consolidation	-1	-77				No														46,XY[20]			Normal				9.7	Negative	Negative												75	Unmatched	AML	Leukemia	Acute Myeloid Leukemia	NA
aml_ohsu_2018_1833	aml_ohsu_2018_14-00761	After or at the time transformation from another heme malignancy	None	AML with myelodysplasia-related changes	Intermediate	Not Enough Information	AML with myelodysplasia-related changes	Residual Disease	Peripheral Blood	WES + RNA-seq	Yes	Yes	No	Yes	Yes	No	1	Standard Chemotherapy	3	7+3 (Cytarabine, Idarubicin)|Azacitidine|Decitabine, Midostaurin	2	Induction | Re-induction	Complete Response	Standard Chemotherapy	186	Standard Chemotherapy	7+3 (Cytarabine, Idarubicin)	Re-induction	62	-22				No														46,XX[20]								Negative	Negative												72	Matched	AMLMRC	Leukemia	AML with Myelodysplasia-Related Changes	0.966666666667
aml_ohsu_2018_1843	aml_ohsu_2018_14-00774	Denovo	None	AML with minimal differentiation	Adverse	Intermediate-I	AML with minimal differentiation	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	1	Standard Chemotherapy	1	Decitabine, Midostaurin	1	Induction	Refractory	Standard Chemotherapy	-1	Standard Chemotherapy	Decitabine, Midostaurin	Induction	-1	0		85	88	No											M0			46,XY[20]					CD34, CD38, CD117, CD13, CD4, HLA-DR, AND TDT		30	Positive	Negative	Negative	Negative	Negative	Negative	Negative	Negative		Negative	Negative	Negative	Negative	84	Matched	AMLMD	Leukemia	AML with Minimal Differentiation	0.666666666667
aml_ohsu_2018_1845	aml_ohsu_2018_14-00777	Denovo	None	AML with mutated CEBPA	Favorable	Favorable	AML with mutated CEBPA	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	WES	No	Yes	No	No	Yes	No	1	Standard Chemotherapy	2	7+3 (Cytarabine, Idarubicin)|MiDAC	2	Consolidation | Induction	Complete Response	Standard Chemotherapy	5	Standard Chemotherapy	MiDAC	Consolidation	5	0	0	60		Yes	2.6	2.6	33.6	14.7	18.1	0.7	19	22	2.3	0.87	M4	30.5	9.9	46,XY[20]		99	FISH normal	118	CD7, CD13, CD33, CD34, CD38,  CD64, CD117, HLA-DR and MPO positive	7.3	7.62	Negative	Negative	p.P23fs*81; MAF 41%		Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	69	Matched	AMLCEBPA	Leukemia	AML with Biallelic Mutations of CEBPA	0.533333333333
aml_ohsu_2018_1098	aml_ohsu_2018_14-00780	After or at the time transformation from another heme malignancy	None	AML with myelodysplasia-related changes	Intermediate	Not Enough Information	AML with myelodysplasia-related changes	Post-Chemotherapy|Post-Transplant|Residual Disease	Bone Marrow Aspirate	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	4	Standard Chemotherapy | Bone Marrow Transplant | Targeted Therapy - Other | Targeted Therapy - Kinase Inhibitor(s)	9	Fludarabine, Melphalan|Dasatinib|7+3 (Cytarabine, Idarubicin)|HiDAC|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Azacitidine|MEC (Cytarabine, Etoposide, Mitoxantrone)|Rituximab|Busulfan, Cyclophosphamide	7	Allogeneic - Sibling | Hypomethylating/Low Dose Cytarabine | Consolidation | Salvage | Induction | Experimental | Re-induction	Complete Response	Standard Chemotherapy	-1	Targeted Therapy - Kinase Inhibitor(s)	Dasatinib	Experimental	24	-480		7	1	No							15	21	4.2			31.9	11	46,XX			nuc ish(DXZ1x2)[200]	45		6.2	2.2	Negative	Negative												38	Unmatched	AMLMRC	Leukemia	AML with Myelodysplasia-Related Changes	0.3
aml_ohsu_2018_1847	aml_ohsu_2018_14-00781	Denovo	None	Acute monoblastic and monocytic leukaemia	Adverse	Adverse	Acute monoblastic and monocytic leukaemia	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	1	Standard Chemotherapy	2	7+3 (Cytarabine, Idarubicin)|MiDAC	2	Consolidation | Induction	Complete Response	Standard Chemotherapy	5	Standard Chemotherapy	MiDAC	Consolidation	5	0	0	95	80	No	0	2	21	4	1	0.8	29	282	3.2	1.61	M5	31.8	10	47,XY,t(1;11)(p32;q23),+8[cp20]	7759	102.3	c/w karyotype	59	CD11b, CD13, partial CD14, CD15, CD33,CD38, CD45, CD56, CD58, CD64, HLA-DR and MPO-positive	6.1	71.19	Negative	Negative	Negative		Negative	Negative				Negative	p.G13D; MAF 27%	Negative	Negative	71	Matched	AMOL	Leukemia	Acute Monoblastic/Monocytic Leukemia	0.333333333333
aml_ohsu_2018_1848	aml_ohsu_2018_14-00787	Denovo	None	AML with mutated CEBPA	Intermediate	Favorable	AML with mutated CEBPA	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	2	Standard Chemotherapy | Bone Marrow Transplant	3	Fludarabine, Melphalan|7+3 (Cytarabine, Idarubicin)|MiDAC	3	Allogeneic - Sibling | Consolidation | Induction	Complete Response	Standard Chemotherapy	6	Bone Marrow Transplant	Fludarabine, Melphalan	Allogeneic - Sibling	-1	0	0	90	90.5	No	0	0	8.2	2.2	0.9	0.8	22	43	3.1	1.21	M1	17.3	5.2	46,XY[20]	1873	96.1	Normal	34	CD7, CD13, CD33, CD34, CD117, HLA-DR, cMPO (+)	6.9	427.46	Negative	Negative	p.N307_V308ins; MAF 50%		Negative		Negative	Negative		Negative	Negative	Negative	Negative	61	Matched	AMLCEBPA	Leukemia	AML with Biallelic Mutations of CEBPA	0.4
aml_ohsu_2018_1863	aml_ohsu_2018_14-00793		Unknown	unknown	Intermediate	Not Enough Information	unknown	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	WES	No	Yes	No	No	Yes	No	0		0		0					NONE	NONE	NONE		0				No																						Negative	Negative													Unmatched	AML	Leukemia	Acute Myeloid Leukemia	0.0666666666667
aml_ohsu_2018_1852	aml_ohsu_2018_14-00798	Denovo	CBFB-MYH11	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	Favorable	Favorable	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	1	Standard Chemotherapy	1	7+3 (Cytarabine, Idarubicin)	1	Induction	Unknown	Standard Chemotherapy	6	Standard Chemotherapy	7+3 (Cytarabine, Idarubicin)	Induction	6	0	0	74	82	No	1.7	1.7	6.7	82.3	3.4	0	45	36	2.7	0.68	M4	20.4	7.1	46,XX,inv(16)(p13.1q22)[20]		87.6	CBFB; 76/100 cells (76%) had the abnormal 1 red/ 1 green/1 yellow signal pattern, reflecting CBFB rearrangement.	12		5.8	117.53	Negative	Negative	Negative		Negative	Negative	Negative	Negative	Negative	Negative	p.G12D; MAF 9%	p.G12D; MAF 10%	Negative	36	Matched	AMLCBFBMYH11	Leukemia	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22);CBFB-MYH11	0.2
aml_ohsu_2018_1854	aml_ohsu_2018_14-00800	After or at the time transformation from another heme malignancy	None	Acute myelomonocytic leukaemia	Intermediate	Intermediate-I	Acute myelomonocytic leukaemia	Residual Disease|Post-Chemotherapy	Peripheral Blood	WES	Yes	Yes	Yes	No	Yes	Yes	1	Standard Chemotherapy	2	CPX-351 (Liposomal Cytarabine + Daunorubicin)|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)	3	Salvage | Induction | Re-induction	Refractory	Standard Chemotherapy	4	Standard Chemotherapy	FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)	Salvage	4	-30				No						3.6	26	65	3.1	1.07		20.9	7.2	46,XY[20]	1004	90.1		17		5.4	53.76	Negative	Negative	Negative		Negative	Negative	Negative	Negative		Negative	Negative	Negative	Negative	69	Unmatched	AML	Leukemia	Acute Myeloid Leukemia	0.2
aml_ohsu_2018_1855	aml_ohsu_2018_14-00801	After or at the time transformation from another heme malignancy	None	Myeloid sarcoma	Intermediate	Intermediate-I	Myeloid sarcoma	Post-Chemotherapy|Residual Disease|Post-Transplant	Bone Marrow Aspirate	WES	Yes	Yes	Yes	No	Yes	Yes	3	DLI | Standard Chemotherapy | Bone Marrow Transplant	5	Donor Lymphocyte Infusion|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Azacitidine|MEC (Cytarabine, Etoposide, Mitoxantrone)|Busulfan, Cyclophosphamide	5	Hypomethylating/Low Dose Cytarabine | Consolidation | Induction | Re-induction | Allogeneic - Matched Unrelated Donor	Complete Response	Standard Chemotherapy	5	Standard Chemotherapy	Azacitidine	Hypomethylating/Low Dose Cytarabine	269	1	0.6	3	0	No	7.2	0.4	31.8	13	47	0	51	76	3.3	0.94		42.5	14	46,XY[23]	753	87.6	Normal	188	maturing myeloid population. Myeloid blasts are about 2%. Monocytes are 6/7% and without antigen aberrancy.Lymphocytes are 10-11%. Mostly T cells and these have a 1:1 CD4:CD8 ratio.There are approximately 20% of lymphocytes as B cells and these are polyclonal. NK cells not increased	6.9	5.16	Negative	Negative	Negative		Negative	Negative				Negative	Negative	Negative	Negative	61	Matched	MS	Leukemia	Myeloid Sarcoma	NA
aml_ohsu_2018_1727	aml_ohsu_2018_14-00803	After or at the time transformation from another heme malignancy	None	AML with myelodysplasia-related changes	Adverse	Intermediate-II	AML with myelodysplasia-related changes	Post-Chemotherapy|Residual Disease	Peripheral Blood	WES	No	Yes	Yes	No	Yes	Yes	2	Standard Chemotherapy | Supportive/Palliative Care	5	GCLAM (G-CSF, Cladribine, Cytarabine, and Mitoxantrone) |7+3 (Cytarabine, Idarubicin)|Azacitidine|MEC (Cytarabine, Etoposide, Mitoxantrone)|Decitabine	4	Hypomethylating/Low Dose Cytarabine | Salvage | Induction | Maintenance	Refractory	Standard Chemotherapy	6	Standard Chemotherapy	GCLAM (G-CSF, Cladribine, Cytarabine, and Mitoxantrone)	Salvage	4	-2	0			No	0	0	7.9	76.3	11.4	0	25	12	3.4	0.57		25.1	8.5	47,XY,der(7)t(1;7)(q10;p10)+8[20]	295	93		27		6.5	12.25	Negative	Negative	Negative		Negative		Negative	Negative	Negative	Negative	Negative	Negative	Negative	46	Matched	AMLMRC	Leukemia	AML with Myelodysplasia-Related Changes	1.0
aml_ohsu_2018_1814	aml_ohsu_2018_14-00815		None	Acute myeloid leukaemia, NOS	Intermediate	Intermediate-II	Acute myeloid leukaemia, NOS	Post-Chemotherapy	Bone Marrow Aspirate	RNA-seq	Yes	No	Yes	Yes	No	Yes	2	Standard Chemotherapy | Bone Marrow Transplant	3	Bu/Cy/ATG|7+3 (Cytarabine, Idarubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone)	3	Induction | Re-induction | Allogeneic - Matched Unrelated Donor	Refractory	Standard Chemotherapy	6	Bone Marrow Transplant	Bu/Cy/ATG	Allogeneic - Matched Unrelated Donor	-1	-7	0	2	0	No	0			44	56							23.2	7.7	47,XX,+8[3]/46,XX[17].	130	89.9	nuc ish(D8Z2x3,D20S108x2)[27/200]	113			0.9	Negative	Negative												32	Matched	AMLNOS	Leukemia	AML, NOS	NA
aml_ohsu_2018_1865	aml_ohsu_2018_14-00817	Denovo	None	Acute myelomonocytic leukaemia	Adverse	Not Enough Information	Acute myelomonocytic leukaemia	Initial Acute Leukemia Diagnosis	Leukapheresis	RNA-seq	Yes	No	Yes	Yes	No	Yes	1	Standard Chemotherapy	1	7+3 (Cytarabine, Idarubicin)	1	Induction	Complete Response	Standard Chemotherapy	-1	Standard Chemotherapy	7+3 (Cytarabine, Idarubicin)	Induction	-1	-1		66	56	No														46,XY[20]			Normal	123	large population of atypical CD117 positive myeloblasts (partial CD34+, weak CD4+, weak partial CD7+, partial CD64+), representing approximately 57% of the leukocytes and increased   promonocytes/monoblasts representing approximately 13% of the total leukocytes		180	Positive	Negative	Negative							Negative				53	Matched	AML	Leukemia	Acute Myeloid Leukemia	NA
aml_ohsu_2018_1866	aml_ohsu_2018_14-00831	Denovo	PML-RARA	Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA	Favorable	Intermediate-II	Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	1	Standard Chemotherapy	1	ATRA, Arsenic Trioxide	2	Consolidation | Induction	Complete Response	Standard Chemotherapy	5	Standard Chemotherapy	ATRA, Arsenic Trioxide	Consolidation	5	0		81	37	No	3		33	1	15		47	44	4.4	0.8		18.6	6.3	46,XY,t(15;17)(q24;q21.1)[10]/46,XY[10]	484		nuc ish(PML,RARA)x3(PML con RARAx2)[173/200]	105	CD2(-), CD4(-), CD7(-), CD11b(-), CD13(+), CD14(-), CD15(partial dim +), CD16(-), CD25(-), CD33(bright +), CD34(-/small subset +), CD36(-), CD38(variably +), CD45(+), CD56(-), CD64(equivocal/appears partial dim +), CD117(+), CD123(-), HLA-DR(-), MPO(appears partial +), TdT(few +).	6.7	4.95	Negative	Negative												26	Matched	APLPMLRARA	Leukemia	APL with PML-RARA	0.8
aml_ohsu_2018_1868	aml_ohsu_2018_14-00832	Denovo	Unknown	AML with myelodysplasia-related changes	Intermediate or Adverse	Intermediate-II	AML with myelodysplasia-related changes	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	2	Standard Chemotherapy | Bone Marrow Transplant	3	Fludarabine, Melphalan|7+3 (Cytarabine, Idarubicin)|MiDAC	3	Consolidation | Induction | Allogeneic - Mismatched Unrelated Donor	Complete Response	Standard Chemotherapy	6	Bone Marrow Transplant	Fludarabine, Melphalan	Allogeneic - Mismatched Unrelated Donor	0	0	0.8		30	No	0	12.5	24.2	28.3	18.4	0	23	29	3	0.78		22.4	7.4		561	107.2		60	CD7, minor subset CD11b, CD13, minor subset CD14,      dim CD33, CD34, CD38, CD58, minor subset CD64, CD117, CD123, HLA-DR, subset      myeloperoxidase positive	6.6	31.66	Positive	Negative	Negative		Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative		65	Matched	AMLMRC	Leukemia	AML with Myelodysplasia-Related Changes	0.8
aml_ohsu_2018_1870	aml_ohsu_2018_14-00901	Denovo	None	Acute myeloid leukaemia, NOS	Intermediate	Intermediate-II	Acute myeloid leukaemia, NOS	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	1	Standard Chemotherapy	3	5+2 (Cytarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin)|MiDAC	3	Consolidation | Induction | Re-induction	Refractory	Standard Chemotherapy	6	Standard Chemotherapy	MiDAC	Consolidation	44	-2	0			No	0	0	45.5	0.8	0	0.3	14	18	2.4	0.73		21.3	6.9	46,XY,t(1;4)(q21;p14)[20]	178	103.4	Normal	57		7	13.68	Negative	Negative	Negative			Negative	Negative	Negative	Negative	Negative	Negative	Negative		61	Matched	AMLNOS	Leukemia	AML, NOS	0.366666666667
aml_ohsu_2018_1876	aml_ohsu_2018_15-00009	Denovo	None	AML without maturation	Intermediate	Not Enough Information	AML without maturation	Initial Acute Leukemia Diagnosis	Peripheral Blood	WES	No	Yes	No	No	Yes	No	3	Standard Chemotherapy | Bone Marrow Transplant | Targeted Therapy - Other	3	Cyclophosphamide, Fludarabine, TBI|Azacitidine|Venetoclax (ABT-199)	3	Hypomethylating/Low Dose Cytarabine | Experimental | Double Umbilical Cord Blood Transplant (DUCBT)				Bone Marrow Transplant	Cyclophosphamide, Fludarabine, TBI	Double Umbilical Cord Blood Transplant (DUCBT)	-1	1		40		No							6	9			M0			46,XY[12]			Normal	31	CD34, dim CD45, CD117		0.9	Negative	Negative	Negative			Negative	Negative	Negative	Negative					71	Matched	AWM	Leukemia	AML without Maturation	NA
aml_ohsu_2018_1877	aml_ohsu_2018_15-00014	After or at the time transformation from another heme malignancy	None	AML with mutated NPM1	Intermediate	Adverse	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	WES + RNA-seq	Yes	Yes	No	Yes	Yes	No	1	Standard Chemotherapy	2	Azacitidine|Decitabine	1	Hypomethylating/Low Dose Cytarabine				Standard Chemotherapy	Azacitidine	Hypomethylating/Low Dose Cytarabine	6	1	0	95	9	No	0	0.9	53	0	28.7	0.8	10	16	4	1.02	M5	25.8	8.6	47,XX,+1,add(1)(p22)[15]/47,XX,+1,i(1)(q10)[5]	601	97	1p36/1q25: 81% of cells had three signals for 1q25 and two for 1p36, consistent with the larger clone above (ie. the clone with add(1)(p22). Another 13% of cells had four signals for 1q25 and two signals for 1p36, consistent with the smaller clone above (ie. the clone with the i(1)(q10)).	8	CD4, CD11b, CD15, CD33, CD38, CD58, CD64, CD123 and partial HLA-DR positive	8.2	3.65	Negative	Positive	Negative		Negative		Negative	Negative	Negative	Negative	Negative	Negative	Negative	77	Matched	AMLNPM1	Leukemia	AML with Mutated NPM1	1.33333333333
aml_ohsu_2018_1889	aml_ohsu_2018_15-00018		None	Acute myeloid leukaemia, NOS	Intermediate	Not Enough Information	Acute myeloid leukaemia, NOS	Post-Chemotherapy|Residual Disease	Peripheral Blood	WES + RNA-seq	Yes	Yes	No	Yes	Yes	No	2	Standard Chemotherapy | Targeted Therapy - Other	3	7+3 (Cytarabine, Idarubicin)|HiDAC|Binimetinib (MEK162)	3	Consolidation | Induction | Experimental	Refractory	Standard Chemotherapy	-1	Targeted Therapy - Other	Binimetinib (MEK162)	Experimental	-1	0		70	8	No				10										46,XY[14]							7.1	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative		Negative	Negative	Negative	Negative	58	Matched	AMLNOS	Leukemia	AML, NOS	0.366666666667
aml_ohsu_2018_1916	aml_ohsu_2018_15-00024	Denovo	None	Acute myelomonocytic leukaemia	Intermediate	Not Enough Information	Acute myelomonocytic leukaemia	Initial Acute Leukemia Diagnosis	Peripheral Blood	WES + RNA-seq	Yes	Yes	No	Yes	Yes	No	1	Standard Chemotherapy	1	Decitabine, Midostaurin	1	Induction	Refractory	Standard Chemotherapy	206	Standard Chemotherapy	Decitabine, Midostaurin	Induction	206	-6				No														46,XX,t(5;16)(q31;p13)[3]/46,XX[14]								Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative		Negative	Negative	Negative	Negative	75	Matched	AML	Leukemia	Acute Myeloid Leukemia	1.63333333333
aml_ohsu_2018_1919	aml_ohsu_2018_15-00029	Denovo	None	Acute myeloid leukaemia, NOS	Intermediate	Not Enough Information	Acute myeloid leukaemia, NOS	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	WES + RNA-seq	Yes	Yes	No	Yes	Yes	No	1	Standard Chemotherapy	2	Decitabine, ABT-199|Hydroxyurea	2	Unknown | Supportive/Palliative Care				Standard Chemotherapy	Decitabine, ABT-199	Unknown	-1	0	0	21	47	No	0		5	10	41		25	52	4.1	1.26		35	11.1	46,XY[20]	639	90.4	nuc ish(D5S2064,D5S630,EGR1)x2[200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[200],(RUNX1T1,RUNX1)x2 [200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	110	CD2(-), CD4(-), CD7(-), CD11b(-), CD13(bright +), CD14(-), CD15(few +), CD16 (-), CD33(variably +), CD34(+), CD36(-), CD38(partial + with an unusual pattern of expression vs. CD34), CD45(moderate to slightly dim +), CD56(-), CD64(-), CD117(+), HLA-DR(dim +).	7.5	64.6	Negative	Negative					Negative	Negative						80	Matched	AMLNOS	Leukemia	AML, NOS	1.1
aml_ohsu_2018_1924	aml_ohsu_2018_15-00043		None	AML with myelodysplasia-related changes	Adverse	Adverse	AML with myelodysplasia-related changes	Post-Chemotherapy	Peripheral Blood	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	2	Standard Chemotherapy | Bone Marrow Transplant	3	7+3 (Cytarabine, Idarubicin)|GCLAC (GCSF, Clofarabine & Cytarabine)|Busulfan, Cyclophosphamide	3	Allogeneic - Sibling | Induction | Re-induction	Refractory	Standard Chemotherapy	12	Bone Marrow Transplant	Busulfan, Cyclophosphamide	Allogeneic - Sibling	-1	-46				No														46,XX,add(3)(q21)[12]/52,sl,+6,+8,+10,+13,+20,+21[8]			Positive for an EVI1 rearrangement					Negative	Negative												44	Unmatched	AMLMRC	Leukemia	AML with Myelodysplasia-Related Changes	0.2
aml_ohsu_2018_1925	aml_ohsu_2018_15-00045	Denovo	CBFB-MYH11	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	Favorable	Favorable	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	1	Standard Chemotherapy	3	HiDAC|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone)	3	Consolidation | Induction | Re-induction	Complete Response	Standard Chemotherapy	40	Standard Chemotherapy	MEC (Cytarabine, Etoposide, Mitoxantrone)	Re-induction	-1	0	0	36	22	No	0		12	44	5		61	44	4.2	0.59		31.8	11	46,XX,inv(16)(p13q22)[20]	441		nuc ish(D5S2064,D5S630,EGR1)x2[200],(D7Z1,D7S522)x2[199],(D8Z2,D20S108)x2 [199],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(RUNX1T1,RUNX1)x2[200],(PML,RARA)x2[200], (5'CBFBx2,3'CBFBx1)(5CBFB sep 3'CBFBx1)[195/200],(ABL1,BCR)x2[200]	33	CD34, CD13, partialCD15, CD38, CD45, CD117, CD123, HLA-DR, dimMPO	7	55	Negative	Negative				Negative	Negative	Negative						30	Matched	AMLCBFBMYH11	Leukemia	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22);CBFB-MYH11	0.4
aml_ohsu_2018_1929	aml_ohsu_2018_15-00051		Unknown	Therapy-related myeloid neoplasms	Favorable	Favorable	Therapy-related myeloid neoplasms	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	2	Standard Chemotherapy | Bone Marrow Transplant	4	5+2 (Cytarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin)|MiDAC|Bu/Flu/TBI (Busulfan, Fludarabine, Total Body Irradiation)	3	Consolidation | Induction | Allogeneic - Matched Unrelated Donor	Complete Response	Standard Chemotherapy	6	Bone Marrow Transplant	Bu/Flu/TBI (Busulfan, Fludarabine, Total Body Irradiation)	Allogeneic - Matched Unrelated Donor	2	0	0	95	90.2	No	0	2.5	4.9	0.8	1.6	0.6	19	23	3	0.5		18.9	6.1		501	100.5	Normal	10	CD13, CD33, dim CD71, CD117, CD123, and MPO	6.4	66.67	Negative	Positive	Negative		Negative	Negative	Negative		Negative	Negative	Negative	Negative	Negative	66	Matched	TMN	Leukemia	Therapy-Related Myeloid Neoplasms	0.333333333333
aml_ohsu_2018_1184	aml_ohsu_2018_15-00053	Relapse	None	AML with myelodysplasia-related changes	Adverse	Not Enough Information	AML with myelodysplasia-related changes	Relapse	Bone Marrow Aspirate	WES	No	Yes	No	No	Yes	No	3	Standard Chemotherapy | Bone Marrow Transplant | Targeted Therapy - Other	5	7+3 (Cytarabine, Idarubicin)|HiDAC|AG-221|HAM (Mitoxantrone, Cytarabine) plus Crenolanib|Fludarabine, Melphalan, ATG	5	Consolidation | Salvage | Induction | Experimental | Allogeneic - Matched Unrelated Donor	Refractory	Standard Chemotherapy	15	Bone Marrow Transplant	Fludarabine, Melphalan, ATG	Allogeneic - Matched Unrelated Donor	-1	-506		6	2	No			54	23	19		18	25		1.03		37.2	12.1	89<4n>,XXY,-Y,-7,-12,+13,+13,-17,-21[2]/46,XY[18]	166		nuc ish(RUNX1T1x4,RUNX1x3)[33/200],(5'MLL,3'MLL)x4(5'MLL con 3'MLLx4)[41/200],(PMLx4,RARAx3~4)[31/200],(5'CBFB,3'CBFB)x4(5'CBFB con 3'CBFBx4)[27/200]	77		8.2	5.94	Positive	Negative												54	Matched	AMLMRC	Leukemia	AML with Myelodysplasia-Related Changes	0.766666666667
aml_ohsu_2018_1933	aml_ohsu_2018_15-00056	After or at the time transformation from another heme malignancy	None	AML with myelodysplasia-related changes	Intermediate	Intermediate-I	AML with myelodysplasia-related changes	Residual Disease	Bone Marrow Aspirate	WES	No	Yes	No	No	Yes	No	2	Standard Chemotherapy | Targeted Therapy - Other	2	AG-221|Decitabine	2	Hypomethylating/Low Dose Cytarabine | Experimental				Targeted Therapy - Other	AG-221	Experimental	-1	0		70	55	No														46,XY[20]			Normal	46	positive for CD13, CD34, CD38, CD117, and HLA-DR; negative for MPO, and B-cell and T-cell markers		4.5	Negative	Negative	Negative			Negative	Negative		Negative					76	Matched	AMLMRC	Leukemia	AML with Myelodysplasia-Related Changes	4.06666666667
aml_ohsu_2018_1933	aml_ohsu_2018_15-00057	After or at the time transformation from another heme malignancy	None	AML with myelodysplasia-related changes	Intermediate	Not Enough Information	AML with myelodysplasia-related changes	Residual Disease	Peripheral Blood	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	2	Standard Chemotherapy | Targeted Therapy - Other	2	AG-221|Decitabine	2	Hypomethylating/Low Dose Cytarabine | Experimental				Targeted Therapy - Other	AG-221	Experimental	-1	0		70	55	No														46,XY[20]			Normal	46	positive for CD13, CD34, CD38, CD117, and HLA-DR; negative for MPO, and B-cell and T-cell markers		4.5	Negative	Negative	Negative			Negative	Negative		Negative					76	Matched	AMLMRC	Leukemia	AML with Myelodysplasia-Related Changes	3.9
aml_ohsu_2018_1962	aml_ohsu_2018_15-00071		None	AML with myelodysplasia-related changes	Adverse	Adverse	AML with myelodysplasia-related changes	Post-Chemotherapy|Post-Transplant	Bone Marrow Aspirate	WES	Yes	Yes	No	No	Yes	No	2	Standard Chemotherapy | Bone Marrow Transplant	4	7+3 (Cytarabine, Idarubicin)|HiDAC|MEC (Cytarabine, Etoposide, Mitoxantrone)|Busulfan, Cyclophosphamide	4	Consolidation | Induction | Re-induction | Allogeneic - Matched Unrelated Donor	Complete Response	Standard Chemotherapy	6	Standard Chemotherapy	MEC (Cytarabine, Etoposide, Mitoxantrone)	Re-induction	4	0	0.9	1	0	No	3.5		7.8	5.2	82.6		9	16	2.7	1.14		31.3	10.2	45~49,X,-Y,add(5)(q11.2),+der(9;8)(q10;q10),+10,der(11)t(11;17)(p15;q11.2)del(11)(q21q22),add(12)(q12),del(13)(q12q22),-17,add(18)(p11.2),add(19)(q13.3),-20,+1~4mar[cp4]/46,XX[16]		97.2	nuc ish(RUNX1T1x3,RUNX1x2)[9/200], (5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[198](5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	365	CD2(-), CD4(-), CD7(-), CD11b(partial +), CD13(+), CD14(-), CD15(partial dim +), CD16(-), CD25(-), CD33(bright +), CD34(+), CD36(-), CD38(partial +), CD45(+), CD56(+), CD64(-), CD117(+), CD123(dim +), HLA-DR (+), MPO(few +), TdT(-).	4.9	7.5	Negative	Negative				Negative	Negative	Negative						56	Unmatched	AMLMRC	Leukemia	AML with Myelodysplasia-Related Changes	0.0333333333333
aml_ohsu_2018_1963	aml_ohsu_2018_15-00073	Denovo	None	Acute myeloid leukaemia, NOS	Adverse	Not Enough Information	Acute myeloid leukaemia, NOS	Initial Acute Leukemia Diagnosis	Peripheral Blood	WES + RNA-seq	Yes	Yes	No	Yes	Yes	No	2	Supportive/Palliative Care | Targeted Therapy - Other	2	AG-221|Hydroxyurea	2	Experimental | Supportive/Palliative Care				Targeted Therapy - Other	AG-221	Experimental	14	-8	0		12	No	0		69	5	12		30	41	3.3	0.76		30.3	10.5	46,XY[20]	227	85.6	nuc ish(RUNX1T1,RUNX1)x2[199],(ABL1,BCR)x2[200],(CCND1,IGH)x2[199]	117		8.8	33.1	Negative	Negative												81	Matched	AMLNOS	Leukemia	AML, NOS	1.36666666667
aml_ohsu_2018_1964	aml_ohsu_2018_15-00075	After or at the time transformation from another heme malignancy	None	AML with myelodysplasia-related changes	Adverse	Adverse	AML with myelodysplasia-related changes	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	1	Targeted Therapy - Other	1	AG-221	1	Experimental				Targeted Therapy - Other	AG-221	Experimental	-1	1		90	48	No														46,XY,del(20)(q11.2q13.1)[12]/45,sl,-7[3]/45,XY,-7[5]/46,XY[2]			Tetrasomy 5p/q; Monosomy 7; Loss 20q12 (15.5%); Tetrasomy 8cen and 20q12 (7	65	positive for CD13, dim CD33, CD34, CD38, dim CD45, CD117, HLA-DR and TdT		6.6	Negative	Negative					C.G395A; p.R132H; MAF unknown							80	Matched	AMLMRC	Leukemia	AML with Myelodysplasia-Related Changes	0.466666666667
aml_ohsu_2018_1757	aml_ohsu_2018_15-00081		CBFB-MYH11	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	Intermediate	Favorable	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	Post-Chemotherapy	Bone Marrow Aspirate	WES + RNA-seq	Yes	Yes	No	Yes	Yes	No	3	Standard Chemotherapy | Bone Marrow Transplant | Intrathecal	6	Busulfan, Fludarabine, Thymoglobulin (Bu/Flu/ATG)|7+3 (Cytarabine, Idarubicin)|HiDAC|CLAG-M (Cladribine, Cytarabine, Mitoxantrone, Filgrastim)|FLAG-IDA, Gemtuzumab|Cytarabine, Methotrexate	5	Consolidation | Induction | Allogeneic - Mismatched Unrelated Donor | CNS | Re-induction	Complete Response	Standard Chemotherapy	-1	Bone Marrow Transplant	Busulfan, Fludarabine, Thymoglobulin (Bu/Flu/ATG)	Allogeneic - Mismatched Unrelated Donor	-1	-2				No														46,XY[20]			Normal					Negative	Negative												49	Unmatched	AMLCBFBMYH11	Leukemia	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22);CBFB-MYH11	0.0666666666667
aml_ohsu_2018_1953	aml_ohsu_2018_15-00084	After or at the time transformation from another heme malignancy	None	AML with myelodysplasia-related changes	Adverse	Adverse	AML with myelodysplasia-related changes	Residual Disease	Peripheral Blood	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	1	Standard Chemotherapy	1	Azacitidine	1	Hypomethylating/Low Dose Cytarabine				Standard Chemotherapy	Azacitidine	Hypomethylating/Low Dose Cytarabine	122	-21	7.6			No	4.2	8.5	28	6.8	12.7	0.1	24	22	3.1	0.96		31.5	11	43~46,XX,add(2)(q11.2),-4,del(5)(q23),add(7)(q32),+8,add(11)(q23),-16,del(17)(p12),-18,+22[cp19]/46,XX[1]	1304	86.8		21		7.3	17.63	Negative	Negative				Negative								82	Unmatched	AMLMRC	Leukemia	AML with Myelodysplasia-Related Changes	0.133333333333
aml_ohsu_2018_1969	aml_ohsu_2018_15-00123	Denovo	Unknown	AML with mutated NPM1	Intermediate	Intermediate-I	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Peripheral Blood	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	2	Standard Chemotherapy | Bone Marrow Transplant	3	Bu/Cy/ATG|7+3 (Cytarabine, Idarubicin)|HiDAC	3	Consolidation | Induction | Allogeneic - Matched Unrelated Donor	Complete Response	Standard Chemotherapy	5	Bone Marrow Transplant	Bu/Cy/ATG	Allogeneic - Matched Unrelated Donor	-1	0		81	85	No			4	7	4		89	50	3	0.94		27.8	9.5		945	95.5		39	partialCD4, partial/dimCD7, partialCDllb, CD13, partialCD15, partialCD22, partialCD25, brightCD33, partialCD34, CD38, CD45, CD117, partialCD123, HLA-DR, partialMPO, partialTdT	5.7	48.03	Positive	Positive	Negative			Negative								42	Matched	AMLNPM1	Leukemia	AML with Mutated NPM1	0.2
aml_ohsu_2018_1972	aml_ohsu_2018_15-00129		None	AML with myelodysplasia-related changes	Intermediate	Intermediate-I	AML with myelodysplasia-related changes	Post-Chemotherapy|Residual Disease	Peripheral Blood	WES	No	Yes	No	No	Yes	No	1	Unknown	1	Azacitidine	1	Hypomethylating/Low Dose Cytarabine				Unknown	Azacitidine	Hypomethylating/Low Dose Cytarabine	-1	0		15		No														46,XY[19]			Normal	51	positive for CD34, CD117,  CD13, CD33 and HLA-DR		2.9	Negative	Negative	Negative			Negative	Negative	Negative	Negative					68	Matched	AMLMRC	Leukemia	AML with Myelodysplasia-Related Changes	NA
aml_ohsu_2018_1721	aml_ohsu_2018_15-00140		None	AML with mutated NPM1	Intermediate	Not Enough Information	AML with mutated NPM1	Post-Chemotherapy	Bone Marrow Aspirate	WES + RNA-seq	Yes	Yes	No	Yes	Yes	No	1	Standard Chemotherapy	4	7+3 (Cytarabine, Idarubicin)|HiDAC|Azacitidine|MEC (Cytarabine, Etoposide, Mitoxantrone)	4	Consolidation | Induction | Re-induction | Maintenance	Complete Response	Standard Chemotherapy	-1	Standard Chemotherapy	Azacitidine	Maintenance	-1	0		1	0	No							23	24	4.6			35.4	12	46,XY			nuc ish(D5S2064,D5S630,EGR1)x2[200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[200],(RUNX1T1, RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	61	CD38(bright +), CD45(-), CD56(+), intracellular kappa(+), intracellular lambda(-)	7.5	2.6	Negative	Negative				Negative	Negative	Negative						68	Matched	AMLNPM1	Leukemia	AML with Mutated NPM1	0.133333333333
aml_ohsu_2018_1876	aml_ohsu_2018_15-00143		None	AML without maturation	Intermediate	Not Enough Information	AML without maturation	Post-Chemotherapy	Peripheral Blood	WES	No	Yes	No	No	Yes	No	3	Standard Chemotherapy | Bone Marrow Transplant | Targeted Therapy - Other	3	Cyclophosphamide, Fludarabine, TBI|Azacitidine|Venetoclax (ABT-199)	3	Hypomethylating/Low Dose Cytarabine | Experimental | Double Umbilical Cord Blood Transplant (DUCBT)				Bone Marrow Transplant	Cyclophosphamide, Fludarabine, TBI	Double Umbilical Cord Blood Transplant (DUCBT)	-1	-29		4		No														46,XY[12]			Normal				0.8	Negative	Negative	Negative			Negative	Negative	Negative	Negative					71	Matched	AWM	Leukemia	AML without Maturation	NA
aml_ohsu_2018_1981	aml_ohsu_2018_15-00147		None	AML with mutated CEBPA	Intermediate	Intermediate-II	AML with mutated CEBPA	Post-Chemotherapy|Residual Disease	Peripheral Blood	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	1	Standard Chemotherapy	5	GCLAM (G-CSF, Cladribine, Cytarabine, and Mitoxantrone) |7+3 (Cytarabine, Idarubicin)|HiDAC|MEC (Cytarabine, Etoposide, Mitoxantrone)|Decitabine	5	Hypomethylating/Low Dose Cytarabine | Consolidation | Salvage | Induction | Re-induction	Complete Response	Standard Chemotherapy	6	Standard Chemotherapy	GCLAM (G-CSF, Cladribine, Cytarabine, and Mitoxantrone)	Salvage	5	-27	0			No	0	0	4.1	0	2.1	32.3	54	37	3.7	0.3	NOS	27.3	9.2	46,XX,t(2;9)(q31;p21)[17]/46,X,t(X;9)(q22;p21)[3]		91.3		8		6.3	20.18	Negative	Negative												30	Unmatched	AMLCEBPA	Leukemia	AML with Biallelic Mutations of CEBPA	0.2
aml_ohsu_2018_1988	aml_ohsu_2018_15-00148	Denovo	None	AML with mutated NPM1	Favorable	Favorable	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	WES	No	Yes	Yes	No	Yes	Yes	1	Standard Chemotherapy	2	7+3 (Cytarabine, Idarubicin)|MiDAC	2	Consolidation | Induction	Complete Response	Standard Chemotherapy	6	Standard Chemotherapy	MiDAC	Consolidation	113	0	0	25	39	No	0	2	58.4	2	12.9	24.7	16	42	2.9	0.92		19.4	6.7	46,XY[20]	1146	97.5	Normal	21	CD13, CD33, CD38, CD58, CD117, CD123, MPO      positive	5.6	3.28	Negative	Positive	Negative		Negative	Negative	Negative	Negative	Negative	Negative	Negative	p.G13D; MAF 17%	Negative	61	Matched	AMLNPM1	Leukemia	AML with Mutated NPM1	1.3
aml_ohsu_2018_1989	aml_ohsu_2018_15-00150		None	AML with mutated NPM1	Favorable or Intermediate	Intermediate-I	AML with mutated NPM1	Residual Disease|Post-Chemotherapy	Bone Marrow Aspirate	WES	No	Yes	Yes	No	Yes	Yes	1	Standard Chemotherapy	5	HiDAC|GCLAC (GCSF, Clofarabine & Cytarabine)|SWOG S1203 (7+3 +/- Vorinostat)|MEC, Lenalidomide|Etoposide, Cytarabine	4	Consolidation | Salvage | Induction | Re-induction	Complete Response	Standard Chemotherapy	6	Standard Chemotherapy	GCLAC (GCSF, Clofarabine & Cytarabine)	Salvage	-1	0	0			No	0	0	7.2	0	8.9	1.5	38	22	2.9	0.82		24.5	8.2	46,XY[20]		87.5	Normal	18		5.4	5.98	Positive	Positive	Negative		p.R882C; MAF 47%	Negative	p.R132C; MAF 47%	Negative	Negative	Negative	Negative	p.G13D; MAF 17%	Negative	47	Matched	AMLNPM1	Leukemia	AML with Mutated NPM1	1.3
aml_ohsu_2018_1993	aml_ohsu_2018_15-00159		None	Acute myeloid leukaemia, NOS	Intermediate	Not Enough Information	Acute myeloid leukaemia, NOS	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	WES	No	Yes	Yes	No	Yes	Yes	0		0		0					NONE	NONE	NONE		0	0	58	31	No	0		24	9	31		11	23	3.9	1.72		37.6	12.1	46,XY[20]	379	94	nuc ish(D5S2064,D5S630,EGR1)x2[200],(D7Z1,D7S522)x2[199],(D8Z2,D20S108)x2[200],(RUNX1T1,RUNX1)x2 [200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	36	CD4(partial +), CD7(-), CD11b(-), CD13(variably +), CD14(-), CD15(partial dim +), CD16(-), CD33(partial +), CD34(+), CD36(subset +), CD38(variably +), CD45(moderate to dim +), CD56(-), CD64(-), CD117(partial +), HLA-DR(variably +), MPO(partial +), TdT(small subset +)	6.7	12.8	Negative	Negative					Negative	Negative						75	Matched	AMLNOS	Leukemia	AML, NOS	0.133333333333
aml_ohsu_2018_1998	aml_ohsu_2018_15-00167	Denovo	None	AML with mutated NPM1	Favorable	Favorable	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	WES	No	Yes	Yes	No	Yes	Yes	1	Standard Chemotherapy	1	SWOG S1203 (7+3 +/- Vorinostat)	1	Induction	Complete Response	Standard Chemotherapy	3	Standard Chemotherapy	SWOG S1203 (7+3 +/- Vorinostat)	Induction	3	0	1.7	50	55	No	0.9	4.4	13.2	23.7	14	0	22	30	2.1	0.91		23.2	7.3	46,XY[20]		90.6	Normal	176	CD13, CD33, CD38, CD58, dim CD64, CD117, CD123, dim HLA-DR and partial MPO+	6.3	93.94	Negative	Positive	Negative		Negative	Negative	Negative		Negative	Negative	Negative	Negative	Negative	42	Matched	AMLNPM1	Leukemia	AML with Mutated NPM1	0.0666666666667
aml_ohsu_2018_2001	aml_ohsu_2018_15-00169		None	Therapy-related myeloid neoplasms	Intermediate	Intermediate-I	Therapy-related myeloid neoplasms	Post-Chemotherapy|Post-Transplant|Post-DLI|Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	4	Standard Chemotherapy | Supportive/Palliative Care | Targeted Therapy - Kinase Inhibitor(s) | Targeted Therapy - Other	4	AG-120|MEC (Cytarabine, Etoposide, Mitoxantrone)|Sorafenib|Hydroxyurea	3	Salvage | Experimental | Supportive/Palliative Care				Targeted Therapy - Kinase Inhibitor(s)	Sorafenib	Experimental	-1	0	0	24	6	No	0		77	10	7		29	37	4.1	0.89		30.1	9.9	46,XX[20]	511		nuc ish(DXZ1x2)[182]//(DXZ1,DYZ3)x1[18]. nuc ish(D5S2064,D5S630,EGR1)x2[197],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[200],(RUNX1T1,RUNX1)x2 [200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2) [200]	288	CD2(-), CD7(-), CD11b(-), CD13(+), CD14(-), CD15(partial +), CD33(variably +), CD34(+), CD36 (-), CD38(+), CD45(+), CD56(-), CD64(partial dim +), CD117(+), HLA-DR(+)	8	3.3	Negative	Negative						Negative						67	Unmatched	TMN	Leukemia	Therapy-Related Myeloid Neoplasms	0.166666666667
aml_ohsu_2018_2002	aml_ohsu_2018_15-00171		None	AML with minimal differentiation	Adverse	Intermediate-II	AML with minimal differentiation	Initial Acute Leukemia Diagnosis	Peripheral Blood	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	3	Standard Chemotherapy | Targeted Therapy - Other | Targeted Therapy - Kinase Inhibitor(s)	3	Cytarabine|Decitabine|PF-04449913 (Hedgehog Inhibitor), LDAC	3	Consolidation | Salvage | Experimental				Targeted Therapy - Kinase Inhibitor(s)	Decitabine	Salvage	-1	1		80	86	No														46,XY,del(20)(q11.2q13.1)[15]/46,XY[5]			Positive for deletion of 20q12 in 11.5% of 200 cells	4	positive for dim CD7, dim CD10, CD34, CD38, dim CD45, cCD79a, CD99, HLA-DR, TdT, dim PAX5			Negative	Negative	Negative		Negative	Negative	Negative	Negative	Negative	Negative			Negative	80	Matched	AMLMD	Leukemia	AML with Minimal Differentiation	0.966666666667
aml_ohsu_2018_1999	aml_ohsu_2018_15-00175	After or at the time transformation from another heme malignancy	None	AML with myelodysplasia-related changes	Adverse	Adverse	AML with myelodysplasia-related changes	Initial Acute Leukemia Diagnosis	Peripheral Blood	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	1	Standard Chemotherapy	2	7+3 (Cytarabine, Idarubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone)	2	Salvage | Induction	Refractory	Standard Chemotherapy	6	Standard Chemotherapy	MEC (Cytarabine, Etoposide, Mitoxantrone)	Salvage	4	0	0	76	93	No	0	0	6.1	1.7	1.8	0	7	10	2.2	0.44		18.8	6.3	43~47,XY,del(1)(q42),r(2)(p2?3q37),t(3;5)(q27;q31),del(4)(q31),+del(5)(q31),add(5)(q11.2),-7,del(11)(q23),add(12)(p13),-22,+mar[cp11]/43~46,idem,add(14)(q24)[cp8]		85.8	deleted 5q and three short arm signals;  monosomy 7 and the metaphase karyotype;  no evidence for MLL deletion or rearrangement	14		5.9	50.74	Negative	Negative	Negative		Negative		Negative	Negative	Negative		Negative	 p.Q61K; MAF 37%	p.R273H; MAF 44%	50	Matched	AMLMRC	Leukemia	AML with Myelodysplasia-Related Changes	0.5
aml_ohsu_2018_2005	aml_ohsu_2018_15-00180	After or at the time transformation from another heme malignancy	None	Unknown	Adverse	Intermediate-I	AML with myelodysplasia-related changes	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	WES	No	Yes	No	No	Yes	No	3	Standard Chemotherapy | Targeted Therapy - Other | Targeted Therapy - Kinase Inhibitor(s)	3	FLX925|Azacitidine, Lenalidomide|Venetoclax (ABT-199)	2	Salvage | Experimental				Standard Chemotherapy	Azacitidine, Lenalidomide	Salvage	76	0		55	39	No											M5			46,XY[20]			Normal	25	positive for CD34, CD117, CD13, CD33, and HLA-DR		46.8	Negative	Negative	Negative			Negative	p.G105G; MAF 50%	Negative	Negative	Negative				73	Matched	AML	Leukemia	Acute Myeloid Leukemia	0.333333333333
aml_ohsu_2018_1973	aml_ohsu_2018_15-00194		None	AML with minimal differentiation	Adverse	Intermediate-II	AML with minimal differentiation	Residual Disease|Post-Chemotherapy	Bone Marrow Aspirate	WES + RNA-seq	Yes	Yes	No	Yes	Yes	No	2	Standard Chemotherapy | Supportive/Palliative Care	3	7+3 (Cytarabine, Idarubicin)|Azacitidine|Decitabine	3	Hypomethylating/Low Dose Cytarabine | Induction | Supportive/Palliative Care	Refractory	Standard Chemotherapy	6	Supportive/Palliative Care	Decitabine	Hypomethylating/Low Dose Cytarabine	-1	1	0			No	0	0	78.1	0.9	1.7	0	46	27	2	0.74		24.4	8.1	47,XY,+4[9]/46,XY[11]		103.8		23		4.7	4.85	Negative	Negative	Negative		Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	70	Matched	AMLMD	Leukemia	AML with Minimal Differentiation	0.233333333333
aml_ohsu_2018_2013	aml_ohsu_2018_15-00196	Denovo	None	Acute myeloid leukaemia, NOS	Adverse	Adverse	Acute myeloid leukaemia, NOS	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	WES	No	Yes	No	No	Yes	No	1	Targeted Therapy - Other	1	AG-221	1	Experimental				Targeted Therapy - Other	AG-221	Experimental	-1	1		85	92	No														45,XX,-7[20]			Monosomy 7	77	positive for CD13, HLA-DR, CD34, and CD117, with aberrant loss of CD33, and with aberrant expression of CD7		20.1	Negative	Negative	Negative			Negative	Negative		Negative					83	Matched	AMLNOS	Leukemia	AML, NOS	0.7
aml_ohsu_2018_2016	aml_ohsu_2018_15-00200	Denovo	None	AML with mutated NPM1	Favorable	Favorable	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	WES	No	Yes	No	No	Yes	No	2	Standard Chemotherapy | Targeted Therapy - Other	2	Azacitidine|Venetoclax (ABT-199), Azacitidine	2	Induction | Experimental	Complete Response	Standard Chemotherapy	-1	Targeted Therapy - Other	Venetoclax (ABT-199), Azacitidine	Experimental	115	0		65		No														46,XX[20]				96	positive for CD33, CD13, CD117, and myeloperoxidase; negative for CD34 and HLA-DR		1.6	Negative	Positive	Negative			Negative	p.A1312V; MAF 32.1%	Negative	Negative	Negative				71	Matched	AMLNPM1	Leukemia	AML with Mutated NPM1	0.833333333333
aml_ohsu_2018_2016	aml_ohsu_2018_15-00201	Denovo	None	AML with mutated NPM1	Favorable	Not Enough Information	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Peripheral Blood	RNA-seq	Yes	No	No	Yes	No	No	2	Standard Chemotherapy | Targeted Therapy - Other	2	Azacitidine|Venetoclax (ABT-199), Azacitidine	2	Induction | Experimental	Complete Response	Standard Chemotherapy	-1	Targeted Therapy - Other	Venetoclax (ABT-199), Azacitidine	Experimental	115	0		65		No														46,XX[20]				96	positive for CD33, CD13, CD117, and myeloperoxidase; negative for CD34 and HLA-DR		1.6	Negative	Positive	Negative			Negative	p.A1312V; MAF 32.1%	Negative	Negative	Negative				71	Matched	AMLNPM1	Leukemia	AML with Mutated NPM1	NA
aml_ohsu_2018_2018	aml_ohsu_2018_15-00208		None	AML with myelodysplasia-related changes	Adverse	Adverse	AML with myelodysplasia-related changes	Post-Chemotherapy|Residual Relapse	Bone Marrow Aspirate	WES	No	Yes	No	No	Yes	No	1	Standard Chemotherapy	3	7+3 (Cytarabine, Idarubicin)|Azacitidine|Clofarabine, Cytarabine	3	Hypomethylating/Low Dose Cytarabine | Induction | Re-induction	Complete Response	Standard Chemotherapy	-1	Standard Chemotherapy	Clofarabine, Cytarabine	Re-induction	-1	0		35	44	No														46,XX,add(2)(q13),-3,-5,add(6)(q21),del(7)(q22),+11,dic(11;17)(p11.2;p11.2),inv(11)(q13q23),add(12)(p12),add(14)(q22),-17,add(19)(p12),-22,+3mar[1]/45-48,sl,+add(1)(q12),del(7)(q22),+3-5mar[cp8]/47-48,sdl1,+8[cp4]/46,XX[3]			FISH assays were positive for loss of 5q31 sequences in 91.5% of cells, and positive for trisomy for 7 centromere with disomy for 7q31 in 54.2% of cells.	51	The myeloblasts were positive for CD34, CD117, CD13, CD33, and HLA-DR. A subset of the myeloblasts showed aberrant expression of CD56.		4.7	Negative	Negative	Negative			Negative	p.G105G; MAF 52.8%	Negative	Negative	Negative			loss exons 10-11	65	Matched	AMLMRC	Leukemia	AML with Myelodysplasia-Related Changes	0.566666666667
aml_ohsu_2018_2024	aml_ohsu_2018_15-00229	Denovo	PML-RARA	Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA	Favorable	Adverse	Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	RNA-seq	Yes	No	No	Yes	No	No	1	Standard Chemotherapy	1	APML4 Protocol (ATRA, Arsenic Trioxide, Idarubicin)	1	Induction	Complete Response	Standard Chemotherapy	28	Standard Chemotherapy	APML4 Protocol (ATRA, Arsenic Trioxide, Idarubicin)	Induction	28	0	0			No	0	0	22.3	0	0.9	0.7	25	50	3.2	0.9	M3	21.3	7.7	46,XY,t(4;15;17)(q21;q22;q21),add(12)(p12)[1]/46,idem,t(5;22)(q11.2;q11.2)[18]/46,XY[1]	921	92.2	FISH c/w PML/RARA fusion	16		6.8	18.25	Positive	Negative	Negative		Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	25	Matched	APLPMLRARA	Leukemia	APL with PML-RARA	NA
aml_ohsu_2018_1727	aml_ohsu_2018_15-00231	After or at the time transformation from another heme malignancy	None	AML with myelodysplasia-related changes	Intermediate	Intermediate-II	AML with myelodysplasia-related changes	Post-Chemotherapy|Residual Disease	Peripheral Blood	WES + RNA-seq	Yes	Yes	No	Yes	Yes	No	2	Standard Chemotherapy | Supportive/Palliative Care	5	GCLAM (G-CSF, Cladribine, Cytarabine, and Mitoxantrone) |7+3 (Cytarabine, Idarubicin)|Azacitidine|MEC (Cytarabine, Etoposide, Mitoxantrone)|Decitabine	4	Hypomethylating/Low Dose Cytarabine | Salvage | Induction | Maintenance	Refractory	Standard Chemotherapy	6	Standard Chemotherapy	GCLAM (G-CSF, Cladribine, Cytarabine, and Mitoxantrone)	Salvage	4	-86	0			No	0	1.7	7.8	51.3	18.3	0	29	19	3	0.52		20.6	7	47,XY,der(7)t(1;7)(q10;p10)+8[20]		87.3		5		5.8	11.13	Negative	Negative												46	Matched	AMLMRC	Leukemia	AML with Myelodysplasia-Related Changes	1.06666666667
aml_ohsu_2018_2028	aml_ohsu_2018_15-00237	Denovo	None	Acute myeloid leukaemia, NOS	Intermediate or Adverse	Not Enough Information	Acute myeloid leukaemia, NOS	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	2	Standard Chemotherapy | Bone Marrow Transplant	4	7+3 (Cytarabine, Idarubicin)|HiDAC|Busulfan, Cyclophosphamide|Transplant	3	Consolidation | Induction | Allogeneic - Matched Unrelated Donor	Complete Response	Standard Chemotherapy	24	Bone Marrow Transplant	Transplant	Allogeneic - Matched Unrelated Donor	-1	0	0	95	78	No	0.9	0	11.7	0	13.5	1.8	20	25	3	0.54		23	7.9	46,XX[20]	1119	95.8	Normal	12	dim CD2, dim CD7, CD13, dim CD19, dim CD20,      CD33, partial CD34, variable CD38, dim CD64, CD117, CD123, and HLA-DR      positive.	6.1	68.79	Positive	Negative												29	Matched	AMLNOS	Leukemia	AML, NOS	0.433333333333
aml_ohsu_2018_2032	aml_ohsu_2018_15-00246	Denovo	None	AML with mutated NPM1	Favorable	Not Enough Information	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	WES + RNA-seq	Yes	Yes	No	Yes	Yes	No	1	Standard Chemotherapy	1	Decitabine	1	Hypomethylating/Low Dose Cytarabine				Standard Chemotherapy	Decitabine	Hypomethylating/Low Dose Cytarabine	214	0		10	1	No	0		80	2	17		24	27	4.3	1.48		20.4	7.2	46,XY[20]	275	93.3	nuc ish(D5S2064,D5S630,EGR1)x2[200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[199](RUNX1T1, RUNX1)x2[199],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	23	CD2(-), CD7(-), CD11b(-), CD13(+), CD14(-), CD15(partial dim +), CD16(-), CD33 (bright +), CD34(partial +), CD36(-), CD38(variably +), CD45(+), CD56(-), CD64(-), CD117(+), HLA-DR (+), GLy-A(-), MPO(partial +), TdT(-).	6.9	1.6	Negative	Positive			W297*; MAF 44%		Negative	Negative						65	Matched	AMLNPM1	Leukemia	AML with Mutated NPM1	0.9
aml_ohsu_2018_2033	aml_ohsu_2018_15-00248	Denovo	None	AML with mutated CEBPA	Adverse	Favorable	AML with mutated CEBPA	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	1	Standard Chemotherapy	3	7+3 (Cytarabine, Idarubicin)|HiDAC|Azacitidine	3	Hypomethylating/Low Dose Cytarabine | Consolidation | Induction	Complete Response	Standard Chemotherapy	-1	Standard Chemotherapy	Azacitidine	Hypomethylating/Low Dose Cytarabine	-1	0	0	64	47.4	No	1.7		23.3	27.6	0		29	26	3.7	1.01		32.9	10.3	46,XY[20]	578	99.7	nuc ish(D5S2064,D5S630,EGR1)x2[199],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[200],(RUNX1T1, RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	20	CD2(-), CD7(partial +), CD11b(partial +), CD13(+), CD14(-), CD15(partial +), CD16(-), CD19(few appear very dim +), CD25(-), CD33(variably +), CD34(variably +), CD36(subset +), CD38(+), CD45 (variably +), CD56(+), CD64(partial +), CD117(+), CD123(-), HLA-DR(+), MPO(+), TdT(-).	7.2	20.8	Negative	Negative	A111FS*56; MAF 48%				Negative	Negative				G13V; MAF 37%		61	Matched	AMLCEBPA	Leukemia	AML with Biallelic Mutations of CEBPA	2.16666666667
aml_ohsu_2018_2052	aml_ohsu_2018_15-00261	Denovo	None	Acute myelomonocytic leukaemia	Adverse	Intermediate-I	Acute myelomonocytic leukaemia	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	2	Standard Chemotherapy | Supportive/Palliative Care	3	7+3 (Cytarabine, Idarubicin)|Cytarabine|MEC (Cytarabine, Etoposide, Mitoxantrone)	3	Induction | Re-induction | Supportive/Palliative Care	Refractory	Standard Chemotherapy	6	Supportive/Palliative Care	Cytarabine	Supportive/Palliative Care	125	0	0			No	0	0	31.9	12.4	2.6	0.1	26	16	3	0.77	M4	22.1	7.5	46,XY[20]	297	95.7	Normal	59		6.5	22.95	Positive	Negative	Negative		Negative	Negative					Negative	Negative	Negative	43	Matched	AML	Leukemia	Acute Myeloid Leukemia	0.5
aml_ohsu_2018_2053	aml_ohsu_2018_15-00269	Denovo	None	AML with mutated NPM1	Favorable	Favorable	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Peripheral Blood	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	1	Standard Chemotherapy	2	7+3 (Cytarabine, Idarubicin)|HiDAC	2	Consolidation | Induction	Complete Response	Standard Chemotherapy	6	Standard Chemotherapy	HiDAC	Consolidation	107	-1	0	35	27.4	No	0		36.8	6.6	29.2		13	25	2.9	1.4		23.6	7.6	46,XY[20]	383		nuc ish(RUNX1T1,RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200], (5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	35		6	3.6	Negative	Positive	Y181*; MAF 15%											59	Matched	AMLNPM1	Leukemia	AML with Mutated NPM1	0.733333333333
aml_ohsu_2018_1992	aml_ohsu_2018_15-00275		None	Therapy-related myeloid neoplasms	Adverse	Not Enough Information	Therapy-related myeloid neoplasms	Post-Chemotherapy|Residual Disease	Peripheral Blood	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	1	Standard Chemotherapy	2	7+3 (Cytarabine, Idarubicin)|GCLAC (GCSF, Clofarabine & Cytarabine)	2	Induction | Re-induction	Complete Response	Standard Chemotherapy	29	Standard Chemotherapy	GCLAC (GCSF, Clofarabine & Cytarabine)	Re-induction	17	-33				No														53~55,XX,+1,+2,der(5)t(5;13)(q13;q12),+6,add(7)(q32),+8,+11,-13,+14,i(17)(q10),+19,+19,+21,+mar[cp7]/46,XX[7]			Gain of 8 (4/301 cells); Gain of 8q22/21q22 (7.7/301 cells); Gain 11q23 (5/200 cells)					Negative	Negative												53	Matched	TMN	Leukemia	Therapy-Related Myeloid Neoplasms	0.266666666667
aml_ohsu_2018_2059	aml_ohsu_2018_15-00276	Denovo	None	AML with mutated NPM1	Favorable	Favorable	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Peripheral Blood	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	2	Standard Chemotherapy | Other	3	FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Azacitidine|SWOG S1203 (7+3 +/- Vorinostat)	3	Salvage | Induction | Re-induction	Complete Response	Other	167	Standard Chemotherapy	Azacitidine	Salvage	6	0	0	90	39.6	No	1	4	47	10	1	0.1	30	26	2.4	1.17	M4	14	4.6	46,XY[20]	612	104.5	Normal	80	dim CD4, dim CD7, dim CD11b,      CD13, CD33, variable CD34, CD38, CD58, variable CD64, CD117, CD123, dim HLA-DR, MPO, and dim TdT	5.8	70.84	Negative	Positive												60	Matched	AMLNPM1	Leukemia	AML with Mutated NPM1	0.766666666667
aml_ohsu_2018_2087	aml_ohsu_2018_15-00279	Denovo	None	AML with mutated NPM1	Intermediate	Intermediate-I	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Peripheral Blood	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	3	Standard Chemotherapy | Bone Marrow Transplant | Intrathecal	4	7+3 (Cytarabine, Idarubicin)|HiDAC|Cytarabine|TBI, VP-16	4	Consolidation | Induction | CNS | Allogeneic - Matched Unrelated Donor	Complete Response	Standard Chemotherapy	-1	Bone Marrow Transplant	TBI, VP-16	Allogeneic - Matched Unrelated Donor	-1	0		86	77	No											M5b			46,XX					Large population of atypical monocytic cells (weaker than  normal CD33, partial loss of CD13) including  promonocytes/monoblasts representing approximately 50% of  the leukocytes suggestive of acute monoblastic or monocytic  leukemia.		81	Positive	Positive	Negative		p.Arg882Cys; MAF 47.1%	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	48	Unmatched	AMLNPM1	Leukemia	AML with Mutated NPM1	0.133333333333
aml_ohsu_2018_2061	aml_ohsu_2018_15-00281	After or at the time transformation from another heme malignancy	None	Acute myeloid leukaemia, NOS	Adverse	Intermediate-I	Acute myeloid leukaemia, NOS	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	WES	No	Yes	No	No	Yes	No	1	Standard Chemotherapy	1	Decitabine	1	Induction	Unknown	Standard Chemotherapy	8	Standard Chemotherapy	Decitabine	Induction	8	0	0	15	3.5	No	3.5	0	92.2	0	0.8	0	46	35	1.8	0.56		22.6	7.1	46,XY[20]	293	89.3	Normal	417	partial dim CD7, CD13, dim CD33, CD34, CD38, CD58, CD117,  HLA-Dr and variable MPO	6.5	0.94	Negative	Negative	Negative			Negative	p.R132C; MAF 34%		Negative		Negative	Negative		60	Matched	AMLNOS	Leukemia	AML, NOS	0.733333333333
aml_ohsu_2018_2073	aml_ohsu_2018_15-00287		None	AML with mutated CEBPA	Intermediate	Favorable	AML with mutated CEBPA	Post-Chemotherapy|Residual Disease	Peripheral Blood	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	1	Standard Chemotherapy	1	Azacitidine	1	Hypomethylating/Low Dose Cytarabine				Standard Chemotherapy	Azacitidine	Hypomethylating/Low Dose Cytarabine	105	2	0			No	2.5	0	14.6	2.4	0	0.5	14	15	3.5	0.98		33.2	10.7	46,XY[20]	289	89.5	Normal	8		7.4	25.63	Negative	Negative	p.K313_V314insK; MAF 50%		Negative	Negative				Negative	Negative	Negative	Negative	85	Unmatched	AMLCEBPA	Leukemia	AML with Biallelic Mutations of CEBPA	0.0333333333333
aml_ohsu_2018_2010	aml_ohsu_2018_15-00294	After or at the time transformation from another heme malignancy	None	Acute myeloid leukaemia, NOS	Intermediate	Not Enough Information	Acute myeloid leukaemia, NOS	Post-Chemotherapy|Residual Disease	Bone Marrow Aspirate	WES	No	Yes	No	No	Yes	No	2	Standard Chemotherapy | Targeted Therapy - Other	3	AG-221|Azacitidine|Clofarabine	3	Hypomethylating/Low Dose Cytarabine | Unknown | Experimental				Targeted Therapy - Other	AG-221	Experimental	-1	-34		60		No														46,XY,r(7)(p1?3q2?2)[12]/46,XY[5]			loss of 7q31 sequences in 85% of assayed cells					Negative	Negative												68	Matched	AMLNOS	Leukemia	AML, NOS	1.03333333333
aml_ohsu_2018_2079	aml_ohsu_2018_15-00296	Denovo	MLLT3-KMT2A	AML with t(9;11)(p22;q23); MLLT3-MLL	Adverse	Adverse	AML with t(9;11)(p22;q23); MLLT3-MLL	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	1	Standard Chemotherapy	1	COG-AAML1031 (IT/IV Cytarabine, Daunorubicin, Etoposide, Mitoxantrone +/- Bortezomib or Sorafenib)	1	Induction	Complete Response	Standard Chemotherapy	10	Standard Chemotherapy	COG-AAML1031 (IT/IV Cytarabine, Daunorubicin, Etoposide, Mitoxantrone +/- Bortezomib or Sorafenib)	Induction	10	0	0	93	0	No	0	0	33	67	0	0				0.72	M5	18.2	6.1	46,XX,t(9;11)(p22;q23)[3]/50,sl,+6,+8,+der(9)t(9;11),+19[14]/51,sdl1,+5[3]	934	100	MLL:   14% of cells had a 1 red / 1 green / 1 fused split pattern consistent with the t(9;11) seen on metaphase analysis.  An addition 65% of cells had two red / 1 green / 1 fused signal pattern, consistent with the clone with the +der(9).	39	CD11b, dim CD13, dim CD15, CD33, CD38, dim CD45, CD56,      CD58, bright CD64, dim CD117, CD123, HLA-DR, and variable MPO positive		24.72	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	p.G13D; MAF 6%	p.Q61H; MAF 19%	Negative	16	Unmatched	AMLRGA	Leukemia	AML with Recurrent Genetic Abnormalities	0.0666666666667
aml_ohsu_2018_2067	aml_ohsu_2018_15-00300	Denovo	None	AML with myelodysplasia-related changes	Adverse	Adverse	AML with myelodysplasia-related changes	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	0		0		0					NONE	NONE	NONE		0		20		No														41~42,XY,del(3)(p13p21),add(4)(q21),add(5)(q11.2),-7,-10,add(12)(p11.2),-15,add(15)(q21),add(17)(p11.2),-19,-20,-22,+2mar[cp6]/42~43,sl,+21[cp5]/42,sl,i(21)(q10)[cp2]/43~44,sl,+add(7)(p11)[cp2]/43~46,sl,+add(7)(p11),+21[cp4]/81~87<4n>,slx2[cp2]			Loss of chromosome 5q31 sequences (73.5%)                Loss of chromosome 7 sequences (monosomy 7) (61.5%)                Gain of 21q22 (AML1) sequences (11.5%)                Polysomy for 8, 20q (7.5%), 11q, 15q, 16q and 17q sequences	91			5.6	Negative	Negative	Negative		p.F543C; MAF 35.7%	Negative	Negative	Negative	Negative	Negative			Negative	76	Matched	AMLMRC	Leukemia	AML with Myelodysplasia-Related Changes	1.7
aml_ohsu_2018_2068	aml_ohsu_2018_15-00302	Denovo	Unknown	AML with mutated NPM1	Favorable	Not Enough Information	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Peripheral Blood	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	1	Standard Chemotherapy	1	7+3 (Cytarabine, Idarubicin)	1	Induction	UNKNOWN	Standard Chemotherapy	-1	Standard Chemotherapy	7+3 (Cytarabine, Idarubicin)	Induction	-1	0				No																			Large population of atypical myeloblasts (CD56 positive,  weak CD117 positive, CD34 negative, HLA-DR negative),  representing approximately 87% of the leukocytes,  consistent with acute myeloid leukemia			Negative	Positive	Negative		Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	65	Unmatched	AMLNPM1	Leukemia	AML with Mutated NPM1	0.133333333333
aml_ohsu_2018_2069	aml_ohsu_2018_15-00303	Denovo	CBFB-MYH11	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	Favorable	Favorable	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	Initial Acute Leukemia Diagnosis	Peripheral Blood	WES + RNA-seq	Yes	Yes	No	Yes	Yes	No	1	Standard Chemotherapy	2	7+3 (Cytarabine, Idarubicin)|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)	2	Induction | Re-induction	Refractory	Standard Chemotherapy	6	Standard Chemotherapy	FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)	Re-induction	5	-8	0			No	0	0.9	48.7	30.1	5.3	0	10	7	2.6	1.33		23.2	7.7	46,XY,inv(16)(p13q22)[17]/46,XY[3]		87.2	c/w karyotype	53		5.9	8.69	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	p.G12D; MAF 27%	Negative	Negative	64	Unmatched	AMLCBFBMYH11	Leukemia	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22);CBFB-MYH11	0.1
aml_ohsu_2018_2075	aml_ohsu_2018_15-00309		None	AML with mutated NPM1	Intermediate	Intermediate-I	AML with mutated NPM1	Residual Disease|Post-Chemotherapy|Post-Transplant	Peripheral Blood	WES	Yes	Yes	Yes	No	Yes	Yes	3	Standard Chemotherapy | Bone Marrow Transplant | Targeted Therapy - Kinase Inhibitor(s)	5	Busulfan, Fludarabine|7+3 (Cytarabine, Idarubicin)|HiDAC|Azacitidine|Sorafenib	5	Allogeneic - Sibling | Hypomethylating/Low Dose Cytarabine | Consolidation | Induction | Experimental	Complete Response	Standard Chemotherapy	-1	Targeted Therapy - Kinase Inhibitor(s)	Sorafenib	Experimental	-1	-11				No														46,XY[6]							25.7	Positive	Positive												64	Unmatched	AMLNPM1	Leukemia	AML with Mutated NPM1	0.133333333333
aml_ohsu_2018_1967	aml_ohsu_2018_15-00312	After or at the time transformation from another heme malignancy	None	Therapy-related myeloid neoplasms	Adverse	Not Enough Information	Therapy-related myeloid neoplasms	Post-Chemotherapy	Bone Marrow Aspirate	WES + RNA-seq	Yes	Yes	No	Yes	Yes	No	2	Standard Chemotherapy | Targeted Therapy - Other	3	7+3 (Cytarabine, Idarubicin)|Azacitidine, Lenalidomide|Rituximab	2	Induction | Experimental	Unknown	Standard Chemotherapy	-1	Targeted Therapy - Other	Rituximab	Experimental	-1	-54				No														46,XY[18]			Normal					Positive	Negative												70	Matched	TMN	Leukemia	Therapy-Related Myeloid Neoplasms	0.633333333333
aml_ohsu_2018_2084	aml_ohsu_2018_15-00320	Denovo	None	AML with mutated NPM1	Favorable or Intermediate	Intermediate-I	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	WES + RNA-seq	Yes	Yes	No	Yes	Yes	No	1	Standard Chemotherapy	1	7+3 (Cytarabine, Idarubicin) plus Crenolanib	1	Induction	Complete Response i	Standard Chemotherapy	-1	Standard Chemotherapy	7+3 (Cytarabine, Idarubicin) plus Crenolanib	Induction	-1	0		55	47	No														46,XX[20]			Normal		It reveals 0.23% CD34 (+) myeloid blasts with the following immunophenotype: CD2(-), CD7(-), CD13(+), CD15(-/few +), CD33 (bright +), CD36(few +), CD38(partial +), CD45(+), CD64(-), CD117(+), HLA-DR(-), MPO (partial +).		26.5	Positive	Positive			F290fs*24; MAF 40%									57	Matched	AMLNPM1	Leukemia	AML with Mutated NPM1	0.666666666667
aml_ohsu_2018_2091	aml_ohsu_2018_15-00331	Denovo	CBFB-MYH11	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	Favorable	Favorable	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	WES + RNA-seq	Yes	Yes	No	Yes	Yes	No	2	Standard Chemotherapy | Bone Marrow Transplant	3	HiDAC|7+3 (Cytarabine, Idarubicin) plus Sorafenib|Fludarabine, Cyclophosphamide, Thiotepa, TBI	3	Consolidation | Induction | Double Umbilical Cord Blood Transplant (DUCBT)	Complete Response	Standard Chemotherapy	-1	Bone Marrow Transplant	Fludarabine, Cyclophosphamide, Thiotepa, TBI	Double Umbilical Cord Blood Transplant (DUCBT)	-1	0		33	23	No														46,XY,inv(16)(p13.1q22)[18]/47,sl,+22[2]			FISH positive for CBFB rearrangement in 49% of cells	42	Flow cytometry shows the large majority of analyzed cells fall within the monocyte gate, which are predominantly mature as evidenced by coexpression of CD14 and CD64. A smaller subset of cells within the monocyte gate consists of immature monocytes with decreased expression of CD14 and/or CD64.		29	Negative	Negative	Negative			Negative	Negative	Negative	Negative	Negative		p.Q61K; MAF 24.1%		60	Matched	AMLCBFBMYH11	Leukemia	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22);CBFB-MYH11	0.833333333333
aml_ohsu_2018_2094	aml_ohsu_2018_15-00338	Denovo	PML-RARA	Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA	Favorable	Intermediate-II	Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	3	Standard Chemotherapy | Targeted Therapy - Other | Intrathecal	3	ATRA, Arsenic Trioxide|ATRA, 6-MP, Methotrexate|Methotrexate	3	Induction | Experimental | Maintenance	Unknown	Intrathecal	22	Standard Chemotherapy	ATRA, 6-MP, Methotrexate	Maintenance	-1	0	0	92	83	No	0		11	4	0		35	35	3.9	0.66		22.2	7.6	46,XX,t(15;17)(q24;q21.1)[1]	475	88.4	nuc ish(RUNX1T1,RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML, RARA)x3(PML con RARAx2)[154/200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	35	CD2(-), CD4(partial +), CD11b(few dim +), CD13(+), CD14(-), CD15(-), CD16 (-), CD25(-), CD33(bright +), CD34(-), CD36(-), CD38(variably +), CD45(variably +), CD56(-), CD64(+), CD117(variably +), CD123(+), HLA-DR(-), myeloperoxidase(+), and TdT(-).	5.8		Negative	Negative					Negative	Negative						42	Matched	APLPMLRARA	Leukemia	APL with PML-RARA	0.4
aml_ohsu_2018_2102	aml_ohsu_2018_15-00351		None	Acute myeloid leukaemia, NOS	Adverse	Adverse	Acute myeloid leukaemia, NOS	Residual Relapse|Post-Chemotherapy|Post-DLI|Post-Transplant	Bone Marrow Aspirate	WES + RNA-seq	Yes	Yes	No	Yes	Yes	No	3	DLI | Standard Chemotherapy | Bone Marrow Transplant	7	7+3 (Cytarabine, Idarubicin)|HiDAC|Donor Lymphocyte Infusion|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone)|Cytarabine, Mitoxantrone|Busulfan, Cyclophosphamide	5	Allogeneic - Sibling | Consolidation | Unknown | Induction | Re-induction	Refractory	Standard Chemotherapy	6	Standard Chemotherapy	MEC (Cytarabine, Etoposide, Mitoxantrone)	Re-induction	5	0	0	62	5	No	0	0	83.2	1.8	0	0	28	21	2.5	0.8		24.1	8.3	46,XX,t(1;11)(q44;q13),del(6)(p23)[9]/46,idem,t(17;20)(q25;q11.2)[11]	290	94.5	All probe results were within normal laboratory limits.      *Note: while it was not disrupted, MLL (11q23) was observed on the end of      the derivative chromosome 1 on available metaphase cells, reflecting the      t(1;11).	53	dim CD2, CD13, CD33, CD34, CD38, CD117, dim CD123, dim      HLA-DR, and TdT positive	6.5	1.46	Negative	Negative			p.R882H; MAF 15%									56	Matched	AMLNOS	Leukemia	AML, NOS	1.9
aml_ohsu_2018_2104	aml_ohsu_2018_15-00353	After or at the time transformation from another heme malignancy	None	Acute megakaryoblastic leukaemia	Intermediate	Intermediate-II	Acute megakaryoblastic leukaemia	Initial Acute Leukemia Diagnosis	Peripheral Blood	WES + RNA-seq	Yes	Yes	No	Yes	Yes	No	1	Standard Chemotherapy	1	Azacitidine	1	Hypomethylating/Low Dose Cytarabine				Standard Chemotherapy	Azacitidine	Hypomethylating/Low Dose Cytarabine	-1	-6		13		No														46,XY,del(13)(q12q14)[3]/46,XY[17]			Normal	136	CD3  - Scattered cells positive, 5-10% of marrow cells CD20  - Scattered cells positive, 5-10% of marrow cells CD34  - Rare cells positive, <1% of marrow cells CD30  - Negative CD43  - Positive in >60% of marrow cells, including the clusters of immature cells		3.1	Negative	Negative	Negative			Negative	Negative	Negative		Negative				60	Matched	AMKL	Leukemia	Acute Megakaryoblastic Leukemia	0.8
aml_ohsu_2018_2106	aml_ohsu_2018_15-00357		None	Acute myeloid leukaemia, NOS	Intermediate	Not Enough Information	Acute myeloid leukaemia, NOS	Post-Transplant|Post-Chemotherapy|Residual Relapse	Peripheral Blood	WES	No	Yes	No	No	Yes	No	4	DLI | Standard Chemotherapy | Bone Marrow Transplant | Targeted Therapy - Other	6	AG-221|Donor Lymphocyte Infusion|GCLAC (GCSF, Clofarabine & Cytarabine)|Azacitidine|7+3 (Cytarabine, Idarubicin) plus Sorafenib|Busulfan, Cyclophosphamide	6	Hypomethylating/Low Dose Cytarabine | Unknown | Induction | Experimental | Re-induction | Allogeneic - Matched Unrelated Donor	Refractory	Standard Chemotherapy	-1	Targeted Therapy - Other	AG-221	Experimental	-1	1		30	0	No														46,XY[20]					positive for CD13, CD33, CD34, CD38, dim CD45, CD117, HLA-DR and MPO		0.7	Negative	Negative	Negative			Negative	Negative		Negative	Negative				53	Unmatched	AMLNOS	Leukemia	AML, NOS	0.1
aml_ohsu_2018_2106	aml_ohsu_2018_15-00358		None	Acute myeloid leukaemia, NOS	Intermediate	Intermediate-I	Acute myeloid leukaemia, NOS	Residual Relapse|Post-Transplant|Post-Chemotherapy	Bone Marrow Aspirate	WES	No	Yes	No	No	Yes	No	4	DLI | Standard Chemotherapy | Bone Marrow Transplant | Targeted Therapy - Other	6	AG-221|Donor Lymphocyte Infusion|GCLAC (GCSF, Clofarabine & Cytarabine)|Azacitidine|7+3 (Cytarabine, Idarubicin) plus Sorafenib|Busulfan, Cyclophosphamide	6	Hypomethylating/Low Dose Cytarabine | Unknown | Induction | Experimental | Re-induction | Allogeneic - Matched Unrelated Donor	Refractory	Standard Chemotherapy	-1	Targeted Therapy - Other	AG-221	Experimental	-1	1		30	0	No														46,XY[20]					positive for CD13, CD33, CD34, CD38, dim CD45, CD117, HLA-DR and MPO		0.7	Negative	Negative	Negative			Negative	Negative		Negative	Negative				53	Unmatched	AMLNOS	Leukemia	AML, NOS	0.133333333333
aml_ohsu_2018_2108	aml_ohsu_2018_15-00361	Denovo	None	AML with myelodysplasia-related changes	Adverse	Adverse	AML with myelodysplasia-related changes	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	WES	No	Yes	No	No	Yes	No	1	Supportive/Palliative Care	1	Vincristine, Dexamethasone	1	Supportive/Palliative Care				Supportive/Palliative Care	Vincristine, Dexamethasone	Supportive/Palliative Care	13	0	0	86	12.9	No	0.9		71.6	1.7	8.6		10	24	2.9	0.62		17.9	6.1	45~54,XX,+2,del(5)(q22q35),+6,+6,+8,-11,add(13)(p11.2),+19,+22,+r,1~48dmin[cp19]/69~70,idem,+1,+3,+4,+del(5),+8,+8,+10,+10,+11,+13,+14,+14,+15,+15,+17,+18,+19[cp3]/46,XX[1].ishadd(13)(5'MLLamp,3'MLLamp)[2]	599	93.7	(D5S2064x3~4,D5S630x3~4, EGR1x2)[7/200],(D7Z1,D7S522)x2[200],(D8Z2x3~5,D20S108x2)[115/200],(RUNX1T1x3~5,RUNX1x2)[109/200], (ABL1x2,BCRx3)[110/200],(5'MLL,3'MLL)x1(5'MLL con 3'MLLx1,5'MLL amp,3'MLL amp)[110/200],(ETV6,RUNX1)x2 [199],(PMLx4,RARAx3)[95/200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[198]	5	CD7(-), CD10(-), CD11b(partial dim +), CD13(variably +), CD15(+), CD19(+), CD20(-), CD22(partial +), CD25(few +), CD33(-), CD34(+), CD36 (-), CD38(variably +), CD45(dim+/variably +), CD56(-), CD64(appears partially dim +), CD117(partial +), CD123(dim +), CD79a(partial +),	4.8	2.1	Negative	Negative				Negative	Negative	Negative						77	Matched	AMLMRC	Leukemia	AML with Myelodysplasia-Related Changes	0.866666666667
aml_ohsu_2018_2113	aml_ohsu_2018_15-00371		None	AML with mutated CEBPA	Intermediate	Favorable	AML with mutated CEBPA	Post-Chemotherapy|Residual Disease	Bone Marrow Aspirate	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	1	Standard Chemotherapy	3	7+3 (Cytarabine, Idarubicin)|HiDAC|Decitabine	3	Hypomethylating/Low Dose Cytarabine | Consolidation | Induction	Refractory	Standard Chemotherapy	-1	Standard Chemotherapy	HiDAC	Consolidation	48	0	0	32	5	No	0		69	8	18		23	22	4.3	1.21		32.9	11.1	46,XY[18]	199		nuc ish(D5S2064,D5S630,EGR1)x2[200],(D7Z1,D7S522)x2[198],(D8Z2,D20S108)x2[200],(RUNX1T1, RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	178	CD2(-), CD4(partial dim +), CD7(partial +), CD11b(partial dim +), CD13(+), CD14(-), CD15(-), CD16(-), CD19(-), CD22 (-), CD25(-), CD33(variably +), CD34(bright +), CD36(-), CD38(bright +), CD45(moderate/dim +), CD56(-), CD64(-), CD79a (-), CD117(+), CD123(-), HLA-DR(+), MPO(+), TdT(partial +)	7.1	2.3	Negative	Negative					Negative	Negative						75	Matched	AMLCEBPA	Leukemia	AML with Biallelic Mutations of CEBPA	1.1
aml_ohsu_2018_2116	aml_ohsu_2018_15-00377	Denovo	None	AML with mutated CEBPA	Intermediate	Favorable	AML with mutated CEBPA	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	1	Standard Chemotherapy	3	COG-AAML1031 (IT/IV Cytarabine, Daunorubicin, Etoposide, Mitoxantrone +/- Bortezomib or Sorafenib)|ADE (Cytarabine, Daunorubicin & Etoposide)|FLAG (Fludarabine, High-dose Cytarabine, G-CSF)	2	Induction | Re-induction	Complete Response	Standard Chemotherapy	33	Standard Chemotherapy	FLAG (Fludarabine, High-dose Cytarabine, G-CSF)	Re-induction	-1	0	0	80	75	No	1.7	6.1	17.4	7.8	11.3	0.7	24	22	3.7	0.51		30.3	9.1	46,XX[20]	688	83.7	Normal	74	variable CD7, variable CD13, CD33, partial CD34, bright CD38, partial CD56, CD58, variable CD71, CD117, CD123, HLA-DR, and MPO positive	7.3	39.69	Negative	Negative	p.G96fs*12; MAF ~50%		Negative	Negative	Negative	Negative	Negative	Negative	Negative	p.G12D; MAF 5%	Negative	10	Unmatched	AMLCEBPA	Leukemia	AML with Biallelic Mutations of CEBPA	0.133333333333
aml_ohsu_2018_2127	aml_ohsu_2018_15-00383	After or at the time transformation from another heme malignancy	None	AML with mutated NPM1	Intermediate	Intermediate-I	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	1	Supportive/Palliative Care	2	Ruxolitinib|Hydroxyurea	1	Supportive/Palliative Care				Supportive/Palliative Care	Hydroxyurea	Supportive/Palliative Care	103	0	1	9	15.4	No	2.9		20.2	16.3	42.3					0.6		22.7	7	46,XY[20]	1086		nuc ish(RUNX1T1,RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[199], (5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	126	CD34(+), CD7(partial +), CD13(+), CD33(+), CD38(partial +), CD45(moderately +), CD56 (+), CD117(+), HLA-DR(variably +), other myeloid and lymphoid antigens(-).		73.4	Positive	Positive				Negative	Negative	Negative			Foundation; A59T mutation; MAF 47%			63	Matched	AMLNPM1	Leukemia	AML with Mutated NPM1	0.4
aml_ohsu_2018_2129	aml_ohsu_2018_15-00392		None	Acute myeloid leukaemia, NOS	Adverse	Intermediate-II	Acute myeloid leukaemia, NOS	Post-Chemotherapy|Post-Transplant|Residual Relapse	Bone Marrow Aspirate	WES	No	Yes	No	No	Yes	No	3	Standard Chemotherapy | Bone Marrow Transplant | Targeted Therapy - Other	5	Busulfan, Fludarabine|7+3 (Cytarabine, Idarubicin)|HiDAC|AG-221|Azacitidine	5	Hypomethylating/Low Dose Cytarabine | Consolidation | Induction | Experimental | Allogeneic - Matched Unrelated Donor	Complete Response	Standard Chemotherapy	-1	Targeted Therapy - Other	AG-221	Experimental	-1	1		10	9.5	No														48,XY,+8,+8[14]/46,XY[6]			Gain of chromosome 8 centromere, trisomy 3.5%, and terasomy 19.0%		positive for CD13, HLA-DR, CD34, and CD117, with aberrant expression of CD7 and aberrant loss of CD33, and with a subset of these blasts showing aberrant co-expression of CD34 and myeloperoxidase.		1.6	Negative	Negative	Negative		Negative	Negative	Negative		Negative	Negative			Negative	58	Unmatched	AMLNOS	Leukemia	AML, NOS	0.266666666667
aml_ohsu_2018_2119	aml_ohsu_2018_15-00395	Denovo	None	AML with myelodysplasia-related changes	Adverse	Intermediate-II	AML with myelodysplasia-related changes	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	WES + RNA-seq	Yes	Yes	No	Yes	Yes	No	1	Standard Chemotherapy	3	CPX-351 (Liposomal Cytarabine + Daunorubicin)|Decitabine|Incyte trial (azacitidine and JAK 1 inhibitor)	2	Consolidation | Induction	Complete Response	Standard Chemotherapy	35	Standard Chemotherapy	Incyte trial (azacitidine and JAK 1 inhibitor)	Induction	77	0	0	50	5	No	2	0.2	52.2	37.1	8.5	0	18	16	3.7	1.45	M0	22.3	7.6	47,XY,+8[3]/46,XY[17]		118.6	5% trisomy 8 (c/w karyotype)	104	#1 Immunophenotype: CD13, CD34, CD38, dim CD45, CD58, CD117, HLA-DR and TdT positive	7.7	4.48	Negative	Negative	Negative		Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	76	Matched	AMLMRC	Leukemia	AML with Myelodysplasia-Related Changes	0.633333333333
aml_ohsu_2018_2120	aml_ohsu_2018_15-00396	Relapse	None	Acute megakaryoblastic leukaemia	Adverse	Adverse	Acute megakaryoblastic leukaemia	Relapse|Post-Transplant|Post-Chemotherapy	Bone Marrow Aspirate	WES	No	Yes	Yes	No	Yes	Yes	2	Standard Chemotherapy | Bone Marrow Transplant	5	FLAG (Fludarabine, High-dose Cytarabine, G-CSF)|Busulfan, Cyclophosphamide, Thymoglobulin|Etoposide|COG-AAML0531 (Cytarabine, Daunorubicin, Etoposide, L-Asparaginase, Mitoxantrone +/- Gemtuzumab)|Doxorubicin	4	Induction | Allogeneic - Mismatched Unrelated Donor | Re-induction | Maintenance	Complete Response	Standard Chemotherapy	-1	Standard Chemotherapy	Etoposide	Maintenance	-1	0	0	35	7	No	0	0	16.1	9.8	68.7	0				0.21		29.6	9.3	48,XX,+14,der(14)t(14;17)(q32;q21),+21[10]/46,XY[10]		86.5	37% trisomy 21, 38.5% XX, 61.5% XY (donor)	247	partial CD7, dim/partial CD33, CD34, CD38, CD56, CD58,  and CD117 positive		3.87	Negative	Negative												3	Unmatched	AMKL	Leukemia	Acute Megakaryoblastic Leukemia	0.1
aml_ohsu_2018_2130	aml_ohsu_2018_15-00406		None	Refractory cytopenia with multilineage dysplasia	Adverse		Refractory cytopenia with multilineage dysplasia	Post-Chemotherapy	Peripheral Blood	WES + RNA-seq	Yes	No	No	No	No	No	1	Unknown	1	R-CVP (Rituximab, Cyclophosphamide, Vincristine, Prednisolone)	1	Unknown				Unknown	R-CVP (Rituximab, Cyclophosphamide, Vincristine, Prednisolone)	Unknown	-1	0		2		No														46,XX,del(9)(q21q31-33)[10]/46,XX[10]			positive for a low level of findings consistent with trisomy 8, seen in 1.7% of cells.				2.8	Negative	Negative	p.E10K; MAF 26.7%			Negative	Negative	Negative	Negative	Negative				59	Unmatched	MDSMD	Myelodysplastic Syndromes	MDS with Multilineage Dysplasia	NA
aml_ohsu_2018_2130	aml_ohsu_2018_15-00407		None	Refractory cytopenia with multilineage dysplasia	Adverse		Refractory cytopenia with multilineage dysplasia	Post-Chemotherapy	Bone Marrow Aspirate	WES	No	Yes	No	No	Yes	No	1	Unknown	1	R-CVP (Rituximab, Cyclophosphamide, Vincristine, Prednisolone)	1	Unknown				Unknown	R-CVP (Rituximab, Cyclophosphamide, Vincristine, Prednisolone)	Unknown	-1	0		2		No														46,XX,del(9)(q21q31-33)[10]/46,XX[10]			positive for a low level of findings consistent with trisomy 8, seen in 1.7% of cells.				2.8	Negative	Negative	p.E10K; MAF 26.7%			Negative	Negative	Negative	Negative	Negative				59	Unmatched	MDSMD	Myelodysplastic Syndromes	MDS with Multilineage Dysplasia	0.166666666667
aml_ohsu_2018_2133	aml_ohsu_2018_15-00416		None	Acute myeloid leukaemia, NOS	Adverse	Intermediate-II	Acute myeloid leukaemia, NOS	Residual Disease|Post-Chemotherapy	Bone Marrow Aspirate	WES	No	Yes	No	No	Yes	No	1	Standard Chemotherapy	2	7+3 (Cytarabine, Idarubicin)|Clofarabine, Cytarabine	2	Induction | Re-induction	Refractory	Standard Chemotherapy	-1	Standard Chemotherapy	Clofarabine, Cytarabine	Re-induction	-1	1		80		No														45,XX,-17[15]/46,XX[2]			90.5% monosomy 17, 6% trisomy 11q23	21	positive for CD13, CD33, CD34, CD38, CD45, CD117, HLA-DR and MPO		0.1	Negative	Negative	Negative		p.V468M; MAF 51.2%	Negative	Negative		Negative	Negative			p.R43H; MAF 76.7%	33	Matched	AMLNOS	Leukemia	AML, NOS	0.733333333333
aml_ohsu_2018_2135	aml_ohsu_2018_15-00417	After or at the time transformation from another heme malignancy	None	AML with myelodysplasia-related changes	Adverse	Intermediate-II	AML with myelodysplasia-related changes	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	0		0		0					NONE	NONE	NONE		0	0	62	19	No	1		18	35	25		24	90	1.8	0.73		22.4	7.2	47,XY,+21[19]/46,XY[1]			nuc ish(RUNX1T1x2,RUNX1x3)[140/200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML, RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	18	CD2(-), CD7(dim + to -), CD11b(-), CD13(+), CD14(-), CD15 (partial +), CD33(bright +), CD34(partial +), CD36(-), CD38(variably +), CD45(+), CD56(-), CD64(partial +), CD117(+), HLA-DR(variably +)	7.1	8	Positive	Negative												44	Matched	AMLMRC	Leukemia	AML with Myelodysplasia-Related Changes	0.466666666667
aml_ohsu_2018_2147	aml_ohsu_2018_15-00464	Denovo	None	Acute myeloid leukaemia, NOS	Adverse	Intermediate-II	Acute myeloid leukaemia, NOS	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	1	Supportive/Palliative Care	1	Azacitidine	1	Hypomethylating/Low Dose Cytarabine				Supportive/Palliative Care	Azacitidine	Hypomethylating/Low Dose Cytarabine	-1	-3	0.9			No	2.8						28	27	4.2	1.18		29.3	9.8	46,XY,inv(4)(p14p16.1)[3]/46,XY[16]	194		nuc ish(D5S2064,D5S630,EGR1)x4[32/200],(D7Z1,D7S522)x4[17/200],(D8Z2, D20S108)x4[27/200],(RUNX1T1,RUNX1)x4[32/200],(5'MLL,3'MLL)x4(5'MLL con 3'MLLx4)[21/200],(PML,RARA)x4 [34/200],(5'CBFB,3'CBFB)x4(5'CBFB con 3'CBFBx4)[35/200]	73		7.1		Negative	Negative				Negative	Negative	Negative						71	Matched	AMLNOS	Leukemia	AML, NOS	1.83333333333
aml_ohsu_2018_2144	aml_ohsu_2018_15-00470	Denovo	PML-RARA	Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA	Favorable	Intermediate-II	Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	2	Standard Chemotherapy | Targeted Therapy - Other	1	ATRA, Arsenic Trioxide	2	Consolidation | Experimental				Standard Chemotherapy	ATRA, Arsenic Trioxide	Consolidation	232	-2	0			No	0	19.6	56.3	0.9	3.6	0.1	31	20	3	0.84		19.1	6.3	46,XY,t(15;17)(q22;q21)[20]		96.5	70% PML/RARA	49		6.9	7.19	Positive	Negative	Negative		Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	32	Unmatched	APLPMLRARA	Leukemia	APL with PML-RARA	0.0333333333333
aml_ohsu_2018_2142	aml_ohsu_2018_15-00471	Denovo	Unknown	AML with mutated CEBPA	Favorable	Not Enough Information	AML with mutated CEBPA	Initial Acute Leukemia Diagnosis	Peripheral Blood	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	1	Standard Chemotherapy	1	Azacitidine	1	Hypomethylating/Low Dose Cytarabine				Standard Chemotherapy	Azacitidine	Hypomethylating/Low Dose Cytarabine	-1	0		60		Yes																			weak  CD7, CD13, partial CD15, weak CD33, CD34, weak CD64, CD117,  myeloperoxidase, and HLA-DR, but do not express CD14(MO2),  CD42b, or CD61.		33	Negative	Negative	c.117delC; MAF 27.2%											69	Matched	AMLCEBPA	Leukemia	AML with Biallelic Mutations of CEBPA	1.06666666667
aml_ohsu_2018_2167	aml_ohsu_2018_15-00479	Denovo	None	AML with myelodysplasia-related changes	Adverse	Not Enough Information	AML with myelodysplasia-related changes	Initial Acute Leukemia Diagnosis	Peripheral Blood	WES + RNA-seq	Yes	Yes	No	Yes	Yes	No	3	Standard Chemotherapy | Bone Marrow Transplant | Targeted Therapy - Other	4	7+3 (Cytarabine, Idarubicin)|Azacitidine|Fludarabine, Cyclophosphamide, TBI |Venetoclax (ABT-199)	4	Hypomethylating/Low Dose Cytarabine | Experimental | Re-induction | Double Umbilical Cord Blood Transplant (DUCBT)				Bone Marrow Transplant	Fludarabine, Cyclophosphamide, TBI	Double Umbilical Cord Blood Transplant (DUCBT)	-1	-1		95	62	No														48,XY,+8,der(11)t(11;?)(q23;?),+21[19]/46,XY[1]			Gain of 8q22 and 21q22 (88%)	33	positive for CD11b, CD13, CD33, CD38, dim CD45, dim CD56, CD64, and HLA-DR		19.8	Negative	Negative	Negative			Negative	Negative	Negative	Negative	Negative				65	Matched	AMLMRC	Leukemia	AML with Myelodysplasia-Related Changes	0.1
aml_ohsu_2018_1532	aml_ohsu_2018_15-00482	Relapse	None	AML with mutated NPM1	Favorable	Favorable	AML with mutated NPM1	Relapse	Bone Marrow Aspirate	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	1	Standard Chemotherapy	4	7+3 (Cytarabine, Idarubicin)|Azacitidine|MEC (Cytarabine, Etoposide, Mitoxantrone)|MiDAC	3	Consolidation | Induction | Re-induction	Complete Response	Standard Chemotherapy	7	Standard Chemotherapy	Azacitidine	Consolidation	339	0	0	70	64.6	No	3.5	0.9	17.7	0	13.3	0	184	77	2.8	0.72		37	12.6	46,XX[20]		94.4	Normal	138	CD13, CD33, partial CD34, partial CD38, dim partial  CD64, CD117 and CD123 positive	5.7	16.95	Negative	Positive	Negative		p.R882C; MAF 39%		Negative	Negative	Negative	Negative	Negative	Negative	Negative	47	Matched	AMLNPM1	Leukemia	AML with Mutated NPM1	0.9
aml_ohsu_2018_2172	aml_ohsu_2018_15-00491		Unknown	Therapy-related myeloid neoplasms	Intermediate	Not Enough Information	Therapy-related myeloid neoplasms	Initial Acute Leukemia Diagnosis	Peripheral Blood	WES + RNA-seq	Yes	Yes	No	Yes	Yes	No	0		0		0					NONE	NONE	NONE		0				No																						Negative	Negative												83	Unmatched	TMN	Leukemia	Therapy-Related Myeloid Neoplasms	0.133333333333
aml_ohsu_2018_2140	aml_ohsu_2018_15-00492	Denovo	None	AML with minimal differentiation	Adverse	Adverse	AML with minimal differentiation	Initial Acute Leukemia Diagnosis	Peripheral Blood	WES	No	Yes	No	No	Yes	No	2	Standard Chemotherapy | Bone Marrow Transplant	4	Bellicum Trial (Flu/Cy/TBI + ATG + Rituximab then BPX-501)|7+3 (Cytarabine, Idarubicin)|HiDAC|MEC (Cytarabine, Etoposide, Mitoxantrone)	4	Consolidation | Induction | Allogeneic - Mismatched Unrelated Donor | Re-induction	Refractory	Standard Chemotherapy	6	Bone Marrow Transplant	Bellicum Trial (Flu/Cy/TBI + ATG + Rituximab then BPX-501)	Allogeneic - Mismatched Unrelated Donor	30	-15	0		27.8	No	0	0	72.2	0	0	0	42	17	2.7	0.59		22.4	7.6	46,XY,t(6;11)(q27;q23),del(12)(p11.2p13)[13]/46,XY[7]		88.5	MLL Rearrangement (53%), 6;11 translocations, ETV6 (44%), deleted chomosome 12 short arm	193		6	1.23	Negative	Negative	Negative		Negative	Negative	Negative	Negative	Negative	Negative		p.G12D; MAF 15%	Negative	29	Matched	AMLMD	Leukemia	AML with Minimal Differentiation	1.1
aml_ohsu_2018_2188	aml_ohsu_2018_15-00514		None	Therapy-related myeloid neoplasms	Adverse	Adverse	Therapy-related myeloid neoplasms	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	WES	No	Yes	No	No	Yes	No	2	Standard Chemotherapy | Targeted Therapy - Other	2	Azacitidine|Venetoclax (ABT-199)	2	Hypomethylating/Low Dose Cytarabine | Experimental				Targeted Therapy - Other	Venetoclax (ABT-199)	Experimental	-1	1		50	11	No														46,XX,-7,+8[7]/47,sl,+8[6]/46,XX[6]			44% loss chromosome 7, 28% trisomy 8, 28% tetrasomy 8,	104	positive for CD34, CD38, dim CD45, CD117, HLA-DR and MPO		1	Negative	Negative	Negative			Negative	p.R132C; MAF 16.3%	Negative	Negative	Negative				81	Matched	TMN	Leukemia	Therapy-Related Myeloid Neoplasms	1.66666666667
aml_ohsu_2018_2192	aml_ohsu_2018_15-00525	Denovo	PML-RARA	Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA	Favorable	Intermediate-II	Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	WES + RNA-seq	Yes	Yes	No	Yes	Yes	No	2	Standard Chemotherapy | Targeted Therapy - Other	2	ATRA, Arsenic Trioxide|APML4 Protocol (ATRA, Arsenic Trioxide, Idarubicin)	2	Induction | Experimental	Complete Response	Standard Chemotherapy	27	Targeted Therapy - Other	ATRA, Arsenic Trioxide	Experimental	-1	2	0	90	69.14	No	0	28.8	1.8	1.8	0.9	0.4	37	27	3.9	0.76	M3	26.3	8.2	46,XX,der(15)t(15;17)(q22;q21),der(17)t(15;17)del(17)(q21)[15]/46,XX[1]	605	89.2	95% of cells had a variant abnormal signal pattern with PML/RARA fusion.  PML (15q22) (SO) / RARA (17q21) (SG) t(15;17)	25	Immunophenotype: CD13, CD33, partial CD34, CD64, CD117, CD123 and MPO positive	7.5	103.66	Positive	Negative	Negative		Negative		Negative	Negative	Negative	Negative	Negative	Negative	Negative	36	Matched	APLPMLRARA	Leukemia	APL with PML-RARA	0.5
aml_ohsu_2018_2195	aml_ohsu_2018_15-00534	After or at the time transformation from another heme malignancy	None	AML with mutated CEBPA	Adverse	Intermediate-II	AML with mutated CEBPA	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	2	Standard Chemotherapy | Targeted Therapy - Other	2	AG-120|Decitabine	2	Hypomethylating/Low Dose Cytarabine | Experimental				Targeted Therapy - Other	AG-120	Experimental	-1	1		60	39	No				2										47,XY,+21[3]/46,XY[9]			9.5% gain 21q22	43	A distinct blastic population, expressing CD7, CD13, CD15, CD33, CD34, CD38, dim CD45, CD64, MPO, and HLA-DR		139.9	Negative	Negative	p.A66fs; MAF 37.3%				p.R132C; MAF 48.7%						p.N107D; MAF 97.6%	87	Matched	AMLCEBPA	Leukemia	AML with Biallelic Mutations of CEBPA	0.233333333333
aml_ohsu_2018_2196	aml_ohsu_2018_15-00539	After or at the time transformation from another heme malignancy	None	AML with myelodysplasia-related changes	Adverse	Intermediate-II	AML with myelodysplasia-related changes	Post-Chemotherapy|Residual Disease	Peripheral Blood	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	2	Standard Chemotherapy | Other	4	Lenalidomide|Azacitidine|Decitabine|Clofarabine, Cytarabine	2	Hypomethylating/Low Dose Cytarabine | Maintenance				Other	Clofarabine, Cytarabine	Hypomethylating/Low Dose Cytarabine	-1	-79	0		25	No	0		2	54	18		41	34	3.6	0.58		27.5	8.8	46,XX,+1,der(1;21)(q10;q10)[6]/46,XX[14]			nuc ish(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200]			6.2	58.2	Negative	Negative												73	Matched	AMLMRC	Leukemia	AML with Myelodysplasia-Related Changes	0.3
aml_ohsu_2018_2202	aml_ohsu_2018_15-00556	Denovo	None	AML with mutated CEBPA	Intermediate or Adverse	Not Enough Information	AML with mutated CEBPA	Initial Acute Leukemia Diagnosis	Peripheral Blood	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	3	Standard Chemotherapy | Intrathecal | Other	3	COG-AAML1031 (IT/IV Cytarabine, Daunorubicin, Etoposide, Mitoxantrone +/- Bortezomib or Sorafenib)|Cytarabine|MiDAC	2	Induction | Re-induction	Refractory	Intrathecal	10	Standard Chemotherapy	MiDAC	Re-induction	31	1	0	75	86	No	0	0	7.5	1.8	4.7	0.1	13	23	3.6	0.47		21.6	6.9	46,XY[20]	970	96		42	variable CD7, dim CD11b, CD13, CD33, partial CD34, dim CD64, CD117, CD123, HLA-DR, and dim MPO positive	7.8	133.63	Positive	Negative	p.R142fs*19; MAF 52%		Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	10	Unmatched	AMLCEBPA	Leukemia	AML with Biallelic Mutations of CEBPA	0.1
aml_ohsu_2018_2205	aml_ohsu_2018_15-00559		None	Acute myelomonocytic leukaemia	Adverse	Not Enough Information	Acute myelomonocytic leukaemia	Post-Chemotherapy|Residual Disease	Peripheral Blood	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	2	Standard Chemotherapy | Targeted Therapy - Other	3	7+3 (Cytarabine, Idarubicin)|AG-221|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)	3	Salvage | Induction | Experimental	Refractory	Standard Chemotherapy	-1	Targeted Therapy - Other	AG-221	Experimental	-1	0		50	51	No														46,XX[20]			Normal	256	positive for CD13, CD34, CD38, dim CD45, CD117, HLA-DR, and MPO		10.7	Negative	Negative	Negative		p.S307fs; MAF 45.6%	Negative	c.C315T; p.G105G; MAF 46.6%		Negative	Negative				42	Matched	AML	Leukemia	Acute Myeloid Leukemia	0.766666666667
aml_ohsu_2018_2204	aml_ohsu_2018_15-00563	Denovo	None	AML without maturation	Adverse	Adverse	AML without maturation	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	3	Standard Chemotherapy | Bone Marrow Transplant | Intrathecal	4	COG-AAML1031 (IT/IV Cytarabine, Daunorubicin, Etoposide, Mitoxantrone +/- Bortezomib or Sorafenib)|Cytarabine|FLAG (Fludarabine, High-dose Cytarabine, G-CSF)|Busulfan, Cyclophosphamide	3	Induction | Re-induction | Allogeneic - Matched Unrelated Donor	Complete Response	Standard Chemotherapy	136	Bone Marrow Transplant	Busulfan, Cyclophosphamide	Allogeneic - Matched Unrelated Donor	-1	0	0	80	52.2	No	0	1.8	46	0	0	0.2	22	53		0.24	M1	22	6.9	46,XX,t(6;11)(q27;q23)[19]/46,XX[1]		92.8		40	CD4, CD11b, variable CD13, CD15, CD33, variable CD56, CD58, CD64, lysozyme, and dim HLA-DR positive		57.08	Negative	Negative												2	Unmatched	AWM	Leukemia	AML without Maturation	0.133333333333
aml_ohsu_2018_2213	aml_ohsu_2018_15-00571	Denovo	None	AML with maturation	Adverse	Not Enough Information	AML with maturation	Initial Acute Leukemia Diagnosis	Peripheral Blood	WES	No	Yes	Yes	No	Yes	Yes	1	Standard Chemotherapy	1	7+3 (Cytarabine, Idarubicin)	1	Induction	Refractory	Standard Chemotherapy	-1	Standard Chemotherapy	7+3 (Cytarabine, Idarubicin)	Induction	-1	0		84	91	No											M2			46,XY[20]			Normal		partial  weak CD4 (20% positive), CD13, partial weak CD11b (60%  positive), partial weak CD15 (20% positive), CD34, CD117,  myeloperoxidase, and partial HLA-DR (60% positive)		25	Positive	Negative												61	Matched	AM	Leukemia	AML with Maturation	1.6
aml_ohsu_2018_2213	aml_ohsu_2018_15-00572	Denovo	None	AML with maturation	Adverse	Not Enough Information	AML with maturation	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	WES + RNA-seq	Yes	Yes	No	Yes	Yes	No	1	Standard Chemotherapy	1	7+3 (Cytarabine, Idarubicin)	1	Induction	Refractory	Standard Chemotherapy	-1	Standard Chemotherapy	7+3 (Cytarabine, Idarubicin)	Induction	-1	0		84	91	No											M2			46,XY[20]			Normal		partial  weak CD4 (20% positive), CD13, partial weak CD11b (60%  positive), partial weak CD15 (20% positive), CD34, CD117,  myeloperoxidase, and partial HLA-DR (60% positive)		25	Negative	Negative												61	Matched	AM	Leukemia	AML with Maturation	1.53333333333
aml_ohsu_2018_2214	aml_ohsu_2018_15-00578	Denovo	None	AML with myelodysplasia-related changes	Adverse	Adverse	AML with myelodysplasia-related changes	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	3	Standard Chemotherapy | Bone Marrow Transplant | Other	4	3+7 (Cytarabine, Daunorubicin)|MiDAC|Hydroxyurea|Fludarabine, Melphalan, TBI, ATG	4	Hypomethylating/Low Dose Cytarabine | Consolidation | Induction | Allogeneic - Child	Complete Response	Standard Chemotherapy	7	Bone Marrow Transplant	Fludarabine, Melphalan, TBI, ATG	Allogeneic - Child	-1	0	0	95	67.25	No	0	0	9.5	23.3	0	0.1	54	57	3.3	0.78	M5	27.4	9.1	46,XX,t(1;11)(p36.1;q23),add(9)(p22)[13]/46,sl,del(2)(p21p23),del(20)(q11.2-13.1)[4]/46,sl,add(12)(p11.2)[2]	861	93.2	MLL: 85%  The t(1;11) with these breakpoints in not common, but has been associated with monoblastic leukemia	26	CD4, partial CD11b, CD15, CD33, CD38, moderate CD45, partial CD56, CD64, CD123, partial CD117, and HLA-DR	6.8	87.72	Negative	Negative	Negative		Negative		Negative	Negative	Negative	Negative	Negative	p.G12S; MAF 19%	Negative	62	Unmatched	AMLMRC	Leukemia	AML with Myelodysplasia-Related Changes	0.233333333333
aml_ohsu_2018_2222	aml_ohsu_2018_15-00581		None	Myelodysplastic syndrome associated with isolated del(5q)	Adverse		Myelodysplastic syndrome associated with isolated del(5q)	Residual Disease|Post-Chemotherapy	Bone Marrow Aspirate	WES	No	Yes	No	No	Yes	No	2	Standard Chemotherapy | Supportive/Palliative Care	2	Lenalidomide|Azacitidine	2	Hypomethylating/Low Dose Cytarabine | Maintenance				Supportive/Palliative Care	Azacitidine	Hypomethylating/Low Dose Cytarabine	6	0		4	2	No	1		37	7	50		42	42	3.6	0.68		22.4	7.4	42~44,XX,-3,del(4)(q25q33),der(5)t(3;5)(q21;q22),del(7)(p15p22),-9,-9,-13,-16,add(17)(p11.2),add(19)(p13.3), +mar1,+mar2[cp4]/41~43,idem,-del(7),+der(7)t(7;15)(p12;q15)add(7)(q11.2),+der(7;9)(q11.2;q13)del(7)(q11.2q22), -15,-21,+mar3[cp5]/42~44,idem,-del(7),+der(7),+der(7;9),-15,-add(19)			nuc ish(D5S2064x2,D5S630x2,EGR1x1) [91/200],(D7Z1x3,D7S522x2)[11/200],(D8Z2,D20S108)x2[196],(RUNX1T1,RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[196],(PMLx3,RARAx2)[28/200],(5'CBFB,3'CBFB)x1(5'CBFB con 3'CBFBx1)[101/200]	18	CD2(-), CD7(partial dim +), 11b(-), CD13(+), CD14 (-), CD15(-), CD33(variably +), CD34(bright +), CD36(+), CD38(slightly variably +), CD45(+), CD117(variably +), HLA-DR(-).	6.6	2.5	Negative	Negative				Negative	Negative	Negative					Foundation; R337L	74	Matched	MDSID5Q	Myelodysplastic Syndromes	MDS with Isolated Del(5q)	1.06666666667
aml_ohsu_2018_2225	aml_ohsu_2018_15-00593		None	Therapy-related myeloid neoplasms	Intermediate	Intermediate-II	Therapy-related myeloid neoplasms	Initial Acute Leukemia Diagnosis	Peripheral Blood	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	2	Standard Chemotherapy | Supportive/Palliative Care	5	7+3 (Cytarabine, Idarubicin)|Azacitidine|CLAG-M (Cladribine, Cytarabine, Mitoxantrone, Filgrastim)|Hydroxyurea|Mitoxantrone	4	Hypomethylating/Low Dose Cytarabine | Induction | Re-induction | Supportive/Palliative Care	Refractory	Standard Chemotherapy	-1	Supportive/Palliative Care	Hydroxyurea	Supportive/Palliative Care	-1	-1		82	66	No														46,XX,del(7)(q22q36)[20]			ABNORMAL FISH RESULT 7cen (D7Z1), 7q31 (D7S486): deletion present		CD7, CD13, weak CD33, CD34, CD117, and HLA-DR		133.7	Negative	Negative												71	Matched	TMN	Leukemia	Therapy-Related Myeloid Neoplasms	1.4
aml_ohsu_2018_2226	aml_ohsu_2018_15-00595	Denovo	None	AML without maturation	Intermediate	Adverse	AML without maturation	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	WES + RNA-seq	Yes	Yes	No	Yes	Yes	No	1	Standard Chemotherapy	1	7+3 (Cytarabine, Idarubicin)	1	Induction	Unknown	Standard Chemotherapy	8	Standard Chemotherapy	7+3 (Cytarabine, Idarubicin)	Induction	8	0	0	91	61	No	0		46.1	1.7	9.4		391	343	2.8	0.74	M1	22.8	7.1	92<4n>,XXYY[13]/46,XY[7]			nuc ish(D5S2064,D5S630,EGR1)x3~4[193/200],(D7Z1,D7S522)x3~4[194/200],(D8Z2, D20S108)x3~4[195/200],(RUNX1T1,RUNX1)x3~4[191/200],(ABL1,BCR)x3~4[191/200],(5'MLL,3'MLL)x3~4(5'MLL con 3'MLLx3~4)[193/200],(PML,RARA)x3~4[191/200],(5'CBFB,3'CBFB)x3~4(5CBFB con 3CBFBx3~4)[192/200]	34	CD2(-), CD4(partial dim +), CD7(-), CD11b (variably +), CD13(variably +), CD14(predominantly -), CD15(predominantly -/few scattered +), CD16(-), CD20(small subset +), CD33(partial +), CD34(variably +), CD36(small subset +), CD38(variably +), CD45(variably +), CD56(-), CD61 (-), CD64(-), (cont.above)	5.8	9.4	Positive	Negative	Negative				p.R132C; MAF unlisted	Negative						55	Matched	AWM	Leukemia	AML without Maturation	1.0
aml_ohsu_2018_2232	aml_ohsu_2018_15-00608	After or at the time transformation from another heme malignancy	None	AML with myelodysplasia-related changes	Adverse	Not Enough Information	AML with myelodysplasia-related changes	Initial Acute Leukemia Diagnosis	Peripheral Blood	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	2	Standard Chemotherapy | Bone Marrow Transplant	2	Cyclophosphamide, Fludarabine, TBI|7+3 (Cytarabine, Idarubicin) plus Sorafenib	2	Induction | Double Umbilical Cord Blood Transplant (DUCBT)	Complete Response	Standard Chemotherapy	-1	Bone Marrow Transplant	Cyclophosphamide, Fludarabine, TBI	Double Umbilical Cord Blood Transplant (DUCBT)	-1	1		40	28	No														46,XX,del(5)(q31q33),der(21)(qter->q22::p11.2->qter),del(21)(q22)[19]			65% Loss 5q31; 14.5% Gain of 8 centromere, trisomy; Trisomy for 21q22  (40.5%), and trisomy for 8q22 and 21q22 (7.0%)	26	positive CD13, CD34, dim CD45, CD117 and HLA-DR		4.8	Negative	Negative	Negative			Negative	Negative	Negative	Negative	Negative		p.G12D; MAF 10%		61	Matched	AMLMRC	Leukemia	AML with Myelodysplasia-Related Changes	1.2
aml_ohsu_2018_2233	aml_ohsu_2018_15-00610	Denovo	None	Acute monoblastic and monocytic leukaemia	Adverse	Intermediate-I	Acute monoblastic and monocytic leukaemia	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	2	Standard Chemotherapy | Bone Marrow Transplant	4	HiDAC|GCLAC (GCSF, Clofarabine & Cytarabine)|7+3 (Cytarabine, Idarubicin) plus Sorafenib|Fludarabine, Cyclophosphamide, TBI	3	Induction | Re-induction | Double Umbilical Cord Blood Transplant (DUCBT)	Refractory	Standard Chemotherapy	-1	Bone Marrow Transplant	Fludarabine, Cyclophosphamide, TBI	Double Umbilical Cord Blood Transplant (DUCBT)	-1	0		35	2	No														46,XX[20]			Normal	35	The immature cells were positive for CD13, CD33, and many showed aberrant expression of CD7. The myeloblast portion was positive for CD34, CD117, and HLA-DR.  The immature monocyte portion was negative for CD34 and CD117, and expressed variable CD64 (including some cells with bright CD64), CD11b, an		49.7	Positive	Negative	Negative			Negative	Negative	Negative	Negative	Negative				42	Matched	AMOL	Leukemia	Acute Monoblastic/Monocytic Leukemia	0.166666666667
aml_ohsu_2018_2234	aml_ohsu_2018_15-00614	Denovo	None	AML with myelodysplasia-related changes	Adverse	Adverse	AML with myelodysplasia-related changes	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	2	Standard Chemotherapy | Bone Marrow Transplant	3	HiDAC|SWOG S1203 (7+3 +/- Vorinostat)|Bu/Cy/TBI	4	Consolidation | Induction | Allogeneic - Mismatched Unrelated Donor | Re-induction	Refractory	Standard Chemotherapy	6	Bone Marrow Transplant	Bu/Cy/TBI	Allogeneic - Mismatched Unrelated Donor	-1	0	0			No	0	0	85.8	1.9	8.5	0	25	25	3	0.93	M0	25.1	8.2	60~61<3n>,XYY,-1,-2,-3,-4,-5,del(5)(q13q33),-6,-7,+8,-9,+11,-12,+13,-15,-16,-17,-18,+21,+22[cp15]/70~73,idem,+Y,+1,+2,+5,+del(5)(q13q33),+6,+9,+11,+12,+20,+20[cp4]/46,XY[1]	634	81.8	EGR-1/ D5S23, D5S721: 60/100 cells (60%) had a 1 red/ 2 green signal pattern, indicating a deleted 5q, consistent with the first clone, above; 38 cells (38%) had a 2 red/ 4 green signal pattern, consistent with two copies of the deleted 5q in the second clone.	77		6.5	0.5	Negative	Negative	Negative		Negative	Negative	Negative	Negative	Negative	Negative	Negative	p.G13D; MAF ~40%	Splice site (5' splice site mutation in intron 4); MAF 44%	51	Matched	AMLMRC	Leukemia	AML with Myelodysplasia-Related Changes	1.03333333333
aml_ohsu_2018_2235	aml_ohsu_2018_15-00615	Denovo	None	AML with mutated CEBPA	Adverse	Intermediate-I	AML with mutated CEBPA	Initial Acute Leukemia Diagnosis	Leukapheresis	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	2	Standard Chemotherapy | Bone Marrow Transplant	6	Busulfan, Fludarabine|7+3 (Cytarabine, Idarubicin)|HiDAC|CLAG (Cladribine, Cytarabine, Filgrastim)|Azacitidine|CLAG-M (Cladribine, Cytarabine, Mitoxantrone, Filgrastim)	5	Allogeneic - Sibling | Consolidation | Salvage | Induction | Re-induction	Refractory	Standard Chemotherapy	-1	Bone Marrow Transplant	Busulfan, Fludarabine	Allogeneic - Sibling	-1	-3				No														46,XX[20]			Normal					Positive	Negative	p.Gln41fs; MAF 4%											24	Matched	AMLCEBPA	Leukemia	AML with Biallelic Mutations of CEBPA	0.733333333333
aml_ohsu_2018_2236	aml_ohsu_2018_15-00616	Denovo	None	AML with myelodysplasia-related changes	Adverse	Adverse	AML with myelodysplasia-related changes	Initial Acute Leukemia Diagnosis	Peripheral Blood	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	2	Standard Chemotherapy | Bone Marrow Transplant	3	Fludarabine, Melphalan|3+7 (Cytarabine, Daunorubicin)|MiDAC	3	Consolidation | Induction | Allogeneic - Mismatched Unrelated Donor	Complete Response	Standard Chemotherapy	6	Bone Marrow Transplant	Fludarabine, Melphalan	Allogeneic - Mismatched Unrelated Donor	-1	-14	2.6		49	No	5.1	6.8	36.8	0.9	14.5	0.2	18	16	2.8	0.67		21.9	7.5	43-45,XX,del(5)(q16q33),der(7)t(7;12)(q11.1;q12)ins(7;?)(q11.1;?),-12,der(21;22)(q10;q10),+mar[cp20]/46,XX[1]	821	88.7		8	CD13, CD33, CD34, CD71, CD117, dimCD123, HLA-DR, and dim CD 64 positive	7.2	11.01	Negative	Negative	Negative		Negative	Negative	Negative	Negative	Negative	Negative			p.I254N; MAF 40%	68	Unmatched	AMLMRC	Leukemia	AML with Myelodysplasia-Related Changes	0.0333333333333
aml_ohsu_2018_2239	aml_ohsu_2018_15-00626	After or at the time transformation from another heme malignancy	None	AML with mutated CEBPA	Adverse	Intermediate-II	AML with mutated CEBPA	Initial Acute Leukemia Diagnosis	Peripheral Blood	WES + RNA-seq	Yes	Yes	No	Yes	Yes	No	2	Standard Chemotherapy | Targeted Therapy - Other	3	AG-221|Azacitidine|Decitabine	3	Hypomethylating/Low Dose Cytarabine | Induction | Experimental	Refractory	Standard Chemotherapy	212	Targeted Therapy - Other	AG-221	Experimental	-1	0		70	72	No														47,XY,+11[8]/46,XY[12]			35% gain of 11q23	174	CD34, CD117, HLA-DR, CD13, and CD33. A subset of the myeloblasts showed aberrant co-expression of CD34 and myeloperoxidase.  A subset of the myeloblasts showed aberrant expression of CD56.		33.1	Negative	Negative	p.K90fs; MAF 39.1%			Negative	Negative		Negative	Negative				77	Matched	AMLCEBPA	Leukemia	AML with Biallelic Mutations of CEBPA	0.733333333333
aml_ohsu_2018_2241	aml_ohsu_2018_15-00633		MLLT3-KMT2A	Therapy-related myeloid neoplasms	Adverse	Intermediate-II	Therapy-related myeloid neoplasms	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	2	Standard Chemotherapy | Bone Marrow Transplant	3	7+3 (Cytarabine, Idarubicin)|HiDAC|Fludarabine, Melphalan, ATG, Methotrexate	3	Consolidation | Induction | Allogeneic - Matched Unrelated Donor	Complete Response	Standard Chemotherapy	-1	Bone Marrow Transplant	Fludarabine, Melphalan, ATG, Methotrexate	Allogeneic - Matched Unrelated Donor	-1	-3				No														46,XX,t(9;11)(p22;q23)[5]			11q23 (MLL): rearrangement present					Negative	Negative									p.Gly13Asp; MAF 38.9%			52	Unmatched	TMN	Leukemia	Therapy-Related Myeloid Neoplasms	0.0666666666667
aml_ohsu_2018_2251	aml_ohsu_2018_15-00650	After or at the time transformation from another heme malignancy	None	Acute myelomonocytic leukaemia	Intermediate	Intermediate-II	Acute myelomonocytic leukaemia	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	1	Standard Chemotherapy	1	Azacitidine	1	Induction	Refractory	Standard Chemotherapy	232	Standard Chemotherapy	Azacitidine	Induction	232	0	0	36	23.7	No	0	8.7	20.2	27.2	20.2	1.6	24	23	3.4	0.88	M4	31.5	9.6	46,XY,del(12)(p11.2p13)[20]	200	95.7	ETV6: 84% of cells were missing a signal for ETV6 (12p13), consistent with the deletion seen on metaphase analysis.	46	CD34, CD117, dim CD123, CD33, dim HLA-DR, CD13, and CD58.	7	40.53	Negative	Negative										p.Q61R; MAF 30%		85	Unmatched	AML	Leukemia	Acute Myeloid Leukemia	0.1
aml_ohsu_2018_2254	aml_ohsu_2018_15-00653	Denovo	None	Acute myeloid leukaemia, NOS	Favorable	Favorable	Acute myeloid leukaemia, NOS	Initial Acute Leukemia Diagnosis	Peripheral Blood	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	1	Standard Chemotherapy	3	7+3 (Cytarabine, Idarubicin)|HiDAC|MEC (Cytarabine, Etoposide, Mitoxantrone)	3	Consolidation | Salvage | Induction	Complete Response	Standard Chemotherapy	7	Standard Chemotherapy	MEC (Cytarabine, Etoposide, Mitoxantrone)	Salvage	-1	-1	0	83	48.6	No	0		9.4	0.9	40.2		21	47	3.3	0.55	M1	25.3	8.3	46,XX[20]			nuc ish(D4Z1,D10Z1)x2[200],(RUNX1T1,RUNX1)x2[200],(ABL1,BCR)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(ETV6,RUNX1)x2[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	48	CD2(-), CD4(dim +), CD7(-), CD11b(-), CD13(+ and dim +), CD14(-), CD15(+), CD16(-), CD25(-), CD33(slightly bright +), CD34(-), CD36(-), CD38(variably +), CD45(+), CD56(small subset +), CD64(-), CD117(dim and variably +), CD123(variably +), HLA-DR(+), TdT(-), MPO(+).	6.6	22.1	Negative	Positive	Negative				Negative	Negative						52	Unmatched	AMLNOS	Leukemia	AML, NOS	0.233333333333
aml_ohsu_2018_2260	aml_ohsu_2018_15-00655	Denovo	None	AML with myelodysplasia-related changes	Adverse	Intermediate-II	AML with myelodysplasia-related changes	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	WES	No	Yes	No	No	Yes	No	2	Standard Chemotherapy | Bone Marrow Transplant	3	7+3 (Cytarabine, Idarubicin)|HiDAC|Treo/Flu/TBI (Treosulfan, Fludarabine, Total Body Irradiation)	3	Consolidation | Induction | Allogeneic - Matched Unrelated Donor	Complete Response	Standard Chemotherapy	-1	Bone Marrow Transplant	Treo/Flu/TBI (Treosulfan, Fludarabine, Total Body Irradiation)	Allogeneic - Matched Unrelated Donor	-1	-3				No														46,XX,del(7)(q22q36)[11]/46,XX[2]								Positive	Negative			c.2645G>A; MAF 41.8%		c.394C>T; MAF 46.7%							70	Matched	AMLMRC	Leukemia	AML with Myelodysplasia-Related Changes	0.866666666667
aml_ohsu_2018_2265	aml_ohsu_2018_15-00670	Denovo	None	Acute myeloid leukaemia, NOS	Intermediate or Adverse	Intermediate-I	Acute myeloid leukaemia, NOS	Initial Acute Leukemia Diagnosis	Peripheral Blood	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	2	Standard Chemotherapy | Bone Marrow Transplant	4	Fludarabine, Melphalan|3+7 (Cytarabine, Daunorubicin)|MiDAC|Hydroxyurea	4	Allogeneic - Sibling | Hypomethylating/Low Dose Cytarabine | Consolidation | Induction	Complete Response	Standard Chemotherapy	6	Bone Marrow Transplant	Fludarabine, Melphalan	Allogeneic - Sibling	-1	-1	0	92	98	No	0	0.8	2.6	0	0	0.1	35	23	3.2	0.86		19.9	6.8	46,XY[7]	330	106.4	Normal	49	dim CD33, CD34, CD38, dim CD45, CD117, and MPO	8	84.96	Positive	Negative	Negative		p.R882H; MAF ~50%	Negative	p.R132S; MAF ~50%	Negative	Negative	Negative	Negative	Negative	Negative	61	Unmatched	AMLNOS	Leukemia	AML, NOS	0.2
aml_ohsu_2018_2269	aml_ohsu_2018_15-00674	Denovo	None	AML with myelodysplasia-related changes	Adverse	Adverse	AML with myelodysplasia-related changes	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	WES + RNA-seq	Yes	Yes	No	Yes	Yes	No	1	Standard Chemotherapy	1	7+3 (Cytarabine, Idarubicin) plus Sorafenib	1	Induction	Complete Response	Standard Chemotherapy	19	Standard Chemotherapy	7+3 (Cytarabine, Idarubicin) plus Sorafenib	Induction	19	0		75		No				39										50,XX,+8,+10,+12,+21[20]			- Gain of chromosome 8 in 55% of cells - Gain of 8q22 (ETO) sequence in 77.8% of cells; 21q22 (AML1) gain in 12% and loss in 77.8% cells	9	CD11b, CD13, CD14 (subset), CD33, CD34 (subset), CD38, CD45, CD64 (subset), HLA-DR and MPO		37.2	Negative	Negative	Negative			Negative	Negative	Negative	Negative	Negative				54	Matched	AMLMRC	Leukemia	AML with Myelodysplasia-Related Changes	0.3
aml_ohsu_2018_2272	aml_ohsu_2018_15-00680	Denovo	None	AML with mutated NPM1	Favorable or Intermediate	Intermediate-I	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	2	Standard Chemotherapy | Bone Marrow Transplant	3	HiDAC|3+7 (Cytarabine, Daunorubicin)|Bu/Flu/TBI (Busulfan, Fludarabine, Total Body Irradiation)	3	Consolidation | Induction | Allogeneic - Matched Unrelated Donor	Complete Response	Standard Chemotherapy	23	Bone Marrow Transplant	Bu/Flu/TBI (Busulfan, Fludarabine, Total Body Irradiation)	Allogeneic - Matched Unrelated Donor	-1	0	0.9	86	74.8	No	0	0	2.6	20.8	0.9	0.2	20	28	2.9	1.49	M5	33	10.8	46,XY[20]	1211	95.9	Normal	83	Variable CD13, variable CD14, CD33, variable CD64, CD117, CD123, and partial HLA-DR positive	7.2	134.36	Positive	Positive												68	Matched	AMLNPM1	Leukemia	AML with Mutated NPM1	0.433333333333
aml_ohsu_2018_2273	aml_ohsu_2018_15-00682		None	AML with myelodysplasia-related changes	Adverse	Not Enough Information	AML with myelodysplasia-related changes	Initial Acute Leukemia Diagnosis	Peripheral Blood	WES	No	Yes	No	No	Yes	No	1	Targeted Therapy - Other	1	AG-221	1	Experimental				Targeted Therapy - Other	AG-221	Experimental	-1	0		45		No														46,XX,+8,-16,der(17)t(16;17)(p11.2;p11.1),del(19)(p13.3)[20]			FISH assays were positive for findings consistent with trisomy 8 in 79% to 90% of assayed cells, and positive for loss of 16q22 sequences in 91.5% of assayed cells.	133	positive for CD34, CD117, HLA-DR, and CD13, with aberrant loss of CD33, and with a subset of the blasts showing aberrant co-expression of CD34 and myeloperoxidase		2.2	Negative	Negative	Negative			Negative	p.G105G; MAF 50%		Negative					83	Matched	AMLMRC	Leukemia	AML with Myelodysplasia-Related Changes	0.566666666667
aml_ohsu_2018_2273	aml_ohsu_2018_15-00683		None	AML with myelodysplasia-related changes	Adverse	Adverse	AML with myelodysplasia-related changes	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	RNA-seq	Yes	No	No	Yes	No	No	1	Targeted Therapy - Other	1	AG-221	1	Experimental				Targeted Therapy - Other	AG-221	Experimental	-1	0		45		No														46,XX,+8,-16,der(17)t(16;17)(p11.2;p11.1),del(19)(p13.3)[20]			FISH assays were positive for findings consistent with trisomy 8 in 79% to 90% of assayed cells, and positive for loss of 16q22 sequences in 91.5% of assayed cells.	133	positive for CD34, CD117, HLA-DR, and CD13, with aberrant loss of CD33, and with a subset of the blasts showing aberrant co-expression of CD34 and myeloperoxidase		2.2	Negative	Negative	Negative			Negative	p.G105G; MAF 50%		Negative					83	Matched	AMLMRC	Leukemia	AML with Myelodysplasia-Related Changes	NA
aml_ohsu_2018_2276	aml_ohsu_2018_15-00688	Denovo	None	AML with myelodysplasia-related changes	Adverse	Adverse	AML with myelodysplasia-related changes	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	1	Standard Chemotherapy	1	Decitabine	1	Induction	Unknown	Standard Chemotherapy	9	Standard Chemotherapy	Decitabine	Induction	9	0	1.8	41	2.6	No	0.9	0	79.6	0.9	14.2	0	21	19	2.7	0.98		27.7	9.4	45~46,XX,add(1)(q42),del(5)(q31q35),del(6)(q13),del(9)(q13q34),del(17)(p13),i(21)(q10)[cp12]/46~47,idem,+mar[cp6]/46,XX[2]	404	88.5	EGR1 (5q31): 73% of cells were missing a signal for EGR1 (5q31), consistent with the deletion seen on metaphase analysis.  TP53 (17p13.1): 71% of cells were missing a signal for TP53 (17p13.1), consistent with the deletion seen on metaphase analysis.  RUNX1 (21q22): 77% of cells had three signals fo	6	CD13, dimCD33, CD34, CD38, CD58, partial CD64, CD117, CD123, and HLA-DR positive.	7.6	1.61	Negative	Negative	Negative		Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	p.R248Q; MAF 56%	63	Matched	AMLMRC	Leukemia	AML with Myelodysplasia-Related Changes	0.6
aml_ohsu_2018_2277	aml_ohsu_2018_15-00692	Relapse	None	AML with mutated CEBPA	Adverse	Intermediate-II	AML with mutated CEBPA	Post-Chemotherapy|Relapse	Bone Marrow Aspirate	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	2	Standard Chemotherapy | Supportive/Palliative Care	3	7+3 (Cytarabine, Idarubicin)|HiDAC|Azacitidine	4	Hypomethylating/Low Dose Cytarabine | Consolidation | Salvage | Induction	Complete Response	Standard Chemotherapy	-1	Supportive/Palliative Care	Azacitidine	Hypomethylating/Low Dose Cytarabine	112	0	0	81	43	No	0		51	3	2		11	16	4.5	0.99	M0	28.2	9.6	46,XX,der(3)t(3;17)(q29;q21)[19]/46,XX,t(3;21)(q26.2;q22)[2]			nuc ish(D5S2064,D5S630,EGR1)x2[199],(D7Z1, D7S522)x2[199],(D8Z2,D20S108)x2[200],(RUNX1T1,RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200], (PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	10	CD2(-), CD4(-), CD7(partial +), CD11b(-), CD13(variably +), CD14(-), CD15(partial +), CD16(-), CD19 (-/few dim +), CD25(-), CD33(partial +), CD34(partial +), CD36(-), CD38(bright and variably +), CD45(+), CD56(variably +), CD64(-), CD117(variably +), CD123(-/few +), MPO(+), TdT(-/few dim +)	6.9	35	Negative	Negative	Foundation; M1fs*60; MAF 34%			Negative	Negative	Negative					Foundation; splice site 560-2insA; MAF 44%	73	Matched	AMLCEBPA	Leukemia	AML with Biallelic Mutations of CEBPA	1.16666666667
aml_ohsu_2018_2279	aml_ohsu_2018_15-00693	Denovo	None	Acute myeloid leukaemia, NOS	Adverse	Intermediate-II	Acute myeloid leukaemia, NOS	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	3	Standard Chemotherapy | Bone Marrow Transplant | Targeted Therapy - Other	4	Bortezomib|3+7 (Cytarabine, Daunorubicin)|MiDAC|Fludarabine, Cytarabine	4	Allogeneic - Sibling | Consolidation | Induction | Experimental	Refractory	Standard Chemotherapy	6	Bone Marrow Transplant	Fludarabine, Cytarabine	Allogeneic - Sibling	-1	0	0	60		No	0	0.9	29.8	54.4	1.8	0.5	23	19	2.5	0.84		24.2	7.7	47,XX,+6[6]/46,XX[19]	453	104.8	IGH/MAF: 74/100 cells (74%) had variant abnormal 0-1 red/ 1-4 green/ 2-7 yellow signal patterns reflecting IGH/MAF fusion. The majority of cells (56%) were 0 red/ 1 green/ 3 yellow. IGH: 68/100 (68%) cells scored had signal patterns consistent with IGH rearrangement and the 14;16 translocation,above	92	dimCD4, CD11b, CD13, dimCD14, CD33, CD56, CD58, CD64, dimCD123 and HLA-DR positive; Minor subset of blasts with immunophenotype: CD13, CD33, CD34, CD58, CD117, dimCD123, HLA-DR and MPO positive.	7.4	14.94	Positive	Negative										p.Q61R MAF ~5%		66	Matched	AMLNOS	Leukemia	AML, NOS	0.9
aml_ohsu_2018_2280	aml_ohsu_2018_15-00701		None	AML with minimal differentiation	Intermediate	Intermediate-II	AML with minimal differentiation	Residual Disease	Peripheral Blood	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	2	Standard Chemotherapy | Other	6	5+2 (Cytarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin)|HAM (Cytarabine, Mitoxantrone)|Azacitidine|MEC (Cytarabine, Etoposide, Mitoxantrone)|Hydroxyurea	5	Hypomethylating/Low Dose Cytarabine | Consolidation | Salvage | Induction | Re-induction	Refractory	Standard Chemotherapy	6	Other	Hydroxyurea	Hypomethylating/Low Dose Cytarabine	365	-111	0			No	0	2.6	8.8	17.6	2.6	0					M0	19.8	6.4	48,XX,+11,+13[19]		93.4		31			206.64	Negative	Negative												50	Unmatched	AMLMD	Leukemia	AML with Minimal Differentiation	0.266666666667
aml_ohsu_2018_2281	aml_ohsu_2018_15-00702	Denovo	CBFB-MYH11	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	Favorable	Favorable	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	1	Standard Chemotherapy	2	7+3 (Cytarabine, Idarubicin)|HiDAC	2	Consolidation | Induction	Complete Response	Standard Chemotherapy	10	Standard Chemotherapy	HiDAC	Consolidation	112	0	1.7	42	29.6	No	0.9	0	40	18.3	7.8	0.2	54	23	3.5	0.6		20.3	6.8	46,XX,inv(16)(p13.3q22)[21]	319	102.5	CBFB:  83/100 cells (83%) had the abnormal 1 red/ 1 green/1 yellow signal  pattern, reflecting CBFB rearrangement and consistent with the inverted  chromosome 16 in the metaphase karyotype.	63	Partial CD2, CD33, CD34, CD38, CD117, CD123, partial HLA-DR, dim MPO and partial TdT positive.	6.7	12.78	Negative	Negative	Negative		Negative	Negative			Negative	Negative	Negative	p.Q61P; MAF 15%	Negative	35	Matched	AMLCBFBMYH11	Leukemia	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22);CBFB-MYH11	0.4
aml_ohsu_2018_2282	aml_ohsu_2018_15-00704		None	AML without maturation	Intermediate	Intermediate-I	AML without maturation	Post-Transplant|Post-Chemotherapy	Bone Marrow Aspirate	WES	No	Yes	No	No	Yes	No	3	DLI | Standard Chemotherapy | Bone Marrow Transplant	8	Fludarabine, Melphalan|5+2 (Cytarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin)|Donor Lymphocyte Infusion|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Azacitidine|MEC (Cytarabine, Etoposide, Mitoxantrone)|Busulfan, Cyclophosphamide	6	Allogeneic - Sibling | Consolidation | Unknown | Induction | Re-induction | Allogeneic - Matched Unrelated Donor	Complete Response	Standard Chemotherapy	10	Bone Marrow Transplant	Fludarabine, Melphalan	Allogeneic - Sibling	-1	0	0.4			No	0	1.6	46.5	15.6	35.9	0	51	35	3.6	1		35.2	11.7	46,XY[20]		107.3	Normal	125		6.9	2.56	Negative	Negative												47	Unmatched	AWM	Leukemia	AML without Maturation	0.0666666666667
aml_ohsu_2018_2295	aml_ohsu_2018_15-00717	Denovo	None	AML with mutated NPM1	Favorable	Favorable	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	1	Standard Chemotherapy	1	7+3 (Cytarabine, Idarubicin)	1	Induction	Complete Response	Standard Chemotherapy	6	Standard Chemotherapy	7+3 (Cytarabine, Idarubicin)	Induction	6	0	0.4	68	0	No	0.1	3	17	62.6	16.9	0.1	29	17	3.7	1.51	M5	27.7	8.9	46,XY[20]	296	104.9	Normal	74	dim CD4, CD11b, partial CD14, CD15, dim CD33, CD38, CD56, CD58, CD64 and HLA-DR positive	8	16.84	Negative	Positive			p.S714C; MAF 35%	Negative	Negative	Negative	Negative		Negative	p.G13V; MAF 6%	Negative	61	Matched	AMLNPM1	Leukemia	AML with Mutated NPM1	0.2
aml_ohsu_2018_2287	aml_ohsu_2018_15-00724	Denovo	None	AML with mutated NPM1	Favorable or Intermediate	Intermediate-I	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	WES + RNA-seq	Yes	Yes	No	Yes	Yes	No	2	Standard Chemotherapy | Bone Marrow Transplant	3	Busulfan, Fludarabine|7+3 (Cytarabine, Idarubicin)|HiDAC	3	Allogeneic - Sibling | Consolidation | Induction	Refractory	Standard Chemotherapy	-1	Bone Marrow Transplant	Busulfan, Fludarabine	Allogeneic - Sibling	-1	0		51	54	No														46,XY[20]			Normal		CD13, partial CD15, CD33, CD117,  myeloperoxidase, and partial HLA-DR		12	Positive	Positive												51	Matched	AMLNPM1	Leukemia	AML with Mutated NPM1	0.566666666667
aml_ohsu_2018_2288	aml_ohsu_2018_15-00726	Denovo	None	AML with mutated NPM1	Favorable	Favorable	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	WES	No	Yes	No	No	Yes	No	1	Standard Chemotherapy	2	3+7 (Cytarabine, Daunorubicin)|MiDAC	2	Consolidation | Induction	Complete Response	Standard Chemotherapy	6	Standard Chemotherapy	MiDAC	Consolidation	78	0		25	0	No														46,XX[19]			Normal		CD13, CD33, CD38, CD117 and subset MPO positive			Negative	Positive	Negative		Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	70	Matched	AMLNPM1	Leukemia	AML with Mutated NPM1	0.933333333333
aml_ohsu_2018_2290	aml_ohsu_2018_15-00731	Denovo	None	Myeloid sarcoma	Intermediate	Intermediate-I	Myeloid sarcoma	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	WES	No	Yes	No	No	Yes	No	1	Standard Chemotherapy	3	7+3 (Cytarabine, Idarubicin)|Azacitidine|FLAG (Fludarabine, High-dose Cytarabine, G-CSF)	3	Consolidation | Induction | Re-induction	Complete Response i	Standard Chemotherapy	20	Standard Chemotherapy	Azacitidine	Consolidation	-1	0	0.5	13		No	2.5	0.5	24.7	9.7	62.1	0	58	48	2.7	1.1		24.4	7.7	46,XX[20]		86.8	Normal	226	CD13, CD33, CD34, CD38, CD58, CD117 and  HLA-DR	6.7	4.33	Negative	Negative	Negative		Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	66	Matched	MS	Leukemia	Myeloid Sarcoma	0.433333333333
aml_ohsu_2018_2293	aml_ohsu_2018_15-00734	Denovo	None	AML with mutated NPM1	Favorable	Favorable	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	1	Standard Chemotherapy	1	SWOG S1203 (7+3 +/- Vorinostat)	1	Induction	Complete Response	Standard Chemotherapy	153	Standard Chemotherapy	SWOG S1203 (7+3 +/- Vorinostat)	Induction	153	0	0	93	80	No	0	1.7	19.3	20.2	13.2	0.6	47	37	3.1	0.79	M5	26.8	8.8	46,XX[20]	977	92.1	Normal	36	Blast immunophenotype: partial CD11b, CD13, CD33, CD38, CD58, partial CD64, partial CD117 and a subset with MPO - Blast/promonocyte immunophenotype: CD11b, CD13, partial CD14, CD15, CD33, CD38, CD58 and CD64	6	42.34	Negative	Positive												53	Matched	AMLNPM1	Leukemia	AML with Mutated NPM1	0.4
aml_ohsu_2018_2300	aml_ohsu_2018_15-00742		PML-RARA	Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA	Favorable	Adverse	Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	WES	Yes	Yes	Yes	No	Yes	Yes	1	Standard Chemotherapy	1	ATRA, Arsenic Trioxide	1	Induction	Unknown	Standard Chemotherapy	-1	Standard Chemotherapy	ATRA, Arsenic Trioxide	Induction	-1	1	0	96	47	No	0	4	60	14	22	0	21	15	4	0.58	M3	30.1	10.7	46,XX,t(15;17)(q22;q21)[8]/46,idem,add(6)(p23),der(6)add(6)(p21)add(6)(q13),add(9)(p22),add(11)(q21),add(14)(q24)[12]	191	95.9	21/200 (10.5%) interphase cells  scored had the 1 red/ 1 green/ 2 yellow fusion signal pattern consistent  with PML/RARA fusion.	32	CD13, CD33, CD38, CD58, CD64, CD117, CD123, and  MPO-positive	7	0.5	Negative	Negative	Negative		Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	34	Unmatched	APLPMLRARA	Leukemia	APL with PML-RARA	0.0333333333333
aml_ohsu_2018_2304	aml_ohsu_2018_15-00755	Relapse	None	AML with mutated NPM1	Intermediate	Intermediate-II	AML with mutated NPM1	Relapse|Post-Chemotherapy	Bone Marrow Aspirate	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	1	Standard Chemotherapy	3	Azacitidine, Sorafenib|5+2 (Cytarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin)	3	Consolidation | Induction | Re-induction	Complete Response	Standard Chemotherapy	-1	Standard Chemotherapy	Azacitidine, Sorafenib	Re-induction	-1	-1		93.2	47.5	No														46,XY,t(3;4)(p21;q25)[3]/46,XY[17]					CD4, CD7, CD11b, CD13,  CD33, partial CD34, CD117, HLA-DR, partial weak TdT and  partial CD64		42.91	Positive	Positive			c.2251T>C; MAF 36.9% (33.1% on 3/13/15)									59	Unmatched	AMLNPM1	Leukemia	AML with Mutated NPM1	0.133333333333
aml_ohsu_2018_2305	aml_ohsu_2018_15-00756	Denovo	RUNX1-RUNX1T1	AML with t(8;21)(q22;q22); RUNX1-RUNX1T1	Intermediate	Favorable	AML with t(8;21)(q22;q22); RUNX1-RUNX1T1	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	1	Standard Chemotherapy	3	HiDAC|3+7 (Cytarabine, Daunorubicin)|Hydroxyurea	2	Consolidation | Induction	Refractory	Standard Chemotherapy	-1	Standard Chemotherapy	HiDAC	Consolidation	103	0	0	25	38	No	0	3.4	29.1	2.6	23.9	0	32	39	2.3	0.7		21	7.5	45,X,-Y,t(8;2;21)(q22;p21;q22)[20]		104.5	RUNX1T1/RUNX1: (92%)	29	CD13, CD33, partial CD34, CD64, CD19 dim, CD71, CD117 partial, HLA-DR, dim CD123, CD58 and MPO	6.7	24.98	Negative	Negative												36	Unmatched	AMLRUNX1RUNX1T1	Leukemia	AML with t(8;21)(q22;q22.1);RUNX1-RUNX1T1	0.0333333333333
aml_ohsu_2018_2307	aml_ohsu_2018_15-00763	Denovo	RUNX1-RUNX1T1	AML with t(8;21)(q22;q22); RUNX1-RUNX1T1	Adverse	Adverse	AML with t(8;21)(q22;q22); RUNX1-RUNX1T1	Initial Acute Leukemia Diagnosis	Peripheral Blood	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	2	Standard Chemotherapy | Bone Marrow Transplant	2	7+3 (Cytarabine, Idarubicin)|Busulfan, Fludarabine, Cyclophosphamide, Thymoglobulin (Bu/Flu/Cy/ATG)	2	Induction | Allogeneic - Matched Unrelated Donor	Complete Response	Standard Chemotherapy	-1	Bone Marrow Transplant	Busulfan, Fludarabine, Cyclophosphamide, Thymoglobulin (Bu/Flu/Cy/ATG)	Allogeneic - Matched Unrelated Donor	-1	-4				No														46,XY,add(6)(q23),del(7)(q33),t(8;21)(q22;q22)[2]/46,sl,add(17)(p11.1)[5]/46,sdl1,add(16)(p11.2)[2]/46,sdl2,add(3)(q21)[8]/46,sdl3,add(20)(q11.2)[3]			62% t(8;21) (RUNX1T1;RUNX1) translocation present					Negative	Negative				Negative								23	Unmatched	AMLRUNX1RUNX1T1	Leukemia	AML with t(8;21)(q22;q22.1);RUNX1-RUNX1T1	0.0666666666667
aml_ohsu_2018_2308	aml_ohsu_2018_15-00764	Relapse	Unknown	AML with t(6;9)(p23;q34); DEK-NUP214	Adverse	Adverse	AML with t(6;9)(p23;q34); DEK-NUP214	Relapse|Post-Chemotherapy|Post-Transplant	Peripheral Blood	WES	Yes	Yes	Yes	No	Yes	Yes	3	Standard Chemotherapy | Bone Marrow Transplant | Targeted Therapy - Kinase Inhibitor(s)	6	Azacitidine, Sorafenib|Busulfan, Fludarabine|7+3 (Cytarabine, Idarubicin)|Gilteritinib (ASP2215)|Sorafenib|Cladribine, Cytarabine, Idarubicin	7	Allogeneic - Sibling | Hypomethylating/Low Dose Cytarabine | Salvage | Induction | Experimental | Intensification | Re-induction	Refractory	Standard Chemotherapy	-1	Targeted Therapy - Kinase Inhibitor(s)	Sorafenib	Experimental	38	0		71	46	No																	Normal		CD4,  CD11b, dim CD13, variable CD15, CD33, partial CD34  (approximately 25%), variable CD64 (dim to bright), CD117,  HLA-DR, and myeloperoxidase		34	Positive	Negative												40	Unmatched	AMLDEKNUP214	Leukemia	AML with t(6;9)(p23;q34.1);DEK-NUP214	0.1
aml_ohsu_2018_2310	aml_ohsu_2018_15-00766	After or at the time transformation from another heme malignancy	None	Therapy-related myeloid neoplasms	Adverse	Adverse	Therapy-related myeloid neoplasms	Initial Acute Leukemia Diagnosis	Peripheral Blood	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	1	Standard Chemotherapy	2	Lenalidomide|Decitabine	2	Hypomethylating/Low Dose Cytarabine | Supportive/Palliative Care				Standard Chemotherapy	Decitabine	Hypomethylating/Low Dose Cytarabine	-1	0		60	14	No				7										45,XY,add(3)(p10),add(5)(q11.2),psu dic(9;?;6)(6qter- > 6p22::?::9p22- > 9qter)[1]/44,sl,-add(3)(p10), +der(3;13)(q10;q10)[2]/48,sdl1,+8,+14,+21,+22[8]/42-44,sl,-add(3)(p10),add(4)(p15),-7,-8, add(12)(p11.2),+mar,+1-2r[cp7]/80-82 < 4n > ,slx2,-2,add(4)(q22)x2,-6,+8,+8,add(8)(p23)x2,			FISH assays were positive for loss of 5q31 sequences in 85.5% of cells, positive for findings consistent with trisomy 8 in 49% of cells, and positive for findings consistent with monosomy 7 in around 8% of cells.	17	Flow cytometry was negative for increased myeloblasts. The flow showed a mild increase in   immature monocytic cells, but not to the degree seen in the marrow smears. This is likely   attributable to hemodilution of the sample received for flow cytometry.		21.6	Negative	Negative	Negative		Negative	Negative	Negative	Negative	Negative	Negative			p.P19H; MAF 8.9%	71	Matched	TMN	Leukemia	Therapy-Related Myeloid Neoplasms	0.8
aml_ohsu_2018_2311	aml_ohsu_2018_15-00767	After or at the time transformation from another heme malignancy	None	AML with mutated CEBPA	Intermediate	Favorable	AML with mutated CEBPA	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	1	Standard Chemotherapy	1	Decitabine	1	Hypomethylating/Low Dose Cytarabine				Standard Chemotherapy	Decitabine	Hypomethylating/Low Dose Cytarabine	-1	0	0.2	25	4	No	1		25	10	60		22	21	4.5	0.82		47.3	15.3	46,XY[20]			nuc ish(D5S2064,D5S630,EGR1)x2[200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[199],(RUNX1T1, RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	15	CD2(-), CD7 (-), CD10(-), CD11b(-), CD13(dim +), CD14(-), CD15(+), CD16(-), CD19(-), CD22(partial +), CD33(-), CD34(bright +), CD36 (-), CD38(variably +), CD45(partial dim +), CD56(-), CD64(-), CD117(partial +), HLA-DR(partial +), MPO(-) and TdT(+)	7.5	5.79	Negative	Negative					Negative	Negative						78	Matched	AMLCEBPA	Leukemia	AML with Biallelic Mutations of CEBPA	1.7
aml_ohsu_2018_2314	aml_ohsu_2018_15-00777	After or at the time transformation from another heme malignancy	None	AML with myelodysplasia-related changes	Adverse	Not Enough Information	AML with myelodysplasia-related changes	Initial Acute Leukemia Diagnosis|Post-Chemotherapy	Leukapheresis	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	1	Standard Chemotherapy	1	3+7 (Cytarabine, Daunorubicin)	1	Induction	Refractory	Standard Chemotherapy	7	Standard Chemotherapy	3+7 (Cytarabine, Daunorubicin)	Induction	7	-1	0		83	No	0	0.8	8.1	9.8	1.6	0.7	29	137	3.3	2.67	M5	35.5	11.4	46,XY[20]	3615	92.4	Normal	104	CD11b, partial CD13, partial CD14, CD33, partial CD56, CD58, CD64, subset HLA-DR (20%) and partial MPO positive	6.4	140.18	Negative	Negative					p.R132L; MAF 47%				p.G12A; MAF 36%			68	Unmatched	AMLMRC	Leukemia	AML with Myelodysplasia-Related Changes	0.266666666667
aml_ohsu_2018_2315	aml_ohsu_2018_15-00778	After or at the time transformation from another heme malignancy	None	AML with myelodysplasia-related changes	Adverse	Adverse	AML with myelodysplasia-related changes	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	WES + RNA-seq	Yes	Yes	No	Yes	Yes	No	1	Standard Chemotherapy	2	Decitabine|Hydroxyurea	2	Induction | Re-induction	Complete Response i	Standard Chemotherapy	-1	Standard Chemotherapy	Hydroxyurea	Re-induction	-1	0	0	21	2.5	No	1.7	0	68.3	1.7	25	0	22	9	3.2	0.81		20.6	6.8	46,XY,del(5)(q22q35),del(12)(q24.1q24.1),add(17)(p11.2)[19]/46,XY[1]		100.5	EGR1 (73.5%) ;  TP53: (85.5%)	174	CD7, CD34, CD117, HLA-DR, CD13, CD33, dim CD123, variable CD15 and subset MPO	5.8	3.74	Negative	Negative	Negative		Negative	Negative	Negative	Negative		Negative	Negative	Negative	p.G266V; MAF 55%	62	Matched	AMLMRC	Leukemia	AML with Myelodysplasia-Related Changes	0.5
aml_ohsu_2018_2320	aml_ohsu_2018_15-00782	Denovo	None	Acute myeloid leukaemia, NOS	Adverse	Not Enough Information	Acute myeloid leukaemia, NOS	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	WES + RNA-seq	Yes	Yes	No	Yes	Yes	No	1	Standard Chemotherapy	2	7+3 (Cytarabine, Idarubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone)	2	Induction | Re-induction	Complete Response	Standard Chemotherapy	-1	Standard Chemotherapy	MEC (Cytarabine, Etoposide, Mitoxantrone)	Re-induction	-1	0	0	45	48	No	2		69	4	2		12	15	3.8			22.7	7.6	46,XY[19]			nuc ish(D5S2064,D5S630,EGR1)x2[200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[200],(RUNX1T1, RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[199]	27	CD2(-), CD4(-), CD7(subset +), CD11b(-), CD13(+), CD14(-), CD15(partial dim +), CD16(-), CD33(-), CD34(+), CD36(-), CD38(variably +), CD45(moderately +), CD56(-), CD64(-), CD117(+), HLA-DR(+).	6.8	1.39	Negative	Negative				Negative	R132C; MAF 42%	Negative						61	Matched	AMLNOS	Leukemia	AML, NOS	1.2
aml_ohsu_2018_2322	aml_ohsu_2018_15-00786	Denovo	None	AML with mutated CEBPA	Favorable	Favorable	AML with mutated CEBPA	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	1	Standard Chemotherapy	2	HiDAC|3+7 (Cytarabine, Daunorubicin)	2	Consolidation | Induction	Complete Response	Standard Chemotherapy	6	Standard Chemotherapy	HiDAC	Consolidation	5	0	0	80	27.8	Yes	0	0	62.6	4.4	5.2	0	26	22	3.9	0.78		37.6	13.2	46,XY[20]		91.7	Normal	66	dim CD7, CD13, CD33, CD34, CD38, partial CD56 (25%), CD58, dim CD64, CD117, dim CD123, HLA-DR, and MPO+.	7.4	2.68	Negative	Negative	p.S28fs*81; MAF 28%											40	Matched	AMLCEBPA	Leukemia	AML with Biallelic Mutations of CEBPA	0.366666666667
aml_ohsu_2018_1690	aml_ohsu_2018_15-00805	Relapse	None	AML with mutated NPM1	Favorable	Favorable	AML with mutated NPM1	Post-Chemotherapy|Relapse	Bone Marrow Aspirate	WES	No	Yes	No	No	Yes	No	2	Standard Chemotherapy | Bone Marrow Transplant	4	Fludarabine, Melphalan|7+3 (Cytarabine, Idarubicin)|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|MiDAC	4	Consolidation | Induction | Re-induction | Allogeneic - Matched Unrelated Donor	Complete Response	Standard Chemotherapy	7	Bone Marrow Transplant	Fludarabine, Melphalan	Allogeneic - Matched Unrelated Donor	-1	-178	0	6	0	No	1.1		50.8	3.9	44.2		27	22	3.7	0.8		33.7	11.7	46,XX[18]		100.3	Normal	15	CD7, CD13, CD33, CD34, CD38, and CD123 positive	6.5	1.8	Negative	Positive												62	Matched	AMLNPM1	Leukemia	AML with Mutated NPM1	1.26666666667
aml_ohsu_2018_2333	aml_ohsu_2018_15-00807	Denovo	RUNX1-RUNX1T1	AML with t(8;21)(q22;q22); RUNX1-RUNX1T1	Adverse	Adverse	AML with t(8;21)(q22;q22); RUNX1-RUNX1T1	Initial Acute Leukemia Diagnosis	Peripheral Blood	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	2	Standard Chemotherapy | Bone Marrow Transplant	2	COG-AAML1031 (IT/IV Cytarabine, Daunorubicin, Etoposide, Mitoxantrone +/- Bortezomib or Sorafenib)|Busulfan, Cyclophosphamide	2	Allogeneic - Sibling | Induction	Complete Response	Standard Chemotherapy	189	Bone Marrow Transplant	Busulfan, Cyclophosphamide	Allogeneic - Sibling	-1	-3				No														46,XX,t(8;21)(q21.3;q22)[17]/49,sl,+4,+15,+der(21)t(8;21)[2]/53,sdl,-4,+13,+18,+19,+20,+21[4]			All twenty-three metaphase cells examined were abnormal, with t(8;21), leading to RUNX1/RUNX1T1 fusion.   Two subclones, comprising 6 cells total, had an additional copy of the der(21).					Negative	Negative										p.G12D; MAF 45%		14	Unmatched	AMLRUNX1RUNX1T1	Leukemia	AML with t(8;21)(q22;q22.1);RUNX1-RUNX1T1	0.266666666667
aml_ohsu_2018_2337	aml_ohsu_2018_15-00811		None	AML with mutated NPM1	Intermediate	Intermediate-II	AML with mutated NPM1	Post-Chemotherapy|Residual Disease	Peripheral Blood	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	2	Standard Chemotherapy | Targeted Therapy - Kinase Inhibitor(s)	4	HAM (Cytarabine, Mitoxantrone)|3+7 (Cytarabine, Daunorubicin)|Sorafenib|Hydroxyurea	4	Induction | Experimental | Re-induction | Maintenance	Unknown	Standard Chemotherapy	6	Targeted Therapy - Kinase Inhibitor(s)	Sorafenib	Experimental	-1	-7	0			No	1.7	0.9	6.1	8.8	43	0.4	38	29	3.4	0.71		27	9.1	46,XY,add(3)(p24)[cp4]/46,XY[14]	321	95.1	Normal	170		6.7	16.65	Positive	Positive			p.R882C; MAF 0.9%									54	Matched	AMLNPM1	Leukemia	AML with Mutated NPM1	1.03333333333
aml_ohsu_2018_2339	aml_ohsu_2018_15-00813	Denovo	None	Acute myeloid leukaemia, NOS	Intermediate	Not Enough Information	Acute myeloid leukaemia, NOS	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	1	Standard Chemotherapy	2	FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone)	2	Induction | Re-induction	Refractory	Standard Chemotherapy	4	Standard Chemotherapy	MEC (Cytarabine, Etoposide, Mitoxantrone)	Re-induction	7	1	0	45	50	No	0	19.4	6.4	1.6	11.3	0	73	83	3.3	0.88		29.4	9.6	46,XX[20]	2008	109.3	Normal	33	partial CD7, CD13, CD33, CD34, variable CD38, CD117, CD123, partial HLA-DR and dim MPO	6.8	137.54	Negative	Negative			p.R882H; MAF 45%							p.G13D; MAF 35%		53	Unmatched	AMLNOS	Leukemia	AML, NOS	0.133333333333
aml_ohsu_2018_2342	aml_ohsu_2018_15-00819	Denovo	CBFB-MYH11	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	Favorable	Favorable	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	WES + RNA-seq	Yes	Yes	No	Yes	Yes	No	2	Standard Chemotherapy | Intrathecal	4	7+3 (Cytarabine, Idarubicin)|MiDAC|Hydroxyurea|Cytarabine, Methotrexate	3	Consolidation | Induction | CNS	Complete Response	Standard Chemotherapy	6	Standard Chemotherapy	MiDAC	Consolidation	82	0	0.9	90	25.2	No	4.3	0.9	9.6	44.3	13.9	0.1	31	45	2.6	0.79	M5	22.7	7.7	46,XY,inv(16)(p13q22)[20]	1151	93.8	CBFB	10	dim CD2, variable CD5, CD13, CD33, CD34, CD38, variable CD64, CD117, dim CD123, HLA-DR, and MPO	5.5	24.64	Negative	Negative	Negative		Negative	Negative	Negative	Negative	Negative		Negative	Negative	Negative	64	Matched	AMLCBFBMYH11	Leukemia	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22);CBFB-MYH11	0.5
aml_ohsu_2018_2343	aml_ohsu_2018_15-00821		None	AML with myelodysplasia-related changes	Intermediate	Not Enough Information	AML with myelodysplasia-related changes	Post-Chemotherapy	Bone Marrow Aspirate	WES + RNA-seq	Yes	Yes	No	Yes	Yes	No	2	Standard Chemotherapy | Bone Marrow Transplant	3	Fludarabine, Melphalan|7+3 (Cytarabine, Idarubicin)|MiDAC	3	Consolidation | Induction | Allogeneic - Matched Unrelated Donor	Refractory	Standard Chemotherapy	6	Bone Marrow Transplant	Fludarabine, Melphalan	Allogeneic - Matched Unrelated Donor	-1	-20	0.8	0	0	No	0	2	18.6	9.3	69.3	0						32.1	10.2	46,XY[20]		94.7	Normal	345	The analysis was performed by flow cytometry on the bone marrow aspiratespecimen. The analysis shows CD34+ blasts account for 1% of CD45+ events. Maturing myeloid precursors and monocytic cells demonstrate a normal pattern of myelomonocytic antigen expression.		8.94	Negative	Negative												66	Matched	AMLMRC	Leukemia	AML with Myelodysplasia-Related Changes	0.233333333333
aml_ohsu_2018_2001	aml_ohsu_2018_15-00829		None	Therapy-related myeloid neoplasms	Adverse	Intermediate-II	Therapy-related myeloid neoplasms	Post-Chemotherapy|Post-DLI|Post-Transplant|Residual Disease	Peripheral Blood	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	4	Standard Chemotherapy | Supportive/Palliative Care | Targeted Therapy - Kinase Inhibitor(s) | Targeted Therapy - Other	4	AG-120|MEC (Cytarabine, Etoposide, Mitoxantrone)|Sorafenib|Hydroxyurea	3	Salvage | Experimental | Supportive/Palliative Care				Targeted Therapy - Kinase Inhibitor(s)	Sorafenib	Experimental	-1	-17				No							18	25	4.1			20.4	6.8	47,XX,+11[5]/48,idem,+19[15]			nuc ish(DXZ1x2)[181]//(DXZ1,DYZ3)x1[19] nuc ish(RUNX1T1,RUNX1)x2[199],(5'MLL,3'MLL)x3(5'MLL con 3'MLLx3)[176/200],(PML,RARA)x2[196], (5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[199]	24		7.4	27.5	Positive	Negative				Negative	p.R132G; MAF 51%	Negative					p.R283C; MAF 49%	68	Unmatched	TMN	Leukemia	Therapy-Related Myeloid Neoplasms	0.166666666667
aml_ohsu_2018_2350	aml_ohsu_2018_15-00837	After or at the time transformation from another heme malignancy	CBFB-MYH11	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	Favorable	Favorable	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	Post-Chemotherapy|Residual Disease	Peripheral Blood	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	2	Standard Chemotherapy | Targeted Therapy - Kinase Inhibitor(s)	2	Azacitidine|Momelotinib	2	Hypomethylating/Low Dose Cytarabine | Experimental				Standard Chemotherapy	Azacitidine	Hypomethylating/Low Dose Cytarabine	-1	-141			58	No														46,XY,inv(16)(p13.1q22)[20]							8.21	Negative	Negative												72	Unmatched	AMLCBFBMYH11	Leukemia	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22);CBFB-MYH11	0.2
aml_ohsu_2018_2347	aml_ohsu_2018_15-00839	Denovo	None	AML with mutated NPM1	Favorable or Intermediate	Intermediate-I	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	WES + RNA-seq	Yes	Yes	No	Yes	Yes	No	1	Standard Chemotherapy	1	ADE (Cytarabine, Daunorubicin & Etoposide)	1	Induction	Unknown	Standard Chemotherapy	7	Standard Chemotherapy	ADE (Cytarabine, Daunorubicin & Etoposide)	Induction	7	0	0.2	13		No	0	0.5	10.2	4.4	84.7	0	84	28	3.9	0.95		42.1	14	46,XY[20]	231	89.2	Normal	330	CD33, CD117 positive, negative for CD34 and HLA-DR	8.2	6.3	Positive	Positive												48	Matched	AMLNPM1	Leukemia	AML with Mutated NPM1	0.266666666667
aml_ohsu_2018_2357	aml_ohsu_2018_15-00850	Denovo	CBFB-MYH11	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	Favorable	Favorable	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	WES + RNA-seq	Yes	Yes	No	Yes	Yes	No	1	Standard Chemotherapy	1	7+3 (Cytarabine, Idarubicin)	1	Induction	Complete Response	Standard Chemotherapy	-1	Standard Chemotherapy	7+3 (Cytarabine, Idarubicin)	Induction	-1	1		50	20	No														46,XY,inv(16)(p13.1q22)[20]			positive for rearrangement of CBFB in 60.5% of cells.	32	positive for CD13, CD33, HLA-DR, CD34, and CD117, with partial aberrant expression of CD7.		52.8	Negative	Negative	Negative		Negative	Negative	Negative	Negative	Negative	Negative			Negative	62	Matched	AMLCBFBMYH11	Leukemia	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22);CBFB-MYH11	0.566666666667
aml_ohsu_2018_2360	aml_ohsu_2018_15-00855	Denovo	None	Myeloid leukaemia associated with Down syndrome	Favorable	Intermediate-II	Myeloid leukaemia associated with Down syndrome	Initial Acute Leukemia Diagnosis	Peripheral Blood	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	2	Standard Chemotherapy | Intrathecal	2	ADE (Cytarabine, Daunorubicin & Etoposide)|Cytarabine	2	Induction | CNS	Complete Response	Standard Chemotherapy	151	Intrathecal	Cytarabine	CNS	151	-2	10.8			No	0	1.8	8.1	13.5	8.1	0	13	25	3.2	0.72		26.8	9.3	47,XY,+21c[20]		90.5	RUNX1 (21q22): 89% of cells had three signals for RUNX1 (21q22) consistent with the three copies of chromosome 21 seen on metaphase analysis.	40		8.2	67.53	Negative	Positive	Negative		Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	8	Unmatched	MLADS	Leukemia	Myeloid Leukemia Associated with Down Syndrome	0.0333333333333
aml_ohsu_2018_2362	aml_ohsu_2018_15-00858	Denovo	None	AML with mutated NPM1	Favorable or Intermediate	Intermediate-I	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	1	Standard Chemotherapy	2	5+2 (Cytarabine, Idarubicin)|Decitabine	2	Induction | Re-induction	Refractory	Standard Chemotherapy	8	Standard Chemotherapy	5+2 (Cytarabine, Idarubicin)	Re-induction	4	0	0	95	0	No	0	0.9	16.8	3.5	24.8	1.1	23	22	3.5	1.33		31.5	10.3	46,XX[22]	244	92.6	Normal	29	dimCD13, CD33, CD45, CD56, dimCD117 and MPO positive	7	27.17	Positive	Positive	Negative		p.R736H; MAF 45%	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	76	Matched	AMLNPM1	Leukemia	AML with Mutated NPM1	0.433333333333
aml_ohsu_2018_2337	aml_ohsu_2018_15-00864		None	AML with mutated NPM1	Favorable or Intermediate	Not Enough Information	AML with mutated NPM1	Residual Disease|Post-Chemotherapy	Peripheral Blood	WES + RNA-seq	Yes	Yes	No	Yes	Yes	No	2	Standard Chemotherapy | Targeted Therapy - Kinase Inhibitor(s)	4	HAM (Cytarabine, Mitoxantrone)|3+7 (Cytarabine, Daunorubicin)|Sorafenib|Hydroxyurea	4	Induction | Experimental | Re-induction | Maintenance	Unknown	Standard Chemotherapy	6	Targeted Therapy - Kinase Inhibitor(s)	Sorafenib	Experimental	-1	0	0	8	1	No	4.7	0.9	40.6	10.4	43.4	0	40	34	3.8	0.73		20.2	7.1	46,XY[12]	235	93.5	Normal	17	dim variable CD7, dim CD11b, CD13, CD33, CD34, CD58, CD117, and CD123	6.8	1.06	Positive	Positive			p.R882C, MAF 6%									54	Matched	AMLNPM1	Leukemia	AML with Mutated NPM1	0.0333333333333
aml_ohsu_2018_2364	aml_ohsu_2018_15-00870	After or at the time transformation from another heme malignancy	None	AML with myelodysplasia-related changes	Adverse	Not Enough Information	AML with myelodysplasia-related changes	Initial Acute Leukemia Diagnosis|Post-Chemotherapy	Peripheral Blood	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	1	Standard Chemotherapy	3	Vidaza|Rituximab|Decitabine	2	Consolidation | Maintenance				Standard Chemotherapy	Decitabine	Maintenance	86	0		20	10	No	1		22	48	16		6	33	3.7	1.57		26	8.1	46,XY[20]		91.9		13	Positive for CD34, CD117, HLADR, CD33, CD13 but negative for CD14, CD64, CD11b, CD19, and CD3	7	44.8	Negative	Negative									p.G12V; MAF 49%			71	Unmatched	AMLMRC	Leukemia	AML with Myelodysplasia-Related Changes	0.333333333333
aml_ohsu_2018_2367	aml_ohsu_2018_15-00872	Denovo	None	AML with mutated NPM1	Favorable or Intermediate	Intermediate-I	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	3	Standard Chemotherapy | Bone Marrow Transplant | Other	4	Fludarabine, Melphalan|7+3 (Cytarabine, Idarubicin)|MiDAC|Hydroxyurea	4	Consolidation | Unknown | Induction | Allogeneic - Matched Unrelated Donor	Complete Response	Standard Chemotherapy	6	Bone Marrow Transplant	Fludarabine, Melphalan	Allogeneic - Matched Unrelated Donor	-1	0	0	74	60	No	1.9	15.1	21.7	50	11.3	0	23	32	2.6	0.78		21.6	7.2	46,XX[20]	905	100.5	Normal	150	partial variable CD7, subset CD11b (75%), CD13, CD33, partial CD14 (30%), partial CD64 (70%), CD38, CD58, partial CD117 (30%), CD123, HLA-DR, and partial (50%) MPO positive	6.7	84.69	Positive	Positive	p.K298Q; MAF 25%		p.R882C; MAF 44%									65	Unmatched	AMLNPM1	Leukemia	AML with Mutated NPM1	0.266666666667
aml_ohsu_2018_1973	aml_ohsu_2018_15-00874		None	AML with minimal differentiation	Adverse	Intermediate-II	AML with minimal differentiation	Post-Chemotherapy|Residual Disease	Bone Marrow Aspirate	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	2	Standard Chemotherapy | Supportive/Palliative Care	3	7+3 (Cytarabine, Idarubicin)|Azacitidine|Decitabine	3	Hypomethylating/Low Dose Cytarabine | Induction | Supportive/Palliative Care	Refractory	Standard Chemotherapy	6	Supportive/Palliative Care	Decitabine	Hypomethylating/Low Dose Cytarabine	-1	0	0	90	90	No	0	0	27.8	2.9	8.6	0.4	81	43	3.3			31.9	10.2	47,XY,+4[2]/46,XY[18]	235	94.7	Two of twenty metaphase cells examined were abnormal, with trisomy 4, as seen previously.	91	partial CD7 (~35%), CD13, partial dim CD33, CD34, CD38, variable CD56, and CD117	6.6	73.42	Negative	Negative												71	Matched	AMLMD	Leukemia	AML with Minimal Differentiation	0.266666666667
aml_ohsu_2018_2416	aml_ohsu_2018_15-00883		None	AML with mutated NPM1	Favorable or Intermediate	Intermediate-I	AML with mutated NPM1	Post-Chemotherapy|Residual Disease	Peripheral Blood	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	2	Standard Chemotherapy | Targeted Therapy - Kinase Inhibitor(s)	3	7+3 (Cytarabine, Idarubicin)|Sorafenib|Ponatinib	2	Induction | Experimental	Refractory	Standard Chemotherapy	10	Targeted Therapy - Kinase Inhibitor(s)	Ponatinib	Experimental	15	0	0.9	90	78	No	0	0	2.7	3.6	17.3	1.4	28	23	2.8	0.56		31.7	9.9	46,XX[20]	261	98.1	Normal	211	CD13, CD33, CD38, partial CD56, partialCD64, CD117, dimCD123, and MPO	6.5	24.01	Positive	Positive	p.E163*; MAF 39%											72	Matched	AMLNPM1	Leukemia	AML with Mutated NPM1	0.9
aml_ohsu_2018_2421	aml_ohsu_2018_15-00892	Denovo	Unknown	AML with mutated NPM1	Favorable	Not Enough Information	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Peripheral Blood	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	1	Targeted Therapy - Other	1	SGN-CD33A	1	Experimental				Targeted Therapy - Other	SGN-CD33A	Experimental	-1	0				No																	Normal					Negative	Positive			c.2645G>A; MAF 45.4%									72	Unmatched	AMLNPM1	Leukemia	AML with Mutated NPM1	0.266666666667
aml_ohsu_2018_2418	aml_ohsu_2018_15-00895	Denovo	None	AML with mutated NPM1	Favorable	Intermediate-II	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	WES	No	Yes	No	No	Yes	No	1	Standard Chemotherapy	1	3+7 (Cytarabine, Daunorubicin)	1	Induction	Complete Response	Standard Chemotherapy	5	Standard Chemotherapy	3+7 (Cytarabine, Daunorubicin)	Induction	5	0	0.4	4		No	1.2	0.5	18.4	9.4	70.1	0	124	106	3.6	0.92		39.5	13.2	47,XY,+8[3]/46,XY[17]	491	87.8	1% RUNX1T1	358		7.9	8.43	Negative	Positive	Negative		Negative		Negative	Negative	Negative	Negative	Negative	Negative	Negative	54	Matched	AMLNPM1	Leukemia	AML with Mutated NPM1	0.1
aml_ohsu_2018_2422	aml_ohsu_2018_15-00898	Denovo	None	AML with mutated NPM1	Favorable	Favorable	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	WES	No	Yes	No	No	Yes	No	1	Standard Chemotherapy	2	7+3 (Cytarabine, Idarubicin)|HiDAC	2	Consolidation | Induction	Complete Response	Standard Chemotherapy	-1	Standard Chemotherapy	HiDAC	Consolidation	4	0	0	18	2	No	1		29	2	66		13	13	4.2	0.84		31.5	10.6	46,XX[20]	252		nuc ish(D5S2064,D5S630,EGR1)x2[200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[199],(RUNX1T1, RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[199],(PML,RARA)x2[198],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	36	CD2 (-), CD4(partial +), CD7(-), CD11b(-), CD13(bright +), CD14(-), CD15(partial +), CD16(-), CD33(bright +), CD34 (-), CD36(-), CD38(bright +/variable), CD45(+), CD56(-), CD64(-), CD117(+) and HLA-DR(partial +).	7.2	3.63	Negative	Positive					Negative	Negative						44	Matched	AMLNPM1	Leukemia	AML with Mutated NPM1	0.9
aml_ohsu_2018_2420	aml_ohsu_2018_15-00900	Denovo	None	Acute myelomonocytic leukaemia	Intermediate	Not Enough Information	Acute myelomonocytic leukaemia	Initial Acute Leukemia Diagnosis	Peripheral Blood	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	2	Standard Chemotherapy | Bone Marrow Transplant	5	7+3 (Cytarabine, Idarubicin)|HAM (Cytarabine, Mitoxantrone)|Azacitidine|Decitabine|Busulfan, Cyclophosphamide	5	Hypomethylating/Low Dose Cytarabine | Consolidation | Induction | Allogeneic - Mismatched Unrelated Donor | Re-induction	Refractory	Standard Chemotherapy	7	Bone Marrow Transplant	Busulfan, Cyclophosphamide	Allogeneic - Mismatched Unrelated Donor	-1	0	0			No	1.8	0.9	23.9	23	7.9	0	37	28	3.7	0.95		32.3	11.3	46,XY[20]	243	92.8	Normal	102		7.1	21.84	Negative	Negative										p.G12C; MAF 40%		24	Matched	AML	Leukemia	Acute Myeloid Leukemia	0.7
aml_ohsu_2018_2423	aml_ohsu_2018_15-00903		None	Therapy-related myeloid neoplasms	Adverse	Intermediate-II	Therapy-related myeloid neoplasms	Residual Disease	Peripheral Blood	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	1	Standard Chemotherapy	1	Azacitidine	1	Hypomethylating/Low Dose Cytarabine				Standard Chemotherapy	Azacitidine	Hypomethylating/Low Dose Cytarabine	7	-24			79	No														45,X,-Y[20]			Normal				19.64	Negative	Negative												73	Unmatched	TMN	Leukemia	Therapy-Related Myeloid Neoplasms	0.0666666666667
aml_ohsu_2018_2425	aml_ohsu_2018_15-00909		None	AML with minimal differentiation	Adverse	Not Enough Information	AML with minimal differentiation	Post-Chemotherapy|Residual Disease	Peripheral Blood	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	1	Targeted Therapy - Other	1	Radiation	1	Unknown				Targeted Therapy - Other	Radiation	Unknown	14	0		90	45	No	0		28	5	1		30	41	3.3	0.82		29.3	9.6	46,XX[20]		89.9	This test has not detected clonal abnormalities in the cells analyzed. Subtle structural changes cannot be ruled out due to the limitations of resolution. Small precentage of tumor cells with chromosome abnormalities may not be detected due to the cells examined.	5	The blasts are positive for HLA-DR, CD34, CD117 (PARTIAL), CD13, CD(PARTIAL/DIM), CD33, TDT (DIM, SUBSET) and are negative for CD11b, CD14, CD64, MPO and all B and T cell markers.	7.3	6.5	Positive	Negative												47	Unmatched	AMLMD	Leukemia	AML with Minimal Differentiation	0.233333333333
aml_ohsu_2018_2426	aml_ohsu_2018_15-00912		None	Therapy-related myeloid neoplasms	Adverse	Adverse	Therapy-related myeloid neoplasms	Residual Disease|Post-Chemotherapy	Bone Marrow Aspirate	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	1	Unknown	1	Azacitidine	1	Unknown				Unknown	Azacitidine	Unknown	424	0		86	50	No	1		14	5	20		32	20	2.9	0.62		24.3	7.8	48-51,XX,del(4)(q25),del(5)(q11.2),-17,-18,+22,+3-5mar[20]		84.1		27	POSITIVE FOR DIM CD45, HLADR, CD34, CD117, CD13, CD33, CD43, CD81, CD58.	5.4	14.3	Negative	Negative												77	Unmatched	TMN	Leukemia	Therapy-Related Myeloid Neoplasms	0.0333333333333
aml_ohsu_2018_2429	aml_ohsu_2018_15-00921		None	Acute myeloid leukaemia, NOS	Unknown	Not Enough Information	Acute myeloid leukaemia, NOS	Post-Chemotherapy	Peripheral Blood	RNA-seq	Yes	No	No	Yes	No	No	1	Standard Chemotherapy	4	5+2 (Cytarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin)|ATRA (Tretinoin)|MiDAC	2	Consolidation | Induction	Refractory	Standard Chemotherapy	8	Standard Chemotherapy	MiDAC	Consolidation	3	-105	0.9			No	1.9	0.2	27.7	3.5	65.8	0	30	36	4.3	0.8		38.7	13	46,XX[20]		102.9	Normal	206		7.3	4.26														74	Matched	AMLNOS	Leukemia	AML, NOS	NA
aml_ohsu_2018_2433	aml_ohsu_2018_15-00929		None	AML with myelodysplasia-related changes	Intermediate	Intermediate-I	AML with myelodysplasia-related changes	Post-Chemotherapy	Bone Marrow Aspirate	WES + RNA-seq	Yes	Yes	No	Yes	Yes	No	1	Standard Chemotherapy	4	7+3 (Cytarabine, Idarubicin)|Azacitidine|SWOG S1203 (7+3 +/- Vorinostat)|MiDAC	4	Consolidation | Induction | Re-induction | Maintenance	Refractory	Standard Chemotherapy	-1	Standard Chemotherapy	Azacitidine	Maintenance	8	-1				No														46,XX[20]			showed multiple RUNX1 signals as well as a 3rd RUNX1 signal at 7p consistent with t(7;21)(p22;q22).				10.08	Negative	Negative												50	Unmatched	AMLMRC	Leukemia	AML with Myelodysplasia-Related Changes	0.0333333333333
aml_ohsu_2018_2337	aml_ohsu_2018_15-00936		None	AML with mutated NPM1	Adverse	Not Enough Information	AML with mutated NPM1	Post-Chemotherapy|Residual Disease	Peripheral Blood	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	2	Standard Chemotherapy | Targeted Therapy - Kinase Inhibitor(s)	4	HAM (Cytarabine, Mitoxantrone)|3+7 (Cytarabine, Daunorubicin)|Sorafenib|Hydroxyurea	4	Induction | Experimental | Re-induction | Maintenance	Unknown	Standard Chemotherapy	6	Targeted Therapy - Kinase Inhibitor(s)	Sorafenib	Experimental	-1	2	1.8			No	3.6	6.2	23.2	18.7	17	1.3	29	41	3.6	1		20.9	6.9	46,XY,t(7;17)(q22;q21)[3]/46,XY,t(2;4)(q33;q25),del(9)(q2?1;q3?2),add(17)(q21)[cp3]/46,XY,t(1;2)(q31;p25),inv(9)(q3?1q34)[2]/46,XY,t(13;14)(q14;q32)[cp2]/46,XY,add(3)(p24)[1]/46,XY[3]		96.3	Normal	21		6.8	20.77	Positive	Positive			p.R882C; MAF 45%									54	Matched	AMLNPM1	Leukemia	AML with Mutated NPM1	1.13333333333
aml_ohsu_2018_2314	aml_ohsu_2018_15-00939	After or at the time transformation from another heme malignancy	None	AML with myelodysplasia-related changes	Intermediate	Not Enough Information	AML with myelodysplasia-related changes	Residual Disease|Post-Chemotherapy	Peripheral Blood	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	1	Standard Chemotherapy	1	3+7 (Cytarabine, Daunorubicin)	1	Induction	Refractory	Standard Chemotherapy	7	Standard Chemotherapy	3+7 (Cytarabine, Daunorubicin)	Induction	7	-39	0.8			No	0.9	0	9.3	0	0	0.5	12	14	2.5	0.9		20.6	6.4	46,XY[19]		90.4	Normal	60		6.3	6.21	Negative	Negative												68	Unmatched	AMLMRC	Leukemia	AML with Myelodysplasia-Related Changes	0.233333333333
aml_ohsu_2018_2437	aml_ohsu_2018_15-00942		MLLT3-KMT2A	AML with t(9;11)(p22;q23); MLLT3-MLL	Intermediate	Intermediate-II	AML with t(9;11)(p22;q23); MLLT3-MLL	Post-Chemotherapy|Residual Disease	Peripheral Blood	WES	Yes	Yes	Yes	No	Yes	Yes	1	Standard Chemotherapy	2	7+3 (Cytarabine, Idarubicin)|HiDAC	2	Consolidation | Induction	Complete Response i	Standard Chemotherapy	27	Standard Chemotherapy	HiDAC	Consolidation	93	0		27	43	No			12	40	5		35	62	4.6	1.01		26.1	8.5	46,XX,t(4;15)(q31;q22),t(9;11)(p22;q23)[19]/46,XX[1]		90.6	This test has detected t(4;15) and t(9;11) in 19 of 20 cells analyzed. Translocation t(9;11) was reported previously in this case as the primary abnormality. Translocation t(4;15) represents a secondary chromosome change, that was already reported on previous sample.	5	There are increased abnormal cells in the monocyte gate that stain positive for CD38, CD11b, CD14, CD64, CD33, with partial MPO, HLADR, CD13 expression.	7.3	5.3	Negative	Negative												31	Unmatched	AMLRGA	Leukemia	AML with Recurrent Genetic Abnormalities	0.166666666667
aml_ohsu_2018_2439	aml_ohsu_2018_15-00947	After or at the time transformation from another heme malignancy	None	AML with myelodysplasia-related changes	Adverse	Adverse	AML with myelodysplasia-related changes	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	WES	No	Yes	No	No	Yes	No	1	Standard Chemotherapy	1	Decitabine	1	Induction	Unknown	Standard Chemotherapy	-1	Standard Chemotherapy	Decitabine	Induction	-1	0	0		23	No	3.5	4.3	39.1	4.4	34.8	4.5	17	20	3.8	1.09	M0	27.1	8.4	46,XY,t(4;9)(q21;p22)[7]/46,sl,add(1)(p13),add(15)(q15)[6]/45,sdl1,-18[4]/49,sdl2,+add(1)(p13),+6,+8,+18[2]/46,XY[1]		98.9	20% CEP 8, 24% RUNX1T1/RUNX1, 23% PML/RARA	21	CD13, CD33, CD34, CD38, CD58, CD117, and HLA-DR positive	7	4.42	Negative	Negative	Negative		Negative	Negative	Negative	Negative		Negative	Negative	Negative	Negative	66	Matched	AMLMRC	Leukemia	AML with Myelodysplasia-Related Changes	0.633333333333
aml_ohsu_2018_2444	aml_ohsu_2018_15-00961	Denovo	Unknown	Acute myelomonocytic leukaemia	Intermediate	Not Enough Information	Acute myelomonocytic leukaemia	Initial Acute Leukemia Diagnosis	Peripheral Blood	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	1	Standard Chemotherapy	2	7+3 (Cytarabine, Idarubicin)|HiDAC	2	Consolidation | Induction	Complete Response	Standard Chemotherapy	8	Standard Chemotherapy	HiDAC	Consolidation	81	0	0			No	30	13	9	21	19	0.1	54	50	2.2	0.84		18.8	6.5			98.9		21		6.5	65.58	Negative	Negative												52	Unmatched	AML	Leukemia	Acute Myeloid Leukemia	0.0666666666667
aml_ohsu_2018_2337	aml_ohsu_2018_15-00964		None	AML with mutated NPM1	Adverse	Not Enough Information	AML with mutated NPM1	Residual Disease|Post-Chemotherapy	Peripheral Blood	WES	No	Yes	Yes	No	Yes	Yes	2	Standard Chemotherapy | Targeted Therapy - Kinase Inhibitor(s)	4	HAM (Cytarabine, Mitoxantrone)|3+7 (Cytarabine, Daunorubicin)|Sorafenib|Hydroxyurea	4	Induction | Experimental | Re-induction | Maintenance	Unknown	Standard Chemotherapy	6	Targeted Therapy - Kinase Inhibitor(s)	Sorafenib	Experimental	-1	-10	0			No	0	0	14.3	2.4	3.2	1.3	41	36	2.6	0.86		22.9	7.6	46,XY,t(7;17)(q22;q21)[3]/46,XY,t(2;4)(q33;q25),del(9)(q2?1;q3?2),add(17)(q21)[cp3]/46,XY,t(1;2)(q31;p25),inv(9)(q3?1q34)[2]/46,XY,t(13;14)(q14;q32)[cp2]/46,XY,add(3)(p24)[1]/46,XY[3]	346	92.3	Normal	23		5.9	19.3	Positive	Positive			p.R882C; MAF 45%									54	Matched	AMLNPM1	Leukemia	AML with Mutated NPM1	0.933333333333
aml_ohsu_2018_2447	aml_ohsu_2018_15-00965	Denovo	Unknown	AML with mutated NPM1	Favorable	Not Enough Information	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Peripheral Blood	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	2	Standard Chemotherapy | Bone Marrow Transplant	4	Fludarabine, Melphalan|7+3 (Cytarabine, Idarubicin)|FLAG (Fludarabine, High-dose Cytarabine, G-CSF)|MiDAC	4	Consolidation | Induction | Re-induction | Allogeneic - Matched Unrelated Donor	Refractory	Standard Chemotherapy	6	Bone Marrow Transplant	Fludarabine, Melphalan	Allogeneic - Matched Unrelated Donor	-1	0	0			No	0	0	89.9	9.3	0.8	0	43	31	2.4	0.5		19.5	6.5		313	92.4	Normal	32		5.8	67.36	Negative	Positive												61	Matched	AMLNPM1	Leukemia	AML with Mutated NPM1	0.2
aml_ohsu_2018_2416	aml_ohsu_2018_15-00967		None	AML with mutated NPM1	Intermediate	Not Enough Information	AML with mutated NPM1	Post-Chemotherapy|Residual Disease	Peripheral Blood	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	2	Standard Chemotherapy | Targeted Therapy - Kinase Inhibitor(s)	3	7+3 (Cytarabine, Idarubicin)|Sorafenib|Ponatinib	2	Induction | Experimental	Refractory	Standard Chemotherapy	10	Targeted Therapy - Kinase Inhibitor(s)	Ponatinib	Experimental	15	-15	0	70	3.56	No	0	1.8	34.8	3.6	0.9	23.2	13	40	3.2	0.55		22.7	7.5	46,XX[5]	339	89.7	Normal	32	CD13+, CD33+, CD38+, variable partial CD56+, partial CD64+, CD117+, dimCD123+, and MPO+	6.4	6.04	Positive	Positive	p.E163*; MAF 40%											72	Matched	AMLNPM1	Leukemia	AML with Mutated NPM1	0.866666666667
aml_ohsu_2018_1745	aml_ohsu_2018_15-00974		GATA2-MECOM	AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1	Adverse	Adverse	AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1	Residual Disease|Post-Chemotherapy|Post-DLI|Post-Transplant	Peripheral Blood	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	3	DLI | Standard Chemotherapy | Bone Marrow Transplant	7	GCLAM (G-CSF, Cladribine, Cytarabine, and Mitoxantrone) |7+3 (Cytarabine, Idarubicin)|Donor Lymphocyte Infusion|Azacitidine|FLAG (Fludarabine, High-dose Cytarabine, G-CSF)|Decitabine|Busulfan, Cyclophosphamide	5	Hypomethylating/Low Dose Cytarabine | Unknown | Induction | Re-induction | Allogeneic - Matched Unrelated Donor	Refractory	Standard Chemotherapy	4	Standard Chemotherapy	Decitabine	Hypomethylating/Low Dose Cytarabine	4	-11	0			No	0.9	0	13.9	0	0.9	0.4	59	28	2.8			32.6	10.3	46,XX,inv(3)(q21q26)[5]		99.4	FISH) was performed with a MECOM/RPN1 probe set. 125/200 (62.5%) interphase cells scored had a 1 red/ 1 green/ 2 yellow double fusion signal pattern reflecting MECOM/RPN1 fusion and the paracentric inversion of the long arm of a chromosome 3 observed in the metaphase karyotype.  FISH was also perfor	38		6.7	7.08	Negative	Negative												38	Unmatched	AMLRGA	Leukemia	AML with Recurrent Genetic Abnormalities	0.2
aml_ohsu_2018_2452	aml_ohsu_2018_15-00975	Denovo	None	Acute myeloid leukaemia, NOS	Adverse	Adverse	Acute myeloid leukaemia, NOS	Initial Acute Leukemia Diagnosis	Peripheral Blood	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	1	Standard Chemotherapy	1	Azacitidine	1	Induction	Unknown	Standard Chemotherapy	37	Standard Chemotherapy	Azacitidine	Induction	37	0		90	17	No			20	18	2		24	26	3.8	0.76		25	8.2	46,XX,del(5)(q22q35)[20]		87.7	Positive for 5q deletion in 91% of cells.	35	POSITIVE FOR CD34, HLA-DR, CD117 AND CD33, AND NEGATIVE FOR MPO, TdT, CD13, CD19, CD20 AND CD10.	6.2	7.7	Positive	Negative				Negative								70	Unmatched	AMLNOS	Leukemia	AML, NOS	0.166666666667
aml_ohsu_2018_2453	aml_ohsu_2018_15-00976	After or at the time transformation from another heme malignancy	None	AML with myelodysplasia-related changes	Intermediate	Not Enough Information	AML with myelodysplasia-related changes	Residual Relapse|Post-Chemotherapy	Bone Marrow Aspirate	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	2	Standard Chemotherapy | Targeted Therapy - Other	2	AG-221|Azacitidine, SGN-CD33A	2	Induction | Experimental	Refractory	Standard Chemotherapy	-1	Targeted Therapy - Other	AG-221	Experimental	-1	0	0.3	12	3	No	0	9.4	26.9	24.5	38.9	0	42	47	3.2	1.3		21.1	6.8	46,XY[20]		87.9	Normal	213	CD13, CD33, CD34, CD38, dim CD58, CD117, and dim HLA-DR positive	6	3.72	Negative	Negative										p.G12D; MAF 49%		83	Matched	AMLMRC	Leukemia	AML with Myelodysplasia-Related Changes	1.0
aml_ohsu_2018_2455	aml_ohsu_2018_15-00979	Denovo	None	AML with mutated NPM1	Favorable or Intermediate	Intermediate-I	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	RNA-seq	Yes	No	Yes	Yes	No	Yes	3	Standard Chemotherapy | Bone Marrow Transplant | Targeted Therapy - Kinase Inhibitor(s)	6	Azacitidine|MEC (Cytarabine, Etoposide, Mitoxantrone)|Sorafenib|Hydroxyurea|Busulfan, Cyclophosphamide|7+3 (Cytarabine, Idarubicin) plus Dasatinib	5	Allogeneic - Sibling | Induction | Experimental | Re-induction | Post-Transplant Relapse	Complete Response i	Standard Chemotherapy	28	Targeted Therapy - Kinase Inhibitor(s)	Sorafenib	Experimental	-1	0	0	75	80	No	0	7.7	10.3	22.2	6.8	0	21	25	2.4	1.25		22.9	7.4	46,XX[20]	705	96.2	Normal	42	CD13, CD33, subset CD34, variable CD117, CD123, HLA-DR, and variable MPO positive - Monocytic/blast equivalent immunophenotype: CD11b, CD13, subset CD14, variable CD16, CD33, CD64, dim CD123, and HLA-DR positive	6.2	69.84	Positive	Positive			p.R882H; MAF 48%									44	Matched	AMLNPM1	Leukemia	AML with Mutated NPM1	NA
aml_ohsu_2018_2454	aml_ohsu_2018_15-00981		None	Therapy-related myeloid neoplasms	Favorable	Favorable	Therapy-related myeloid neoplasms	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	WES + RNA-seq	Yes	Yes	No	Yes	Yes	No	1	Supportive/Palliative Care	2	Hydroxyurea|Decitabine	1	Supportive/Palliative Care				Supportive/Palliative Care	Decitabine	Supportive/Palliative Care	4	0	0	90	90	No	0	0	5.1	0.8	0.9	1	23	51	2.9	0.97		25.3	8.5	46,XY[20]	728	91.3	Normal	28	CD33, dim CD38, variable CD56, CD58, dim CD64, CD117, CD123, and MPO positive.	6.6	62.87	Negative	Positive												75	Matched	TMN	Leukemia	Therapy-Related Myeloid Neoplasms	0.5
aml_ohsu_2018_2420	aml_ohsu_2018_15-00988		None	Acute myelomonocytic leukaemia	Intermediate	Not Enough Information	Acute myelomonocytic leukaemia	Residual Disease|Post-Chemotherapy	Bone Marrow Aspirate	WES	No	Yes	No	No	Yes	No	2	Standard Chemotherapy | Bone Marrow Transplant	5	7+3 (Cytarabine, Idarubicin)|HAM (Cytarabine, Mitoxantrone)|Azacitidine|Decitabine|Busulfan, Cyclophosphamide	5	Hypomethylating/Low Dose Cytarabine | Consolidation | Induction | Allogeneic - Mismatched Unrelated Donor | Re-induction	Refractory	Standard Chemotherapy	7	Bone Marrow Transplant	Busulfan, Cyclophosphamide	Allogeneic - Mismatched Unrelated Donor	-1	0	0	80		No	0	0	47.9	45.5	0	0	48	29	3.7	0.92		22.5	8.1	46,XY[21]	176	81.2	Normal	8		6.6	0.6	Negative	Negative												24	Matched	AML	Leukemia	Acute Myeloid Leukemia	0.566666666667
aml_ohsu_2018_2459	aml_ohsu_2018_15-00990	Denovo	None	AML with mutated NPM1	Favorable	Favorable	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	1	Supportive/Palliative Care	1	Azacitidine	1	Supportive/Palliative Care				Supportive/Palliative Care	Azacitidine	Supportive/Palliative Care	6	0	0	90	70	No	0	0.8	6.1	72.2	12.2	0.4	62	50	2.9	4.22	M5	22.8	7.3	46,XX[20]	262	90.8	Normal	29	CD11b, variable CD13, variable CD14, CD33, CD56, CD64, dim CD123 and dim HLA-DR positive	5.8	97.26	Negative	Positive												81	Matched	AMLNPM1	Leukemia	AML with Mutated NPM1	0.2
aml_ohsu_2018_2460	aml_ohsu_2018_16-00001	Denovo	CBFB-MYH11	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	Favorable	Favorable	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	Initial Acute Leukemia Diagnosis	Peripheral Blood	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	2	Standard Chemotherapy | Targeted Therapy - Kinase Inhibitor(s)	4	Dasatinib|7+3 (Cytarabine, Idarubicin)|HiDAC|Hydroxyurea	3	Consolidation | Induction | Experimental	Refractory	Standard Chemotherapy	1	Standard Chemotherapy	HiDAC	Consolidation	122	-2	0	40	60	No	1.7	0	33.4	5.1	18.8	0.1	38	28	3.2	0.53		22.9	7.6	46,XX,t(16;16)(p13.2;q22)[20]	508	99.6	CBFB: 191/200 cells (95.5%) had the abnormal 1 red/ 1 green/1 yellow signal pattern, reflecting CBFB rearrangement, consistent with the 16;16 translocation observed in the metaphase karyotype.	24	Immunophenotype: CD13, partial CD15, dim CD33, CD34, CD38, dim CD45, CD58, variable CD64, variable CD117, CD123, and dim HLA-DR positive.	7.3	20.44	Negative	Negative												36	Matched	AMLCBFBMYH11	Leukemia	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22);CBFB-MYH11	0.433333333333
aml_ohsu_2018_2461	aml_ohsu_2018_16-00003	Denovo	None	AML with mutated NPM1	Favorable	Favorable	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Peripheral Blood	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	1	Standard Chemotherapy	2	7+3 (Cytarabine, Idarubicin)|HiDAC	2	Consolidation | Induction	Complete Response	Standard Chemotherapy	16	Standard Chemotherapy	HiDAC	Consolidation	-1	-7				No														46,XY[15]			Normal					Negative	Positive												27	Matched	AMLNPM1	Leukemia	AML with Mutated NPM1	0.433333333333
aml_ohsu_2018_2462	aml_ohsu_2018_16-00004		None	Therapy-related myeloid neoplasms	Intermediate	Not Enough Information	Therapy-related myeloid neoplasms	Initial Acute Leukemia Diagnosis	Peripheral Blood	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	0		0		0					NONE	NONE	NONE		0	0	50		No	0	1.8	42.8	0	5.4	3.7	13	18	2.8	1.03		27.7	9.2	46,XX	279	91.1	trisomy 8 in 5 of 20 metaphase cells	44		7	1.36	Negative	Negative			p.R882H; MAF 39%									82	Unmatched	TMN	Leukemia	Therapy-Related Myeloid Neoplasms	0.2
aml_ohsu_2018_2464	aml_ohsu_2018_16-00006	After or at the time transformation from another heme malignancy	None	AML with myelodysplasia-related changes	Intermediate or Adverse	Intermediate-I	AML with myelodysplasia-related changes	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	WES	No	Yes	No	No	Yes	No	1	Standard Chemotherapy	2	Azacitidine, Sorafenib|Decitabine, Midostaurin	2	Induction | Re-induction	Refractory	Standard Chemotherapy	165	Standard Chemotherapy	Azacitidine, Sorafenib	Re-induction	-1	0		41	18	No														46,XY[20]			CD15, AND PARTIAL CD56 -7/DEL(7q) TRISOMY #8MLL GENE REARRANGEMENTDEL(20q)		ABNORMAL CD34+ BLAST POPULATION EXPRESSING ABERRANT CD7,CD4, AND CD2, AND CD38, CD10, CD22, CD11C, HLA-DR, CD117,CD13, CD33,CD15, AND PARTIAL CD56		2.2	Positive	Negative				Negative				Negative				77	Matched	AMLMRC	Leukemia	AML with Myelodysplasia-Related Changes	0.733333333333
aml_ohsu_2018_2464	aml_ohsu_2018_16-00007	After or at the time transformation from another heme malignancy	None	AML with myelodysplasia-related changes	Adverse	Not Enough Information	AML with myelodysplasia-related changes	Initial Acute Leukemia Diagnosis	Peripheral Blood	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	1	Standard Chemotherapy	2	Azacitidine, Sorafenib|Decitabine, Midostaurin	2	Induction | Re-induction	Refractory	Standard Chemotherapy	165	Standard Chemotherapy	Azacitidine, Sorafenib	Re-induction	-1	0		41	18	No														46,XY[20]			CD15, AND PARTIAL CD56 -7/DEL(7q) TRISOMY #8MLL GENE REARRANGEMENTDEL(20q)		ABNORMAL CD34+ BLAST POPULATION EXPRESSING ABERRANT CD7,CD4, AND CD2, AND CD38, CD10, CD22, CD11C, HLA-DR, CD117,CD13, CD33,CD15, AND PARTIAL CD56		2.2	Positive	Negative				Negative				Negative				77	Matched	AMLMRC	Leukemia	AML with Myelodysplasia-Related Changes	0.966666666667
aml_ohsu_2018_2437	aml_ohsu_2018_16-00010		MLLT3-KMT2A	AML with t(9;11)(p22;q23); MLLT3-MLL	Intermediate	Intermediate-II	AML with t(9;11)(p22;q23); MLLT3-MLL	Residual Disease|Post-Chemotherapy	Peripheral Blood	RNA-seq	Yes	No	Yes	Yes	No	Yes	1	Standard Chemotherapy	2	7+3 (Cytarabine, Idarubicin)|HiDAC	2	Consolidation | Induction	Complete Response i	Standard Chemotherapy	27	Standard Chemotherapy	HiDAC	Consolidation	93	0		79	64	No			2	15	1		44	53	4	0.52		29.5	9.6	46,XX,t(4;15)(q31;q22),t(9;11)(p22;q23)[20]		89.4	This test has detected t(4;15) and t(9;11) in 19 of 20 cells analyzed. Translocation t(9;11) was reported previously in this case as the primary abnormality. Translocation t(4;15) represents a secondary chromosome change, that was already reported on previous sample.	69	POSITIVE FOR CD33, CD11B, CD64, CD4 AND MPO (SUBSET/DIM) AND ARE NEGATIVE FOR CD117, CD13, CD34, HLA-DR AND TDT	7.3	20.3	Negative	Negative												31	Unmatched	AMLRGA	Leukemia	AML with Recurrent Genetic Abnormalities	NA
aml_ohsu_2018_2467	aml_ohsu_2018_16-00015	Relapse	None	AML with mutated NPM1	Favorable or Intermediate	Intermediate-I	AML with mutated NPM1	Post-Transplant|Relapse|Post-Chemotherapy	Peripheral Blood	WES	No	Yes	Yes	No	Yes	Yes	4	DLI | Standard Chemotherapy | Bone Marrow Transplant | Targeted Therapy - Kinase Inhibitor(s)	7	7+3 (Cytarabine, Idarubicin)|Donor Lymphocyte Infusion|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Azacitidine|Sorafenib|MiDAC|Treo/Flu/TBI (Treosulfan, Fludarabine, Total Body Irradiation)	7	Allogeneic - Sibling | Consolidation | Unknown | Induction | Experimental | Post-Transplant Relapse | Supportive/Palliative Care	Complete Response	Standard Chemotherapy	32	Targeted Therapy - Kinase Inhibitor(s)	Sorafenib	Experimental	-1	-1	0	95	50	No	2.6	0.9	29.8	0	30.7	0.4	15	18	2.8	1.22		27.2	9.6	46,XY[18]	230	96.8	Normal	103	Immunophenotype: dim CD13, CD33, CD117, CD123 and MPO positive.	5.6	7.92	Positive	Positive	p.A240fs*83 (7 bp insertion with frameshift); MAF 19%											72	Unmatched	AMLNPM1	Leukemia	AML with Mutated NPM1	0.2
aml_ohsu_2018_2468	aml_ohsu_2018_16-00017		None	Chronic myelomonocytic leukaemia	Favorable	Favorable	Chronic myelomonocytic leukaemia	Unknown	Bone Marrow Aspirate	WES	No	Yes	No	No	Yes	No	2	Standard Chemotherapy | Supportive/Palliative Care	3	7+3 (Cytarabine, Idarubicin)|MiDAC|Hydroxyurea	3	Consolidation | Induction | Supportive/Palliative Care	Complete Response	Standard Chemotherapy	23	Standard Chemotherapy	MiDAC	Consolidation	100	0	0	1		No	0	2.1	41.7	47.9	8.3	0			1.9	0.84	M4	21.9	7.5	46,XX[20]	533	96.1	Normal	20	CD19, CD20, and surface kappa light chain positive		3.38	Negative	Positive			p.R882H; MAF 34%						p.G13D; MAF 8%			68	Matched	CMML	Myelodysplastic/Myeloproliferative Neoplasms	Chronic Myelomonocytic Leukemia	1.26666666667
aml_ohsu_2018_2472	aml_ohsu_2018_16-00026		None	AML with mutated NPM1	Favorable	Favorable	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	WES	No	Yes	Yes	No	Yes	Yes	2	Standard Chemotherapy | Bone Marrow Transplant	4	Busulfan, Fludarabine|7+3 (Cytarabine, Idarubicin)|HiDAC|CLAG (Cladribine, Cytarabine, Filgrastim)	4	Consolidation | Induction | Re-induction | Allogeneic - Matched Unrelated Donor	Complete Response i	Standard Chemotherapy	12	Bone Marrow Transplant	Busulfan, Fludarabine	Allogeneic - Matched Unrelated Donor	-1	-1		89.6	51	No														46,XY[20]			Normal	54	84% are monocytes, and 9% are myeloid  cells. The monocytic cells (percentages shown) appear  atypical with expression of CD13, bright CD33, and bright  CD64, but weaker than normal HLA-DR and include 48% that  are phenotypically consistent with promonocytes/monoblasts		31.02	Negative	Positive			p.Val716Asp; MAF 45%									56	Matched	AMLNPM1	Leukemia	AML with Mutated NPM1	1.26666666667
aml_ohsu_2018_2473	aml_ohsu_2018_16-00027	Denovo	None	Acute myeloid leukaemia, NOS	Adverse	Intermediate-I	Acute myeloid leukaemia, NOS	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	2	Standard Chemotherapy | Bone Marrow Transplant	4	HiDAC|Cyclophosphamide|Fludarabine, Cyclophosphamide, TBI |7+3 (Cytarabine, Idarubicin) plus Crenolanib	4	Consolidation | Induction | Allogeneic - Child | Maintenance	Complete Response	Standard Chemotherapy	7	Standard Chemotherapy	Cyclophosphamide	Maintenance	1	0	0	91	99.2	No	0		0.8	0	0		33	27	3	0.85		18.8	6.2	46,XY[29]	808		nuc ish(D5S2064,D5S630,EGR1)x2[200],(D7Z1,D7S522)x2[199],(D8Z2,D20S108)x2[199],(RUNX1T1, RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	28	CD2(-), CD4(partial dim +), CD7(-), CD11b(-), CD13(dim +), CD14(-), CD15(-/few dim +), CD16(-), CD33(+), CD34 (partial +), CD36(equivocal/small subset appears +), CD38(partial +), CD45(+), CD56(-), CD64(-/few dim +), CD117(+), HLA-DR(+ and variable), TDT(-), MPO(+)	6.1	181.08	Positive	Negative	Negative			Negative	R132H; MAF 47.0%	Negative						55	Matched	AMLNOS	Leukemia	AML, NOS	0.833333333333
aml_ohsu_2018_2477	aml_ohsu_2018_16-00031		None	Acute myeloid leukaemia, NOS	Adverse	Not Enough Information	Acute myeloid leukaemia, NOS	Post-Chemotherapy|Residual Disease	Peripheral Blood	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	2	Standard Chemotherapy | Bone Marrow Transplant	3	Busulfan, Fludarabine|7+3 (Cytarabine, Idarubicin)|HiDAC	3	Allogeneic - Sibling | Induction | Re-induction	Unknown	Standard Chemotherapy	-1	Bone Marrow Transplant	Busulfan, Fludarabine	Allogeneic - Sibling	97	0		75	73	No			6	6	8		44	20	3.5	1		24.8	8	46,XY[20]		91.5	Not Available (no FISH done)	26	These are postive for CD34, CD117, HLADR, CD13 and CD33. These are negative for CD3, CD20, CD4, CD11b.	5.8	17.1	Positive	Negative												50	Matched	AMLNOS	Leukemia	AML, NOS	0.733333333333
aml_ohsu_2018_2474	aml_ohsu_2018_16-00033		CBFB-MYH11	Therapy-related myeloid neoplasms	Favorable	Favorable	Therapy-related myeloid neoplasms	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	WES	No	Yes	No	No	Yes	No	1	Standard Chemotherapy	3	7+3 (Cytarabine, Idarubicin)|HiDAC|MEC (Cytarabine, Etoposide, Mitoxantrone)	3	Consolidation | Salvage | Induction	Complete Response	Standard Chemotherapy	7	Standard Chemotherapy	MEC (Cytarabine, Etoposide, Mitoxantrone)	Salvage	-1	0	0	23	3	No	0	0.9	50.2	29.8	19.1	0	33	25	3.8	0.76		35.2	11.9	46,XX,inv(16)(p13.1q22)[16]/46,XX[4]		99.7	CBFB: 69/100 cells (69%) had the abnormal 1 red/ 1 green/1 yellow signal pattern, reflecting CBFB rearrangement and consistent with the inverted chromosome 16 in the metaphase karyotype.	119	CD13, variable CD15, CD33, CD34, variable CD64, CD117, dim CD123, dim HLA-DR, MPO and subset TdT-positive	7.1	2.35	Negative	Negative									p.G12D; MAF 4%	p.G12S; MAF 6%		58	Matched	TMN	Leukemia	Therapy-Related Myeloid Neoplasms	0.466666666667
aml_ohsu_2018_2475	aml_ohsu_2018_16-00035	Denovo	Unknown	AML with mutated NPM1	Favorable	Favorable	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Peripheral Blood	WES	No	Yes	Yes	No	Yes	Yes	1	Standard Chemotherapy	2	HiDAC|7+3 (Cytarabine, Idarubicin) plus Crenolanib	2	Consolidation | Induction	Complete Response	Standard Chemotherapy	-1	Standard Chemotherapy	HiDAC	Consolidation	88	0	0		97	No	0		1	0	2		135	113	2.7	0.51		19.4	6.6		1259		nuc ish(D5S2064,D5S630,EGR1)x2[200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[196],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[198]	28	CD2(-), CD4(dim +), CD7(-), CD11b(-), CD13(-), CD14(-), CD15(-), CD16(-), CD33(variably +), CD34(-), CD36(-), CD38(variably +), CD45(+), CD56(partial +), CD64 (partial +), CD117(variably +), HLA-DR(-).	5.3	175.91	Negative	Positive	Negative				Negative							54	Matched	AMLNPM1	Leukemia	AML with Mutated NPM1	0.833333333333
aml_ohsu_2018_2480	aml_ohsu_2018_16-00041		Unknown	AML with mutated NPM1	Intermediate	Not Enough Information	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Peripheral Blood	WES	No	Yes	Yes	No	Yes	Yes	1	Standard Chemotherapy	1	Hydroxyurea	1	Induction	Refractory	Standard Chemotherapy	1	Standard Chemotherapy	Hydroxyurea	Induction	1	0				No																	Negative				96	Positive	Positive			p.R882H; MAF 50%					Negative				70	Matched	AMLNPM1	Leukemia	AML with Mutated NPM1	0.5
aml_ohsu_2018_2482	aml_ohsu_2018_16-00046		None	Acute myeloid leukaemia, NOS	Adverse	Adverse	Acute myeloid leukaemia, NOS	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	WES	No	Yes	No	No	Yes	No	1	Standard Chemotherapy	3	5+2 (Cytarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin)|Azacitidine	2	Induction | Re-induction	Refractory	Standard Chemotherapy	7	Standard Chemotherapy	Azacitidine	Re-induction	-1	0	0	40	8	No	0	1	80	3	8	15.4	15	9	3.8	0.87		25.4	8.2	46,XY,t(8;17)(p21;q11.2),del(17)(q2?4)[5]/46,XY[15]		100.8	Normal	35	dim/partial cCD3, variable CD7, CD13, dimCD33, CD34,  CD38, CD117, dim CD123, dim HLA-DR, partial TdT, and partial MPO positive Monoclonal B cell population identified	7.1	1.04	Negative	Negative												62	Matched	AMLNOS	Leukemia	AML, NOS	1.0
aml_ohsu_2018_2483	aml_ohsu_2018_16-00048		None	Therapy-related myeloid neoplasms	Adverse	Adverse	Therapy-related myeloid neoplasms	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	2	Standard Chemotherapy | Bone Marrow Transplant	7	7+3 (Cytarabine, Idarubicin)|HAM (Cytarabine, Mitoxantrone)|Azacitidine|Hydroxyurea|Decitabine|ME (Etoposide, Mitoxantrone)|Fludarabine, Melphalan, ATG	4	Consolidation | Induction | Re-induction | Double Umbilical Cord Blood Transplant (DUCBT)	Refractory	Standard Chemotherapy	1	Bone Marrow Transplant	Fludarabine, Melphalan, ATG	Double Umbilical Cord Blood Transplant (DUCBT)	-1	0	0.9	25	26.7	No	1.7	4.3	6.1	32.2	48.7	0.2	14	15	3.1	0.64		32	9.5	46,XX,del(3)(p25),add(6)(p22),t(10;12)(p15;q13)[5]/46,XX[18]	440	80.6	Normal	92	Immunophenotype: CD13, CD34, CD38, CD58, CD117, CD123, HLA-DR and TdT-positive; small subset of blasts also express CD19, CD22, and CD79a	6.8	42.57	Negative	Negative			p.I824V; VAF 50%							p.G13R; MAF 50%		46	Matched	TMN	Leukemia	Therapy-Related Myeloid Neoplasms	1.26666666667
aml_ohsu_2018_2485	aml_ohsu_2018_16-00050		Unknown	Therapy-related myeloid neoplasms	Adverse	Not Enough Information	Therapy-related myeloid neoplasms	Residual Disease	Peripheral Blood	WES + RNA-seq	Yes	Yes	No	Yes	Yes	No	1	Standard Chemotherapy	1	Azacitidine	1	Hypomethylating/Low Dose Cytarabine				Standard Chemotherapy	Azacitidine	Hypomethylating/Low Dose Cytarabine	253	0	0.8			No	2.5	0	15.8	0	70.9	0	62	28	3.3	1.01		24.2	7.9		241	87.7	EGR-1/ D5S23, D5S721: 58/200 cells (29%) had a 1 red/ 2 green signal pattern, consistent with a deleted 5q. D7S522/CEP 7: 38/200 cells (19%) had a 1 red/ 2 green signal pattern, consistent with a deleted 7q. CBFB: 40/200 cells (20%) had a single signal indicating deleted 16q22. TP53/CEP 17: 12/200 c	16		8	8.29	Negative	Negative			p.E285D; MAF 40%								p.V272_R273insL; MAF 75% (previously 71% in 4/21/15 peripheral blood)	77	Unmatched	TMN	Leukemia	Therapy-Related Myeloid Neoplasms	0.0333333333333
aml_ohsu_2018_2490	aml_ohsu_2018_16-00056	Denovo	None	AML with mutated NPM1	Favorable	Favorable	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	1	Standard Chemotherapy	3	HiDAC|Hydroxyurea|7+3 (Cytarabine, Idarubicin) plus Sorafenib	2	Consolidation | Induction	Complete Response	Standard Chemotherapy	2	Standard Chemotherapy	HiDAC	Consolidation	-1	0	0	95	95	No	0	0	7.8	0	3.1	0.1	22	12	2.9	0.93		20.6	6.6	46,XX[20]	189	112.6	Normal	57	Immunophenotype: CD7, CD13, CD33, CD38, CD117, CD123 and MPO positive	6.5	25.02	Negative	Positive												51	Matched	AMLNPM1	Leukemia	AML with Mutated NPM1	1.16666666667
aml_ohsu_2018_2492	aml_ohsu_2018_16-00062		None	Myelodysplastic syndrome, unclassifiable	Adverse		Myelodysplastic syndrome, unclassifiable	Residual Disease	Bone Marrow Aspirate	WES	No	Yes	No	No	Yes	No	1	Standard Chemotherapy	1	Azacitidine	1	Hypomethylating/Low Dose Cytarabine				Standard Chemotherapy	Azacitidine	Hypomethylating/Low Dose Cytarabine	-1	0	0.3	6		No	3		54.1	3.7	38.4							26.7	8.8	46,XX,add(5)(q11.2),inv(9)(p11q12)c[1]/46,idem,add(4)(p14),-add(5),+del(5)(q31q35),del(7)(q11.2q34),add(18)(q23) [cp4]/45,idem,-7,der(12)inv(12)(p13q24.1)add(12)(p13),-18,der(21)t(1;21)(p13;p11.2),+mar[cp11]/46,XX[4].		91.8	nuc ish (D5S2064x2,D5S630x2,EGR1x1)[62/200],(D7Z1x2,D7S522x1)[79/200],(D8Z2,D20S108)x2[198],(RUNX1T1x2, RUNX1x3)[10/200],(5'MLL,3'MLL)x3~5(5'MLL con 3'MLLx3~5)[22/200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2 (5'CBFB con 3'CBFBx2)[200]	31	The cytospin and smear preparations reveal maturing hematopoietic precursors and scattered small lymphocytes.		2.68	Negative	Negative					Negative	Negative					H193Y; MAF 65.0%	63	Matched	MDSU	Myelodysplastic Syndromes	MDS, Unclassifiable	0.633333333333
aml_ohsu_2018_2496	aml_ohsu_2018_16-00067	Denovo	None	Acute myelomonocytic leukaemia	Intermediate	Not Enough Information	Acute myelomonocytic leukaemia	Initial Acute Leukemia Diagnosis	Peripheral Blood	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	3	Standard Chemotherapy | Bone Marrow Transplant | Supportive/Palliative Care	4	7+3 (Cytarabine, Idarubicin)|HiDAC|Cyclophosphamide|Fludarabine, Cyclophosphamide, TBI	4	Consolidation | Induction | Allogeneic - Child | Maintenance	Complete Response	Standard Chemotherapy	-1	Supportive/Palliative Care	Cyclophosphamide	Maintenance	1	-1	0	20	8	No	0		37	20	30		18	23	3.3	0.86		20	6.2	46,XX[20]	426	105.3	nuc ish(D5S2064,D5S630,EGR1)x2[200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[200],(RUNX1T1, RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	38	CD34(+), CD13(dim +), CD15(partial +), CD33(dim to partial +), CD34(+), CD38(variably +), CD45(dim +), CD56(-), CD64 (small subset +), CD117(+), HLA-DR(partial +), other myeloid and lymphoid antigens(-).	7	6.63	Negative	Negative					Negative							53	Matched	AML	Leukemia	Acute Myeloid Leukemia	0.6
aml_ohsu_2018_2497	aml_ohsu_2018_16-00070	Denovo	PML-RARA	Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA	Favorable	Intermediate-II	Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	WES	No	Yes	Yes	No	Yes	Yes	1	Standard Chemotherapy	2	Hydroxyurea|APML4 Protocol (ATRA, Arsenic Trioxide, Idarubicin)	1	Induction	Complete Response	Standard Chemotherapy	24	Standard Chemotherapy	APML4 Protocol (ATRA, Arsenic Trioxide, Idarubicin)	Induction	24	0	3.6	86	73	No	0	46	12.6	2.7	5.4	0.6	76	35	3.5	1		23.8	8.3	46,XY,t(15;17)(q22;q21)[20]	467	86.2	Cytogenetic testing (FISH) for the t(15;17) - PML-RARA translocation is positive in about 98% of the cells (GLC-16-338);	55	CD13, CD33, CD64, dim CD71, dim CD117 and MPO (+).	7.2	42.35	Negative	Negative												24	Matched	APLPMLRARA	Leukemia	APL with PML-RARA	0.333333333333
aml_ohsu_2018_2443	aml_ohsu_2018_16-00073		None	AML with myelodysplasia-related changes	Intermediate	Not Enough Information	AML with myelodysplasia-related changes	Residual Relapse	Peripheral Blood	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	3	Standard Chemotherapy | Supportive/Palliative Care | Targeted Therapy - Other	6	7+3 (Cytarabine, Idarubicin)|Cytarabine|Azacitidine|Sorafenib|Decitabine|Hydroxyurea	6	Hypomethylating/Low Dose Cytarabine | Consolidation | Induction | Experimental | Maintenance | Supportive/Palliative Care	Complete Response	Standard Chemotherapy	-1	Supportive/Palliative Care	Hydroxyurea	Supportive/Palliative Care	29	-44	1.5		38.5	No	0	0	55	3.5	1.5	0	25	22	3.8	1.3		21.1	7.1	48,XX,+8,+21[16]/46,XX[4]		91.3	RUNX1/RUNX1T1/CEP8: 81% of cells had three signals for all probes, consistent with +8 and +21, as seen on metaphase analysis.  MLL: 68% of cells had a split signal pattern consistent with MLL (11q23) rearrangement. Disruption of MLL was not apparent on banded chromosomes and the partner remains unkn	18		7.7	19.76	Negative	Negative												64	Matched	AMLMRC	Leukemia	AML with Myelodysplasia-Related Changes	1.23333333333
aml_ohsu_2018_2498	aml_ohsu_2018_16-00075	Denovo	None	AML with myelodysplasia-related changes	Adverse	Adverse	AML with myelodysplasia-related changes	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	1	Standard Chemotherapy	1	7+3 (Cytarabine, Idarubicin)	1	Induction	Refractory	Standard Chemotherapy	7	Standard Chemotherapy	7+3 (Cytarabine, Idarubicin)	Induction	7	0		39	11	No														45,XY,add(1)(p13),del(5)(q13q33),add(6)(q13),-7,del(7)(q11.2),der(9)t(1;9)(p13;q22),add(12)(p13),-15,-16,-17,+3mar[19]/43~45,idem,der(3)t(3;17)(p21;q11.2),-17[cp3]			COMPLEX DEL(5q)/DEL(7q)/-7 CLONE OBSERVED, CONSISTENT WITH AML		Positive		1.6	Negative	Negative	Negative			Negative				Negative				69	Matched	AMLMRC	Leukemia	AML with Myelodysplasia-Related Changes	0.666666666667
aml_ohsu_2018_2500	aml_ohsu_2018_16-00077		None	Therapy-related myeloid neoplasms	Adverse	Adverse	Therapy-related myeloid neoplasms	Residual Disease|Post-Chemotherapy	Peripheral Blood	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	2	Standard Chemotherapy | Targeted Therapy - Other	5	AG-120|5+2 (Cytarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin)|Azacitidine|Decitabine	4	Consolidation | Induction | Experimental | Maintenance	Complete Response	Standard Chemotherapy	7	Targeted Therapy - Other	AG-120	Experimental	-1	-29	0		70	No	0		7	3	9		11	57	2.6	1.28		25.6	8.1	45,XY,-7[2]/45,XY,t(6;8)(q21;q21.2),-7,del(10)(q24q26),t(12;15)(p13;q15)[19]	1897		nuc ish(D5S2064,D5S630,EGR1)x2 [200],(D7Z1x2,D7S522x1)[1/200]/(D7Z1,D7S522)x1[185/200],(D8Z2,D20S108)x2[200],(RUNX1T1,RUNX1)x2[200], (5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	23	CD2(subset +), CD4(dim +), CD7(partial +), CD11b(partial +), CD13(+), CD14(-), CD15(partial +), CD16(-), CD33(variably +), CD34(partial +), CD38(variably +), CD45(+), CD56(partial +), CD64(-), CD117(+), HLA-DR(partial +).	4.3	240.43	Negative	Negative						Negative						80	Unmatched	TMN	Leukemia	Therapy-Related Myeloid Neoplasms	0.1
aml_ohsu_2018_2499	aml_ohsu_2018_16-00078	Denovo	None	AML with mutated NPM1	Favorable	Favorable	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	1	Standard Chemotherapy	1	Decitabine	1	Supportive/Palliative Care				Standard Chemotherapy	Decitabine	Supportive/Palliative Care	-1	0	0.8	85	7.7	No	0		5.1	42.7	40.2		27	41	1.9	0.66		28.7	9.5	46,XX[20]	670	102.5	nuc ish(D5S2064,D5S630,EGR1)x2[200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[200],(RUNX1T1, RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	42	CD2(-), CD4(partial dim +), CD7(few dim +), CD11b(-), CD13 (variably +), CD14(-), CD15(partial +), CD16(-), CD19(partial dim +), CD33(variably +), CD34(-), CD36(-), CD38(+), CD45 (moderate +), CD56(-), CD64(partial dim +), CD117(+), HLA-DR(+), MPO(+).	5.7	56.03	Negative	Positive					Negative	Negative				Q61K; MAF 43.0%		67	Matched	AMLNPM1	Leukemia	AML with Mutated NPM1	1.13333333333
aml_ohsu_2018_2495	aml_ohsu_2018_16-00087		Unknown	Therapy-related myeloid neoplasms	Favorable or Intermediate	Not Enough Information	Therapy-related myeloid neoplasms	Post-Chemotherapy	Leukapheresis	WES + RNA-seq	Yes	Yes	No	Yes	Yes	No	2	Standard Chemotherapy | Targeted Therapy - Other	3	ATRA (Tretinoin)|HiDAC|3+7 (Cytarabine, Daunorubicin)	3	Consolidation | Induction | Experimental	Complete Response	Standard Chemotherapy	6	Standard Chemotherapy	HiDAC	Consolidation	114	0	0		97	No	0	0	1.9	0	1.9	0.2	14	18	2.7	0.51		19.6	6.2		364	108.3	Normal	15	CD13, CD33, CD38, CD58, CD117 and CD123 positive.	6.4	181.66	Positive	Positive					p.W288fs*12; MAF 50%							24	Unmatched	TMN	Leukemia	Therapy-Related Myeloid Neoplasms	0.1
aml_ohsu_2018_2442	aml_ohsu_2018_16-00088		None	Acute myeloid leukaemia, NOS	Adverse	Adverse	Acute myeloid leukaemia, NOS	Residual Disease|Post-Chemotherapy	Bone Marrow Aspirate	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	1	Standard Chemotherapy	4	Azacitidine, Sorafenib|7+3 (Cytarabine, Idarubicin)|HiDAC|Cladribine, Cytarabine, Idarubicin	3	Consolidation | Induction | Re-induction	Unknown	Standard Chemotherapy	-1	Standard Chemotherapy	Azacitidine, Sorafenib	Re-induction	67	0		98	95	No			2	3			46	30	4.1	0.54		27.2	8.9	46,XX,t(7;12)(q22;p13)[12]/46,XX,t(7;17)(p10;q10),-9,+mar[7]/46,XX[1]		90.4	This test has detected a translocation between 7 and 12 in 12 cells; a translocation between 7 and 17 with loss of a chromosome 9 and a marker in 7 cells.	81	These are positive for CD34, CD117, HLADR, CD33 but negative for CD13 and CD11b. TdT and CD79a are partially expressed.	6.9	67.7	Positive	Negative												26	Unmatched	AMLNOS	Leukemia	AML, NOS	0.133333333333
aml_ohsu_2018_2501	aml_ohsu_2018_16-00094	Denovo	None	Acute myeloid leukaemia, NOS	Adverse	Not Enough Information	Acute myeloid leukaemia, NOS	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	1	Standard Chemotherapy	4	HiDAC|3+7 (Cytarabine, Daunorubicin)|Azacitidine|Hydroxyurea	4	Hypomethylating/Low Dose Cytarabine | Consolidation | Induction | Re-induction	Refractory	Standard Chemotherapy	8	Standard Chemotherapy	Azacitidine	Consolidation	-1	0	1.7	95	74	No	2.5	0.8	13.6	14.4	10.2	0.4	23	14	3.1	0.46		27.9	9.2	46,XX[20]		89.4	Normal	49	variable CD11b, CD13, dim CD19, dim CD33, CD34, variable CD64, CD117, CD123, and HLA-DR	7	26.57	Negative	Negative									p.K117N; MAF 48%			37	Matched	AMLNOS	Leukemia	AML, NOS	0.3
aml_ohsu_2018_2508	aml_ohsu_2018_16-00102	Denovo	None	AML with mutated NPM1	Favorable	Favorable	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	1	Standard Chemotherapy	2	CPX-351 (Liposomal Cytarabine + Daunorubicin)|Hydroxyurea	1	Induction	Complete Response	Standard Chemotherapy	-1	Standard Chemotherapy	CPX-351 (Liposomal Cytarabine + Daunorubicin)	Induction	-1	0		97	96	No											M1			46,XY[5]			D5S721, EGR1  del(5q)/monosomy 5, D7Z1, D7S522  del(7q)/monosomy 7, D8Z2 trisomy #8, D20S108, 20qter del(20q)		CD117, MPO,CD38(PARTIAL), CD33(DIM) AND NOT EXPRESSING CD34 AND HLA-DR		125.9	Negative	Positive								Negative				72	Matched	AMLNPM1	Leukemia	AML with Mutated NPM1	0.5
aml_ohsu_2018_2511	aml_ohsu_2018_16-00109	After or at the time transformation from another heme malignancy	None	AML with mutated NPM1	Favorable	Intermediate-I	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Leukapheresis	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	1	Supportive/Palliative Care	1	Hydroxyurea	1	Supportive/Palliative Care				Supportive/Palliative Care	Hydroxyurea	Supportive/Palliative Care	7	-1	0	96	93.3	No	0	0.7	4.7	0	1.3	0.6	23	43	2.3	0.46		31	10.4	46,XY[20]	839	93.9	Normal	17	CD13, CD33, CD38, variable CD56, CD58, CD117 and MPO positive	5.1	230.05	Positive	Positive												76	Unmatched	AMLNPM1	Leukemia	AML with Mutated NPM1	0.2
aml_ohsu_2018_2521	aml_ohsu_2018_16-00113		None	Myeloid sarcoma	Intermediate	Intermediate-I	Myeloid sarcoma	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	0		0		0					NONE	NONE	NONE		0	1.5	2		No	24		11.5	8	55		4	8	3.7	1.2		48.8	16.1	46,XY[20]			Normal	141		6.3	11.4	Negative	Negative	Negative		Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	85	Unmatched	MS	Leukemia	Myeloid Sarcoma	0.3
aml_ohsu_2018_2522	aml_ohsu_2018_16-00115	Denovo	None	Acute myeloid leukaemia, NOS	Adverse	Adverse	Acute myeloid leukaemia, NOS	Initial Acute Leukemia Diagnosis	Peripheral Blood	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	0		0		0					NONE	NONE	NONE		0		19	7	No	4		12	2	51		29	38	3.7	0.86		24.2	7.8	45,XY,-7,del(12)(p11.2p13)[20]		90.6	Monosomy 7 is detected in 87% of cells.	35		6.6	47.5	Negative	Negative												74	Unmatched	AMLNOS	Leukemia	AML, NOS	0.233333333333
aml_ohsu_2018_2443	aml_ohsu_2018_16-00118		None	AML with myelodysplasia-related changes	Intermediate	Intermediate-II	AML with myelodysplasia-related changes	Residual Relapse	Peripheral Blood	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	3	Standard Chemotherapy | Supportive/Palliative Care | Targeted Therapy - Other	6	7+3 (Cytarabine, Idarubicin)|Cytarabine|Azacitidine|Sorafenib|Decitabine|Hydroxyurea	6	Hypomethylating/Low Dose Cytarabine | Consolidation | Induction | Experimental | Maintenance | Supportive/Palliative Care	Complete Response	Standard Chemotherapy	-1	Supportive/Palliative Care	Hydroxyurea	Supportive/Palliative Care	29	-58	0			No	0	0	12.6	0	0	0.2	16	36	3.1	1.57		20.9	7	48,XX,+8,+21[16]/46,XX[4]	887	89.7	RUNX1/RUNX1T1/CEP8: 81% of cells had three signals for all probes, consistent with +8 and +21, as seen on metaphase analysis.  MLL: 68% of cells had a split signal pattern consistent with MLL (11q23) rearrangement. Disruption of MLL was not apparent on banded chromosomes and the partner remains unkn	21		7.3	49.93	Negative	Negative												64	Matched	AMLMRC	Leukemia	AML with Myelodysplasia-Related Changes	1.86666666667
aml_ohsu_2018_2515	aml_ohsu_2018_16-00120	Denovo	PML-RARA	Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA	Favorable	Intermediate-II	Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA	Initial Acute Leukemia Diagnosis	Peripheral Blood	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	1	Standard Chemotherapy	3	Methotrexate, Mercaptopurine, Tretinoin|ATRA, Idarubicin|ATRA, Cytarabine, Idarubicin	3	Consolidation | Induction | Maintenance	Complete Response	Standard Chemotherapy	-1	Standard Chemotherapy	Methotrexate, Mercaptopurine, Tretinoin	Maintenance	-1	-1		91.8	95	No														46,XY,t(15;17)(q24;q21)[18]/46,XY[2]			Normal		weak partial CD2, CD13, CD33, CD64, CD117, and  myeloperoxidase		55.42	Positive	Negative	Negative											36	Unmatched	APLPMLRARA	Leukemia	APL with PML-RARA	0.0333333333333
aml_ohsu_2018_2477	aml_ohsu_2018_16-00124		None	Acute myeloid leukaemia, NOS	Adverse	Not Enough Information	Acute myeloid leukaemia, NOS	Post-Chemotherapy|Residual Disease	Peripheral Blood	WES + RNA-seq	Yes	Yes	No	Yes	Yes	No	2	Standard Chemotherapy | Bone Marrow Transplant	3	Busulfan, Fludarabine|7+3 (Cytarabine, Idarubicin)|HiDAC	3	Allogeneic - Sibling | Induction | Re-induction	Unknown	Standard Chemotherapy	-1	Bone Marrow Transplant	Busulfan, Fludarabine	Allogeneic - Sibling	97	-30			68	No			12		3		20	11	3.8	0.81		24.1	7.9	46,XY[20]		89.6	Not Available (no FISH done)	39		6.4	2.1	Positive	Negative			p.r882H; MAF 45%	Negative								50	Matched	AMLNOS	Leukemia	AML, NOS	0.666666666667
aml_ohsu_2018_2519	aml_ohsu_2018_16-00129	Denovo	None	AML with mutated NPM1	Favorable	Favorable	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	WES + RNA-seq	Yes	Yes	No	Yes	Yes	No	1	Standard Chemotherapy	2	7+3 (Cytarabine, Idarubicin)|HiDAC	2	Consolidation | Induction	Complete Response	Standard Chemotherapy	-1	Standard Chemotherapy	HiDAC	Consolidation	-1	0	0	90		No	0		17		20		17	13	3.6	0.98		21.7	7.3	46,XX[19]			Normal	71	Positive	6.6	18.3	Negative	Positive	Negative		Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	42	Matched	AMLNPM1	Leukemia	AML with Mutated NPM1	0.466666666667
aml_ohsu_2018_2526	aml_ohsu_2018_16-00132	After or at the time transformation from another heme malignancy	None	AML with myelodysplasia-related changes	Adverse	Not Enough Information	AML with myelodysplasia-related changes	Post-Chemotherapy	Peripheral Blood	WES + RNA-seq	Yes	Yes	No	Yes	Yes	No	1	Standard Chemotherapy	1	Azacitidine, MLN4924	1	Induction	Complete Response	Standard Chemotherapy	498	Standard Chemotherapy	Azacitidine, MLN4924	Induction	498	0		6		No	3.8		48.1	9.5	38.1		41	25	4.4	0.73		36.5	12.7	48,XY,+8,del(20)(q11.2),+21[14]/46,XY[6]		94.8	This test has detected a 20q deletion, trisomy 8, and trisomy 21 in 14 cells. All these abnormalities are commonly seen in AML and MDS.	43	These are positive for CD34, CD117, HLA-DR, and CD33.	6.4	2.1	Negative	Negative												75	Unmatched	AMLMRC	Leukemia	AML with Myelodysplasia-Related Changes	0.133333333333
aml_ohsu_2018_2429	aml_ohsu_2018_16-00135		MLLT3-KMT2A	Therapy-related myeloid neoplasms	Intermediate	Intermediate-II	Therapy-related myeloid neoplasms	Initial Acute Leukemia Diagnosis|Post-Chemotherapy	Bone Marrow Aspirate	WES	No	Yes	No	No	Yes	No	1	Standard Chemotherapy	1	Azacitidine	1	Hypomethylating/Low Dose Cytarabine				Standard Chemotherapy	Azacitidine	Hypomethylating/Low Dose Cytarabine	-1	0		95		No						0	21	23	2.8			17.1	6.1	46,XX,t(9;11)(p22;q23)[20]		97.7	85% MLL rearrangement (c/w karyotype)	19	dim CD13, CD33, CD56, bright CD64, CD117, CD123 and HLA-DR-positive; MPO and CD34-negative	6.1	0.39	Negative	Negative												75	Matched	TMN	Leukemia	Therapy-Related Myeloid Neoplasms	0.0666666666667
aml_ohsu_2018_2530	aml_ohsu_2018_16-00139	After or at the time transformation from another heme malignancy	Unknown	AML with mutated NPM1	Favorable	Not Enough Information	AML with mutated NPM1	Post-Chemotherapy	Peripheral Blood	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	1	Standard Chemotherapy	1	Ruxolitinib	1	Induction	Unknown	Standard Chemotherapy	28	Standard Chemotherapy	Ruxolitinib	Induction	28	0				No	0.5		39.2	7.5	52.5		10	21	4.5	0.87		34.1	10.9			92.4		6		7.6	3.8	Negative	Positive												73	Unmatched	AMLNPM1	Leukemia	AML with Mutated NPM1	0.266666666667
aml_ohsu_2018_2532	aml_ohsu_2018_16-00143	Denovo	None	AML with myelodysplasia-related changes	Intermediate	Intermediate-II	AML with myelodysplasia-related changes	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	WES + RNA-seq	Yes	Yes	No	Yes	Yes	No	3	Standard Chemotherapy | Bone Marrow Transplant | Targeted Therapy - Kinase Inhibitor(s)	4	Sorafenib|Hydroxyurea|7+3 (Cytarabine, Idarubicin) plus Sorafenib|Busulfan, Cyclophosphamide	3	Allogeneic - Sibling | Induction | Experimental	Refractory	Standard Chemotherapy	1	Bone Marrow Transplant	Busulfan, Cyclophosphamide	Allogeneic - Sibling	-1	-1		57	24	No											M2			47,XY,t(8;22)(p11.2;q11.2),+19[20]			t(8;22) clone observed, consistent with a neoplastic process		Positive		100.2	Negative	Negative	Negative		Negative	Negative				Negative				58	Matched	AMLMRC	Leukemia	AML with Myelodysplasia-Related Changes	0.166666666667
aml_ohsu_2018_2533	aml_ohsu_2018_16-00145	After or at the time transformation from another heme malignancy	None	AML with myelodysplasia-related changes	Adverse	Intermediate-II	AML with myelodysplasia-related changes	Initial Acute Leukemia Diagnosis|Post-Chemotherapy	Bone Marrow Aspirate	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	1	Standard Chemotherapy	3	Vidaza|Decitabine|Fludarabine, Cytarabine	2	Salvage | Supportive/Palliative Care				Standard Chemotherapy	Fludarabine, Cytarabine	Salvage	-1	0	0	27	2	No	0		60.2	8.4	29.4		12	15	4.8	0.98		30.7	9.3	46,XY,t(1;12)(p32;p13)[3]/46,XY[17]	215		nuc ish(D5S2064,D5S630,EGR1)x2[197],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[194],(RUNX1T1,RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[199],(PML,RARA)x2[199],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[198]	121	CD2(-), CD4(-),CD7(-), CD10(partial +), CD11b(-), CD13(dim +), CD14(-), CD38(variably +/small subset -), CD45(dim to moderately +), CD56(-), CD64(-), CD117(variably +), HLA-DR(variably +).	7.5	3.09	Negative	Negative				Negative	Negative	Negative			G12R; MAF 5.0%			75	Matched	AMLMRC	Leukemia	AML with Myelodysplasia-Related Changes	0.833333333333
aml_ohsu_2018_2546	aml_ohsu_2018_16-00150	After or at the time transformation from another heme malignancy	None	AML with myelodysplasia-related changes	Adverse	Adverse	AML with myelodysplasia-related changes	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	WES + RNA-seq	Yes	Yes	No	Yes	Yes	No	1	Standard Chemotherapy	4	Vidaza|Cytarabine|3+7 (Cytarabine, Daunorubicin)|Decitabine	4	Consolidation | Salvage | Induction | Supportive/Palliative Care	Complete Response	Standard Chemotherapy	-1	Standard Chemotherapy	Decitabine	Salvage	106	0		60		No				0										46, XY, del (3) (q12q21) [2]/47, idem, +8[11]/47, idem, der (15) t (1;15) (q21;p11.2) [7]			Trisomy 8 is detected in 28% of cells.		Positive for CD34, CD117, HLADR, CD33, CD13 and Negative for CD11b and CD64			Negative	Negative										p.G12A; MAF 24%		67	Matched	AMLMRC	Leukemia	AML with Myelodysplasia-Related Changes	1.36666666667
aml_ohsu_2018_2547	aml_ohsu_2018_16-00151	After or at the time transformation from another heme malignancy	None	Acute myeloid leukaemia, NOS	Adverse	Not Enough Information	Acute myeloid leukaemia, NOS	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	WES + RNA-seq	Yes	Yes	No	Yes	Yes	No	1	Standard Chemotherapy	1	3+7 (Cytarabine, Daunorubicin)	1	Unknown				Standard Chemotherapy	3+7 (Cytarabine, Daunorubicin)	Unknown	-1	0		80	10	No	2		68	4	8		8	10	3.9	0.85		21.2	7.2	46,XY[20]		110.4	The translocations commonly seen in AML are not detected. Loss of RARA and CBFB genes are detected in 14-39% of cells.	84	These are positive for CD34, CD117, HLADR, CD33, CD13, CD14 and CD11b.	5.9	0.9	Negative	Negative				Negative	p.R132C MAF 12%						p.Y220C; MAF 35%	67	Matched	AMLNOS	Leukemia	AML, NOS	1.06666666667
aml_ohsu_2018_2538	aml_ohsu_2018_16-00157	Denovo	None	AML with mutated NPM1	Favorable	Favorable	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	2	Standard Chemotherapy | Targeted Therapy - Other	4	AG-120|7+3 (Cytarabine, Idarubicin)|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|MiDAC	4	Consolidation | Salvage | Induction | Experimental	Complete Response	Standard Chemotherapy	6	Standard Chemotherapy	FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)	Salvage	-1	0	0	93	94	No	0	0	1	2.8	1.9	0.1	20	30	2.4	1.23		31.2	10.1	46,XY[20]		96.3	Normal	30	partial CD7, CD13, dim CD15, CD33, CD38, CD58, CD117, dim CD123, HLA-DR and partial MPO+.		125.16	Negative	Positive	Negative		p.R882H; MAF 46%		p.R132H; MAF 46%	Negative		Negative	Negative	Negative	Negative	67	Matched	AMLNPM1	Leukemia	AML with Mutated NPM1	0.166666666667
aml_ohsu_2018_2543	aml_ohsu_2018_16-00161		None	AML with minimal differentiation	Intermediate	Not Enough Information	AML with minimal differentiation	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	WES	No	Yes	No	No	Yes	No	1	Standard Chemotherapy	3	5+2 (Cytarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin)|MiDAC	3	Consolidation | Induction | Re-induction	Refractory	Standard Chemotherapy	12	Standard Chemotherapy	MiDAC	Consolidation	-1	0	0.3	40	3	No	1.4	0	76.5	2.9	18.9	0	32	14	3.7	0.71	M0	28.5	10.2	46,XY[20]	122	96	Normal	41	CD13, CD33, bright CD34, CD38, CD58, CD117, and TdT	6.4	3.49	Negative	Negative												65	Matched	AMLMD	Leukemia	AML with Minimal Differentiation	0.4
aml_ohsu_2018_2569	aml_ohsu_2018_16-00217		None	AML with mutated CEBPA	Intermediate	Intermediate-II	AML with mutated CEBPA	Residual Disease	Bone Marrow Aspirate	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	2	Standard Chemotherapy | Targeted Therapy - Other	3	AG-221|Azacitidine|Hydroxyurea	3	Hypomethylating/Low Dose Cytarabine | Consolidation | Experimental				Standard Chemotherapy	Hydroxyurea	Consolidation	55	0	0	23	12.1	No	0	0.8	8.6	19	59.5	0	16	15	3.4	1.52		27.8	9	47,XY,+8[20]	398	97.5	(FISH) was performed with a chromosome 8 probe, listed below. 95/100 (95%) interphase cells scored had three signals, consistent with trisomy 8 and the metaphase karyotype.	299	dimCD7, CD13, dimCD14, dimCD20, CD33, CD34, CD117, CD123, dim HLA-DR and MPO positive	7.6	10	Negative	Negative	p.R343fs*79; MAF 40%		p.G707fs*72; MAF 45%									86	Matched	AMLCEBPA	Leukemia	AML with Biallelic Mutations of CEBPA	0.4
aml_ohsu_2018_2571	aml_ohsu_2018_16-00220	Denovo	None	AML with mutated NPM1	Favorable	Favorable	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	1	Standard Chemotherapy	2	7+3 (Cytarabine, Idarubicin)|IDAC	2	Consolidation | Induction	Complete Response	Standard Chemotherapy	-1	Standard Chemotherapy	IDAC	Consolidation	-1	0		71.5	56	No														46,XY[20]			Normal		CD33, CD38, CD56, CD117, and myeloperoxidase		16.24	Negative	Positive												67	Matched	AMLNPM1	Leukemia	AML with Mutated NPM1	1.43333333333
aml_ohsu_2018_2503	aml_ohsu_2018_16-00226	After or at the time transformation from another heme malignancy	None	AML with myelodysplasia-related changes	Intermediate	Not Enough Information	AML with myelodysplasia-related changes	Post-Chemotherapy|Residual Disease	Peripheral Blood	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	3	Standard Chemotherapy | Supportive/Palliative Care | Targeted Therapy - Other	4	Azacitidine|Decitabine|Hydroxyurea|V212	2	Hypomethylating/Low Dose Cytarabine | Supportive/Palliative Care				Supportive/Palliative Care	Hydroxyurea	Supportive/Palliative Care	-1	-35	1.7		35	No	0	0	0.9	64.4	8.7	0.2	9	22	3.1	2.11		25.5	7.8	46,XY[22]	722	95.5	Normal	438	CD13, dim CD33, bright CD34, CD38, CD117, dim HLA-DR positive	5.8	116.52	Negative	Negative												79	Unmatched	AMLMRC	Leukemia	AML with Myelodysplasia-Related Changes	0.133333333333
aml_ohsu_2018_2584	aml_ohsu_2018_16-00232	Denovo	None	AML with myelodysplasia-related changes	Adverse	Adverse	AML with myelodysplasia-related changes	Initial Acute Leukemia Diagnosis	Peripheral Blood	WES	No	Yes	No	No	Yes	No	1	Standard Chemotherapy	2	7+3 (Cytarabine, Idarubicin)|CLAG (Cladribine, Cytarabine, Filgrastim)	2	Induction | Re-induction	Refractory	Standard Chemotherapy	-1	Standard Chemotherapy	CLAG (Cladribine, Cytarabine, Filgrastim)	Re-induction	143	-1		78.3	37	No														46,XY,ins(10;11)(p12;q23q23)[9]/49,sl,+4,+6,+21[4]/46,XY[7]			- 11q23 rearrangement involving the KMT2A (MLL) locus in  51/200 (25.5 percent) cells scored,  - 3 copies of the RUNX1 locus at 21q22 in 91/200 (45.5  percent) cells scored.		CD13, partial CD15, CD33, CD34, weak CD64,  very weak partial CD117, and myeloperoxidase		2.64	Negative	Negative												58	Matched	AMLMRC	Leukemia	AML with Myelodysplasia-Related Changes	0.466666666667
aml_ohsu_2018_2581	aml_ohsu_2018_16-00249	After or at the time transformation from another heme malignancy	None	Acute myeloid leukaemia, NOS	Intermediate	Not Enough Information	Acute myeloid leukaemia, NOS	Post-Chemotherapy|Residual Disease	Bone Marrow Aspirate	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	1	Standard Chemotherapy	1	Vidaza	1	Supportive/Palliative Care				Standard Chemotherapy	Vidaza	Supportive/Palliative Care	-1	0		60	50	No				2										46,XY[20]					These are positive for HLA-DR, CD34,CD117, CD33, CD11B, CD64 but Negative for CD13, CD14, CD16, MPO, TDT and all B and T cell markers		25	Negative	Negative												75	Matched	AMLNOS	Leukemia	AML, NOS	0.4
aml_ohsu_2018_2477	aml_ohsu_2018_16-00261		None	Acute myeloid leukaemia, NOS	Intermediate	Not Enough Information	Acute myeloid leukaemia, NOS	Post-Chemotherapy|Residual Disease	Bone Marrow Aspirate	WES	No	Yes	No	No	Yes	No	2	Standard Chemotherapy | Bone Marrow Transplant	3	Busulfan, Fludarabine|7+3 (Cytarabine, Idarubicin)|HiDAC	3	Allogeneic - Sibling | Induction | Re-induction	Unknown	Standard Chemotherapy	-1	Bone Marrow Transplant	Busulfan, Fludarabine	Allogeneic - Sibling	97	0		20		No	0		90	0	10		15	11	3.6	0.8		20.3	6.9	46,XY[20]		85.7	Not Available (no FISH done)	48	CD117 stains clusters and scattered immature mononuclear cells with atypia, 20%. CD34 is negative.	6.1	0.2	Negative	Negative				Negative								50	Matched	AMLNOS	Leukemia	AML, NOS	0.6
aml_ohsu_2018_2225	aml_ohsu_2018_16-00264		None	Therapy-related myeloid neoplasms	Intermediate	Intermediate-II	Therapy-related myeloid neoplasms	Residual Disease|Post-Chemotherapy	Bone Marrow Aspirate	WES + RNA-seq	Yes	Yes	No	Yes	Yes	No	2	Standard Chemotherapy | Supportive/Palliative Care	5	7+3 (Cytarabine, Idarubicin)|Azacitidine|CLAG-M (Cladribine, Cytarabine, Mitoxantrone, Filgrastim)|Hydroxyurea|Mitoxantrone	4	Hypomethylating/Low Dose Cytarabine | Induction | Re-induction | Supportive/Palliative Care	Refractory	Standard Chemotherapy	-1	Supportive/Palliative Care	Hydroxyurea	Supportive/Palliative Care	-1	-37		95	99	No														46,XX,del(7)(q22q36)[18]/46,sl,t(1;10)(p13;q24)[2]			- 3 copies of the MECOM locus at 3q26.2, suggestive of a  rearrangement or gain of this locus, in 156/200 (78.0  percent) cells scored.  - deletion 7q31 involving the D7S486 locus in 162/200 (81.0  percent) cells scored.				20.39	Positive	Negative												72	Matched	TMN	Leukemia	Therapy-Related Myeloid Neoplasms	1.4
aml_ohsu_2018_1241	aml_ohsu_2018_16-00267		None	Acute myelomonocytic leukaemia	Intermediate	Not Enough Information	Acute myelomonocytic leukaemia	Post-Chemotherapy	Bone Marrow Aspirate	WES	No	Yes	No	No	Yes	No	1	Standard Chemotherapy	4	7+3 (Cytarabine, Idarubicin)|HiDAC|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Azacitidine	4	Consolidation | Induction | Re-induction | Maintenance	Complete Response	Standard Chemotherapy	6	Standard Chemotherapy	Azacitidine	Maintenance	-1	0	0.9		1	No	0	8.9	18.8	15.2	56.2	5	50	59	3.1	1.2		26.9	9.5	46,XY[20]	420	97.5		152	The atypical, previously identified myeloid blast population (CD117+/CD34-) is not seen. Lymphocytes are about 5%, and mostly T cells which have a reversed CD4:CD8 ratio and no antigen aberrancy. B cells are essentially absent, and NK cells are not increased	6.2	4	Negative	Negative												60	Matched	AML	Leukemia	Acute Myeloid Leukemia	0.3
aml_ohsu_2018_2593	aml_ohsu_2018_16-00269	Denovo	Unknown	AML with mutated NPM1	Favorable	Not Enough Information	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	1	Standard Chemotherapy	2	HiDAC|3+7 (Cytarabine, Daunorubicin)	2	Consolidation | Induction	Complete Response	Standard Chemotherapy	8	Standard Chemotherapy	HiDAC	Consolidation	99	0	0	65	11.2	No	3.5	0	76.7	0	8.6	0	19	11	2.8	0.53		23.7	7.8		197	100.4	Normal	222	CD13, CD33, CD117, CD123, dim HLA-DR and MPO	6.1	2.41	Negative	Positive					p.R132H; MAF 44%							44	Matched	AMLNPM1	Leukemia	AML with Mutated NPM1	0.5
aml_ohsu_2018_2594	aml_ohsu_2018_16-00271	Denovo	None	AML with mutated NPM1	Intermediate	Intermediate-I	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Peripheral Blood	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	3	Standard Chemotherapy | Bone Marrow Transplant | Targeted Therapy - Kinase Inhibitor(s)	3	Fludarabine, Melphalan|Crenolanib|7+3 (Cytarabine, Idarubicin) plus Crenolanib	3	Allogeneic - Sibling | Induction | Experimental	Complete Response	Standard Chemotherapy	39	Bone Marrow Transplant	Fludarabine, Melphalan	Allogeneic - Sibling	-1	-1	0	63	42	No	0		32.7	4.4	26.6		27	39	3.1	0.68		19.3	6	46,XX[20]			nuc ish(D5S2064,D5S630,EGR1)x2[199],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[200],(RUNX1T1,RUNX1)x2[199],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con3'CBFBx2)[200]	176	CD2(-), CD4(partial dim +), CD7(variably +), CD11b(-), CD13(+), CD14(-), CD15(partial +), CD16(-), CD33(variably +), CD34(partial+), CD36(-), CD38(variably +), CD45(variably +), CD56(-), CD64(-), CD117(+), HLA-DR(partial +).	6.3	22.01	Positive	Positive				Negative								22	Matched	AMLNPM1	Leukemia	AML with Mutated NPM1	0.333333333333
aml_ohsu_2018_2595	aml_ohsu_2018_16-00273	Denovo	None	AML with mutated CEBPA	Intermediate	Favorable	AML with mutated CEBPA	Initial Acute Leukemia Diagnosis	Peripheral Blood	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	1	Standard Chemotherapy	1	7+3 (Cytarabine, Idarubicin)	1	Induction	Refractory	Standard Chemotherapy	7	Standard Chemotherapy	7+3 (Cytarabine, Idarubicin)	Induction	7	-2				No														46,XX[20]			Normal					Negative	Negative	c.68dup; MAF 21%		c.2645G>A; MAF 43.9%							c.35G>A; MAF 30.2%		62	Unmatched	AMLCEBPA	Leukemia	AML with Biallelic Mutations of CEBPA	0.233333333333
aml_ohsu_2018_2597	aml_ohsu_2018_16-00278	Denovo	None	AML with mutated NPM1	Favorable	Intermediate-I	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	2	Standard Chemotherapy | Bone Marrow Transplant	2	7+3 (Cytarabine, Idarubicin)|Fludarabine, Cyclophosphamide, Thiotepa, TBI	2	Induction | Double Umbilical Cord Blood Transplant (DUCBT)	Complete Response	Standard Chemotherapy	41	Bone Marrow Transplant	Fludarabine, Cyclophosphamide, Thiotepa, TBI	Double Umbilical Cord Blood Transplant (DUCBT)	-1	0	0	83	74	No	0		13	0	13		15	45	4	1.27		25.2	8.7	46,XY[20]			Normal	39	Positive	6	53.3	Positive	Positive	Negative		c.2645G>A; p.R882H	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	64	Matched	AMLNPM1	Leukemia	AML with Mutated NPM1	0.9
aml_ohsu_2018_2606	aml_ohsu_2018_16-00289	Denovo	None	AML with mutated NPM1	Intermediate	Intermediate-I	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	1	Standard Chemotherapy	2	Azacitidine|7+3 (Cytarabine, Idarubicin) plus Sorafenib	2	Consolidation | Induction	Complete Response i	Standard Chemotherapy	45	Standard Chemotherapy	Azacitidine	Consolidation	34	0	0	95	92.9	No	0	0.7	3.6	1.4	1.4	0.1	101	55	3.2	0.83		37	12.4	46,XX[20]	697	95.1	Normal	42	CD13, CD33, CD38, CD56, CD58, partial CD64, CD117, CD123, and MPO positive	6.3	166.91	Positive	Positive												65	Matched	AMLNPM1	Leukemia	AML with Mutated NPM1	0.333333333333
aml_ohsu_2018_2607	aml_ohsu_2018_16-00292	Denovo	None	AML with mutated NPM1	Favorable	Intermediate-I	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	1	Standard Chemotherapy	1	7+3 (Cytarabine, Idarubicin)	1	Induction	Unknown	Standard Chemotherapy	3	Standard Chemotherapy	7+3 (Cytarabine, Idarubicin)	Induction	3	0	0	90	98.4	No	0	0	0.8	0	0.8	0.1	18	36	2.9	1.44		25.9	8.2	46,XX[20]		90.6	Normal	19	CD13, CD33, CD38, CD58, dim CD64, CD117, CD123, and MPO	7.7	122.89	Positive	Positive			p.R326P; MAF 50%									73	Matched	AMLNPM1	Leukemia	AML with Mutated NPM1	0.3
aml_ohsu_2018_2547	aml_ohsu_2018_16-00294	After or at the time transformation from another heme malignancy	None	Acute myeloid leukaemia, NOS	Intermediate	Not Enough Information	Acute myeloid leukaemia, NOS	Post-Chemotherapy	Bone Marrow Aspirate	WES	No	Yes	No	No	Yes	No	1	Standard Chemotherapy	1	3+7 (Cytarabine, Daunorubicin)	1	Unknown				Standard Chemotherapy	3+7 (Cytarabine, Daunorubicin)	Unknown	-1	0		1		No				1										46,XY[20]			The translocations normally seen in AML are not detected.	266	No increased or immunophenotypically abnormal blast cell populations identified.		3.2	Negative	Negative												67	Matched	AMLNOS	Leukemia	AML, NOS	0.233333333333
aml_ohsu_2018_2611	aml_ohsu_2018_16-00303	Denovo	None	AML with mutated NPM1	Favorable	Intermediate-I	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	2	Standard Chemotherapy | Bone Marrow Transplant	4	7+3 (Cytarabine, Idarubicin)|HiDAC|GCLAC (GCSF, Clofarabine & Cytarabine)|Fludarabine, Cyclophosphamide, Thiotepa, TBI	4	Consolidation | Salvage | Induction | Double Umbilical Cord Blood Transplant (DUCBT)	Complete Response	Standard Chemotherapy	27	Standard Chemotherapy	GCLAC (GCSF, Clofarabine & Cytarabine)	Salvage	-1	0	0	1.5	2	No	0		23	57	13		67	33	3	1.87		29	9.5	46,XX[19]			Normal	28	Positive	7.5	58.7	Positive	Positive	Negative		c.2644C>T; p.R882C		Negative	Negative	Negative	Negative	Negative	Negative	Negative	56	Matched	AMLNPM1	Leukemia	AML with Mutated NPM1	0.166666666667
aml_ohsu_2018_2612	aml_ohsu_2018_16-00307	After or at the time transformation from another heme malignancy	None	Acute myeloid leukaemia, NOS	Adverse	Intermediate-II	Acute myeloid leukaemia, NOS	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	WES + RNA-seq	Yes	Yes	No	Yes	Yes	No	0		0		0					NONE	NONE	NONE		0		75	26	No	2		15	8	43		118	53	3.8	1.26		22.9	7.7	46,XY,del(7)(q32),add(13)(p11.2)[15]		81.8	This test has detected 7q deletion and an abnormal chromosome 13 in all 15 metaphase cells analyzed. 7q deletion is the most cp,,om abnormality in MDS and other types of myeloid malignancies.	24	These are positive for CD34, CD117, HLADR, CD33 and CD13	8.7	5	Negative	Negative	Negative			Negative	p.R132C; MAF 45%							71	Matched	AMLNOS	Leukemia	AML, NOS	1.06666666667
aml_ohsu_2018_1973	aml_ohsu_2018_16-00315		None	AML with minimal differentiation	Intermediate	Not Enough Information	AML with minimal differentiation	Post-Chemotherapy|Residual Disease	Peripheral Blood	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	2	Standard Chemotherapy | Supportive/Palliative Care	3	7+3 (Cytarabine, Idarubicin)|Azacitidine|Decitabine	3	Hypomethylating/Low Dose Cytarabine | Induction | Supportive/Palliative Care	Refractory	Standard Chemotherapy	6	Supportive/Palliative Care	Decitabine	Hypomethylating/Low Dose Cytarabine	-1	-142	0			No	0	0	15.5	6.9	5.2	0	79	38	3.1	0.8		27.9	9.1	47,XY,+4[2]/46,XY[18]		87.7	Two of twenty metaphase cells examined were abnormal, with trisomy 4, as seen previously.	44		6.3	50.58	Negative	Negative												72	Matched	AMLMD	Leukemia	AML with Minimal Differentiation	0.2
aml_ohsu_2018_2615	aml_ohsu_2018_16-00316		Unknown	unknown	Intermediate	Not Enough Information	unknown	Residual Disease	Bone Marrow Aspirate	WES + RNA-seq	Yes	Yes	No	Yes	Yes	No	0		0		0					NONE	NONE	NONE		0		20		No																						Negative	Negative												73	Unmatched	AML	Leukemia	Acute Myeloid Leukemia	0.233333333333
aml_ohsu_2018_2621	aml_ohsu_2018_16-00332		Unknown	Myelodysplastic syndrome, unclassifiable	Adverse	Not Enough Information	Myelodysplastic syndrome, unclassifiable	Residual Disease	Peripheral Blood	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	1	Standard Chemotherapy	1	Vidaza	1	Supportive/Palliative Care				Standard Chemotherapy	Vidaza	Supportive/Palliative Care	268	0			4	No	1		13	5	23		13	57	2.5	1.83		25	8.2			105.9		32		5.8	66.7	Negative	Negative									p.Q61P, MAF 13%			73	Unmatched	MDSU	Myelodysplastic Syndromes	MDS, Unclassifiable	0.466666666667
aml_ohsu_2018_2626	aml_ohsu_2018_16-00339		None	Atypical chronic myeloid leukaemia, BCR-ABL1 negative	Intermediate		Atypical chronic myeloid leukaemia, BCR-ABL1 negative	Unknown	Bone Marrow Aspirate	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	1	Targeted Therapy - Kinase Inhibitor(s)	1	Hydroxyurea	1	Induction	Unknown	Targeted Therapy - Kinase Inhibitor(s)	-1	Targeted Therapy - Kinase Inhibitor(s)	Hydroxyurea	Induction	-1	0	1.6	13	6.8	No	0.8	0	5.7	2.5	72.1	5.7	24	36	2.9	0.95		29.1	8.9	46,XX[20]	953	105.1	Normal	208	CD13, CD33, CD34, partial CD117, CD123, HLA-DR	6.7	109.77	Positive	Negative												70	Matched	ACML	Myelodysplastic/Myeloproliferative Neoplasms	Atypical Chronic Myeloid Leukemia, BCR-ABL1-	0.533333333333
aml_ohsu_2018_2628	aml_ohsu_2018_16-00344	Denovo	None	AML with mutated NPM1	Favorable	Favorable	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	1	Standard Chemotherapy	2	7+3 (Cytarabine, Idarubicin)|HiDAC	2	Consolidation | Induction	Complete Response	Standard Chemotherapy	7	Standard Chemotherapy	HiDAC	Consolidation	96	0	0	30	10.5	No	0	0	19.7	0.9	71.4	0	77	27	3.4	1.01		26.4	8.9	46,XY[20]	479	96.4	Normal	101	CD13, CD33, CD117, CD123, and HLA-DR	6.4	4.4	Negative	Positive			p.R882C; MAF 40%									59	Matched	AMLNPM1	Leukemia	AML with Mutated NPM1	0.9
aml_ohsu_2018_2630	aml_ohsu_2018_16-00351	Denovo	None	AML with mutated CEBPA	Favorable	Favorable	AML with mutated CEBPA	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	1	Standard Chemotherapy	2	7+3 (Cytarabine, Idarubicin)|HiDAC	2	Consolidation | Induction	Complete Response	Standard Chemotherapy	5	Standard Chemotherapy	HiDAC	Consolidation	120	-3				Yes														46,XX[20]			Normal					Negative	Negative	p.T98fs*10 ; MAF 40%											46	Matched	AMLCEBPA	Leukemia	AML with Biallelic Mutations of CEBPA	1.0
aml_ohsu_2018_2632	aml_ohsu_2018_16-00354	Denovo	None	AML with myelodysplasia-related changes	Adverse	Adverse	AML with myelodysplasia-related changes	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	0		0		0					NONE	NONE	NONE		-1		86	87	No														43-45,X,-Y,del(5)(q22q35),del(7)(q22),+8,-9,add(9)(p13),+11,-13,-14,add(16)(q24),-17,-18,del(20)(q11.2q13.2),+2-3mar[cp21]			5q31 (EGR1): deletion present  8q22 (RUNX1T1): gain present  11q23 (KMT2A; also known as MLL): gain present	27			70.01	Negative	Negative											p.?; MAF 91%	79	Unmatched	AMLMRC	Leukemia	AML with Myelodysplasia-Related Changes	0.2
aml_ohsu_2018_2633	aml_ohsu_2018_16-00356	After or at the time transformation from another heme malignancy	Unknown	AML with myelodysplasia-related changes	Intermediate	Not Enough Information	AML with myelodysplasia-related changes	Post-Chemotherapy|Residual Disease	Peripheral Blood	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	1	Standard Chemotherapy	2	Lenalidomide|3+7 (Cytarabine, Daunorubicin)	2	Unknown | Supportive/Palliative Care				Standard Chemotherapy	3+7 (Cytarabine, Daunorubicin)	Unknown	-1	0			1	No	9		1	6	58		135	44	3.2	0.79		21.6	7.3			85		22		5.9	9.1	Negative	Negative										p.Q61H, MAF 21%		59	Unmatched	AMLMRC	Leukemia	AML with Myelodysplasia-Related Changes	0.1
aml_ohsu_2018_2530	aml_ohsu_2018_16-00358	After or at the time transformation from another heme malignancy	None	AML with mutated NPM1	Favorable	Favorable	AML with mutated NPM1	Post-Chemotherapy	Bone Marrow Aspirate	RNA-seq	Yes	No	Yes	Yes	No	Yes	1	Standard Chemotherapy	1	Ruxolitinib	1	Induction	Unknown	Standard Chemotherapy	28	Standard Chemotherapy	Ruxolitinib	Induction	28	1		5		No				1										46,XX[20]			This test has not detected clonal abnormalities in the cells analyzed. Subtle structural changes cannot be ruled out due to the limitations of resolution. Small percentage of tumor cells with chromosome abnormalities may not be detected due to the limited number of cells examined.	24	CD34 positive blasts are rare, <1%		1.8	Negative	Positive												73	Unmatched	AMLNPM1	Leukemia	AML with Mutated NPM1	NA
aml_ohsu_2018_2546	aml_ohsu_2018_16-00359	After or at the time transformation from another heme malignancy	None	AML with myelodysplasia-related changes	Adverse	Not Enough Information	AML with myelodysplasia-related changes	Post-Chemotherapy	Bone Marrow Aspirate	WES	No	Yes	No	No	Yes	No	1	Standard Chemotherapy	4	Vidaza|Cytarabine|3+7 (Cytarabine, Daunorubicin)|Decitabine	4	Consolidation | Salvage | Induction | Supportive/Palliative Care	Complete Response	Standard Chemotherapy	-1	Standard Chemotherapy	Decitabine	Salvage	106	-55		2		No				1										46, XY, del (3) (q12q21) [2]/47, idem, +8[11]/47, idem, der (15) t (1;15) (q21;p11.2) [7]			Trisomy 8 is detected in 28% of cells.	47	Positive for CD34, CD117, CD13, HLA-DR, CD33 and CD38		2.5	Negative	Negative				Negative								67	Matched	AMLMRC	Leukemia	AML with Myelodysplasia-Related Changes	0.4
aml_ohsu_2018_2640	aml_ohsu_2018_16-00366	Denovo	None	AML with mutated CEBPA	Adverse	Favorable	AML with mutated CEBPA	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	WES	No	Yes	Yes	No	Yes	Yes	2	Standard Chemotherapy | Bone Marrow Transplant	3	7+3 (Cytarabine, Idarubicin)|HiDAC|Busulfan, Cyclophosphamide	4	Consolidation | Induction | Allogeneic - Mismatched Unrelated Donor | Re-induction	Refractory	Standard Chemotherapy	13	Bone Marrow Transplant	Busulfan, Cyclophosphamide	Allogeneic - Mismatched Unrelated Donor	-1	0	0.8	63	12	No	0.8	0	80.9	1.7	7.5	0	26	9	3.2	0.95		30.2	9.8	46,XX[20]		92.1	Normal	94	CD13, dimCD33, CD34, CD38, CD117, dimCD123, dim HLA-DR, and dim MPO positive.	6.2	1.13	Negative	Negative	p.N321D; MAF 20%		p.R882C; MAF 20%		p.R132C; MAF 20%							50	Matched	AMLCEBPA	Leukemia	AML with Biallelic Mutations of CEBPA	0.566666666667
aml_ohsu_2018_2653	aml_ohsu_2018_16-00373	Denovo	None	Myeloid sarcoma	Intermediate	Not Enough Information	Myeloid sarcoma	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	WES + RNA-seq	Yes	Yes	No	Yes	Yes	No	3	Standard Chemotherapy | Bone Marrow Transplant | Other	4	7+3 (Cytarabine, Idarubicin)|HiDAC|Radiation|Busulfan, Cyclophosphamide	4	Consolidation | Induction | Allogeneic - Mismatched Unrelated Donor | Supportive/Palliative Care	Unknown	Standard Chemotherapy	24	Bone Marrow Transplant	Busulfan, Cyclophosphamide	Allogeneic - Mismatched Unrelated Donor	-1	0	1.1	1	0	No	2.8	0.2	30.3	5.2	60.4	0	34	20	4.2	0.93		39.2	14.4	46,XY[20]	154	94.9	Normal	162	dim/partial CD1a, dimCD4, dimCD5, CD33, CD43, dimCD45, CD56, CD68, CD117, and lysozyme positive with Ki67 activity >90%.	7.5	5.35	Negative	Negative												37	Matched	MS	Leukemia	Myeloid Sarcoma	0.133333333333
aml_ohsu_2018_2654	aml_ohsu_2018_16-00374		None	Therapy-related myeloid neoplasms	Intermediate	Not Enough Information	Therapy-related myeloid neoplasms	Post-Chemotherapy	Bone Marrow Aspirate	WES	No	Yes	No	No	Yes	No	2	Supportive/Palliative Care | Other	5	Radiation|Paclitaxel|Doxorubicin|Cisplatin|5-FU	2	Symptom Control | Supportive/Palliative Care				Supportive/Palliative Care	Paclitaxel	Supportive/Palliative Care	274	0		1		No				0										46,XX[20]				100	Granulocytes are significantly decreased		4.2	Negative	Negative												64	Matched	TMN	Leukemia	Therapy-Related Myeloid Neoplasms	0.333333333333
aml_ohsu_2018_2664	aml_ohsu_2018_16-00392	After or at the time transformation from another heme malignancy	None	AML with myelodysplasia-related changes	Adverse	Adverse	AML with myelodysplasia-related changes	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	2	Standard Chemotherapy | Targeted Therapy - Kinase Inhibitor(s)	3	Ruxolitinib|Hydroxyurea|Decitabine	2	Consolidation | Experimental				Targeted Therapy - Kinase Inhibitor(s)	Ruxolitinib	Experimental	7	-1	0			No	0	1.6	43.7	9.4	29.7	5.5	27	39	2	0.41	M7	26.2	8.2	46,XX,t(7;13)(q22;q12),del(20)(q11.2)[1]/46,sl,dup(1)(p25),del(2)(q21q23),add(8)(q13q22)[3]/46,sdl,add(5)(p15)[8]/46,sdl,add(12)(p13)[3]/46,sdl,add(12)(p13),add(13)(p12)[4]/46,XX[1]	1024	89.4	RUNX1T1 (8q21.3): 35% of cells had three signals for RUNX1T1 on 8q. No evidence for t(8;21).	17		5.5	6.28	Negative	Negative												78	Matched	AMLMRC	Leukemia	AML with Myelodysplasia-Related Changes	0.566666666667
aml_ohsu_2018_2665	aml_ohsu_2018_16-00400	Denovo	None	AML with myelodysplasia-related changes	Adverse	Adverse	AML with myelodysplasia-related changes	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	WES	No	Yes	No	No	Yes	No	1	Standard Chemotherapy	1	Azacitidine	1	Induction	UNKNOWN	Standard Chemotherapy	-1	Standard Chemotherapy	Azacitidine	Induction	-1	0	4.5	50	33	No	0	0	47.3	8.9	6.3	3.7	39	27	3.4	0.9		29.8	10.3	41~47,XY,+1,del(1)(q42),add(2)(q33),del(5)(q13q33),der(7)add(7)(p22)add(7)(q11.2),-9,10,der(12)add(12)(p13)ins(?;12)(?q13),13,add(13)(q34),-16,17,add(19)(q13.3),21,+r,+1~4mar[cp13]/41~47,idem,-der(7)[cp7]	2840	85.4	deleted 5q, deleted 7q, and monosomy 17 in the majority of cells scored. 52% of cells also had three RUNX1 (21q22) signals consistent with chromosome 21 material being present in marker and/or additional material of uncertain origin	29	dimCD7, CD13, CD33, CD34, partial CD56, CD117, dimCD123	7.1	3.49	Negative	Negative											p.R248W; MAF 57%	66	Matched	AMLMRC	Leukemia	AML with Myelodysplasia-Related Changes	0.633333333333
aml_ohsu_2018_2675	aml_ohsu_2018_16-00406	Denovo	None	Acute myeloid leukaemia, NOS	Intermediate	Not Enough Information	Acute myeloid leukaemia, NOS	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	WES + RNA-seq	Yes	Yes	No	Yes	Yes	No	1	Standard Chemotherapy	3	Vidaza|7+3 (Cytarabine, Idarubicin)|Azacitidine	3	Induction | Frontline | Re-induction	Complete Response	Standard Chemotherapy	7	Standard Chemotherapy	Vidaza	Re-induction	-1	0	0	23		No	1		51	11.2	36.8		23	16	3.4	0.55		27.1	9.1	46,XY[19]	178	88	Normal	28	CD13, CD33, CD34, CD38, CD117, CD123, dim HLA-DR, TdT, and MPO positive	6.4	1	Negative	Negative			p.R882H; MAF 41%									75	Matched	AMLNOS	Leukemia	AML, NOS	1.16666666667
aml_ohsu_2018_2678	aml_ohsu_2018_16-00410	Denovo	PML-RARA	Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA	Favorable	Adverse	Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	1	Standard Chemotherapy	1	ATRA, Arsenic Trioxide	1	Induction	Complete Response	Standard Chemotherapy	-1	Standard Chemotherapy	ATRA, Arsenic Trioxide	Induction	-1	0	0	90	53	No	0.9	3.5	35.7	1.7	5.2	0.7	28	24	2.8	1.12	M3	19.8	7	46,XY,t(3;16)(p13;q22),t(13;14)(q32;q24),t(15;17)(q22;q21)[20]	519	85.7	PML/RARA: 98/100 cells (98%) had a 1 red/ 1 green/ 2 yellow signal pattern, reflecting PML/RARA fusion and consistent with the 15;17 translocation observed in the metaphase karyotype.	38	CD13, CD33, CD38, CD58, CD64, dim CD71, CD123, CD117, MPO positive -FISH for t(15;17)	5.4	9.87	Negative	Negative												62	Matched	APLPMLRARA	Leukemia	APL with PML-RARA	0.2
aml_ohsu_2018_2687	aml_ohsu_2018_16-00459		Unknown	AML with mutated NPM1	Intermediate	Intermediate-I	AML with mutated NPM1	Post-Chemotherapy|Residual Disease	Peripheral Blood	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	2	Standard Chemotherapy | Targeted Therapy - Kinase Inhibitor(s)	5	7+3 (Cytarabine, Idarubicin)|HiDAC|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Sorafenib|Hydroxyurea	4	Consolidation | Induction | Experimental | Re-induction	Complete Response	Standard Chemotherapy	7	Targeted Therapy - Kinase Inhibitor(s)	Sorafenib	Experimental	55	0	0			No	0	0	30.8	10.3	0	0.3	195	75	3.6	0.68		25.4	8.2		1033	95.5		49		6.7	73.28	Positive	Positive												61	Unmatched	AMLNPM1	Leukemia	AML with Mutated NPM1	0.133333333333
aml_ohsu_2018_2688	aml_ohsu_2018_16-00460	Denovo	None	Acute myeloid leukaemia, NOS	Intermediate	Not Enough Information	Acute myeloid leukaemia, NOS	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	WES + RNA-seq	Yes	Yes	No	Yes	Yes	No	2	Standard Chemotherapy | Supportive/Palliative Care	3	7+3 (Cytarabine, Idarubicin)|CLAG (Cladribine, Cytarabine, Filgrastim)|Azacitidine	3	Salvage | Induction | Symptom Control	Refractory	Standard Chemotherapy	10	Supportive/Palliative Care	Azacitidine	Symptom Control	-1	-3				No														[46,XY]			Normal				4.17	Negative	Negative			 p.Trp297* (NM_175629.2); MAF 82.1%		p.Arg132Cys (NM_005896.3); MAF 39.1%							58	Matched	AMLNOS	Leukemia	AML, NOS	0.766666666667
aml_ohsu_2018_2690	aml_ohsu_2018_16-00465	Denovo	None	Acute myelomonocytic leukaemia	Adverse	Intermediate-II	Acute myelomonocytic leukaemia	Initial Acute Leukemia Diagnosis	Leukapheresis	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	3	Standard Chemotherapy | Bone Marrow Transplant | Intrathecal	4	Cytarabine|Sorafenib|Cytarabine, Daunorubicin, and Etoposide|Busulfan, Cyclophosphamide	3	Induction | Allogeneic - Mismatched Unrelated Donor | Re-induction	Refractory	Intrathecal	0	Bone Marrow Transplant	Busulfan, Cyclophosphamide	Allogeneic - Mismatched Unrelated Donor	-1	1	0	70	85	No	0	1.8	14.7	51.4	8.3	50	28	150	3.7	0.64	M4	14.3	4.6	47,XY,+8[19]/46,XY[1]		132.4	RUNX1T1 signal consistent with the trisomy 8 clone	49	dimCD11b, dimCD13, CD14, dimCD33, CD64, variable CD123, HLA-DR CD13,dimCD33, dim variable CD34, CD117, CD123, HLA-DR	7.1	214.49	Positive	Negative												12	Unmatched	AML	Leukemia	Acute Myeloid Leukemia	0.1
aml_ohsu_2018_2685	aml_ohsu_2018_16-00466	After or at the time transformation from another heme malignancy	None	Primary myelofibrosis	Adverse	Not Enough Information	Therapy-related myeloid neoplasms	Post-Transplant|Initial Acute Leukemia Diagnosis|Post-Chemotherapy	Peripheral Blood	WES	Yes	Yes	Yes	No	Yes	Yes	3	Standard Chemotherapy | Bone Marrow Transplant | Targeted Therapy - Kinase Inhibitor(s)	3	Fludarabine, Melphalan|Azacitidine|Sorafenib	4	Induction | Allogeneic - Mismatched Unrelated Donor | Experimental | Re-induction	Refractory	Standard Chemotherapy	153	Targeted Therapy - Kinase Inhibitor(s)	Sorafenib	Experimental	56	0	0	30	25	No	0.9	0	23.2	11.6	36.6	0	39	22	2.7			27.3	8.6	45,X,-Y,der(2)t(2;5)(q37;p13),-5,-18,add(19)(p13.3),+21,+21[cp13]/45,sl,-der(2)t(2;5)(q37;p13),add(2)(q11.2),add(12)(q15)[7]		97.2	EGR-1/ D5S23, D5S721/CEP 8: 64/100 cells (56%) had a 1 red/ 2 green/ 2 aqua signal pattern, indicating a deleted 5q,	11	CD13, dim CD33, CD43, CD117	6.8	4.54	Negative	Negative												59	Unmatched	PMF	Myeloproliferative Neoplasms	Primary Myelofibrosis	0.1
aml_ohsu_2018_2694	aml_ohsu_2018_16-00474	Denovo	RUNX1-RUNX1T1	AML with t(8;21)(q22;q22); RUNX1-RUNX1T1	Favorable	Favorable	AML with t(8;21)(q22;q22); RUNX1-RUNX1T1	Initial Acute Leukemia Diagnosis	Peripheral Blood	RNA-seq	Yes	No	Yes	Yes	No	Yes	1	Standard Chemotherapy	2	HiDAC|3+7 (Cytarabine, Daunorubicin)	2	Consolidation | Induction	Unknown	Standard Chemotherapy	20	Standard Chemotherapy	HiDAC	Consolidation	182	-1		70	91	No	0		7	2	0		23	25	2.4	0.66		26.6	8.7	46,XY,t(8;21)(q22;q22)[20]		94.7		28		6.3	71.1	Negative	Negative												50	Matched	AMLRUNX1RUNX1T1	Leukemia	AML with t(8;21)(q22;q22.1);RUNX1-RUNX1T1	NA
aml_ohsu_2018_2695	aml_ohsu_2018_16-00477		None	Acute monoblastic and monocytic leukaemia	Intermediate	Favorable	Acute monoblastic and monocytic leukaemia	Post-Chemotherapy|Post-Transplant	Peripheral Blood	WES	Yes	Yes	Yes	No	Yes	Yes	4	DLI | Standard Chemotherapy | Bone Marrow Transplant | Supportive/Palliative Care	7	HiDAC|Donor Lymphocyte Infusion|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|SWOG S1203 (7+3 +/- Vorinostat)|Hydroxyurea|Decitabine|Bu/Flu/TBI (Busulfan, Fludarabine, Total Body Irradiation)	6	Allogeneic - Sibling | Hypomethylating/Low Dose Cytarabine | Consolidation | Induction | Re-induction | Supportive/Palliative Care	Complete Response	Standard Chemotherapy	13	Supportive/Palliative Care	Decitabine	Supportive/Palliative Care	115	-55	0			No	0	0	19.8	12.9	53.5	5.3	44	29	2.8			30	10.3	46,XY[20]		87.7		193		6.8	4.53	Negative	Negative												51	Unmatched	AMOL	Leukemia	Acute Monoblastic/Monocytic Leukemia	0.0666666666667
aml_ohsu_2018_2697	aml_ohsu_2018_16-00479	After or at the time transformation from another heme malignancy	None	Therapy-related myeloid neoplasms	Intermediate	Intermediate-II	Therapy-related myeloid neoplasms	Residual Disease|Post-Chemotherapy|Post-Transplant	Peripheral Blood	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	2	Standard Chemotherapy | Bone Marrow Transplant	4	Busulfan, Fludarabine|7+3 (Cytarabine, Idarubicin)|Azacitidine|CLAG-M (Cladribine, Cytarabine, Mitoxantrone, Filgrastim)	5	Allogeneic - Sibling | Salvage | Induction | Re-induction | Supportive/Palliative Care	Refractory	Standard Chemotherapy	30	Standard Chemotherapy	Azacitidine	Salvage	4	0				No														46,XX,der(7)t(3;7)(q26;q21)[9]/46,XX[11]					Increased atypical CD34 positive, CD7 positive myeloblasts			Negative	Negative												40	Unmatched	TMN	Leukemia	Therapy-Related Myeloid Neoplasms	0.133333333333
aml_ohsu_2018_2699	aml_ohsu_2018_16-00481		CBFB-MYH11	Therapy-related myeloid neoplasms	Favorable	Favorable	Therapy-related myeloid neoplasms	Post-Chemotherapy|Residual Disease	Peripheral Blood	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	1	Standard Chemotherapy	2	7+3 (Cytarabine, Idarubicin)|IDAC	2	Consolidation | Induction	UNKNOWN	Standard Chemotherapy	-1	Standard Chemotherapy	IDAC	Consolidation	-1	0				No														46,XX,inv(16)(p13q22)[20]					Increased atypical CD34+myeloblasts representing 80%of leukocytes suggestive of recurrent AML.			Negative	Negative												61	Unmatched	TMN	Leukemia	Therapy-Related Myeloid Neoplasms	0.1
aml_ohsu_2018_2612	aml_ohsu_2018_16-00483	After or at the time transformation from another heme malignancy	None	Acute myeloid leukaemia, NOS	Intermediate	Intermediate-II	Acute myeloid leukaemia, NOS	Post-Chemotherapy|Residual Disease	Bone Marrow Aspirate	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	0		0		0					NONE	NONE	NONE		0		33		No				8										46,XY,del(7)(q32),add(13)(p11.2)[20]			Not Available. Pathogenic alterations are DETECTED in the ASXL1, IDH1, JAK2 and RUNX1 genes. Genomic alterations of uncertain significance are DETECTED in the CEBPA and TET2 genes (not seeing specific mutations or MAF)	22	They are positive for CD34, HLADR, CD117, CD13 and MPO and negative for TDT.			Negative	Negative				Negative								71	Matched	AMLNOS	Leukemia	AML, NOS	1.06666666667
aml_ohsu_2018_2701	aml_ohsu_2018_16-00484		None	Myelodysplastic/myeloproliferative neoplasm, unclassifiable	Intermediate		Myelodysplastic/myeloproliferative neoplasm, unclassifiable	Unknown	Bone Marrow Aspirate	WES	No	Yes	Yes	No	Yes	No	0		0		0					NONE	NONE	NONE		-2				No														46,XX[20], normal female chromosome complement.								Negative	Negative												74	Matched	MDSMPNU	Myelodysplastic/Myeloproliferative Neoplasms	MDS/MPN, Unclassifiable	NA
aml_ohsu_2018_2687	aml_ohsu_2018_16-00486		None	AML with mutated NPM1	Favorable or Intermediate	Intermediate-I	AML with mutated NPM1	Post-Chemotherapy|Residual Disease	Peripheral Blood	WES	No	Yes	No	No	Yes	No	2	Standard Chemotherapy | Targeted Therapy - Kinase Inhibitor(s)	5	7+3 (Cytarabine, Idarubicin)|HiDAC|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Sorafenib|Hydroxyurea	4	Consolidation | Induction | Experimental | Re-induction	Complete Response	Standard Chemotherapy	7	Targeted Therapy - Kinase Inhibitor(s)	Sorafenib	Experimental	55	0	0	98	90	No	0	0	34.5	5.5	0	0	101	36	3.6	0.56		32.9	11	46,XX[19]		91.9	Normal	23	CD7, CD13, CD33, partial CD34, partial CD64, CD117, CD123, HLA-DR and partial MPO+	6.9	5.84	Positive	Positive			p.P777S; MAF 90%		p.R132H; MAF 45%;p.R132H; MAF 41%							61	Unmatched	AMLNPM1	Leukemia	AML with Mutated NPM1	0.133333333333
aml_ohsu_2018_2704	aml_ohsu_2018_16-00491		None	AML with mutated NPM1	Adverse	Adverse	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Peripheral Blood	WES + RNA-seq	Yes	Yes	No	Yes	Yes	No	3	Standard Chemotherapy | Bone Marrow Transplant | Supportive/Palliative Care	5	FLAG (Fludarabine, High-dose Cytarabine, G-CSF)|Hydroxyurea|Decitabine|Fludarabine, Cyclophosphamide, TBI |Trametinib	3	Induction | Supportive/Palliative Care | Allogeneic - Matched Unrelated Donor	Refractory	Standard Chemotherapy	5	Supportive/Palliative Care	Hydroxyurea	Supportive/Palliative Care	2	-1	0	98	3.1	No	2	1	60	13	24	1.7	393	350	2.5	0.69		27.2	9.4	47,XX,+8,i(8)(q10),del(9)(q21.2q22.3),der(10)t(1;10)(q11;q22)[cp12]/47,idem,add(17)(p13)[8]		105.4	Normal	18	CD11b, CD13, CD14, CD33, CD56 and bright CD64+	5.4	2.42	Negative	Positive												29	Unmatched	AMLNPM1	Leukemia	AML with Mutated NPM1	0.1
aml_ohsu_2018_2705	aml_ohsu_2018_16-00494		None	Therapy-related myeloid neoplasms	Adverse	Adverse	Therapy-related myeloid neoplasms	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	1	Standard Chemotherapy	4	3+7 (Cytarabine, Daunorubicin)|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|FLAG (Fludarabine, High-dose Cytarabine, G-CSF)|Hydroxyurea	3	Salvage | Induction | Re-induction	Refractory	Standard Chemotherapy	6	Standard Chemotherapy	FLAG (Fludarabine, High-dose Cytarabine, G-CSF)	Salvage	5	0	0	90	94	No	1.9	0	4.6	89.8	3.7	0.2			2.8	0.93	M5	37.1	11.9	46,XX,t(1;11)(p32;q23)[20]		96.6	MLL: 94/100 cells (94%) had the abnormal 1 red/ 1 green/1 yellow signal	33	dim CD4, CD11b, partial CD13, partial CD14, CD15, CD33, partial CD56, CD58, bright CD64, partial CD123 and HLA-DR-positive		104.44	Negative	Negative			p.E283*; MAF 30%									72	Matched	TMN	Leukemia	Therapy-Related Myeloid Neoplasms	0.133333333333
aml_ohsu_2018_2706	aml_ohsu_2018_16-00498	Denovo	Unknown	Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA	Favorable	Not Enough Information	Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA	Initial Acute Leukemia Diagnosis	Peripheral Blood	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	1	Standard Chemotherapy	1	ATRA, Arsenic Trioxide	2	Consolidation | Induction	Complete Response	Standard Chemotherapy	-1	Standard Chemotherapy	ATRA, Arsenic Trioxide	Consolidation	-1	0				No																	This analysis showed evidence of a PML-RARA rearrangement in 177/200 (88.5 percent) interphase cells scored.	26	Large population of CD117pos, CD34neg, HLA-DR neg myeloblasts, representing 78% of leukocytes consistent w/AML.		12.75	Positive	Negative												33	Unmatched	APLPMLRARA	Leukemia	APL with PML-RARA	0.0333333333333
aml_ohsu_2018_2708	aml_ohsu_2018_16-00504		None	Therapy-related myeloid neoplasms	Favorable	Intermediate-II	Therapy-related myeloid neoplasms	Post-Chemotherapy|Residual Disease	Bone Marrow Aspirate	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	2	Standard Chemotherapy | Targeted Therapy - Other	5	HiDAC|AG-221|3+7 (Cytarabine, Daunorubicin)|Azacitidine|MEC (Cytarabine, Etoposide, Mitoxantrone)	4	Consolidation | Salvage | Induction | Experimental	Complete Response	Standard Chemotherapy	-1	Targeted Therapy - Other	AG-221	Experimental	-1	0	2	2	0	No	1		12	12	71		27		4.4	0.99		33.5	11.4	46,XX[20]		95.4	nuc ish(D5S2064,D5S630,EGR1)x2[200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[200],(RUNX1T1, RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	219	The study reveals a minute subset of myeloblasts with mild immunophenotypic variation; the significance of this finding is unclear and it is not diagnostic for recurrent or persistent myeloid neoplasia.	7.1	5.54	Negative	Positive					Negative	Negative						60	Matched	TMN	Leukemia	Therapy-Related Myeloid Neoplasms	NA
aml_ohsu_2018_2712	aml_ohsu_2018_16-00510	Denovo	GATA2-MECOM	AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1	Adverse	Adverse	AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	2	Standard Chemotherapy | Targeted Therapy - Kinase Inhibitor(s)	5	7+3 (Cytarabine, Idarubicin)|ATRA (Tretinoin)|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|anti-CD33|Azacitidine	3	Induction | Experimental | Re-induction	Refractory	Standard Chemotherapy	6	Targeted Therapy - Kinase Inhibitor(s)	anti-CD33	Experimental	-1	0	0	60	28.9	No	0	2.1	44.3	8.2	16.5	5.5	117	61	3.9	1		35.6	11.7	46,XY,t(3;3)(q21;q26),der(7)del(7)(p11.1)del(7)(q11.1)[13]/45,idem,-der(7)[6]/46,XY[1]	424	96	D7S522/CEP 7: 65/100 cells (65%) had a signal pattern consistent with the deleted chromosome 7 long arm from the small marker observed in the metaphase karyotype; 9 cells (9%) had a signal pattern consistent with the monosomy 7 sideline observed in the metaphase karyotype.	916		7.7	6.13	Negative	Negative										p.Q61H; MAF 45%		34	Matched	AMLRGA	Leukemia	AML with Recurrent Genetic Abnormalities	0.566666666667
aml_ohsu_2018_2713	aml_ohsu_2018_16-00519	Denovo	None	AML with mutated CEBPA	Intermediate	Favorable	AML with mutated CEBPA	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	2	Standard Chemotherapy | Bone Marrow Transplant	3	HiDAC|Cyclophosphamide, Fludarabine, TBI|3+7 (Cytarabine, Daunorubicin)	3	Allogeneic - Sibling | Consolidation | Induction	Complete Response	Standard Chemotherapy	5	Bone Marrow Transplant	Cyclophosphamide, Fludarabine, TBI	Allogeneic - Sibling	-1	0	0		72.9	No	0	0	20.3	3.4	3.4	6.9	49	21	3.5	1.08		42.6	15	46,XY[20]	353	86.8	Normal	34	CD7, CD13, CD33, CD34, CD38, CD58, CD117, dim CD123 HLA-DR and MPO+ ,	7.4	8.98	Negative	Negative	p.R35fs*125; MAF 50%											47	Matched	AMLCEBPA	Leukemia	AML with Biallelic Mutations of CEBPA	0.3
aml_ohsu_2018_2714	aml_ohsu_2018_16-00524	Denovo	CBFB-MYH11	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	Favorable	Favorable	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	Initial Acute Leukemia Diagnosis	Peripheral Blood	WES	No	Yes	Yes	No	Yes	Yes	1	Standard Chemotherapy	2	7+3 (Cytarabine, Idarubicin)|HiDAC	2	Consolidation | Induction	Complete Response i	Standard Chemotherapy	6	Standard Chemotherapy	HiDAC	Consolidation	-1	-20	1			No	0	0	72.2	0.9	3.7	0	41	22	3.4	0.71		30.6	10.6	46,XX,inv(16)(p13,1q22)[17]/46,XX[3]	310	104.4	Positive for rearrangement of the CBFB gene at 16q22 on chromosome 16. Negative for BCR-ABL1 translocation or other abnormalities in this panel.	148		7.6	3.21	Negative	Negative	Negative		Negative	Negative	Negative	Negative	Negative	Negative	Negative	p.G12D; MAF 6%	Negative	34	Matched	AMLCBFBMYH11	Leukemia	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22);CBFB-MYH11	NA
aml_ohsu_2018_2715	aml_ohsu_2018_16-00525	Denovo	None	AML with myelodysplasia-related changes	Adverse	Adverse	AML with myelodysplasia-related changes	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	2	Standard Chemotherapy | Bone Marrow Transplant	4	HiDAC|Cyclophosphamide, Fludarabine, TBI|3+7 (Cytarabine, Daunorubicin)|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)	4	Consolidation | Induction | Allogeneic - Mismatched Unrelated Donor | Re-induction	Refractory	Standard Chemotherapy	6	Bone Marrow Transplant	Cyclophosphamide, Fludarabine, TBI	Allogeneic - Mismatched Unrelated Donor	-1	0	0	95	40.2	No	0	0	45.5	9.8	4.5	0.2	32	58	3.1	0.69		22.3	7.4	46,XX,r(2)(p23q31),der(4)t(4;16)(q21;q12-13)del(16)(q22q22),der(16)t(4;16)(q21;q12-13),add(18)(p11.2),del(20)(q13.2)[16]/46,XX[4]		97.8	CBFB: 88% of cells were missing a signal for CBFB, consistent withdeletion associated with the unbalanced t(4;16) seen on chromosome analysis. No evidence for disruption. This probe will be useful in following this abnormal clone.	154	CD13, partial CD15, CD34, CD38, partial CD56, CD58, partial CD117 and CD123+	5.8	9.27	Negative	Negative												26	Matched	AMLMRC	Leukemia	AML with Myelodysplasia-Related Changes	0.8
aml_ohsu_2018_2685	aml_ohsu_2018_16-00533	After or at the time transformation from another heme malignancy	None	Primary myelofibrosis	Adverse	Not Enough Information	Therapy-related myeloid neoplasms	Post-Chemotherapy|Post-Transplant|Residual Disease	Peripheral Blood	WES	Yes	Yes	Yes	No	Yes	Yes	3	Standard Chemotherapy | Bone Marrow Transplant | Targeted Therapy - Kinase Inhibitor(s)	3	Fludarabine, Melphalan|Azacitidine|Sorafenib	4	Induction | Allogeneic - Mismatched Unrelated Donor | Experimental | Re-induction	Refractory	Standard Chemotherapy	153	Targeted Therapy - Kinase Inhibitor(s)	Sorafenib	Experimental	56	-21	0.9	70	50	No	0.9	0	22.8	2.6	36.8	0.2	16	43	2.5	1.62		20.4	6.8	45,X,-Y,der(2)t(2;5)(q37;p13),-5,-18,add(19)(p13.3),+21,+21[cp13]/45,sl,-der(2)t(2;5)(q37;p13),add(2)(q11.2),add(12)(q15)[7]	1805	91.5	94/100 cells (94%) had a 1 red/ 2 green/ 2 aqua signal pattern, indicating a deleted 5q, as previously observed. There was no evidence for the previous trisomy 8.	8	CD13, dim CD33, partial CD34, dim CD117	7.4	8.35	Negative	Negative												59	Unmatched	PMF	Myeloproliferative Neoplasms	Primary Myelofibrosis	0.0666666666667
aml_ohsu_2018_2694	aml_ohsu_2018_16-00538		RUNX1-RUNX1T1	AML with t(8;21)(q22;q22); RUNX1-RUNX1T1	Favorable	Favorable	AML with t(8;21)(q22;q22); RUNX1-RUNX1T1	Residual Disease	Peripheral Blood	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	1	Standard Chemotherapy	2	HiDAC|3+7 (Cytarabine, Daunorubicin)	2	Consolidation | Induction	Unknown	Standard Chemotherapy	20	Standard Chemotherapy	HiDAC	Consolidation	182	-22		8	0	No	0		12	29	54		19	9	2.3	0.51		22.8	7.5	46,XY,t(8;21)(q22;q22)[20]		88.7	RUNX1/RUNX1T1 fusion positive in 6.5% of cells	224		5.1	6.8	Negative	Negative												50	Matched	AMLRUNX1RUNX1T1	Leukemia	AML with t(8;21)(q22;q22.1);RUNX1-RUNX1T1	0.0666666666667
aml_ohsu_2018_2721	aml_ohsu_2018_16-00540	Denovo	None	Acute myeloid leukaemia, NOS	Intermediate	Intermediate-II	Acute myeloid leukaemia, NOS	Initial Acute Leukemia Diagnosis	Peripheral Blood	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	1	Standard Chemotherapy	1	7+3 (Cytarabine, Idarubicin)	1	Induction	UNKNOWN	Standard Chemotherapy	6	Standard Chemotherapy	7+3 (Cytarabine, Idarubicin)	Induction	6	0			16	No														47,XX,+8[18]			Normal		Large population of CD117 pos myeloblasts, representing 80% of leukocytes, consistent w/ AML.		129.5	Positive	Negative												66	Unmatched	AMLNOS	Leukemia	AML, NOS	0.0666666666667
aml_ohsu_2018_2720	aml_ohsu_2018_16-00541		None	Plasma cell myeloma	Adverse		Plasma cell myeloma	Unknown	Peripheral Blood	WES + RNA-seq	Yes	Yes	Yes	No	No	No	1	Standard Chemotherapy	2	CyBorD (Cyclophosphamide, Bortezomib, Dexamethasone)|RVD (Bortezomib, Dexamethasone, Lenalidomide)	2	Induction | Re-induction	Unknown	Standard Chemotherapy	16	Standard Chemotherapy	RVD (Bortezomib, Dexamethasone, Lenalidomide)	Re-induction	-1	0	0			No	0	0.9	28.7	8.3	60.2	0.6	22	24	2.6	0.99		22	7	44,XX,+5,add(5)(q11.1),der(8)t(8;13)(p12;q12),-13,-14,t(15;21)(q10;q10),add(20)(p13)[13]/46,XX[7]	249	102.8	Abnormal	69		4.9	7.14	Negative	Negative												63	Matched	PCM	Mature B-Cell Neoplasms	Plasma Cell Myeloma	NA
aml_ohsu_2018_2723	aml_ohsu_2018_16-00547		MLLT3-KMT2A	Therapy-related myeloid neoplasms	Adverse	Intermediate-II	Therapy-related myeloid neoplasms	Initial Acute Leukemia Diagnosis	Peripheral Blood	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	1	Standard Chemotherapy	2	HiDAC|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)	2	Induction | Re-induction	Complete Response	Standard Chemotherapy	19	Standard Chemotherapy	HiDAC	Re-induction	4	0	0.9	82	20	No	0	2.6	26.3	33.4	7.9	3.6	40	19	3.1	0.84		27.3	9.1	46,XY,t(9;11)(p22;q23)[20]	324	89.5	94/100 cells (94%) had the abnormal 1 red/ 1 green/1 yellow signal pattern, consistent with MLL rearrangement and the 9;11 translocation observed in the metaphase karyotype.	52	CD11b, varibleCD13, CD14, brightCD33, CD64, and HLA-DR positive	6.7	3.88	Negative	Negative												29	Matched	TMN	Leukemia	Therapy-Related Myeloid Neoplasms	0.233333333333
aml_ohsu_2018_2119	aml_ohsu_2018_16-00548	Relapse	None	AML with myelodysplasia-related changes	Adverse	Not Enough Information	AML with myelodysplasia-related changes	Post-Chemotherapy|Relapse	Peripheral Blood	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	1	Standard Chemotherapy	3	CPX-351 (Liposomal Cytarabine + Daunorubicin)|Decitabine|Incyte trial (azacitidine and JAK 1 inhibitor)	2	Consolidation | Induction	Complete Response	Standard Chemotherapy	35	Standard Chemotherapy	Incyte trial (azacitidine and JAK 1 inhibitor)	Induction	77	6	0			No	0.9		60.3	38.5	0.3		19	19	3.2	1		24.2	8.6	47,XY,+8[cp14]/47,sl,der(21)t(1;21)(q11;p11.1)[2]/46~47,sl,der(22)t(1;22)(q11;p11.2)[cp2]/46,XY[1]	261	102.5	Eighteen of twenty-one cells examined were trisomy 8, previously observed.Two of these cells also had an extra 1q attached to a chromosome 21 short arm, and two other cells had an extra 1q attached to a chromosome 22 short arm. These are new clonal changes. One cell appeared normal male.	7		7.2	3.4	Negative	Negative												77	Matched	AMLMRC	Leukemia	AML with Myelodysplasia-Related Changes	0.733333333333
aml_ohsu_2018_2739	aml_ohsu_2018_16-00562		None	Primary myelofibrosis	Adverse	Not Enough Information	Primary myelofibrosis	Residual Disease	Bone Marrow Aspirate	WES	No	Yes	Yes	No	Yes	Yes	1	Standard Chemotherapy	1	Hydroxyurea	1	Unknown				Standard Chemotherapy	Hydroxyurea	Unknown	263	0		5	5	No				1										46,XY[17]			This test has not detected clonal abnormalities in the cells analyzed. Subtle structural changes cannot be ruled out due to the limitations of resolution. Small percentage of tumor cells with chromosome abnormalities may not be detected due to the limited number of cells examined.	37	Not detected for the FLT3 Internal Tandem Duplication (ITD). Not detected for the FLT3 TKD Mutation. No BCR-ABL1 transcripts are detected. MLL partial tandem duplication (MLL-PTD) is not detected. Pathogenic alterations are detected in the ASXL1, BRAF, EZH2, JAK2, NRAS and SETBP1 genes.		239	Negative	Negative		p.G469A, MAF 7%		Negative						p.G12S, MAF 18%		67	Matched	PMF	Myeloproliferative Neoplasms	Primary Myelofibrosis	0.3
aml_ohsu_2018_2740	aml_ohsu_2018_16-00564		None	Chronic myelomonocytic leukaemia	Adverse	Adverse	Chronic myelomonocytic leukaemia	Unknown	Bone Marrow Aspirate	WES	Yes	Yes	Yes	No	Yes	Yes	1	Other	1	Radiation	1	Unknown				Other	Radiation	Unknown	22	0		5	0	No				2										45,X,-X,del(9)(q13)[12]/46,sl,i(X)(q10)[8]			9q deletion is present in all metaphase cells analyzed. All cells have also show either missing one X chromosome or an isochromosome for its long arm. It is most likely that the X chromosome abnormalities represent constitutional changes associated with Turner syndrome.	30	Not detected for the FLT3 Internal Tandem Duplication (ITD). Not detected for the FLT3 TKD Mutation. MLL partial tandem duplication (MLL-PTD) is not detected. Pathogenic alteration is detected in the TET2 gene. Genomic alterations of uncertain significance are detected in the EZH2 and NF1 genes.		35.1	Negative	Negative				Negative								81	Matched	CMML	Myelodysplastic/Myeloproliferative Neoplasms	Chronic Myelomonocytic Leukemia	0.566666666667
aml_ohsu_2018_2741	aml_ohsu_2018_16-00566		None	AML with mutated NPM1	Intermediate	Not Enough Information	AML with mutated NPM1	Post-Chemotherapy|Residual Disease	Peripheral Blood	WES + RNA-seq	Yes	Yes	No	Yes	Yes	No	1	Standard Chemotherapy	1	GCLAC (GCSF, Clofarabine & Cytarabine)	1	Re-induction				Standard Chemotherapy	GCLAC (GCSF, Clofarabine & Cytarabine)	Re-induction	-1	0	0	41	14	No	0		5	5	76		12	17	3.6	0.83		29.4	10.2	46,XY[15]			Negative	24	Positive	5.9	3.6	Positive	Positive	Negative		Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	40	Unmatched	AMLNPM1	Leukemia	AML with Mutated NPM1	0.133333333333
aml_ohsu_2018_2483	aml_ohsu_2018_16-00593		None	Therapy-related myeloid neoplasms	Intermediate	Not Enough Information	Therapy-related myeloid neoplasms	Residual Disease|Post-Chemotherapy	Peripheral Blood	WES	No	Yes	Yes	No	Yes	Yes	2	Standard Chemotherapy | Bone Marrow Transplant	7	7+3 (Cytarabine, Idarubicin)|HAM (Cytarabine, Mitoxantrone)|Azacitidine|Hydroxyurea|Decitabine|ME (Etoposide, Mitoxantrone)|Fludarabine, Melphalan, ATG	4	Consolidation | Induction | Re-induction | Double Umbilical Cord Blood Transplant (DUCBT)	Refractory	Standard Chemotherapy	1	Bone Marrow Transplant	Fludarabine, Melphalan, ATG	Double Umbilical Cord Blood Transplant (DUCBT)	-1	-11	2.6			No	0.6		16.2	14	66.6		38	27	3.9			36.3	11.7	46,XX[19]		94.3	Normal	71		6.9	6.8	Negative	Negative										p.G13R;MAF 47%		46	Matched	TMN	Leukemia	Therapy-Related Myeloid Neoplasms	1.73333333333
aml_ohsu_2018_2754	aml_ohsu_2018_16-00595	After or at the time transformation from another heme malignancy	None	AML with myelodysplasia-related changes	Adverse	Adverse	AML with myelodysplasia-related changes	Initial Acute Leukemia Diagnosis	Peripheral Blood	WES	No	Yes	Yes	No	Yes	Yes	1	Standard Chemotherapy	2	7+3 (Cytarabine, Idarubicin)|CLAG (Cladribine, Cytarabine, Filgrastim)	2	Induction | Re-induction	Refractory	Standard Chemotherapy	-1	Standard Chemotherapy	CLAG (Cladribine, Cytarabine, Filgrastim)	Re-induction	-1	-1		60	25	No														44-45,XY,-4,-5,add(7)(q11.2),  der(16)del(16)(p13.1)del(16)(q22),-17,add(18)(q21),+1-3mar[cp18]  /46,XY[2]				75	Increased CD34+ myeloblasts, representing 42% of leukocytes, suspicious for AML		6.69	Negative	Negative												58	Unmatched	AMLMRC	Leukemia	AML with Myelodysplasia-Related Changes	0.133333333333
aml_ohsu_2018_2760	aml_ohsu_2018_16-00599		None	Acute myeloid leukaemia, NOS	Intermediate	Intermediate-I	Acute myeloid leukaemia, NOS	Residual Disease|Post-Chemotherapy	Bone Marrow Aspirate	WES	No	Yes	No	No	Yes	No	2	Standard Chemotherapy | Bone Marrow Transplant	3	Vidaza|Fludarabine, Melphalan|HiDAC	3	Allogeneic - Sibling | Consolidation | Induction	Unknown	Standard Chemotherapy	22	Bone Marrow Transplant	Fludarabine, Melphalan	Allogeneic - Sibling	-1	0		70		No				1										46,XY[20]				66	These are positive for CD34, CD117, HLADR, CD33, and CD13.		3.5	Positive	Negative				Negative								68	Matched	AMLNOS	Leukemia	AML, NOS	0.833333333333
aml_ohsu_2018_2695	aml_ohsu_2018_16-00611		None	Acute monoblastic and monocytic leukaemia	Favorable	Not Enough Information	Acute monoblastic and monocytic leukaemia	Residual Disease|Post-Transplant|Post-Chemotherapy	Peripheral Blood	WES	Yes	Yes	Yes	No	Yes	Yes	4	DLI | Standard Chemotherapy | Bone Marrow Transplant | Supportive/Palliative Care	7	HiDAC|Donor Lymphocyte Infusion|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|SWOG S1203 (7+3 +/- Vorinostat)|Hydroxyurea|Decitabine|Bu/Flu/TBI (Busulfan, Fludarabine, Total Body Irradiation)	6	Allogeneic - Sibling | Hypomethylating/Low Dose Cytarabine | Consolidation | Induction | Re-induction | Supportive/Palliative Care	Complete Response	Standard Chemotherapy	13	Supportive/Palliative Care	Decitabine	Supportive/Palliative Care	115	-32	0			No	0	0	4.2	1.7	6.8	0.6	91	102	3.5			29.9	10.8	46,XY[19]		85.4	Normal	31		6.9	162.21	Negative	Positive												51	Unmatched	AMOL	Leukemia	Acute Monoblastic/Monocytic Leukemia	0.3
aml_ohsu_2018_2780	aml_ohsu_2018_16-00618		None	AML with myelodysplasia-related changes	Intermediate	Intermediate-II	AML with myelodysplasia-related changes	Post-Chemotherapy|Residual Disease	Bone Marrow Aspirate	WES	No	Yes	No	No	Yes	No	2	Standard Chemotherapy | Targeted Therapy - Other	2	FLX925|7+3 (Cytarabine, Idarubicin)	2	Induction | Experimental	Complete Response	Standard Chemotherapy	-1	Targeted Therapy - Other	FLX925	Experimental	-1	0	0	35	40	No	0		30	14	12		11	23	2.7			20.4	6.6	46,XX,t(11;19)(q23;p13.1)[16]/46,sl,add(1)(p34)[2]/46,XX[2]	369		MLL Rearrangment	35	Negative	5.9	42.9	Negative	Negative	Negative		Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	65	Matched	AMLMRC	Leukemia	AML with Myelodysplasia-Related Changes	0.9
aml_ohsu_2018_2785	aml_ohsu_2018_16-00627		Unknown	Chronic myelomonocytic leukaemia	Adverse	Not Enough Information	Chronic myelomonocytic leukaemia	Residual Disease	Bone Marrow Aspirate	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	1	Standard Chemotherapy	2	Cytarabine|Decitabine	2	Induction | Supportive/Palliative Care	UNKNOWN	Standard Chemotherapy	-1	Standard Chemotherapy	Cytarabine	Induction	-1	0		17	7	No																	Trisomy 8					Negative	Negative												66	Matched	CMML	Myelodysplastic/Myeloproliferative Neoplasms	Chronic Myelomonocytic Leukemia	1.13333333333
aml_ohsu_2018_2786	aml_ohsu_2018_16-00632	Denovo	Unknown	AML with mutated NPM1	Favorable or Intermediate	Not Enough Information	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Peripheral Blood	WES	No	Yes	No	No	Yes	No	0		0		0					NONE	NONE	NONE		0				No																			Atypical monocytes (are about 91.5%). They are CD45+, CD33+, HLADR++.CD13+, CD14+. CD15++, CD64++, CD116++, CD11b+++,CD11c++,CD38+ and CD34(-),CD117(-). A small population of monoclonal B-cells, CD19+, CD5+(<1%)			Positive	Positive			p.Arg882His									59	Unmatched	AMLNPM1	Leukemia	AML with Mutated NPM1	0.266666666667
aml_ohsu_2018_2204	aml_ohsu_2018_16-00684	Relapse	None	AML without maturation	Adverse	Adverse	AML without maturation	Relapse|Post-Chemotherapy	Bone Marrow Aspirate	WES	No	Yes	Yes	No	Yes	Yes	3	Standard Chemotherapy | Bone Marrow Transplant | Intrathecal	4	COG-AAML1031 (IT/IV Cytarabine, Daunorubicin, Etoposide, Mitoxantrone +/- Bortezomib or Sorafenib)|Cytarabine|FLAG (Fludarabine, High-dose Cytarabine, G-CSF)|Busulfan, Cyclophosphamide	3	Induction | Re-induction | Allogeneic - Matched Unrelated Donor	Complete Response	Standard Chemotherapy	136	Bone Marrow Transplant	Busulfan, Cyclophosphamide	Allogeneic - Matched Unrelated Donor	-1	0	0	53.74	50	No	1.7	0	68	5.5	24.8	0	23	24	4.2	0.31		30	10.5	46,XX,t(6;11)(q27;q23)[12]/46,XX[8]	276	87	71/100 (71%) interphase cells scored had the 1 red/ 1 green/ 1 yellow signal pattern, consistent with MLL rearrangement and the 6;11 translocation observed in the metaphase karyotype.	166	CD4, CD11b, variable CD13, CD15, CD33, CD58, CD64, CD117, and dim HLA-DR positive	7	1.81	Negative	Negative												3	Unmatched	AWM	Leukemia	AML without Maturation	0.1
aml_ohsu_2018_3975	aml_ohsu_2018_16-00699	Denovo	None	Acute myeloid leukaemia, NOS	Intermediate	Not Enough Information	Acute myeloid leukaemia, NOS	Initial Acute Leukemia Diagnosis	Peripheral Blood	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	1	Standard Chemotherapy	1	7+3 (Cytarabine, Idarubicin)	1	Induction	Unknown	Standard Chemotherapy	6	Standard Chemotherapy	7+3 (Cytarabine, Idarubicin)	Induction	6	0		92	75	No			5	19	1				2.8	1.13		18.4	6.2	46,XY[20]		113.6	nuc ish(RUNX1T1,RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	31	CD2(+), surface CD3(-),  cytoplasmic CD3(dim +), CD4(-), CD7(partial +), CD11b(partial +),  CD13(variably +), CD14(few +), CD15(-), CD16(-),  CD33(-), CD34(partial +), CD36(-), CD38(bright +), CD45(dim  +), CD56(small subset +), CD64(-), CD117(+), HLA-DR(partial +), MPO(partial +), TdT(partial dim+)		151.6	Negative	Negative												46	Matched	AMLNOS	Leukemia	AML, NOS	0.266666666667
aml_ohsu_2018_2747	aml_ohsu_2018_16-00701	After or at the time transformation from another heme malignancy	None	Chronic myelomonocytic leukaemia	Intermediate	Not Enough Information	Acute myelomonocytic leukaemia	Initial Acute Leukemia Diagnosis	Peripheral Blood	WES	Yes	Yes	Yes	No	Yes	Yes	2	Standard Chemotherapy | Bone Marrow Transplant	2	Azacitidine|Fludarabine, Melphalan, ATG	2	Unknown | Allogeneic - Matched Unrelated Donor				Bone Marrow Transplant	Fludarabine, Melphalan, ATG	Allogeneic - Matched Unrelated Donor	-1	-34			1	No	0		22	28	42		37	29	4.7	1.03		38.2	12.4	46, XY [20]		91	The abnormalities normally seen in MDS are not detected.	237		7.8	16.4	Negative	Negative												62	Unmatched	CMML	Myelodysplastic/Myeloproliferative Neoplasms	Chronic Myelomonocytic Leukemia	0.333333333333
aml_ohsu_2018_3976	aml_ohsu_2018_16-00702		Unknown	AML with mutated NPM1	Favorable or Intermediate	Not Enough Information	AML with mutated NPM1	Post-Chemotherapy	Bone Marrow Aspirate	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	1	Standard Chemotherapy	1	Decitabine	1	Induction	Complete Response	Standard Chemotherapy	-1	Standard Chemotherapy	Decitabine	Induction	-1	0				No																	Translocation between the long arm of chromosome 3 and short arm of chromosome 12.					Positive	Positive												79	Unmatched	AMLNPM1	Leukemia	AML with Mutated NPM1	0.0666666666667
aml_ohsu_2018_3978	aml_ohsu_2018_16-00705	Relapse	None	AML with myelodysplasia-related changes	Intermediate	Intermediate-II	AML with myelodysplasia-related changes	Relapse	Peripheral Blood	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	2	Standard Chemotherapy | Bone Marrow Transplant	2	7+3 (Cytarabine, Idarubicin)|Fludarabine, Cyclophosphamide, TBI	2	Induction | Double Umbilical Cord Blood Transplant (DUCBT)	Complete Response	Standard Chemotherapy	-1	Bone Marrow Transplant	Fludarabine, Cyclophosphamide, TBI	Double Umbilical Cord Blood Transplant (DUCBT)	-1	0	0	59.5	12	No	0		55	3	29		37	22	4.1			25.2	8.3	47,XY,+13[2]/94,slx2[2]/46,XY[19]			5p15.2/5q31(EGR1), 7 centromere/7q31, 8 centromere/20q12, 12 centromere/13q14 D13S319/13q34 (13qter)	46	Negative	6.4		Negative	Negative												64	Matched	AMLMRC	Leukemia	AML with Myelodysplasia-Related Changes	0.6
aml_ohsu_2018_3979	aml_ohsu_2018_16-00708		None	AML with myelodysplasia-related changes	Adverse	Intermediate-II	AML with myelodysplasia-related changes	Post-Chemotherapy|Residual Disease	Bone Marrow Aspirate	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	1	Standard Chemotherapy	2	Azacitidine|Decitabine	1	Hypomethylating/Low Dose Cytarabine				Standard Chemotherapy	Azacitidine	Hypomethylating/Low Dose Cytarabine	98	0	0	44	31	No	2		46	0	14		41	18	3.7	0.91		21.6	7.1	47,XY,+21[19]/46,XY[1]	91		nuc ish(D5S2064,D5S630,EGR1)x2[200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[200],	35	CD2(-), CD4(dim +), CD7(-), CD10(-), CD11b(-), CD13(bright +), CD14(-), CD15(partial +), CD16(-), CD22(-), CD19(partial +), CD33(partial +), CD34(+), CD36(-), CD38(bright and variably +), CD45(+), CD56(-), CD64(-), CD79a(-), CD117(+), HLA-DR(predominantly + and variable), TdT(partial +), and MPO(-)	7.7	5.05	Positive	Negative			Foundation; R882H; MAFs: 44%	Negative	Negative	Negative						71	Unmatched	AMLMRC	Leukemia	AML with Myelodysplasia-Related Changes	0.433333333333
aml_ohsu_2018_3980	aml_ohsu_2018_16-00709		None	AML with mutated NPM1	Favorable	Favorable	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	WES	No	Yes	No	No	Yes	No	0		0		0					NONE	NONE	NONE		0				No														46,XX[20]					Relative increase in CD117pos,CD34neg myeloid blasts, representing 16% of total leukocytes, most consistent with myeloid neoplasm such as advanced MDS or AML.			Negative	Positive												71	Unmatched	AMLNPM1	Leukemia	AML with Mutated NPM1	0.1
aml_ohsu_2018_2694	aml_ohsu_2018_16-00710		RUNX1-RUNX1T1	AML with t(8;21)(q22;q22); RUNX1-RUNX1T1	Intermediate	Favorable	AML with t(8;21)(q22;q22); RUNX1-RUNX1T1	Post-Chemotherapy	Bone Marrow Aspirate	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	1	Standard Chemotherapy	2	HiDAC|3+7 (Cytarabine, Daunorubicin)	2	Consolidation | Induction	Unknown	Standard Chemotherapy	20	Standard Chemotherapy	HiDAC	Consolidation	182	0		0		No				0										46,XY[20]			RUNX1/RUNX1T1 fusion negative	126	No morphological evidence of acute leukemia		7.7	Negative	Negative												50	Matched	AMLRUNX1RUNX1T1	Leukemia	AML with t(8;21)(q22;q22.1);RUNX1-RUNX1T1	0.466666666667
aml_ohsu_2018_3986	aml_ohsu_2018_16-00724	After or at the time transformation from another heme malignancy	None	AML with myelodysplasia-related changes	Adverse	Adverse	AML with myelodysplasia-related changes	Post-Chemotherapy|Residual Disease	Bone Marrow Aspirate	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	2	Standard Chemotherapy | Supportive/Palliative Care	4	Vidaza|7+3 (Cytarabine, Idarubicin)|Lenalidomide|Hydroxyurea	3	Hypomethylating/Low Dose Cytarabine | Induction | Supportive/Palliative Care	Refractory	Standard Chemotherapy	7	Supportive/Palliative Care	Hydroxyurea	Supportive/Palliative Care	-1	0	0.8	34	3.3	No	1.6		14.9	5	68.6		13	11	2.6	0.5		32.4	10.7	46~47,XX,del(5)(q15q35),i(8)(q10),add(11)(q23),add(17)(p11.2),add(21)(q22),+2~3mar[cp3]/47~49,idem,add(7)(q11.2),-add(11),+11,+14,-20[cp4]/45~49,idem,del(7)(q22q36),-add(11),+11,+14,-20[cp2]/45~48,idem,der(7)del(7)(q22q31)dic(7;20)(q36;q11.2),-add(11),+11,+14[	304		nuc ish(D5S2064x2,D5S630x2,EGR1x1)[184/200],(D7Z1x2,D7S522x1)[115/200],(D8Z2x2,D20S108x1)[142/200],(RUNX1T1x3,RUNX1x2)[180/200],(5'MLL amp,3'MLL amp)(5'MLL con 3'MLL amp)[66/200],(PML,RARA)x2[197],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	36	CD2(-), CD4(-), CD7(partial +), CD11b(-), CD13(+), CD14(-), CD15(partial +), CD16(-), CD33(+), CD34(+), CD36(-), CD38(partial +), CD45(+),CD56(+), CD64(-), CD117(partial +), HLA-DR(partial +).	5.3	8.35	Negative	Negative				Negative	Negative	Negative					R213fs; MAF 34%	62	Matched	AMLMRC	Leukemia	AML with Myelodysplasia-Related Changes	1.1
aml_ohsu_2018_3990	aml_ohsu_2018_16-00731		None	Acute myeloid leukaemia, NOS	Adverse	Intermediate-I	Acute myeloid leukaemia, NOS	Initial Acute Leukemia Diagnosis	Peripheral Blood	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	3	Standard Chemotherapy | Targeted Therapy - Kinase Inhibitor(s) | Targeted Therapy - Other	7	7+3 (Cytarabine, Idarubicin)|Azacitidine, Midostaurin|Sorafenib|MEC (Cytarabine, Etoposide, Mitoxantrone)|MiDAC|Fludarabine, Cyclophosphamide, Thiotepa, TBI|ALRN-6924	4	Salvage | Induction | Experimental | Re-induction	Refractory	Standard Chemotherapy	6	Targeted Therapy - Other	ALRN-6924	Salvage	-1	0	1.8	40	42.1	No	0.9	8.8	10.5	9.6	26.3	2.8	27	22	3.4	0.64		23.5	7.1	46,XX[20]	399	103.5	Normal	12	CD13, CD34, CD58, CD117, partial MPO and HLA-DR +	6.5	61.22	Positive	Negative												69	Unmatched	AMLNOS	Leukemia	AML, NOS	0.2
aml_ohsu_2018_2119	aml_ohsu_2018_16-00733		None	AML with myelodysplasia-related changes	Adverse	Adverse	AML with myelodysplasia-related changes	Post-Chemotherapy|Residual Disease	Peripheral Blood	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	1	Standard Chemotherapy	3	CPX-351 (Liposomal Cytarabine + Daunorubicin)|Decitabine|Incyte trial (azacitidine and JAK 1 inhibitor)	2	Consolidation | Induction	Complete Response	Standard Chemotherapy	35	Standard Chemotherapy	Incyte trial (azacitidine and JAK 1 inhibitor)	Induction	77	0	0	54	13	No	6.9		51.6	39.6	1.9		20	23	3.2	1		25.4	8.6	47,XY,+8[cp15]/47,sl,der(22)t(1;22)(q11;p11.2)[2]/46,XY,dup(1)(q21q42)[cp2]		92	Seventeen of twenty cells examined were trisomy 8, previously observed.Two of the trisomy 8 cells had additional non-clonal abnormalities and two cells had an extra 1q attached to a chromosome 22 short arm, also previously observed.	22	The myeloid blasts are CD13, CD34, CD38, CD117, and HLA-DR positive. Atypical monocytic cells comprise approximately 41% of analyzed events and are CD11b, CD13, CD14, CD64, and dim HLA-DR positive. T cells show a CD4:CD8 ratio of 6.9:1 without  aberrant antigen expression.	7.2	4.5	Negative	Negative												77	Matched	AMLMRC	Leukemia	AML with Myelodysplasia-Related Changes	0.866666666667
aml_ohsu_2018_4001	aml_ohsu_2018_16-00755	After or at the time transformation from another heme malignancy	GATA2-MECOM	AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1	Adverse	Adverse	AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	WES + RNA-seq	Yes	Yes	No	Yes	Yes	No	2	Standard Chemotherapy | Bone Marrow Transplant	2	SWOG S0919 (Ida/Ara+Pravastatin) |Busulfan, Cyclophosphamide	2	Allogeneic - Sibling | Induction	Complete Response	Standard Chemotherapy	70	Bone Marrow Transplant	Busulfan, Cyclophosphamide	Allogeneic - Sibling	0	0	0	21	0	No	0	2.3	41.7	25.9	30.1	0.1						35.1	11	46,XX,t(3;3)(q21;q26)[20]		107	Abnormal	360	variable CD11b, CD13, dim CD33, CD34, CD58, CD117, CD123		13.83	Negative	Negative										p.G12D; MAF 47%		58	Matched	AMLRGA	Leukemia	AML with Recurrent Genetic Abnormalities	0.766666666667
aml_ohsu_2018_2704	aml_ohsu_2018_16-00765	Relapse	None	AML with mutated NPM1	Adverse	Not Enough Information	AML with mutated NPM1	Post-Transplant|Post-Chemotherapy|Relapse	Peripheral Blood	WES	Yes	Yes	Yes	No	Yes	Yes	3	Standard Chemotherapy | Bone Marrow Transplant | Supportive/Palliative Care	5	FLAG (Fludarabine, High-dose Cytarabine, G-CSF)|Hydroxyurea|Decitabine|Fludarabine, Cyclophosphamide, TBI |Trametinib	3	Induction | Supportive/Palliative Care | Allogeneic - Matched Unrelated Donor	Refractory	Standard Chemotherapy	5	Supportive/Palliative Care	Hydroxyurea	Supportive/Palliative Care	2	-83				No														47,XX,+8,i(8)(q10),del(9)(q21.2q22.3),der(10)t(1;10)(q11;q22)[cp12]/47,idem,add(17)(p13)[8]			Normal					Negative	Positive									p.G12V, Mutant Allele frequency: 76%			29	Unmatched	AMLNPM1	Leukemia	AML with Mutated NPM1	0.0666666666667
aml_ohsu_2018_4006	aml_ohsu_2018_16-00766	After or at the time transformation from another heme malignancy	None	AML with myelodysplasia-related changes	Adverse	Adverse	AML with myelodysplasia-related changes	Post-Chemotherapy|Residual Disease	Bone Marrow Aspirate	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	1	Supportive/Palliative Care	2	Vidaza|Decitabine	2	Hypomethylating/Low Dose Cytarabine | Supportive/Palliative Care				Supportive/Palliative Care	Decitabine	Supportive/Palliative Care	3	-32		33	8	No	4		28	24	44		22	20	4.1	1.07		27.5	9.5	45,XY,add(5)(q11.2),der(6)t(5;6)(p13;p23),der(8)t(8;8)(p23;q11.2),-13,-16,der(22)t(16;22)(q22;q11.2),+r[cp11]/44,idem,-18[cp4]/46,XY[5]	333		nuc ish(D5S2064x3,D5S630x3,EGR1x1)[97/200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[200],(RUNX1T1x3,RUNX1x2)[110/200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5CBFB con 3CBFB dimx1,5CBFB con 3CBFBx1)[200]	28	CD4(+), CD5(partial +), CD7(partial +), CD11b(-), CD13(+), CD14(-), CD15(predominantly -), CD16(-), CD33(+), CD34(+), CD36(-),CD38(variably +), CD45(variably +), CD56(predominantly -), CD64(partial +), CD117(+), HLA-DR(predominantly + and variable),MPO(-), TdT(-).	6.6	2.2	Negative	Negative				Negative	Negative	Negative					Foundation; L206fs*41; MAFs: 31%	81	Matched	AMLMRC	Leukemia	AML with Myelodysplasia-Related Changes	1.06666666667
aml_ohsu_2018_4007	aml_ohsu_2018_16-00770		None	AML without maturation	Intermediate	Not Enough Information	AML without maturation	Residual Disease|Post-Chemotherapy	Bone Marrow Aspirate	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	2	Standard Chemotherapy | Bone Marrow Transplant	4	Busulfan, Fludarabine|5+2 (Cytarabine, Idarubicin)|HiDAC|7+3 (Cytarabine, Idarubicin, Bortezomib	3	Unknown | Induction | Re-induction	Unknown	Standard Chemotherapy	-1	Bone Marrow Transplant	Busulfan, Fludarabine	Unknown	-1	0		12		No				17										46,XX[20]				16	FLT3 (ITD) Not detected. Not detected for the FLT3 TKD Mutation. Pathogenic alterations are detected in the BCOR, IDH2 and WT1 genes. Positive for CD34, HLADR, CD117, CD13, CD33 and CD43 and negative for CD11B, CD14, CD64, TDT and MPO.		1.5	Negative	Negative				Negative								51	Unmatched	AWM	Leukemia	AML without Maturation	0.166666666667
aml_ohsu_2018_4008	aml_ohsu_2018_16-00771		None	Acute monoblastic and monocytic leukaemia	Adverse	Not Enough Information	Acute monoblastic and monocytic leukaemia	Residual Disease|Post-Chemotherapy	Bone Marrow Aspirate	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	2	Standard Chemotherapy | Intrathecal	3	7+3 (Cytarabine, Idarubicin)|Cytarabine|Etoposide, Mitoxantrone	3	Unknown | Induction | Re-induction	Refractory	Standard Chemotherapy	35	Intrathecal	Cytarabine	Unknown	6	0		15		No				12										46,XX[20]				426			26.4	Negative	Negative			p.R882C, MAF 51%	Negative						p.G13R, MAF 48%	p.R282Q, MAF 51%	34	Unmatched	AMOL	Leukemia	Acute Monoblastic/Monocytic Leukemia	0.3
aml_ohsu_2018_2654	aml_ohsu_2018_16-00783		None	Therapy-related myeloid neoplasms	Intermediate	Not Enough Information	Therapy-related myeloid neoplasms	Post-Chemotherapy	Bone Marrow Aspirate	WES	No	Yes	No	No	Yes	No	2	Supportive/Palliative Care | Other	5	Radiation|Paclitaxel|Doxorubicin|Cisplatin|5-FU	2	Symptom Control | Supportive/Palliative Care				Supportive/Palliative Care	Paclitaxel	Supportive/Palliative Care	274	0		0		No				2										46,XX[20]				202	No increased or immunophenotypically abnormal nlast cell populations identified.		3.3	Negative	Negative				Negative								64	Matched	TMN	Leukemia	Therapy-Related Myeloid Neoplasms	0.166666666667
aml_ohsu_2018_4028	aml_ohsu_2018_16-00810	Denovo	None	AML with mutated NPM1	Favorable	Favorable	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	2	Standard Chemotherapy | Bone Marrow Transplant	3	Fludarabine, Melphalan|MiDAC|7+3 (Cytarabine, Idarubicin) plus Sorafenib	3	Consolidation | Induction | Allogeneic - Mismatched Unrelated Donor	Complete Response	Standard Chemotherapy	6	Bone Marrow Transplant	Fludarabine, Melphalan	Allogeneic - Mismatched Unrelated Donor	-1	0	0	83	11.5	No	1.8	1.8	13.3	63.7	7.9	0.1	69	35	3	0.87	M5	34.7	11.6	46,XX[20]	337	95.6	Normal	146	Positive	6.1	44.83	Negative	Positive					p.R132H; MAF 37%					p.G13D; MAF 38%		61	Matched	AMLNPM1	Leukemia	AML with Mutated NPM1	0.266666666667
aml_ohsu_2018_4030	aml_ohsu_2018_16-00815	Denovo	None	AML with mutated NPM1	Favorable	Favorable	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	2	Standard Chemotherapy | Bone Marrow Transplant	5	Fludarabine, Melphalan|7+3 (Cytarabine, Idarubicin)|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|MiDAC|Hydroxyurea	4	Consolidation | Induction | Allogeneic - Mismatched Unrelated Donor | Re-induction	Complete Response	Standard Chemotherapy	18	Bone Marrow Transplant	Fludarabine, Melphalan	Allogeneic - Mismatched Unrelated Donor	-1	-1	0	75	44	No	0	0.9	28.7	46.1	24.3	0	18	13	2.9	1.19	M5	26.4	8.8	46,XX[20]	222	96.4	Normal	175	Positive	6.9	34.6	Negative	Positive										p.G12S; MAF 40%		60	Matched	AMLNPM1	Leukemia	AML with Mutated NPM1	0.166666666667
aml_ohsu_2018_4029	aml_ohsu_2018_16-00818	After or at the time transformation from another heme malignancy	GATA2-MECOM	AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1	Adverse	Adverse	AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1	Initial Acute Leukemia Diagnosis	Peripheral Blood	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	0		0		0					NONE	NONE	NONE		-3				No														47,XX,+X,inv(3)(q21q26.2),-7,+22[2]/48,sl,+21[18]			evidence of monosomy 7 in 191/200 (95.5 percent) cells scored					Negative	Negative			p.Ala571Pro; MAF 51.5%									65	Unmatched	AMLRGA	Leukemia	AML with Recurrent Genetic Abnormalities	0.1
aml_ohsu_2018_4032	aml_ohsu_2018_16-00820	After or at the time transformation from another heme malignancy	None	AML with myelodysplasia-related changes	Adverse	Adverse	AML with myelodysplasia-related changes	Residual Disease	Bone Marrow Aspirate	WES + RNA-seq	Yes	Yes	No	Yes	Yes	No	2	Standard Chemotherapy | Bone Marrow Transplant	4	Fludarabine, Melphalan|Azacitidine|Hydroxyurea|Idarubicin and Cytarabine	3	Allogeneic - Sibling | Induction | Re-induction	Refractory	Standard Chemotherapy	1932	Bone Marrow Transplant	Fludarabine, Melphalan	Allogeneic - Sibling	-1	0	2.6	42.5	54	No	0.9	0	44.2	2.7	0.9	0	21	15	2	2.62		23.1	7.9	45,XY,+5,dic(5;8)(q11.2;p12)x2,del(7)(q22q32),-18,del(20)(p11.2)[cp20]		91.7	5p/5q: 88/100 (88%) cells had one signal for EGR1 (5q31) and three signals for 5p, consistent with the metaphase karyotype; 5 cells (5%) had one EGR1 signal and four 5p signals, consistent with a previous sideline with three copies of the dicentric 5;8 chromosome.	22	Positive	5.3	1.27	Negative	Negative			p.G570E; MAF 44%								p.K132R; MAF 45%	67	Matched	AMLMRC	Leukemia	AML with Myelodysplasia-Related Changes	0.966666666667
aml_ohsu_2018_2747	aml_ohsu_2018_16-00822	After or at the time transformation from another heme malignancy	None	Chronic myelomonocytic leukaemia	Intermediate	Not Enough Information	Acute myelomonocytic leukaemia	Residual Disease	Bone Marrow Aspirate	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	2	Standard Chemotherapy | Bone Marrow Transplant	2	Azacitidine|Fludarabine, Melphalan, ATG	2	Unknown | Allogeneic - Matched Unrelated Donor				Bone Marrow Transplant	Fludarabine, Melphalan, ATG	Allogeneic - Matched Unrelated Donor	-1	0		9		No				7										46,XY[12]			The abnormalities normally seen in MDS are not detected.		A very dim/negative CD45 population was also detected by the flow analysis. This population is negative for all the myeloid and lymphoid markers including CD34. This is mentioned here for documentation purposes but we believe that they do not represent blasts.			Negative	Negative												62	Unmatched	CMML	Myelodysplastic/Myeloproliferative Neoplasms	Chronic Myelomonocytic Leukemia	0.333333333333
aml_ohsu_2018_4038	aml_ohsu_2018_16-00831		None	Acute myeloid leukaemia, NOS	Adverse	Adverse	Acute myeloid leukaemia, NOS	Post-Chemotherapy|Residual Disease	Peripheral Blood	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	2	Supportive/Palliative Care | Targeted Therapy - Other	6	Vidaza|AG-221|Bortezomib|Cytarabine|Lenalidomide|Decitabine	3	Hypomethylating/Low Dose Cytarabine | Experimental | Supportive/Palliative Care				Targeted Therapy - Other	AG-221	Experimental	267	0		95	48	No	1		42	6	2		14	14	3.5	1.1		27.3	9.4	88<4n>,XXYY,+del(1)(p22p36),i(2)(p10),-5,-7,-7,-21,-21[12]	453		nuc ish(RUNX1T1x4,RUNX1x2)[200],(5'MLL,3'MLL)x4(5'MLL con 3'MLLx4)[200],(PML,RARA)x4[200],(5'CBFB,3'CBFB)x4(5'CBFB con 3'CBFBx4)[174/200]	23	92% population of variably-sized cells with the following immunophenotype: CD2(-), CD4(-), CD7(-), CD11b(-), CD13(-), CD14(-), CD15(+), CD16(-), CD33(-), CD34(+), CD36(-), CD38(variably +), CD45(variably +), CD56(-), CD64(-), CD117(variably +), HLA-DR(partial +).	6.5	3	Negative	Negative					Negative							77	Matched	AMLNOS	Leukemia	AML, NOS	0.5
aml_ohsu_2018_4039	aml_ohsu_2018_16-00836	After or at the time transformation from another heme malignancy	None	AML with mutated NPM1	Intermediate	Intermediate-I	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	1	Standard Chemotherapy	2	S0919 Trial (Pravastatin, Idarubicin, Cytarabine)|Hydroxyurea	1	Induction	Refractory	Standard Chemotherapy	167	Standard Chemotherapy	S0919 Trial (Pravastatin, Idarubicin, Cytarabine)	Induction	21	0	0	88	38	No	0	1.7	20.9	60.9	1.7	0.1	27	40	3	1.2		33	11.2	46,XY[20]		105.8	Normal	55	Positive	7.5	58.97	Positive	Positive			p.R882H; MAF 42%									73	Matched	AMLNPM1	Leukemia	AML with Mutated NPM1	0.266666666667
aml_ohsu_2018_4043	aml_ohsu_2018_16-00846	Relapse	Unknown	Acute myeloid leukaemia, NOS	Intermediate	Not Enough Information	Acute myeloid leukaemia, NOS	Post-Chemotherapy|Relapse	Peripheral Blood	WES + RNA-seq	Yes	Yes	No	Yes	Yes	No	1	Standard Chemotherapy	3	Bu/Cy/ATG|7+3 (Cytarabine, Idarubicin)|HiDAC	3	Consolidation | Unknown | Induction	Complete Response	Standard Chemotherapy	79	Standard Chemotherapy	Bu/Cy/ATG	Unknown	22	0			14	No	8		17	2	54		39	49	3.2	0.79		19.3	6.5			101		33		4.9	1.6	Negative	Negative												26	Unmatched	AMLNOS	Leukemia	AML, NOS	0.0666666666667
aml_ohsu_2018_3990	aml_ohsu_2018_16-00852		None	Acute myeloid leukaemia, NOS	Intermediate	Not Enough Information	Acute myeloid leukaemia, NOS	Post-Chemotherapy	Bone Marrow Aspirate	WES	No	Yes	Yes	No	Yes	Yes	3	Standard Chemotherapy | Targeted Therapy - Kinase Inhibitor(s) | Targeted Therapy - Other	7	7+3 (Cytarabine, Idarubicin)|Azacitidine, Midostaurin|Sorafenib|MEC (Cytarabine, Etoposide, Mitoxantrone)|MiDAC|Fludarabine, Cyclophosphamide, Thiotepa, TBI|ALRN-6924	4	Salvage | Induction | Experimental | Re-induction	Refractory	Standard Chemotherapy	6	Targeted Therapy - Other	ALRN-6924	Salvage	-1	-46	0.5	3		No	0		50	25.7	23.8		23	16	3.4			31.1	9.9	46,XX[20]	217	95.4	Normal	201	Positive	7.1	2.1	Positive	Negative												69	Unmatched	AMLNOS	Leukemia	AML, NOS	0.1
aml_ohsu_2018_4042	aml_ohsu_2018_16-00867	Denovo	None	AML with mutated NPM1	Intermediate	Intermediate-I	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	1	Standard Chemotherapy	1	Hydroxyurea	1	Induction	Unknown	Standard Chemotherapy	8	Standard Chemotherapy	Hydroxyurea	Induction	8	-5	0	93	85	No	0.8	0	16.5	0.8	1.6	0.2	19	21	2.7	0.78		21.1	7.1	46,XX[20]	360	84.4	Normal	43	partial CD13, CD33, dim/partial CD56, CD58, dim CD117, CD123 and MPO	5.7	30.54	Positive	Positive												61	Unmatched	AMLNPM1	Leukemia	AML with Mutated NPM1	0.166666666667
aml_ohsu_2018_4052	aml_ohsu_2018_16-00875		None	Acute myeloid leukaemia, NOS	Adverse	Adverse	Acute myeloid leukaemia, NOS	Post-Chemotherapy	Bone Marrow Aspirate	WES + RNA-seq	Yes	Yes	No	Yes	Yes	No	1	Standard Chemotherapy	4	7+3 (Cytarabine, Idarubicin)|HiDAC|Cyclophosphamide|CLAG (Cladribine, Cytarabine, Filgrastim)	4	Consolidation | Salvage | Induction | Re-induction	Refractory	Standard Chemotherapy	25	Standard Chemotherapy	CLAG (Cladribine, Cytarabine, Filgrastim)	Salvage	23	0		3		No				4										45,XX,-7[4]/46,sl,+mar[2]/46,XX[14]				69	MLL-PTD is not detected. FLT3-ITD not detected. FLT3-TKD mutation not detected. Pathogenic alterations are detected in the DNMT3A and IDH1 genes. Genomic alteration of uncertain significance is detected in the DNMT3A gene.		1.3	Negative	Negative				Negative								46	Unmatched	AMLNOS	Leukemia	AML, NOS	0.3
aml_ohsu_2018_4055	aml_ohsu_2018_16-00880		None	AML with mutated NPM1	Favorable	Favorable	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Peripheral Blood	WES	No	Yes	Yes	No	Yes	Yes	1	Standard Chemotherapy	2	7+3 (Cytarabine, Idarubicin)|HiDAC	2	Consolidation | Induction	Complete Response	Standard Chemotherapy	-1	Standard Chemotherapy	HiDAC	Consolidation	-1	0		40	57	Yes														46,XX[20]			Normal	75	Increased atypical CD117pos, partial CD34+, partial HLA-DR pos myeloblasts (CD7+), representing about 55% of leukocytes, consistent with AML.		16.43	Negative	Positive	p.Ala40fs; MAF 20.3%		p.Arg882His; MAF 39.1%									55	Matched	AMLNPM1	Leukemia	AML with Mutated NPM1	0.8
aml_ohsu_2018_4006	aml_ohsu_2018_16-00882	After or at the time transformation from another heme malignancy	None	AML with myelodysplasia-related changes	Adverse	Not Enough Information	AML with myelodysplasia-related changes	Post-Chemotherapy|Residual Disease	Peripheral Blood	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	1	Supportive/Palliative Care	2	Vidaza|Decitabine	2	Hypomethylating/Low Dose Cytarabine | Supportive/Palliative Care				Supportive/Palliative Care	Decitabine	Supportive/Palliative Care	3	-73	0		70	No	0		3	1	36		25	33	4.1	1.26		24.1	8.1	45,XY,add(5)(q11.2),der(6)t(5;6)(p13;p23),der(8)t(8;8)(p23;q11.2),-13,-16,der(22)t(16;22)(q22;q11.2),+r[cp11]/44,idem,-18[cp4]/46,XY[5]	853	98	nuc ish(D5S2064x3,D5S630x3,EGR1x1)[97/200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[200],(RUNX1T1x3,RUNX1x2)[110/200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5CBFB con 3CBFB dimx1,5CBFB con 3CBFBx1)[200]	74	negative		39.12	Negative	Negative												81	Matched	AMLMRC	Leukemia	AML with Myelodysplasia-Related Changes	1.1
aml_ohsu_2018_2695	aml_ohsu_2018_16-00883		None	Acute monoblastic and monocytic leukaemia	Favorable	Not Enough Information	Acute monoblastic and monocytic leukaemia	Post-Transplant|Residual Disease|Post-Chemotherapy	Peripheral Blood	WES	Yes	Yes	Yes	No	Yes	Yes	4	DLI | Standard Chemotherapy | Bone Marrow Transplant | Supportive/Palliative Care	7	HiDAC|Donor Lymphocyte Infusion|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|SWOG S1203 (7+3 +/- Vorinostat)|Hydroxyurea|Decitabine|Bu/Flu/TBI (Busulfan, Fludarabine, Total Body Irradiation)	6	Allogeneic - Sibling | Hypomethylating/Low Dose Cytarabine | Consolidation | Induction | Re-induction | Supportive/Palliative Care	Complete Response	Standard Chemotherapy	13	Supportive/Palliative Care	Decitabine	Supportive/Palliative Care	115	-22	0			No	6.1	0	7.9	0	6.1	0.1	30	26	3.1			26.2	8.9	46,XY,t(6;19)(p23;q13.1)[11]/46,XY[9]		84.5	Positive	32		7	39.25	Negative	Positive												51	Unmatched	AMOL	Leukemia	Acute Monoblastic/Monocytic Leukemia	0.266666666667
aml_ohsu_2018_2704	aml_ohsu_2018_16-00886		None	AML with mutated NPM1	Adverse	Not Enough Information	AML with mutated NPM1	Post-Chemotherapy|Residual Disease|Post-Transplant	Peripheral Blood	WES	Yes	Yes	Yes	No	Yes	Yes	3	Standard Chemotherapy | Bone Marrow Transplant | Supportive/Palliative Care	5	FLAG (Fludarabine, High-dose Cytarabine, G-CSF)|Hydroxyurea|Decitabine|Fludarabine, Cyclophosphamide, TBI |Trametinib	3	Induction | Supportive/Palliative Care | Allogeneic - Matched Unrelated Donor	Refractory	Standard Chemotherapy	5	Supportive/Palliative Care	Hydroxyurea	Supportive/Palliative Care	2	-127	0			No	0	0	0	79.2	1	0.2	65	152	3.3	0.68		28.2	9.7	47,XX,+8,i(8)(q10),del(9)(q21.2q22.3),der(10)t(1;10)(q11;q22)[cp12]/47,idem,add(17)(p13)[8]	9928	90.4	Normal	43		6.3	12.98	Negative	Positive												29	Unmatched	AMLNPM1	Leukemia	AML with Mutated NPM1	0.166666666667
aml_ohsu_2018_4074	aml_ohsu_2018_16-00950		Unknown	AML with mutated NPM1	Favorable	Not Enough Information	AML with mutated NPM1	Post-Chemotherapy|Residual Disease	Peripheral Blood	WES	No	Yes	Yes	No	Yes	Yes	1	Standard Chemotherapy	1	Decitabine	1	Hypomethylating/Low Dose Cytarabine				Standard Chemotherapy	Decitabine	Hypomethylating/Low Dose Cytarabine	-1	0	0			No	0	0	21.2	1.5	0.8	2.3	17	23	3.7	1.12		27.4	9.2		394	88.4		46		8.7	19.67	Negative	Positive												85	Unmatched	AMLNPM1	Leukemia	AML with Mutated NPM1	0.233333333333
aml_ohsu_2018_4075	aml_ohsu_2018_16-00951	Denovo	None	AML with myelodysplasia-related changes	Adverse	Adverse	AML with myelodysplasia-related changes	Initial Acute Leukemia Diagnosis	Peripheral Blood	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	2	Standard Chemotherapy | Bone Marrow Transplant	4	Busulfan, Fludarabine|7+3 (Cytarabine, Idarubicin)|HiDAC|CLAG-M (Cladribine, Cytarabine, Mitoxantrone, Filgrastim)	4	Allogeneic - Sibling | Consolidation | Salvage | Induction	Complete Response	Standard Chemotherapy	-1	Bone Marrow Transplant	Busulfan, Fludarabine	Allogeneic - Sibling	-1	-3				No														45,XY,t(3;17)([21;q11.2),add(4)(q21),add(5)(p15),ins(10;11)(p12;q23q13),der(12;18)(q10;q10)[19]/46,XY[1]			11q23 rearrangement involving the  KMT2A (MLL) locus in 184/200 (92.0 percent) cells scored					Negative	Negative												42	Matched	AMLMRC	Leukemia	AML with Myelodysplasia-Related Changes	NA
aml_ohsu_2018_4077	aml_ohsu_2018_16-00968		None	Acute myeloid leukaemia, NOS	Intermediate	Intermediate-II	Acute myeloid leukaemia, NOS	Post-Chemotherapy	Bone Marrow Aspirate	WES	No	Yes	No	No	Yes	No	1	Standard Chemotherapy	2	7+3 (Cytarabine, Idarubicin)|HiDAC	2	Consolidation | Induction	Complete Response	Standard Chemotherapy	5	Standard Chemotherapy	HiDAC	Consolidation	58	0	0	1		No	0		62	22	16		65	45	4.2	0.71		31.2	9.8	46,X,t(X;2)(q22;p13)[20]	195		nuc ish(D5S2064,D5S630,EGR1)x2[200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[200],(RUNX1T1,RUNX1)x2[200],(ABL1,BCR)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	143	The findings reveal a small population of CD34(+) myeloblasts demonstrating immunophenotypic variation of unclear significance	6.7	2.49	Negative	Negative					Negative							54	Matched	AMLNOS	Leukemia	AML, NOS	1.0
aml_ohsu_2018_4078	aml_ohsu_2018_16-00970	Denovo	None	AML with myelodysplasia-related changes	Adverse	Adverse	AML with myelodysplasia-related changes	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	WES	No	Yes	No	No	Yes	No	1	Standard Chemotherapy	1	7+3 (Cytarabine, Idarubicin)	1	Induction	Unknown	Standard Chemotherapy	-1	Standard Chemotherapy	7+3 (Cytarabine, Idarubicin)	Induction	-1	0	0	26	9.5	No	0		50	0	40.5		27	32	3	0.51		20.9	6.7	39,X,-X,-4,-5,-7,-16,-17,-18[2]/39,idem,add(9)(q22)[3]/38,idem,-12[3]/46,XX[12]	249		nuc ish(RUNX1T1,RUNX1)x2[200],(ABL1,BCR)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PMLx2,RARAx1)[147/200],(5'CBFB,3'CBFB)x1(5'CBFB con 3'CBFBx1)[125/200]	44	CD4(+), CD7(-), CD11b(-), CD13(+), CD14(-), CD15(-), CD16(-), CD33(bright +), CD34(+), CD36(-/small subset +), CD38(partial +), CD45(+),CD56(-), CD64(partial dim +), CD117(+), HLA-DR(partial +), MPO(-), and TdT(-)	7.1	1.04	Negative	Negative				Negative	Negative	Negative						52	Matched	AMLMRC	Leukemia	AML with Myelodysplasia-Related Changes	1.13333333333
aml_ohsu_2018_4083	aml_ohsu_2018_16-00981	Denovo	Unknown	Acute myeloid leukaemia, NOS	Intermediate	Not Enough Information	Acute myeloid leukaemia, NOS	Initial Acute Leukemia Diagnosis	Peripheral Blood	WES	No	Yes	Yes	No	Yes	Yes	2	Standard Chemotherapy | Bone Marrow Transplant	3	Busulfan, Fludarabine|7+3 (Cytarabine, Idarubicin) plus CX-01|IDAC	3	Allogeneic - Sibling | Consolidation | Induction	Complete Response	Standard Chemotherapy	-1	Bone Marrow Transplant	Busulfan, Fludarabine	Allogeneic - Sibling	-1	0				No																			normocytic, normochromic, mild anisopoikilocytosis, no sig. polychromasia. Leukocyte number-decreased,leukocyte morph-within normal limits.			Negative	Negative												69	Matched	AMLNOS	Leukemia	AML, NOS	0.933333333333
aml_ohsu_2018_4195	aml_ohsu_2018_16-01004		Unknown	Acute myelomonocytic leukaemia	Intermediate	Not Enough Information	Acute myelomonocytic leukaemia	Post-Chemotherapy|Residual Disease	Peripheral Blood	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	1	Standard Chemotherapy	3	Vidaza|7+3 (Cytarabine, Idarubicin)|HiDAC	3	Hypomethylating/Low Dose Cytarabine | Consolidation | Induction	Complete Response	Standard Chemotherapy	6	Standard Chemotherapy	Vidaza	Hypomethylating/Low Dose Cytarabine	4	0	0	85	77.8	No	0		7.4	0	11.1		12	32	2.8	0.62		21.8	7		1195			103		5.2	25.85	Negative	Negative					Negative	Negative						70	Matched	AML	Leukemia	Acute Myeloid Leukemia	NA
aml_ohsu_2018_4196	aml_ohsu_2018_16-01005	Denovo	None	AML with myelodysplasia-related changes	Adverse	Adverse	AML with myelodysplasia-related changes	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	2	Standard Chemotherapy | Bone Marrow Transplant	2	7+3 (Cytarabine, Idarubicin) plus Enasidenib|Busulfan, Cyclophosphamide	2	Allogeneic - Sibling | Induction	Complete Response	Standard Chemotherapy	-1	Bone Marrow Transplant	Busulfan, Cyclophosphamide	Allogeneic - Sibling	-1	0	1	30	0	No	0		31	4	6.8		10	11	4.3			32.4	9.9	46,XX,del(5)(q22q35)[2]/46,XX,+8,-16,der(17)t(16;17)(p11.2;p11.2)[14]/46,XX[3]			Probe: 8 centromere/20q12	83	Negative	7.2	10.6	Negative	Negative	Negative		Negative	Negative	Negative		Negative	Negative	Negative	Negative	Negative	55	Matched	AMLMRC	Leukemia	AML with Myelodysplasia-Related Changes	0.6
aml_ohsu_2018_4028	aml_ohsu_2018_16-01009		None	AML with mutated NPM1	Intermediate	Not Enough Information	AML with mutated NPM1	Post-Chemotherapy	Peripheral Blood	WES	No	Yes	Yes	No	Yes	Yes	2	Standard Chemotherapy | Bone Marrow Transplant	3	Fludarabine, Melphalan|MiDAC|7+3 (Cytarabine, Idarubicin) plus Sorafenib	3	Consolidation | Induction | Allogeneic - Mismatched Unrelated Donor	Complete Response	Standard Chemotherapy	6	Bone Marrow Transplant	Fludarabine, Melphalan	Allogeneic - Mismatched Unrelated Donor	-1	0	0.7	3.5	0	No	0	0.7	16.5	5.7	76.4	0	27	12	3.7	0.74		32.7	10.8	46,XX[19]	278	92.6	Normal	295	CD34+ blasts comprise 1% of WBCs. Lymphocytes	7.4	4.05	Negative	Negative												61	Matched	AMLNPM1	Leukemia	AML with Mutated NPM1	0.233333333333
aml_ohsu_2018_4197	aml_ohsu_2018_16-01010		Unknown	AML with mutated NPM1	Favorable	Not Enough Information	AML with mutated NPM1	Residual Disease|Post-Chemotherapy	Peripheral Blood	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	2	Standard Chemotherapy | Supportive/Palliative Care	5	7+3 (Cytarabine, Idarubicin)|Sunitinib|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin) plus Sorafenib|Hydroxyurea	4	Consolidation | Salvage | Induction | Supportive/Palliative Care	Complete Response	Standard Chemotherapy	32	Standard Chemotherapy	Sunitinib	Consolidation	2	0	0			No	0	0	20.4	0	66.7	1	58	44	3.3	1.04		23.8	8.1		401	88.5	Positive	14		7.3	6.18	Positive	Positive												46	Matched	AMLNPM1	Leukemia	AML with Mutated NPM1	0.566666666667
aml_ohsu_2018_4043	aml_ohsu_2018_16-01017		None	Acute myeloid leukaemia, NOS	Adverse	Adverse	Acute myeloid leukaemia, NOS	Post-Chemotherapy|Residual Disease	Bone Marrow Aspirate	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	1	Standard Chemotherapy	3	Bu/Cy/ATG|7+3 (Cytarabine, Idarubicin)|HiDAC	3	Consolidation | Unknown | Induction	Complete Response	Standard Chemotherapy	79	Standard Chemotherapy	Bu/Cy/ATG	Unknown	22	0		70	8	No				4										46,XY,-3,del(5)(q31q35),der(7)t(7;?)(p11.2;?),+der(11)(q23),-12,+mar[20]				10	MONOBLASTS, 61%. These are dim45positive and also express CD13, CD33, CD11b, CD14, CD64  but lack CD16, CD34, CD117, HLADR		30.2	Negative	Negative										p.Q61K; MAF45%		26	Unmatched	AMLNOS	Leukemia	AML, NOS	0.0666666666667
aml_ohsu_2018_2739	aml_ohsu_2018_16-01018		None	Primary myelofibrosis	Intermediate	Not Enough Information	Primary myelofibrosis	Residual Disease	Bone Marrow Aspirate	WES	No	Yes	No	No	Yes	No	1	Standard Chemotherapy	1	Hydroxyurea	1	Unknown				Standard Chemotherapy	Hydroxyurea	Unknown	263	-119		5	0	No	0		12	8	80					0.93		28.7	8.9	46,XY[17]		81.8	This test has not detected clonal abnormalities in the cells analyzed. Subtle structural changes cannot be ruled out due to the limitations of resolution. Small percentage of tumor cells with chromosome abnormalities may not be detected due to the limited number of cells examined.	88	These are positive for CD34, CD117, HLADR, CD33 and CD13.	0	5.6	Negative	Negative												67	Matched	PMF	Myeloproliferative Neoplasms	Primary Myelofibrosis	0.466666666667
aml_ohsu_2018_4201	aml_ohsu_2018_16-01022	Denovo	None	AML with mutated NPM1	Favorable	Favorable	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	WES	No	Yes	Yes	No	Yes	Yes	1	Standard Chemotherapy	3	MiDAC|FLAG-IDA plus Midostaurin|7+3 (Cytarabine, Idarubicin) plus Dasatinib	3	Consolidation | Salvage | Induction	Complete Response	Standard Chemotherapy	-1	Standard Chemotherapy	FLAG-IDA plus Midostaurin	Salvage	-1	0	0	51.5	0	No	0	0	13.2	79.8	4.4	0	52	25	3.6	1.16		30.6	10.2	46,XX[20]	608	102.3	Normal	45	CD11b, CD13, CD14, CD15, CD33, CD56, bright CD64 and dim HLA-DR-positive	7	116.57	Negative	Positive			p.R882C; MAF 45%							p.G12D; 17%		52	Matched	AMLNPM1	Leukemia	AML with Mutated NPM1	0.4
aml_ohsu_2018_4202	aml_ohsu_2018_16-01024	Denovo	Unknown	AML with myelodysplasia-related changes	Intermediate	Not Enough Information	AML with myelodysplasia-related changes	Initial Acute Leukemia Diagnosis	Peripheral Blood	WES	No	Yes	No	No	Yes	No	2	Standard Chemotherapy | Supportive/Palliative Care	2	7+3 (Cytarabine, Idarubicin)|Decitabine	2	Hypomethylating/Low Dose Cytarabine | Induction	Refractory	Standard Chemotherapy	5	Supportive/Palliative Care	Decitabine	Hypomethylating/Low Dose Cytarabine	5	0	0		7	No	0		50.4	5.2	36.5		17	14	3.8	0.78			7.2		183		nuc ish(RUNX1T1x2,RUNX1x1)[34/200],(ABL1x2,BCRx1)[51/200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[199]	32		7	2.18	Negative	Negative					Negative	Negative	Negative					62	Matched	AMLMRC	Leukemia	AML with Myelodysplasia-Related Changes	NA
aml_ohsu_2018_4205	aml_ohsu_2018_16-01047	Relapse	Unknown	AML with mutated NPM1	Intermediate	Not Enough Information	AML with mutated NPM1	Post-Chemotherapy|Relapse	Peripheral Blood	WES + RNA-seq	Yes	Yes	No	Yes	Yes	No	1	Standard Chemotherapy	2	Cytarabine|Idarubicin and Cytarabine	2	Consolidation | Induction	Complete Response	Standard Chemotherapy	9	Standard Chemotherapy	Cytarabine	Consolidation	40	0			94	No	0		3	0	1		18	52	3.2	1.03		24.6	8.6			93.5		28		5.7	108.9	Positive	Positive					p.R132S, MAF 46%							69	Unmatched	AMLNPM1	Leukemia	AML with Mutated NPM1	0.166666666667
aml_ohsu_2018_4207	aml_ohsu_2018_16-01049	Denovo	None	Acute myeloid leukaemia, NOS	Intermediate	Not Enough Information	Acute myeloid leukaemia, NOS	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	2	Standard Chemotherapy | Supportive/Palliative Care	5	7+3 (Cytarabine, Idarubicin)|Decitabine|7+3 (Cytarabine, Idarubicin) plus Azacitidine|IDAC|Etoposide, Cytarabine	4	Induction | Re-induction | Maintenance | Supportive/Palliative Care	Refractory	Supportive/Palliative Care	-1	Standard Chemotherapy	Etoposide, Cytarabine	Supportive/Palliative Care	-1	0	0	20	3.8	No	7.8		40	5.2	40		9	49	3.1	1.41		25.7	8.5	46,XY[20]	675		nuc ish(RUNX1T1,RUNX1)x2[200],(ABL1,BCR)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	30	CD2(-), CD3(-), CD4(dim +), CD10(-), CD11b(-), CD13(+), CD14(-), CD15(small subset+), CD16(-), CD19(-), CD20(-), CD33(+), CD34(+),CD36(-), CD38(dim+), CD45(dim +), CD56(-), CD64(variably+), CD117(+), HLA-DR(dim +), MPO(partial +), and TdT(-).	6.9	4.9	Negative	Negative				Negative	Negative	Negative						78	Unmatched	AMLNOS	Leukemia	AML, NOS	0.166666666667
aml_ohsu_2018_4210	aml_ohsu_2018_16-01055	After or at the time transformation from another heme malignancy	None	AML with myelodysplasia-related changes	Adverse	Not Enough Information	AML with myelodysplasia-related changes	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	WES	No	Yes	Yes	No	Yes	Yes	2	Standard Chemotherapy | Bone Marrow Transplant	3	7+3 (Cytarabine, Idarubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone)|Busulfan, Cyclophosphamide	3	Salvage | Induction | Allogeneic - Matched Unrelated Donor	Refractory	Standard Chemotherapy	-1	Bone Marrow Transplant	Busulfan, Cyclophosphamide	Allogeneic - Matched Unrelated Donor	-1	0	0	73	68	No	0	0.8	19.3	7.6	3.4	0.1	46	25	3.4	0.74		17	5.9	46,XX[20]		91.9	Normal	53	CD13, CD34, CD38, CD117, and dim HLA-DR +.	6.8	40.02	Negative	Negative			p.R882H; MAF 46%							p.Q61K; MAF 9%		56	Matched	AMLMRC	Leukemia	AML with Myelodysplasia-Related Changes	1.6
aml_ohsu_2018_2530	aml_ohsu_2018_16-01059	After or at the time transformation from another heme malignancy	None	AML with mutated NPM1	Intermediate	Not Enough Information	AML with mutated NPM1	Post-Chemotherapy	Bone Marrow Aspirate	WES	No	Yes	No	No	Yes	No	1	Standard Chemotherapy	1	Ruxolitinib	1	Induction	Unknown	Standard Chemotherapy	28	Standard Chemotherapy	Ruxolitinib	Induction	28	-195				No														46,XX[20]			This test has not detected clonal abnormalities in the cells analyzed. Subtle structural changes cannot be ruled out due to the limitations of resolution. Small percentage of tumor cells with chromosome abnormalities may not be detected due to the limited number of cells examined.					Negative	Negative												74	Unmatched	AMLNPM1	Leukemia	AML with Mutated NPM1	0.166666666667
aml_ohsu_2018_4197	aml_ohsu_2018_16-01061		Unknown	AML with mutated NPM1	Favorable	Not Enough Information	AML with mutated NPM1	Post-Chemotherapy|Residual Disease	Peripheral Blood	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	2	Standard Chemotherapy | Supportive/Palliative Care	5	7+3 (Cytarabine, Idarubicin)|Sunitinib|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin) plus Sorafenib|Hydroxyurea	4	Consolidation | Salvage | Induction | Supportive/Palliative Care	Complete Response	Standard Chemotherapy	32	Standard Chemotherapy	Sunitinib	Consolidation	2	0				No																	Positive					Negative	Positive												47	Matched	AMLNPM1	Leukemia	AML with Mutated NPM1	0.633333333333
aml_ohsu_2018_4225	aml_ohsu_2018_16-01080	Denovo	PML-RARA	Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA	Favorable	Intermediate-II	Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA	Initial Acute Leukemia Diagnosis	Peripheral Blood	WES + RNA-seq	Yes	Yes	No	Yes	Yes	No	1	Standard Chemotherapy	1	ATRA, Idarubicin	1	Induction	Complete Response	Standard Chemotherapy	-1	Standard Chemotherapy	ATRA, Idarubicin	Induction	-1	-1	1.7	90	59.5	No	1.7	0.8	13.5	5	6.7	0.9	45	41	3.4	1.09	M3	24.1	8.6	46,XX,t(15;17)(q24;q21)[20]		92.7	PML/RARA fusion	39	dim CD2, CD13, dim CD15, CD33, CD38, CD58, CD64, CD117, CD123, variable HLA-DR and bright MPO positive	6.5	34.36	Positive	Negative	Negative		Negative		Negative	Negative	Negative	Negative	Negative	Negative	Negative	69	Matched	APLPMLRARA	Leukemia	APL with PML-RARA	0.1
aml_ohsu_2018_4226	aml_ohsu_2018_16-01082	Denovo	CBFB-MYH11	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	Favorable	Favorable	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	Initial Acute Leukemia Diagnosis	Peripheral Blood	WES + RNA-seq	Yes	Yes	No	Yes	Yes	No	1	Standard Chemotherapy	1	7+3 (Cytarabine, Idarubicin)	1	Induction	Complete Response	Standard Chemotherapy	-1	Standard Chemotherapy	7+3 (Cytarabine, Idarubicin)	Induction	-1	0	0		10	No	0.9	0	81.8	4.6	10.9	0	27	26	4.1	1		33.6	11.9	46,XY,del(7)(q22),inv(16)(p13.1q22)[18]/46,XY[2]	330	106.7	CBFB, D7S486/ CEP 7	106	CD5, CD19, dim CD20, dim CD22, CD23 and light chain negative	6.9	2.16	Negative	Negative												68	Unmatched	AMLCBFBMYH11	Leukemia	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22);CBFB-MYH11	0.0666666666667
aml_ohsu_2018_4229	aml_ohsu_2018_16-01093	Denovo	None	Acute myeloid leukaemia, NOS	Intermediate	Intermediate-II	Acute myeloid leukaemia, NOS	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	0		0		0					NONE	NONE	NONE		0	0	48	6	No	0		31	14	47		27	27	4.2	0.86		36.9	12.6	47,XY,t(8;19)(q24.1;q13.1),+10[17]/46,XY[3]	294		nuc ish(D5S2064,D5S630,EGR1)x2[200],(D7Z1,D7S522)x2[200], (D8Z2,D20S108)x2[200],(RUNX1T1,RUNX1)x2[200],(ABL1,BCR)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2) [200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	175		7	2.43	Negative	Negative												61	Matched	AMLNOS	Leukemia	AML, NOS	0.833333333333
aml_ohsu_2018_2254	aml_ohsu_2018_16-01094	Relapse	None	Acute myeloid leukaemia, NOS	Intermediate	Not Enough Information	Acute myeloid leukaemia, NOS	Relapse	Bone Marrow Aspirate	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	1	Standard Chemotherapy	3	7+3 (Cytarabine, Idarubicin)|HiDAC|MEC (Cytarabine, Etoposide, Mitoxantrone)	3	Consolidation | Salvage | Induction	Complete Response	Standard Chemotherapy	7	Standard Chemotherapy	MEC (Cytarabine, Etoposide, Mitoxantrone)	Salvage	-1	-463		76	1	No														46,XX[20]			nuc ish(D4Z1,D10Z1)x2[200],(RUNX1T1,RUNX1)x2[200],(ABL1,BCR)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(ETV6,RUNX1)x2[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]					Negative	Negative												53	Unmatched	AMLNOS	Leukemia	AML, NOS	0.2
aml_ohsu_2018_2116	aml_ohsu_2018_16-01097	Relapse	None	AML with mutated CEBPA	Intermediate	Intermediate-II	AML with mutated CEBPA	Post-Chemotherapy|Relapse	Bone Marrow Aspirate	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	1	Standard Chemotherapy	3	COG-AAML1031 (IT/IV Cytarabine, Daunorubicin, Etoposide, Mitoxantrone +/- Bortezomib or Sorafenib)|ADE (Cytarabine, Daunorubicin & Etoposide)|FLAG (Fludarabine, High-dose Cytarabine, G-CSF)	2	Induction | Re-induction	Complete Response	Standard Chemotherapy	33	Standard Chemotherapy	FLAG (Fludarabine, High-dose Cytarabine, G-CSF)	Re-induction	-1	0	0	46		No	0	0	81.3	8.3	10.4	18.1	31	27	3.8	0.53		30.5	10.2	47,XX,+10[19]/46,XX[1]		96.8	Normal	11	variable CD7,  dim CD13, CD33, CD34 bright CD38,CD56, CD58, CD117, HLA-DR positive	7	1.93	Negative	Negative												12	Unmatched	AMLCEBPA	Leukemia	AML with Biallelic Mutations of CEBPA	0.0666666666667
aml_ohsu_2018_4230	aml_ohsu_2018_16-01098	Denovo	None	AML with mutated NPM1	Intermediate	Intermediate-II	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	WES	No	Yes	Yes	No	Yes	Yes	2	Standard Chemotherapy | Bone Marrow Transplant	3	HiDAC|7+3 (Cytarabine, Idarubicin) plus Crenolanib|Busulfan, Cyclophosphamide	3	Consolidation | Induction | Allogeneic - Matched Unrelated Donor	Complete Response	Standard Chemotherapy	-1	Bone Marrow Transplant	Busulfan, Cyclophosphamide	Allogeneic - Matched Unrelated Donor	-1	0		64	74	No							21	34						45,XX,der(13;14)(q10;q10)?c[20]			nuc ish(RUNX1T1,RUNX1)x2[200],(ABL1,BCR)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	90			99.87	Positive	Positive												44	Matched	AMLNPM1	Leukemia	AML with Mutated NPM1	0.766666666667
aml_ohsu_2018_4231	aml_ohsu_2018_16-01100	Denovo	Unknown	AML with mutated NPM1	Favorable	Not Enough Information	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Peripheral Blood	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	1	Standard Chemotherapy	1	Cytarabine	1	Supportive/Palliative Care				Standard Chemotherapy	Cytarabine	Supportive/Palliative Care	-1	0				No																	nuc ish (PML,RARA)x2[199]					Negative	Positive												65	Matched	AMLNPM1	Leukemia	AML with Mutated NPM1	0.833333333333
aml_ohsu_2018_4232	aml_ohsu_2018_16-01102	Denovo	None	AML with myelodysplasia-related changes	Adverse	Adverse	AML with myelodysplasia-related changes	Initial Acute Leukemia Diagnosis	Peripheral Blood	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	1	Standard Chemotherapy	1	Decitabine	1	Supportive/Palliative Care				Standard Chemotherapy	Decitabine	Supportive/Palliative Care	-1	0		30	5	No							37	93						45,XX,der(5)inv(5)(p13q15)del(5)(q15q33),-16,-17,der(17)t(17;17)(p13;q11.2),der(18;22)(q10;q10),+22,+r[cp20] .ish r(MLL+)[2]			nuc ish(D4Z1,D10Z1)x2[200],(D5S2064x2,D5S630x2,EGR1x1)[196/200],(D7Z1,D7S522)x2[200], (D8Z2,D20S108)x2[197],(RUNX1T1,RUNX1)x2[200],(ABL1,BCR)x2[200],(5'MLL,3'MLL)x3(5'MLL con 3'MLLx3) [142/200],(ETV6,RUNX1)x2[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x1(5'CBFB con 3'CBFBx1)[200]	16			44.63	Negative	Negative												72	Matched	AMLMRC	Leukemia	AML with Myelodysplasia-Related Changes	NA
aml_ohsu_2018_4197	aml_ohsu_2018_16-01103		Unknown	AML with mutated NPM1	Intermediate	Not Enough Information	AML with mutated NPM1	Residual Disease|Post-Chemotherapy	Peripheral Blood	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	2	Standard Chemotherapy | Supportive/Palliative Care	5	7+3 (Cytarabine, Idarubicin)|Sunitinib|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin) plus Sorafenib|Hydroxyurea	4	Consolidation | Salvage | Induction | Supportive/Palliative Care	Complete Response	Standard Chemotherapy	32	Standard Chemotherapy	Sunitinib	Consolidation	2	0	0	90	90	No	0	0	5	0	0	0	27	43	1.6	0.93		22.5	7.9			82.1	Positive	43	variable CD7, CD13, dim CD33, partial CD34, CD38,dim CD58, partial and variable CD117 and CD123 positive	5.1	18.38	Positive	Positive												47	Matched	AMLNPM1	Leukemia	AML with Mutated NPM1	0.7
aml_ohsu_2018_4235	aml_ohsu_2018_16-01109	Denovo	CBFB-MYH11	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	Favorable	Favorable	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	Initial Acute Leukemia Diagnosis	Peripheral Blood	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	1	Standard Chemotherapy	2	7+3 (Cytarabine, Idarubicin)|HiDAC	2	Consolidation | Induction	Complete Response	Standard Chemotherapy	-1	Standard Chemotherapy	HiDAC	Consolidation	-1	0	0	72	95	No	0		3	0	1		29	24	3.4			19.8	6.5	46,XY,inv(16)(p13.1q22)[20]			Positive for CBFB rearrangment for 91% of cells	31	Positive	6.6	93.2	Negative	Negative	Negative		Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	33	Matched	AMLCBFBMYH11	Leukemia	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22);CBFB-MYH11	0.333333333333
aml_ohsu_2018_2611	aml_ohsu_2018_16-01118	Relapse	None	AML with mutated NPM1	Intermediate	Not Enough Information	AML with mutated NPM1	Post-Transplant|Relapse	Bone Marrow Aspirate	WES	Yes	Yes	Yes	No	Yes	Yes	2	Standard Chemotherapy | Bone Marrow Transplant	4	7+3 (Cytarabine, Idarubicin)|HiDAC|GCLAC (GCSF, Clofarabine & Cytarabine)|Fludarabine, Cyclophosphamide, Thiotepa, TBI	4	Consolidation | Salvage | Induction | Double Umbilical Cord Blood Transplant (DUCBT)	Complete Response	Standard Chemotherapy	27	Standard Chemotherapy	GCLAC (GCSF, Clofarabine & Cytarabine)	Salvage	-1	-224		90		No														46,XX[19]			Normal					Positive	Positive												56	Unmatched	AMLNPM1	Leukemia	AML with Mutated NPM1	0.233333333333
aml_ohsu_2018_4239	aml_ohsu_2018_16-01121	Denovo	None	AML with mutated NPM1	Favorable	Intermediate-I	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	2	Standard Chemotherapy | Bone Marrow Transplant	3	Busulfan, Fludarabine|IDAC plus Midostaurin|7+3 (Cytarabine, Daunorubicin) plus Sorafenib	3	Consolidation | Induction | Allogeneic - Matched Unrelated Donor	Complete Response	Standard Chemotherapy	-1	Bone Marrow Transplant	Busulfan, Fludarabine	Allogeneic - Matched Unrelated Donor	-1	0		86	89	No														46,XY[20]			Normal	57			115.15	Positive	Positive			p.Arg326Cys; MAF 44.5%									61	Matched	AMLNPM1	Leukemia	AML with Mutated NPM1	0.633333333333
aml_ohsu_2018_4240	aml_ohsu_2018_16-01123	Relapse	None	AML with mutated NPM1	Favorable or Intermediate	Intermediate-I	AML with mutated NPM1	Relapse	Bone Marrow Aspirate	WES	No	Yes	No	No	Yes	No	4	Standard Chemotherapy | Bone Marrow Transplant | Intrathecal | Targeted Therapy - Kinase Inhibitor(s)	7	Bellicum Trial (Flu/Cy/TBI + ATG + Rituximab then BPX-501)|Dasatinib|7+3 (Cytarabine, Idarubicin)|HiDAC|MEC (Cytarabine, Etoposide, Mitoxantrone)|Sorafenib|Methotrexate	6	Allogeneic - Sibling | Consolidation | Induction | Experimental | CNS | Re-induction	Complete Response i	Standard Chemotherapy	-1	Targeted Therapy - Kinase Inhibitor(s)	Dasatinib	Experimental	-1	2	0			No	0.9	0.9	29.5	6.9	52.2	0	51	28	3.6	0.78		40	13.2	46,XX[20]	272	87.3	Normal	145		6.7	8.16	Positive	Positive			p.R882H; MAF 35% (previously 32% on 10/10/16)									46	Matched	AMLNPM1	Leukemia	AML with Mutated NPM1	0.933333333333
aml_ohsu_2018_2538	aml_ohsu_2018_16-01127		None	AML with mutated NPM1	Favorable	Not Enough Information	AML with mutated NPM1	Post-Chemotherapy	Leukapheresis	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	2	Standard Chemotherapy | Targeted Therapy - Other	4	AG-120|7+3 (Cytarabine, Idarubicin)|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|MiDAC	4	Consolidation | Salvage | Induction | Experimental	Complete Response	Standard Chemotherapy	6	Standard Chemotherapy	FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)	Salvage	-1	-52				No														46,XY[20]			Normal					Negative	Positive												68	Matched	AMLNPM1	Leukemia	AML with Mutated NPM1	0.333333333333
aml_ohsu_2018_2315	aml_ohsu_2018_16-01138	Transformation from another heme malignancy and Relapse	None	AML with myelodysplasia-related changes	Adverse	Not Enough Information	AML with myelodysplasia-related changes	Relapse	Peripheral Blood	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	1	Standard Chemotherapy	2	Decitabine|Hydroxyurea	2	Induction | Re-induction	Complete Response i	Standard Chemotherapy	-1	Standard Chemotherapy	Hydroxyurea	Re-induction	-1	-412	0.9			No	0	0	7.8	1.7	4.3	0.1	18	21	2.8	1.43		25	8.2	46,XY,del(5)(q22q35),del(12)(q24.1q24.1),add(17)(p11.2)[19]/46,XY[1]	564	102.5	EGR1 (73.5%) ;  TP53: (85.5%)	139		6.6	46.79	Negative	Negative												63	Matched	AMLMRC	Leukemia	AML with Myelodysplasia-Related Changes	0.5
aml_ohsu_2018_4245	aml_ohsu_2018_16-01139		None	Acute myeloid leukaemia, NOS	Intermediate	Intermediate-I	Acute myeloid leukaemia, NOS	Post-Chemotherapy|Residual Disease	Peripheral Blood	WES	No	Yes	Yes	No	Yes	Yes	1	Supportive/Palliative Care	2	Lenalidomide|Azacitidine	1	Supportive/Palliative Care				Supportive/Palliative Care	Lenalidomide	Supportive/Palliative Care	45	-19				No														46,XX[20]			Normal					Negative	Negative												79	Unmatched	AMLNOS	Leukemia	AML, NOS	0.133333333333
aml_ohsu_2018_4247	aml_ohsu_2018_16-01142		None	AML with mutated CEBPA	Favorable	Favorable	AML with mutated CEBPA	Post-Chemotherapy|Residual Relapse	Bone Marrow Aspirate	WES	No	Yes	No	No	Yes	No	2	Standard Chemotherapy | Bone Marrow Transplant	5	7+3 (Cytarabine, Idarubicin)|HiDAC|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone)|Fludarabine, Cyclophosphamide, TBI, Rituximab	4	Allogeneic - Sibling | Consolidation | Induction | Re-induction	Complete Response	Standard Chemotherapy	-1	Bone Marrow Transplant	Fludarabine, Cyclophosphamide, TBI, Rituximab	Allogeneic - Sibling	-1	0	0	50		Yes	1.8	0.9	21	2.6	71.9	1.8	24	11	3.6	0.61		25.5	9	46,XX[20]	174	87.3	Normal	42	CD7, CD13, CD33, CD34, partial CD56, CD117,  HLA-DR,          MPO and dim TdT-positive	6.8	1.65	Negative	Negative	p.Q311*; MAF 15%											29	Matched	AMLCEBPA	Leukemia	AML with Biallelic Mutations of CEBPA	0.733333333333
aml_ohsu_2018_4248	aml_ohsu_2018_16-01151	Denovo	None	AML with mutated NPM1	Favorable	Not Enough Information	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Peripheral Blood	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	1	Standard Chemotherapy	1	Vidaza, BI836858 (anti-CD33)	1	Induction	Complete Response	Standard Chemotherapy	-1	Standard Chemotherapy	Vidaza, BI836858 (anti-CD33)	Induction	-1	0	0		80	No	0	7	7.8	0	6.9	0.5	31	42	3.2	1.3		25.1	8.8	46,XY[19]	665	85.1	Normal	16	dim CD13, CD33, CD38, CD58, dim CD64, CD71, dim CD117 and CD123-positive	7.2	33.81	Negative	Positive	Negative		Negative	Negative	Negative		Negative	Negative	Negative	Negative	Negative	81	Matched	AMLNPM1	Leukemia	AML with Mutated NPM1	0.7
aml_ohsu_2018_4252	aml_ohsu_2018_16-01185		None	Therapy-related myeloid neoplasms	Adverse	Adverse	Therapy-related myeloid neoplasms	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	2	Standard Chemotherapy | Bone Marrow Transplant	2	GCLAC (GCSF, Clofarabine & Cytarabine)|Fludarabine, Cyclophosphamide, Thiotepa, TBI	2	Induction | Double Umbilical Cord Blood Transplant (DUCBT)	Complete Response	Standard Chemotherapy	-1	Bone Marrow Transplant	Fludarabine, Cyclophosphamide, Thiotepa, TBI	Double Umbilical Cord Blood Transplant (DUCBT)	-1	0	0	75	82	No	2		4	0	8		39	45	3.7			20.1	6.5	46,XY,add(1)(p11),del(5)(q15q33),del(7)(q22q36),der(11)t(1;11)(p31;p12-14)[20]			Loss of 5q31 sequences for 99% of total cells	12	Positive: CD38, CD56, CD13, CD34, CD45, CD117, HLA-DR	6.3	119.6	Positive	Negative	Negative		Negative		Negative	Negative	Negative	Negative	Negative	Negative	Negative	50	Matched	TMN	Leukemia	Therapy-Related Myeloid Neoplasms	0.4
aml_ohsu_2018_4256	aml_ohsu_2018_16-01191	After or at the time transformation from another heme malignancy	None	AML with myelodysplasia-related changes	Adverse	Not Enough Information	AML with myelodysplasia-related changes	Initial Acute Leukemia Diagnosis	Peripheral Blood	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	2	Standard Chemotherapy | Bone Marrow Transplant	3	Vidaza|Fludarabine, Melphalan|7+3 (Cytarabine, Idarubicin)	3	Induction | Supportive/Palliative Care | Allogeneic - Matched Unrelated Donor	Complete Response	Standard Chemotherapy	-1	Bone Marrow Transplant	Fludarabine, Melphalan	Allogeneic - Matched Unrelated Donor	-1	0				No														45,XX,-7[20]			7cen (D7Z1), 7q31 (D7S486): monosomy present					Negative	Negative			p.Gln231fs; MAF 33.2%							p.Gln61Glu; MAF 47.8%		65	Unmatched	AMLMRC	Leukemia	AML with Myelodysplasia-Related Changes	0.233333333333
aml_ohsu_2018_4201	aml_ohsu_2018_16-01192		None	AML with mutated NPM1	Intermediate	Not Enough Information	AML with mutated NPM1	Post-Chemotherapy	Peripheral Blood	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	1	Standard Chemotherapy	3	MiDAC|FLAG-IDA plus Midostaurin|7+3 (Cytarabine, Idarubicin) plus Dasatinib	3	Consolidation | Salvage | Induction	Complete Response	Standard Chemotherapy	-1	Standard Chemotherapy	FLAG-IDA plus Midostaurin	Salvage	-1	-6	1.4			No	0.2		9.2	24.3	64.9		119	151	3.2	0.76		28.4	9.2	46,XX[20]	380	93.4	Normal	395		6.6	6.5	Negative	Negative	Negative		p.R882C; MAF 14%	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	52	Matched	AMLNPM1	Leukemia	AML with Mutated NPM1	0.1
aml_ohsu_2018_4260	aml_ohsu_2018_16-01201		None	Acute myeloid leukaemia, NOS	Adverse	Intermediate-II	Acute myeloid leukaemia, NOS	Post-Chemotherapy|Residual Disease	Bone Marrow Aspirate	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	2	Standard Chemotherapy | Targeted Therapy - Other	7	AG-120|7+3 (Cytarabine, Idarubicin)|Azacitidine|MGD006 (CD123 x CD3) |MEC (Cytarabine, Etoposide, Mitoxantrone)|Decitabine|Incyte trial (azacitidine and JAK 1 inhibitor)	5	Salvage | Induction | Experimental | Re-induction | Maintenance	Refractory	Standard Chemotherapy	6	Standard Chemotherapy	Incyte trial (azacitidine and JAK 1 inhibitor)	Salvage	-1	0	0	75	90	No	0	0	22.1	6.2	1.8	0	19	33	1.8	0.84		25.5	8.1	46,XY,t(4;12)(q12;p13)[10]/46,XY[10]	706	91.4	42/100 (42%) interphase cells scored were positive for  ETV6 rearrangement.  Metaphase FISH showed part of the ETV6 signal (red) on  the long arm of chromosome 4.  Based on the breakpoint, ETV6/CHIC2 fusion  is predicted, consistent with AML	25	partial CD7, CD13, CD33, CD38, CD34, CD58, CD117, CD123,  HLA-DR positive	6.6	118	Negative	Negative	Negative		p.R882H; MAF 49%	Negative	p.R132S; MAF 48%	Negative	Negative		Negative	Negative	Negative	54	Unmatched	AMLNOS	Leukemia	AML, NOS	0.333333333333
aml_ohsu_2018_4263	aml_ohsu_2018_16-01210	Denovo	None	AML with myelodysplasia-related changes	Intermediate	Not Enough Information	AML with myelodysplasia-related changes	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	WES + RNA-seq	Yes	Yes	No	Yes	Yes	No	2	Standard Chemotherapy | Bone Marrow Transplant	3	Busulfan, Fludarabine|7+3 (Cytarabine, Idarubicin) plus Crenolanib|IDAC	3	Consolidation | Induction | Allogeneic - Child	Complete Response	Standard Chemotherapy	-1	Bone Marrow Transplant	Busulfan, Fludarabine	Allogeneic - Child	-1	-17		26.3	12	No														46,XY[11]			Normal	69			9.28	Negative	Negative			p.Thr835Met; MAF 47%		p.Arg132Cys; MAF 2.9%							63	Unmatched	AMLMRC	Leukemia	AML with Myelodysplasia-Related Changes	0.133333333333
aml_ohsu_2018_4263	aml_ohsu_2018_16-01216	Denovo	None	AML with myelodysplasia-related changes	Intermediate	Not Enough Information	AML with myelodysplasia-related changes	Initial Acute Leukemia Diagnosis	Peripheral Blood	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	2	Standard Chemotherapy | Bone Marrow Transplant	3	Busulfan, Fludarabine|7+3 (Cytarabine, Idarubicin) plus Crenolanib|IDAC	3	Consolidation | Induction | Allogeneic - Child	Complete Response	Standard Chemotherapy	-1	Bone Marrow Transplant	Busulfan, Fludarabine	Allogeneic - Child	-1	-18				No														46,XY[11]			Normal					Negative	Negative			p.Thr835Met; MAF 47%		p.Arg132Cys; MAF 2.9%							63	Unmatched	AMLMRC	Leukemia	AML with Myelodysplasia-Related Changes	0.166666666667
aml_ohsu_2018_4271	aml_ohsu_2018_16-01219	Denovo	None	AML with mutated CEBPA	Favorable	Favorable	AML with mutated CEBPA	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	1	Standard Chemotherapy	2	7+3 (Cytarabine, Idarubicin)|HiDAC	2	Consolidation | Induction	Complete Response	Standard Chemotherapy	7	Standard Chemotherapy	HiDAC	Consolidation	-1	0	0	83	82	Yes	3.4	0	23.1	3.4	0	1.6	23	11	3.5	0.95		31.1	10.2	46,XY[20]	290	88.9		24	CD7, CD13, CD33, CD34, CD38, partial CD56,  CD58, dim CD64, CD117, CD123, HLA-DR, and cMPO	6.5	18.71	Negative	Negative	p.I68fs; MAF 50%		Negative	Negative	Negative	Negative	Negative	Negative		p.G13D, MAF 3%	Negative	47	Matched	AMLCEBPA	Leukemia	AML with Biallelic Mutations of CEBPA	0.7
aml_ohsu_2018_4273	aml_ohsu_2018_16-01223	Denovo	None	Acute myeloid leukaemia, NOS	Intermediate	Not Enough Information	Acute myeloid leukaemia, NOS	Initial Acute Leukemia Diagnosis	Peripheral Blood	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	1	Standard Chemotherapy	1	Decitabine	1	Supportive/Palliative Care				Standard Chemotherapy	Decitabine	Supportive/Palliative Care	-1	0		83	59	No							21	23						46,XY[20]			nuc ish(RUNX1T1,RUNX1)x2[200],(ABL1,BCR)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[195],(PML, RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	22			24.23	Negative	Negative												73	Matched	AMLNOS	Leukemia	AML, NOS	1.13333333333
aml_ohsu_2018_4274	aml_ohsu_2018_16-01225	After or at the time transformation from another heme malignancy	None	AML with mutated NPM1	Intermediate	Intermediate-I	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Peripheral Blood	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	1	Supportive/Palliative Care	1	Hydroxyurea	1	Supportive/Palliative Care				Supportive/Palliative Care	Hydroxyurea	Supportive/Palliative Care	-1	-2				No														46,XX[20]			Normal					Positive	Positive	Negative		Negative		Negative	Negative	Negative	Negative	Negative	Negative	Negative	61	Unmatched	AMLNPM1	Leukemia	AML with Mutated NPM1	0.1
aml_ohsu_2018_4275	aml_ohsu_2018_16-01227	Relapse	Unknown	AML with mutated NPM1	Favorable	Not Enough Information	AML with mutated NPM1	Post-Chemotherapy|Relapse	Peripheral Blood	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	1	Standard Chemotherapy	2	7+3 (Cytarabine, Idarubicin)|HiDAC	2	Consolidation | Induction	Complete Response	Standard Chemotherapy	39	Standard Chemotherapy	HiDAC	Consolidation	-1	0			91	No			9				21	34	3.8	0.49		29.3	9.9			93.6		66		5.8	73	Negative	Positive												40	Unmatched	AMLNPM1	Leukemia	AML with Mutated NPM1	0.166666666667
aml_ohsu_2018_4291	aml_ohsu_2018_16-01237	Denovo	None	AML with myelodysplasia-related changes	Adverse	Adverse	AML with myelodysplasia-related changes	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	1	Standard Chemotherapy	1	Decitabine	1	Supportive/Palliative Care				Standard Chemotherapy	Decitabine	Supportive/Palliative Care	-1	0		71	3	No	1		68	8	11		11	23	2.9	0.51		24.9	7.8	46,XX,del(1)(p22),der(15)t(15;?)(q15;?),-17,+mar[19]/46,XX[1]		110.7	Loss of RARA gene at 17q21 is detected in 69% of cells Gain of MLL gene at 11q23 is detected in 8% of cells.	95	blasts 55% of all events; they are positive for cd34, hla-dr, cd117, cd13, cd33, and  negative for cd11b, cd14, cd64, tdt and mpo.	4.8	63.4	Negative	Negative				Negative								73	Unmatched	AMLMRC	Leukemia	AML with Myelodysplasia-Related Changes	0.1
aml_ohsu_2018_4299	aml_ohsu_2018_16-01254	Denovo	None	AML with mutated NPM1	Favorable	Favorable	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	1	Standard Chemotherapy	2	7+3 (Cytarabine, Idarubicin)|HiDAC	2	Consolidation | Induction	Complete Response	Standard Chemotherapy	6	Standard Chemotherapy	HiDAC	Consolidation	-1	0		47	21.7	No														46,XX[20]			Normal		CD117, dimCD4,  heterogeneous CD13, CD33, dimCD64 and  MPO positive		46.27	Negative	Positive	Negative		p.R882H; MAF 46%	Negative	p.R132H; MAF 25%	Negative	Negative	Negative	p.Q61L; MAF 10%	p.G13D; MAF 24%	Negative	38	Matched	AMLNPM1	Leukemia	AML with Mutated NPM1	0.633333333333
aml_ohsu_2018_4303	aml_ohsu_2018_16-01262	Denovo	PML-RARA	Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA	Favorable	Intermediate-II	Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	1	Standard Chemotherapy	1	ATRA, Arsenic Trioxide, Idarubicin	1	Induction	Complete Response	Standard Chemotherapy	-1	Standard Chemotherapy	ATRA, Arsenic Trioxide, Idarubicin	Induction	-1	0	0.9	90	90	No	1.7	44	8.6	0	6	1.5	110	255	2.4	0.86	M3	19.8	6.7	46,XX,t(15;17)(q22;q21)[20]		88.4	86/100 cells (86%) had the 1r/1g/2f dual fusion signal pattern consistent  with PML/RARA fusion and with t(15;17) as seen on metaphase analysis.	30	CD13, CD33, CD58, CD64, CD117, CD123, MPO	5.4	47.35	Negative	Negative	Negative		Negative		Negative	Negative	Negative	Negative	Negative	Negative	Negative	59	Matched	APLPMLRARA	Leukemia	APL with PML-RARA	0.5
aml_ohsu_2018_4307	aml_ohsu_2018_16-01267	Relapse	None	AML with mutated NPM1	Favorable	Favorable	AML with mutated NPM1	Post-Chemotherapy|Relapse	Peripheral Blood	WES	No	Yes	Yes	No	Yes	Yes	0		0		0					NONE	NONE	NONE		0				No														46,XX[20]								Negative	Positive			VAF: 42.8%									62	Unmatched	AMLNPM1	Leukemia	AML with Mutated NPM1	0.333333333333
aml_ohsu_2018_4317	aml_ohsu_2018_16-01270	Relapse	Unknown	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	Intermediate	Favorable	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	Relapse	Peripheral Blood	WES + RNA-seq	Yes	Yes	Yes	Yes	Yes	Yes	1	Targeted Therapy - Kinase Inhibitor(s)	1	Dasatinib	1	Experimental				Targeted Therapy - Kinase Inhibitor(s)	Dasatinib	Experimental	16	0				No																						Negative	Negative												74	Unmatched	AMLCBFBMYH11	Leukemia	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22);CBFB-MYH11	0.0666666666667
aml_ohsu_2018_4310	aml_ohsu_2018_16-01272		None	AML with myelodysplasia-related changes	Adverse	Adverse	AML with myelodysplasia-related changes	Residual Disease|Post-Chemotherapy	Bone Marrow Aspirate	WES + RNA-seq	Yes	Yes	No	Yes	Yes	No	1	Standard Chemotherapy	1	7+3 (Cytarabine, Idarubicin)	1	Induction	Refractory	Standard Chemotherapy	6	Standard Chemotherapy	7+3 (Cytarabine, Idarubicin)	Induction	6	0		17		No				5										42,XY,-3,-7,der(12)t(12;?)(q24.3;?)-17,der(17)t(17;?)(p13;?),-21,der(22)t(22;?)(p11.2:?)[10]/46,XY[10]				43	NOT DETECTED for the MLL partial tandem duplication (PTD). NOT DETECTED for the FLT3 Internal Tandem Duplication (ITD)-Signal Ratio (SR). NOT DETECTED for the FLT3 TKD Mutation. Pathogenic alterations are DETECTED in the DNMT3A, NF1 and TP53 genes.		2.2	Negative	Negative			c.2635_2651delAACATGAGCCGCTTGGC; p.N879Efs*36         c.2656C>T; pQ886*    MAF 43%, 36%	Negative							c.610G>T;p.E204*    MAF 51%	64	Unmatched	AMLMRC	Leukemia	AML with Myelodysplasia-Related Changes	0.133333333333
aml_ohsu_2018_4324	aml_ohsu_2018_17-00021	Relapse	Unknown	AML with mutated NPM1	Favorable	Not Enough Information	AML with mutated NPM1	Post-Chemotherapy|Relapse	Peripheral Blood	WES	No	Yes	Yes	No	Yes	Yes	1	Standard Chemotherapy	2	7+3 (Cytarabine, Idarubicin)|HiDAC	2	Consolidation | Induction	Complete Response	Standard Chemotherapy	23	Standard Chemotherapy	HiDAC	Consolidation	63	0			8	No	1		14	19	46		15	22	4.3	0.88		38.3	12.5			97.2		165		6.2	9	Negative	Positive												67	Unmatched	AMLNPM1	Leukemia	AML with Mutated NPM1	0.266666666667
aml_ohsu_2018_4325	aml_ohsu_2018_17-00025		None	AML with mutated NPM1	Intermediate	Intermediate-I	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Peripheral Blood	WES	No	Yes	Yes	No	Yes	Yes	2	Standard Chemotherapy | Bone Marrow Transplant	3	7+3 (Cytarabine, Idarubicin)|HiDAC + Midostaurin|Fludarabine, TBI	3	Allogeneic - Sibling | Consolidation | Induction	Complete Response	Standard Chemotherapy	-1	Bone Marrow Transplant	Fludarabine, TBI	Allogeneic - Sibling	-1	0		70	80	No														46,XX[20]					Large pop. of promonocytes/monoblasts representing approx 57% of total leukocytes and increased atypicalCD117 pos, partial CD34 pos myeloblasts (partial CD7 pos) representing approx 6% of leukocytes consistent w/AMLw/monocytic differentiation.		190	Positive	Positive			p.Arg882His; MAF 41.8%									39	Unmatched	AMLNPM1	Leukemia	AML with Mutated NPM1	0.2
aml_ohsu_2018_4336	aml_ohsu_2018_17-00029	Relapse	Unknown	Acute myeloid leukaemia, NOS	Adverse	Not Enough Information	Acute myeloid leukaemia, NOS	Post-Transplant|Post-Chemotherapy|Relapse	Bone Marrow Aspirate	WES	No	Yes	No	No	Yes	No	2	Standard Chemotherapy | Bone Marrow Transplant	3	Busulfan, Fludarabine, Thymoglobulin (Bu/Flu/ATG)|HiDAC|3+7 (Cytarabine, Daunorubicin)	4	Unknown | Induction | Re-induction | Allogeneic - Matched Unrelated Donor	Unknown	Standard Chemotherapy	6	Bone Marrow Transplant	Busulfan, Fludarabine, Thymoglobulin (Bu/Flu/ATG)	Allogeneic - Matched Unrelated Donor	0	0		83	80	No			16	1	4		19	20	4.1	0.93		29.7	9.9			96.1		63	POSITIVE for the FLT3 Internal Tandem Duplication (ITD)-Signal Ratio (SR) with a signal ratio of 0.045. NOT DETECTED for the FLT3 TKD Mutation.	7.5	85.5	Positive	Negative				Negative								45	Unmatched	AMLNOS	Leukemia	AML, NOS	0.233333333333
aml_ohsu_2018_4359	aml_ohsu_2018_17-00033		None	AML with mutated NPM1	Favorable	Intermediate-II	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Peripheral Blood	WES	No	Yes	Yes	No	Yes	Yes	1	Standard Chemotherapy	2	7+3 (Cytarabine, Idarubicin)|Azacitidine	2	Induction | Supportive/Palliative Care	UNKNOWN	Standard Chemotherapy	-1	Standard Chemotherapy	7+3 (Cytarabine, Idarubicin)	Induction	-1	0				No														46,XX[20]			Normal		Large population of CD117pos, CD34 neg, HLA-DR neg myeloblasts, representing approx 68% of leukocytes, consistent w/ residual/recurrent AML.			Negative	Positive												74	Unmatched	AMLNPM1	Leukemia	AML with Mutated NPM1	0.166666666667
aml_ohsu_2018_2694	aml_ohsu_2018_17-00059		RUNX1-RUNX1T1	AML with t(8;21)(q22;q22); RUNX1-RUNX1T1	Intermediate	Favorable	AML with t(8;21)(q22;q22); RUNX1-RUNX1T1	Post-Chemotherapy	Bone Marrow Aspirate	WES	No	Yes	Yes	No	Yes	Yes	1	Standard Chemotherapy	2	HiDAC|3+7 (Cytarabine, Daunorubicin)	2	Consolidation | Induction	Unknown	Standard Chemotherapy	20	Standard Chemotherapy	HiDAC	Consolidation	182	0		1		No				6										46,XY[20]			RUNX1/RUNX1T1 fusion negative	94	Positive for CD34, CD117, HLADR, CD13 AND CD33.		6.6	Negative	Negative				Negative								51	Matched	AMLRUNX1RUNX1T1	Leukemia	AML with t(8;21)(q22;q22.1);RUNX1-RUNX1T1	0.666666666667
aml_ohsu_2018_4363	aml_ohsu_2018_17-00064	Denovo	None	AML with mutated NPM1	Intermediate	Intermediate-I	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	WES	No	Yes	Yes	No	Yes	Yes	3	Standard Chemotherapy | Bone Marrow Transplant | Targeted Therapy - Kinase Inhibitor(s)	3	Midostaurin|Fludarabine, Cyclophosphamide, Thiotepa, TBI|7+3 (Cytarabine, Idarubicin) plus Enasidenib	3	Induction | Double Umbilical Cord Blood Transplant (DUCBT) | Maintenance	Complete Response	Standard Chemotherapy	-1	Targeted Therapy - Kinase Inhibitor(s)	Midostaurin	Maintenance	44	0	0	88.5	64	No	0		25	4	7		34	36	3.3			31.3	10.9	46,XY[19]			Normal	54	Negative	7.4	24.9	Positive	Positive	Negative		Negative		c.395G>A; p.R132H; 44%	Negative	Negative	Negative	Negative	Negative	Negative	55	Unmatched	AMLNPM1	Leukemia	AML with Mutated NPM1	0.266666666667
aml_ohsu_2018_4366	aml_ohsu_2018_17-00072	After or at the time transformation from another heme malignancy	None	Acute myeloid leukaemia, NOS	Intermediate	Intermediate-I	Acute myeloid leukaemia, NOS	Residual Disease|Post-Chemotherapy	Peripheral Blood	WES	No	Yes	Yes	No	Yes	Yes	2	Standard Chemotherapy | Targeted Therapy - Kinase Inhibitor(s)	4	Imatinib|Cytarabine|MEC (Cytarabine, Etoposide, Mitoxantrone)|Decitabine	4	Salvage | Induction | Experimental | Re-induction	Refractory	Standard Chemotherapy	61	Standard Chemotherapy	MEC (Cytarabine, Etoposide, Mitoxantrone)	Salvage	-1	0	0		53.2	No	0	16.2	16.2	8.1	6.3	4.5	20	45	4.6	1.5		31.5	9.8	46,XY[20]	851	92.6	Normal	14		7.6	92.55	Negative	Negative	Negative		Negative	Negative	Negative	Negative	Negative	Negative	Negative	p.G13D; MAF 34%	Negative	70	Unmatched	AMLNOS	Leukemia	AML, NOS	0.266666666667
aml_ohsu_2018_4317	aml_ohsu_2018_17-00077		CBFB-MYH11	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	Favorable	Favorable	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	Post-Chemotherapy|Residual Relapse	Bone Marrow Aspirate	WES	No	Yes	Yes	No	Yes	Yes	1	Targeted Therapy - Kinase Inhibitor(s)	1	Dasatinib	1	Experimental				Targeted Therapy - Kinase Inhibitor(s)	Dasatinib	Experimental	16	-25	2.6	90	74	No	0	0	6	2.6	2.6	0	12	22	2.7	0.69		19.5	6.5	46,XX,inv(16)(p13q22)[cp20]	807	86.7	CBFB:  79/100 cells (79%) reflecting CBFB rearrangement and the inverted chromosome 16 observed in the metaphase karyotype.	9	CD13, CD33, CD34, variable CD38, CD117,  CD123, and HLA-DR +.	5.8	34.76	Negative	Negative	Negative		Negative	Negative	Negative	Negative	Negative		Negative	Negative	Negative	74	Unmatched	AMLCBFBMYH11	Leukemia	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22);CBFB-MYH11	0.0666666666667
aml_ohsu_2018_4379	aml_ohsu_2018_17-00093	After or at the time transformation from another heme malignancy	None	Acute myeloid leukaemia, NOS	Intermediate	Intermediate-I	Acute myeloid leukaemia, NOS	Initial Acute Leukemia Diagnosis	Peripheral Blood	WES	No	Yes	Yes	No	Yes	Yes	1	Standard Chemotherapy	1	7+3 (Cytarabine, Idarubicin)	1	Induction	Unknown	Standard Chemotherapy	6	Standard Chemotherapy	7+3 (Cytarabine, Idarubicin)	Induction	6	0			48	No							30	21						46,XX[20]			nucish(D5S2064,D5S630,EGR1)x2[200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[200],(RUNX1T1,RUNX1)x2[200],(ABL1,BCR)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[199],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	27			41.91	Positive	Negative					Negative	Negative						43	Unmatched	AMLNOS	Leukemia	AML, NOS	0.0666666666667
aml_ohsu_2018_4380	aml_ohsu_2018_17-00094	After or at the time transformation from another heme malignancy	None	Acute myeloid leukaemia, NOS	Adverse	Not Enough Information	Acute myeloid leukaemia, NOS	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	WES	No	Yes	Yes	No	Yes	Yes	1	Standard Chemotherapy	2	7+3 (Cytarabine, Idarubicin)|HiDAC	2	Unknown | Induction	Complete Response	Standard Chemotherapy	26	Standard Chemotherapy	HiDAC	Unknown	77	0		20		No				3										46,XY[20]				49	THESE ARE POSITIVE FOR CD34, CD117, HLADR, CD13, AND CD33.		19.3	Negative	Negative			c.2644C>T; p.R882C     MAF 47%	Negative								57	Unmatched	AMLNOS	Leukemia	AML, NOS	0.333333333333
aml_ohsu_2018_2747	aml_ohsu_2018_17-00096	After or at the time transformation from another heme malignancy	None	Chronic myelomonocytic leukaemia	Intermediate	Not Enough Information	Acute myelomonocytic leukaemia	Residual Disease	Peripheral Blood	WES	No	Yes	Yes	No	Yes	Yes	2	Standard Chemotherapy | Bone Marrow Transplant	2	Azacitidine|Fludarabine, Melphalan, ATG	2	Unknown | Allogeneic - Matched Unrelated Donor				Bone Marrow Transplant	Fludarabine, Melphalan, ATG	Allogeneic - Matched Unrelated Donor	-1	-151				No	0.1		13.8	9.9	74.1		9	17	4.9	1		41.7	12.9	46,XY[12]		82.2	The abnormalities normally seen in MDS are not detected.	410		7.6	8	Negative	Negative												63	Unmatched	CMML	Myelodysplastic/Myeloproliferative Neoplasms	Chronic Myelomonocytic Leukemia	0.333333333333
